<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/css" href="gpml.css" ?>
<set>
<article>
<articleinfo>
<bibliomisc>MEDLINE:20081260</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of <cons lex="diethyldithiocarbamate" sem="G_DRUG">diethyldithiocarbamate</cons> (<cons lex="ddc" sem="G_DRUG">DDC</cons>) and <cons lex="ticlopidine" sem="G_DRUG">ticlopidine</cons> on <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> activity and <cons lex="caffeine" sem="G_DRUG">caffeine</cons> <cons sem="G_MECHANISM">metabolism</cons>: an in vitro comparative study with human cDNA-expressed <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> and liver microsomes.</sentence>
</title>
<abstract>
<sentence>The aim of the present study was to test the effect of <cons lex="diethyldithiocarbamate" sem="G_DRUG">diethyldithiocarbamate</cons> (<cons lex="ddc" sem="G_DRUG">DDC</cons>), which is regarded as a cytochrome P450 (CYP) <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons> and <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons> <cons sem="G_MECHANISM">inhibitor</cons>, and <cons lex="ticlopidine" sem="G_DRUG">ticlopidine</cons>, an efficient <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons>, <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> and <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> <cons sem="G_MECHANISM">inhibitor</cons>, on the activity of human <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> and the metabolism of <cons lex="caffeine" sem="G_DRUG">caffeine</cons> (-N-,-N- and-N-demethylation, and C-- hydroxylation).</sentence>
<sentence>The experiment was carried out in vitro using human cDNA-expressed <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> (Supersomes) and human pooled liver microsomes.</sentence>
<sentence>The effects of <cons lex="ddc" sem="G_DRUG">DDC</cons> and <cons lex="ticlopidine" sem="G_DRUG">ticlopidine</cons> were compared to those of <cons lex="furafylline" sem="G_DRUG">furafylline</cons> (a strong <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> <cons sem="G_MECHANISM">inhibitor</cons>).</sentence>
<annotation sem="INVITROCDDIS" ddi="(ticlopidine, CYP1A2,DEI)(DDC, CYP1A2,DEI)(ticlopidine, caffeine,DDI)(DDC, caffeine,DDI)">
<sentence>A comparative in vitro study provides clear evidence that <cons lex="ticlopidine" sem="G_DRUG">ticlopidine</cons> and <cons lex="ddc" sem="G_DRUG">DDC</cons>, applied at concentrations that <cons sem="G_MECHANISM">inhibit</cons> the above-mentioned CYP isoforms, potently (as compared to <cons lex="furafylline" sem="G_DRUG">furafylline</cons>) <cons lex="inhibhit" sem="G_MECHANISM">inhibit</cons> human <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> and <cons lex="caffeine" sem="G_DRUG">caffeine</cons> <cons sem="G_MECHANISM">metabolism</cons>, in particular-N- and-N-demethylation.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:19960413</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem="G_MECHANISM">Inhibitory</cons> effects of deoxypodophyllotoxin from Anthriscus sylvestris on human <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
</title>
<abstract>
<sentence><cons lex= "deoxypodophyllotoxin" sem="G_DRUG">Deoxypodophyllotoxin (DPT)</cons> is a bioactive compound of Anthriscus sylvestris (Apiaceae).</sentence>
<sentence>In the present study, the <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of cytochrome P450 (CYP) by <cons lex= "deoxypodophyllotoxin" sem="G_DRUG">DPT</cons> was evaluated in human liver microsomes (HLM) and the baculovirus-insect cell-expressed human CYPs using a cocktail probe assay.</sentence>
<annotation sem="INVITROCDDIS" ddi="(DPT, diclofenac 4-ydroxylation,DEI)(DPT, midazolam 1-hydroxylation,DEI)">
<sentence>When a mixture of specific CYP substrates was incubated with <cons lex= "deoxypodophyllotoxin" sem="G_DRUG">DPT</cons> in HLM, <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>-<cons lex="catalyzed" sem="G_MECHANISM">catalyzed</cons> <cons lex="diclofenac" sem="G_DRUG">diclofenac</cons> 4-hydroxylation and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>-<cons lex="catalyzed" sem="G_MECHANISM">catalyzed</cons> <cons lex="midazolam" sem="G_DRUG">midazolam</cons> 1-hydroxylation were <cons sem="G_CHANGE">strongly</cons> <cons sem="G_MECHANISM">inhibited</cons> by <cons lex= "deoxypodophyllotoxin" sem="G_DRUG">DPT</cons>, with <cons lex="ic(50)" sem="G_IVITPARA">IC (50)</cons> values of <cons sem="G_NUMBER">6.3</cons> and <cons sem="G_NUMBER">9.2 microM</cons>, respectively.</sentence>
</annotation>
<sentence>The Lineweaver-Burke plots for the <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> in HLM and baculovirus-insect cell-expressed human CYPs were consistent with a competitive type of <cons sem="G_MECHANISM">inhibition</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(DPT, CYP2C9,ADEI)(DPT, CYP3A4,ADEI)">
<sentence>From these results, <cons lex= "deoxypodophyllotoxin" sem="G_DRUG">DPT</cons> was characterized to be a competitive <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, with <cons sem="G_IVITPARA">K(i)</cons> values of <cons sem="G_NUMBER">3.5</cons> and <cons sem="G_NUMBER">10.8 microM</cons> in HLM and <cons sem="G_NUMBER">24.9</cons> and <cons sem="G_NUMBER">3.5 microM</cons> in baculovirus-insect cell-expressed human CYPs, respectively.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:19904008</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="perazine" sem="G_DRUG">Perazine</cons> at therapeutic drug concentrations <cons lex="inhibhits" sem="G_MECHANISM"></cons>inhibits human cytochrome P450 isoenzyme <cons lex="1a2" sem="G_CYP">1A2</cons> (<cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>) and <cons lex="caffeine" sem="G_DRUG">caffeine</cons> <cons sem="G_MECHANISM">metabolism</cons>--an in vitro study.</sentence>
</title>
<abstract>
<sentence>The aim of the present study was to estimate the <cons sem="G_MECHANISM">inhibitory</cons> effect of <sem="G_DRUG">perazine</cons>, a phenothiazine neuroleptic with <cons lex="piperazine" sem="G_DRUG">piperazine</cons> structure in a side chain, on human <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> activity measured as a rate of <cons lex="caffeine" sem="G_DRUG">caffeine</cons> 3-N- and 1-N-demethylation.</sentence>
<sentence>Moreover, the influence of perazine on other <cons lex="caffeine" sem="G_DRUG">caffeine</cons> metabolic pathways such as 7-N-demethylation (<cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, <cons sem="G_CYP">CYP2C8/9</cons>, <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>) and 8-hydroxylation (<cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, <cons sem="G_CYP">CYP2C8/9</cons>) was also determined.</sentence>
<sentence>The Dixon analysis showed that in both human liver microsomes and Supersomes <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> <sem="G_DRUG">perazine</cons> potently and to a similar degree <cons sem="G_MECHANISM">inhibited</cons> <cons lex="caffeine" sem="G_DRUG">caffeine</cons> 3-N-demethylation (<cons sem="G_IVITPARA">K(i)</cons> = <cons sem="G_NUMBER">3.5 microM</cons>) and 1-N-demethylation (<cons sem="G_IVITPARA">K(i)</cons> = <cons sem="G_NUMBER">5 microM</cons>).</sentence>
<annotation sem="INVITROCDDIS" ddi="(Perazine, caffeine 7-N-demethylation,ADDI)(Perazine, caffeine C-8-hydroxylation,ADDI)">
<sentence><cons lex="perazine" sem="G_DRUG">Perazine</cons> <cons sem="G_CHANGE"> <cons sem="G_CHANGE">moderately</cons></cons> diminished the rate of <cons lex="caffeine" sem="G_DRUG">caffeine</cons> 7-N-demethylation in Supersomes <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> (<cons sem="G_IVITPARA">K(i)</cons> = <cons sem="G_NUMBER">11.5 microM</cons>) and liver microsomes (<cons sem="G_IVITPARA">K(i)</cons> = <cons sem="G_NUMBER">20 microM</cons>), and attenuated C-8-hydroxylation (<cons sem="G_IVITPARA">K(i)</cons> = <cons sem="G_NUMBER">15.5 microM</cons>) in Supersomes <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Perazine, caffeine C-8-hydroxylation,ADDI)">
   <sentence>On the other hand, <cons lex="perazine" sem="G_DRUG">perazine</cons> <cons sem="G_CHANGE">weakly</cons> <cons sem="G_MECHANISM">inhibited</cons> <cons lex="caffeine" sem="G_DRUG">caffeine</cons> C-8-hydroxylation in liver microsomes (<cons sem="G_IVITPARA">K(i)</cons> = <cons sem="G_NUMBER">98 microM</cons>).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Perazine, CYP1A2,DEI)">
<sentence>About <cons sem="G_NUMBER">80%</cons> of basal <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> activity was <cons sem="G_CHANGE">reduced</cons> by the therapeutic concentrations of <cons lex="perazine" sem="G_DRUG">perazine</cons> (<cons sem="G_NUMBER">5-10 microM</cons>).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Perazine, CYP1A2,DEI)">
<sentence>The obtained results show that <cons lex="perazine" sem="G_DRUG">perazine</cons> at its therapeutic concentrations is a potent <cons sem="G_MECHANISM">inhibitor</cons> of human <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>.</sentence>
</annotation>
<sentence>Hence, taking account of <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> contribution to the <cons sem="G_MECHANISM">metabolism</cons> of endogenous substances (steroids), drugs (xanthine derivatives, <cons lex="phenacetin" sem="G_DRUG">phenacetin</cons>, <cons lex="propranolol" sem="G_DRUG">propranolol</cons>, <cons lex="imipramine" sem="G_DRUG">imipramine</cons>, phenothiazine neuroleptics, <cons lex="clozapine" sem="G_DRUG">clozapine</cons>) and carcinogenic compounds, the <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> by perazine <cons sem="G_CHANGE">may</cons> be of physiological, pharmacological and toxicological importance.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:19663817</bibliomisc>
</articleinfo>
<title>
<sentence>Roles of different CYP enzymes in the formation of specific <cons lex="fluvastatin" sem="G_DRUG">fluvastatin</cons> metabolites by human liver microsomes.</sentence>
</title>
<abstract>
<sentence><cons lex="fluvastatin" sem="G_DRUG">Fluvastatin</cons> has been considered to be metabolised to 5-hydroxy <cons lex="fluvastatin" sem="G_DRUG">fluvastatin</cons> (M-2), 6-hydroxy <cons lex="fluvastatin" sem="G_DRUG">fluvastatin</cons> (M-3) and N-desisopropyl <cons lex="fluvastatin" sem="G_DRUG">fluvastatin</cons> (M-5) in human liver microsomes by primarily <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>.</sentence>
<sentence>To elucidate the contribution of different CYP enzymes on <cons lex="fluvastatin" sem="G_DRUG">fluvastatin</cons> <cons sem="G_MECHANISM">metabolism</cons>, we examined the effect of CYP <cons sem="G_MECHANISM">inhibitors</cons> and <cons sem="G_CYP">CYP2C</cons>-specific monoclonal antibodies on the formation of <cons lex="fluvastatin" sem="G_DRUG">fluvastatin</cons> metabolites in human liver microsomes.</sentence>
<sentence>Human liver microsomes were incubated with <cons lex="fluvastatin" sem="G_DRUG">fluvastatin</cons> with or without pre-treatment with CYP <cons sem="G_MECHANISM">inhibitors</cons> or monoclonal antibodies.</sentence>
<sentence>Selective <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> (<cons lex="sulfaphenazole" sem="G_DRUG">sulfaphenazole</cons>), <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> (<cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>) and <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> (<cons lex="quercetin" sem="G_DRUG">quercetin</cons>) were employed and monoclonal antibodies were against <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons>, <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> and <cons sem="G_CYP">CYP2C8/9/18/19</cons>.</sentence>
<sentence>According to the amount of <cons lex="fluvastatin" sem="G_DRUG">fluvastatin</cons> metabolites produced, the formation of M-3 was found to be major pathway of <cons lex="fluvastatin" sem="G_DRUG">fluvastatin</cons> <cons sem="G_MECHANISM">metabolism</cons> (the relative contribution was calculated to be more than <cons sem="G_NUMBER">80%</cons>).</sentence>
<annotation sem="INVITROVDDIS" ddi="(Sulfaphenazole, 5-hydroxy fluvastatin,DDI)(Sulfaphenazole, 6-hydroxy fluvastatin,NDDI)">
 <sentence><cons lex="sulfaphenazole" sem="G_DRUG">Sulfaphenazole</cons> <cons sem="G_MECHANISM">inhibited</cons> the formation of M-2 largely, but had <cons sem="G_CHANGE">little</cons> effect on the formation of M-3.</sentence>
</annotation>
<annotation sem="INVITROVDDIS" ddi="(Sulfaphenazole, N-desisopropyl fluvastatin,DDI)">
<sentence>It also <cons sem="G_MECHANISM">inhibited</cons> the <cons sem="G_MECHANISM">formation</cons> of M-5.</sentence>
</annotation>
<annotation sem="INVITROVDDIS" ddi="(Ketoconazole, 6-hydroxy fluvastatin,DDI)(Ketoconazole, 5-hydroxy fluvastatin,NDDI)(Ketoconazole, N-desisopropyl fluvastatin,NDDI)">
<sentence><cons lex="ketoconazole" sem="G_DRUG">Ketoconazole</cons> <cons sem="G_CHANGE">markedly</cons> <cons sem="G_MECHANISM">inhibited</cons> the formation of M-3, but did <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_MECHANISM">inhibit</cons> the formation of M-2 and M-5.</sentence>
</annotation>
<annotation sem="INVITROVDDIS" ddi="(Quercetin, 6-hydroxy fluvastatin,NDDI)(Quercetin, 5-hydroxy fluvastatin,NDDI)(Quercetin, N-desisopropyl fluvastatin,NDDI)">
<sentence><cons lex="quercetin" sem="G_DRUG">Quercetin</cons> had a <cons sem="G_CHANGE">moderate</cons> <cons sem="G_MECHANISM">inhibitory</cons> effect on the formation of all three <cons lex="fluvastatin" sem="G_DRUG">fluvastatin</cons> metabolites.</sentence>
</annotation>
<annotation sem="INVITROVDDIS" ddi="(Anti- CYP2C9 Antibody, 5-hydroxy fluvastatin,DDI)(Anti-CYP2C9 Antibody, N-desisopropyl fluvastatin,DDI)(Anti-CYP2C8/9/18/19 Antibody, 5-hydroxy fluvastatin,DDI)(Anti-CYP2C8/9/18/19 Antibody, N-desisopropyl fluvastatin,DDI)">
<sentence>Monoclonal antibodies against <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> and <cons sem="G_CYP">CYP2C8/9/18/19</cons> <cons sem="G_CHANGE">markedly</cons> <cons sem="G_MECHANISM">inhibited</cons> the formation of M-2 and M-5.</sentence>
</annotation>
<annotation sem="INVITROVDDIS" ddi="(Anti-CYP2C9 Antibody, 6-hydroxy fluvastatin,DDI)(Anti- CYP2C8/9/18/19 Antibody, 6-hydroxy fluvastatin,DDI)">
<sentence>None of monoclonal antibodies showed clear <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> on the formation of M-3.</sentence>
</annotation>
<sentence>In contrast to previous published work, our results suggest that M-2 and M-5 are <cons sem="G_MECHANISM">formed</cons> preferentially by <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, and that M-3 is mainly <cons sem="G_MECHANISM">formed</cons> by <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>.</sentence>
<sentence>In summary, the results contribute to a better understanding of the drug-drug interaction potential for <cons lex="fluvastatin" sem="G_DRUG">fluvastatin</cons> in vivo.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:19593786</bibliomisc>
</articleinfo>
<title>
<sentence>The oxidative <cons sem="G_MECHANISM">metabolism</cons> of <cons sem="G_DRUG">dimemorfan</cons> by human cytochrome P450 enzymes.</sentence>
</title>
<abstract>
<sentence>To characterize the human cytochrome P450 (P450) forms involved in <cons sem="G_DRUG">dimemorfan</cons> <cons lex="oxidation" sem="G_MECHANISM">oxidation</cons> (DFO), human liver microsomes, and recombinant P450s were investigated.</sentence>
<sentence>Liquid chromatography-mass spectral analysis suggested that metabolite (M)1 ( [M + H](+) m/z at 272.200) and M2 ( [M + H](+) m/z at 242.190) were d-3-hydroxymethyl-N-methylmorphinan and d-3-methylmorphinan, respectively.</sentence>
<sentence>Kinetic analyses of microsomal DFO showed that the substrate concentration showing a half-maximal velocity (S(50)) of M1 formation was less than that of M2.</sentence>
<sentence>Microsomal M1 and M2 formation activities <cons lex="correlated" sem="G_MECHANISM">correlated</cons> <cons sem="G_CHANGE">significantly</cons> with the <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> marker, <cons lex="dextromethorphan" sem="G_DRUG">dextromethorphan</cons> O-demethylation activity.</sentence>
<sentence>The M2 formation activity was also <cons lex="correlated" sem="G_MECHANISM">correlated</cons> with the <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> marker, <cons lex="nifedipine" sem="G_DRUG">nifedipine</cons> <cons lex="oxidation" sem="G_MECHANISM">oxidation</cons> activity.</sentence>
<annotation sem="INVITROVDDIS" ddi="(paroxetine, d-3-hydroxymethyl-N-methylmorphinan,DDI)(paroxetine, d-3-methylmorphinan,DDI)(ketoconazole, d-3-hydroxymethyl-N-methylmorphinan,DDI)(ketoconazole, d-3-methylmorphinan,DDI)">
<sentence>Microsomal M1 and M2 formation was most sensitive to the <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> by a <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> <cons sem="G_MECHANISM">inhibitor</cons>, <cons lex="paroxetine" sem="G_DRUG">paroxetine</cons> and a <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitor</cons>, <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>, respectively.</sentence>
</annotation>
<sentence>The immunoinhibition-defined P450 contributions indicated the participation of <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>, and <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> in the M1 formation and <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons>, <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>, <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>, and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> in the M2 formation.</sentence>
<annotation sem="INVITROVDDIS" ddi="(CYP2D6, d-3-hydroxymethyl-N-methylmorphinan,DEI)">
<sentence>Among recombinant P450s, <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> had the <cons sem="G_CHANGE">highest</cons> <cons sem="G_IVITPARA">intrinsic clearance</cons> with a <cons sem="G_IVITPARA">K(m)</cons> value of <cons sem="G_NUMBER">0.02 mM</cons> in forming M1.</sentence>
</annotation>
<annotation sem="INVITROVDDIS" ddi="(CYP2B6, d-3-methylmorphinan,DEI)(CYP2C9, d-3-methylmorphinan,DEI)(CYP2C19, d-3-methylmorphinan,DEI)(CYP2D6, d-3-methylmorphinan,DEI)(CYP3A4, d-3-methylmorphinan,DEI)">
<sentence><cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons>, <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, and <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> had the <cons sem="G_IVITPARA">K(m)</cons> or <cons sem="G_IVITPARA">S(50)</cons> values smaller than those (<cons sem="G_NUMBER">1 mM</cons>) of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> in forming M2.</sentence>
</annotation>
<sentence>These results indicated the participation of multiple P450 forms in DFO.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:19464879</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem="G_DRUG">R(+)XK469</cons> <cons sem="G_MECHANISM">inhibits</cons> hydroxylation of S-<cons lex="warfarin" sem="G_DRUG">warfarin</cons> by <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>.</sentence>
</title>
<abstract>
<sentence><cons sem="G_DRUG">XK469</cons> is a novel topoisomerase II <cons sem="G_MECHANISM">inhibitor</cons> structurally akin to several <cons lex="propionic" sem="G_DRUG">propionic</cons> acid derivatives, such as <cons lex="ibuprofen" sem="G_DRUG">ibuprofen</cons> and <cons lex="diclofenac" sem="G_DRUG">diclofenac</cons>, which are <cons sem="G_MECHANISM">metabolised</cons> by <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>.</sentence>
<sentence>We report eight subjects who experienced <cons sem="G_CHANGE">significant</cons> elevation of INR while receiving concomitant <cons sem="G_DRUG">R(+)XK469</cons> and <cons lex="warfarin" sem="G_DRUG">warfarin</cons>.</sentence>
<sentence>The aim of the study is to investigate whether R(+)XK469 interacts with S-<cons lex="warfarin" sem="G_DRUG">warfarin</cons> by <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>.</sentence>
<sentence>The effect of <cons sem="G_DRUG">R(+)XK469</cons> on S-<cons lex="warfarin" sem="G_DRUG">warfarin</cons> hydroxylation was determined by the measurement of S-7-hydroxywarfarin formation in pooled human liver microsomes and cDNA-expressed <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(R(+)XK469, S-warfarin hydroxylation,DDI)">
<sentence><cons sem="G_DRUG">R(+)XK469</cons> competitively <cons sem="G_MECHANISM">inhibited</cons> S-<cons lex="warfarin" sem="G_DRUG">warfarin</cons> hydroxylation.</sentence>
</annotation>
<sentence>The <cons sem="G_IVITPARA">K(i)</cons> values of <cons sem="G_DRUG">R(+)XK469</cons> were estimated to be <cons sem="G_NUMBER">959+/-426 microM</cons> for human liver microsomes and to be <cons sem="G_NUMBER">377+/-92 microM</cons> for <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>.</sentence>
<sentence>At the recommended phase II dose of <cons sem="G_DRUG">R(+)XK469</cons>, the ratio of <cons sem="G_IVITPARA">C(max)/K(i)</cons> is <cons sem="G_NUMBER">&gt;1</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(R(+)XK469, warfarin,DDI)">
<sentence>This suggests that coadministration of <cons sem="G_DRUG">R(+)XK469</cons> and <cons lex="warfarin" sem="G_DRUG">warfarin</cons> results in a clinically <cons sem="G_CHANGE">significant</cons> pharmacokinetic interaction due to <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> by <cons sem="G_DRUG">R(+)XK469</cons>.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:19336906</bibliomisc>
</articleinfo>
<title>
<sentence>In vitro <cons sem="G_MECHANISM">metabolism</cons> and <cons sem="G_MECHANISM">inhibitory</cons> effects of <cons lex="pranlukast" sem="G_DRUG">pranlukast</cons> in human liver microsomes.</sentence>
</title>
<abstract>
<sentence>We investigated the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="pranlukast" sem="G_DRUG">pranlukast</cons>, a selective leukotriene agonist, and the potential for drug-drug interactions.</sentence>
<annotation sem="INVITROCDDIS" ddi="(ketoconazole, pranlukast,ADDI)">
<sentence>Although cytochrome P450 (CYP) <cons lex="3a4" sem="G_CYP">3A4</cons> appeared to be the major cytochrome P450 isoform involved in the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="pranlukast" sem="G_DRUG">pranlukast</cons>, the results suggested that <cons lex="pranlukast" sem="G_DRUG">pranlukast</cons> <cons sem="G_MECHANISM">metabolism</cons> was <cons sem="G_MECHANISM">inhibited</cons> less than <cons sem="G_NUMBER">50%</cons> by <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>, a reversible <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitor</cons>, or by anti-<cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> antibodies.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(clarithromycin, pranlukast,NDDI)(erythromycin, pranlukast,NDDI)(roxithromycin, pranlukast,NDDI)">
<sentence>Irreversible macrolide <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitors</cons>, <cons lex="clarithromycin" sem="G_DRUG">clarithromycin</cons>, <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> and <cons lex="roxithromycin" sem="G_DRUG">roxithromycin</cons>, exhibited <cons sem="G_CHANGE">little</cons> effect on <cons lex="pranlukast" sem="G_DRUG">pranlukast</cons> <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(CYP2C8, pranlukast,DEI)(CYP3A4, pranlukast,DEI)"> 
<sentence>On the other hand, <cons lex="pranlukast" sem="G_DRUG">pranlukast</cons> reversibly <cons sem="G_MECHANISM">inhibited</cons> <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> and/or <cons lex="2c9" sem="G_CYP">2C9</cons>, and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, with <cons sem="G_IVITPARA">K(i)</cons> values of <cons sem="G_NUMBER">3.9</cons> and <cons sem="G_NUMBER">4.1 micromol/l</cons>, respectively.</sentence>
</annotation>
<sentence>The <cons sem="G_IVITPARA">[I](in,max,u)</cons>/<cons sem="G_IVITPARA">K(i)</cons> ratios were 0.004 and 0.003, respectively.</sentence>
<sentence>The <cons sem="G_IVITPARA">K(i)</cons> values were about <cons sem="G_NUMBER">300-fold</cons> <cons sem="G_CHANGE">greater</cons> than the  [I](in,max,u), therefore it is suggested that, at clinical doses, <cons lex="pranlukast" sem="G_DRUG">pranlukast</cons> will <cons sem="G_NEGATIVEEFFECT">not</cons> affect the pharmacokinetics of concomitantly administered drugs that are primarily <cons sem="G_MECHANISM">metabolized</cons> by <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> and/or <cons lex="2c9" sem="G_CYP">2C9</cons> or <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:19230594</bibliomisc>
</articleinfo>
<title>
<sentence>Evaluation of the <cons lex="inhibitory" sem="G_MECHANISM">inhibitory</cons> and <cons lex="induction" sem="G_MECHANISM">induction</cons> potential of <cons sem="G_DRUG">YM758</cons>, a novel If channel <cons sem="G_MECHANISM">inhibitor</cons>, for human P450-mediated <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
</title>
<abstract>
<sentence>This study was designed to examine the in vitro <cons sem="G_MECHANISM">metabolism</cons> of <cons sem="G_DRUG">YM758</cons>, a novel cardiovascular agent, and to evaluate its potential to cause drug interactions and <cons lex="induction" sem="G_MECHANISM">induction</cons> of CYP isozymes.</sentence>
<sentence>After incubation with pooled human liver microsomes, <cons sem="G_DRUG">YM758</cons> was converted to two major metabolites (AS2036313-00, and YM-394111 or YM-394112).</sentence>
<sentence>The <cons sem="G_MECHANISM">formation</cons> of AS2036313-00, and YM-394111 or YM-394112 were mediated by <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, respectively, which was elucidated by using a bank of human liver microsomes and recombinant CYP enzymes in combination with the utilization of typical substrates and <cons sem="G_MECHANISM">inhibitors</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(YM758, midazolam,ADDI)(YM758, nifedipine,ADDI)(YM758, metoprolol,ADDI)">
<sentence>The <cons sem="G_IVITPARA">Ki</cons> values of <cons sem="G_DRUG">YM758</cons> for <cons lex="midazolam" sem="G_DRUG">midazolam</cons>, <cons lex="nifedipine" sem="G_DRUG">nifedipine</cons>, and <cons lex="metoprolol" sem="G_DRUG">metoprolol</cons> <cons sem="G_MECHANISM">metabolism</cons> ranged from <cons sem="G_NUMBER">59</cons> to <cons sem="G_NUMBER">340 microM</cons>, being much higher than the <cons sem="G_DRUG">YM758</cons> concentration in human plasma.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(quinidine, AS2036313-00,ADDI)(quinidine, YM-394111,ADDI)(ketoconazole, AS2036313-00,DDI)(ketoconazole, YM-394111,DDI)">
<sentence>The <cons sem="G_MECHANISM">formation</cons> of AS2036313-00, and YM-394111 or YM-394112 was <cons sem="G_MECHANISM">inhibited</cons> by <cons lex="quinidine" sem="G_DRUG">quinidine</cons> and <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> with <cons sem="G_IVITPARA">Ki</cons> values of <cons sem="G_NUMBER">140</cons> and <cons sem="G_NUMBER">0.24 microM</cons>, respectively, which indicates that <cons sem="G_DRUG">YM758</cons> <cons sem="G_MECHANISM">metabolism</cons> <cons sem="G_CHANGE">may</cons> be <cons sem="G_CHANGE">affected</cons> by coadministration of strong <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> and <cons lex="3a4" sem="G_CYP">3A4</cons> <cons sem="G_MECHANISM">inhibitors</cons> in vivo, given the clinical plasma concentrations of <cons lex="quinidine" sem="G_DRUG">quinidine</cons> and <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(YM758, CYP1A2,NDEI)(YM758, CYP3A4,NDEI)">
<sentence>After human hepatocytes were exposed to <cons sem="G_NUMBER">10 microM</cons> <cons sem="G_DRUG">YM758</cons>, microsomal activity and mRNA level for <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> were <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_MECHANISM">induced</cons> while those for <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> were <cons sem="G_CHANGE">slightly</cons> <cons sem="G_MECHANISM">induced</cons>.</sentence>
</annotation>
<sentence>The tested concentration was much higher than that in human plasma, which suggests that the <cons lex="induction" sem="G_MECHANISM">induction</cons> potential of <cons sem="G_DRUG">YM758</cons> is also <cons sem="G_CHANGE">negligible</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:18653741</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons>- and <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>-mediated C-demethylation of <cons sem="G_DRUG">(3-{ [(4-tert-butylbenzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid (CP-533,536)</cons>, an EP2 receptor-selective prostaglandin E2 agonist: characterization of metabolites by high-resolution liquid chromatography-tandem mass spectrometry and liquid chromatography/mass spectrometry-nuclear magnetic resonance.</sentence>
</title>
<abstract>
<sentence><cons lex="1" sem="G_DRUG">CP-533,536, (3-{ [(4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid (1)</cons>, an EP2 receptor-selective prostaglandin E2 agonist, is being developed to aid in the healing of bone fractures.</sentence>
<sentence>To support the development of this program, in vitro <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="1" sem="G_DRUG">1</cons> was investigated in human liver microsomes and major recombinant human cytochrome P450 (P450) isoforms.</sentence>
<sentence><cons lex="1" sem="G_DRUG">1</cons> was <cons sem="G_MECHANISM">metabolized</cons> in vitro by at least three recombinant human P450s: <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, <cons lex="cyp3a5" sem="G_CYP">CYP3A5</cons>, and <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(ketoconazole, 1,DDI)(quercetin, 1,DDI)">
<sentence>The turnover of <cons lex="1" sem="G_DRUG">1</cons> was NADPH-dependent and was completely <cons sem="G_MECHANISM">inhibited</cons> by <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> and <cons lex="quercetin" sem="G_DRUG">quercetin</cons> in the <cons lex="cyp3a4/5" sem="G_CYP">CYP3A4/5</cons> and <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> incubations, respectively.</sentence>
</annotation>
<sentence>The major metabolic pathways were caused by <cons lex="oxidation" sem="G_MECHANISM">oxidation</cons> of the tert-butyl moiety to form the omega-hydroxy metabolite (M4), <cons lex="oxidation" sem="G_MECHANISM">oxidation</cons> of the pyridine moiety, and/or N-dealkylation of the methylphenoxy <cons lex="acetic" sem="G_DRUG">acetic acid</cons> moiety.</sentence>
<sentence>The alcohol metabolite M4 was further oxidized to the corresponding carboxylic acid M3.</sentence>
<sentence>In addition to these pathways, three unusual metabolites (M22, M23, and M26) resulting from C-demethylation of the tert-butyl group were identified using high-resolution liquid chromatography/tandem mass spectrometry and liquid chromatography/mass spectrometry/NMR.</sentence>
<sentence>The C-demethylated metabolites were <cons sem="G_NEGATIVEEFFECT">not</cons> detected on incubation of carboxylic acid metabolite M3 with either human liver microsomes or CYP3A/2C8 isoforms, suggesting that these metabolites were <cons sem="G_NEGATIVEEFFECT">not</cons> derived from decarboxylation of M3.</sentence>
<sentence>A possible mechanism for C-demethylation <cons sem="G_CHANGE">may</cons> involve the <cons lex="oxidation" sem="G_MECHANISM">oxidation</cons> of M4 to form an aldehyde metabolite (M24), followed by P450-mediated deformylation, to give an unstable carbon-centered radical and <cons lex="formic" sem="G_DRUG">formic acid</cons>.</sentence>
<sentence>The carbon-centered radical intermediate then undergoes either oxygen rebound to form an alcohol metabolite M23 or hydrogen abstraction leading to an olefin metabolite M26.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:18647599</bibliomisc>
</articleinfo>
<title>
<sentence>Application and interpretation of hPXR screening data: Validation of reporter signal requirements for prediction of clinically relevant <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> inducers.</sentence>
</title>
<abstract>
<sentence>A human pregnane X receptor (PXR) reporter-gene assay was established and validated using 19 therapeutic agents known to be clinical <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> inducers, 5 clinical non-inducers, and 6 known inducers in human hepatocytes.</sentence>
<sentence>The extent of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons lex="induction" sem="G_MECHANISM">induction</cons> (measured as RIF ratio in comparison to rifampicin) and <cons sem="G_IVITPARA">EC50</cons> was obtained from the dose-response curve.</sentence>
<sentence>All of the clinical inducers (19/19) and human hepatocyte inducers (6/6) showed positive responses in the PXR assay.</sentence>
<annotation sem="INVITROVDDIS" ddi="(pioglitazone, CYP3A4,DEI)">
<sentence>One out of five clinical non-inducers, <cons lex="pioglitazone" sem="G_DRUG">pioglitazone</cons>, also showed a positive response.</sentence>
</annotation>
<sentence>An additional series of 18 commonly used drugs with <cons sem="G_NEGATIVEEFFECT">no</cons> reports of clinical <cons lex="induction" sem="G_MECHANISM">induction</cons> was also evaluated as putative negative controls.</sentence>
<annotation sem="INVITROVDDIS" ddi="(flutamide, CYP3A4,DEI)(haloperidol, CYP3A4,DEI)">
<sentence>Sixteen of these were negative (<cons sem="G_NUMBER">89%</cons>), whereas two of these, <cons lex="flutamide" sem="G_DRUG">flutamide</cons> and <cons lex="haloperidol" sem="G_DRUG">haloperidol</cons> showed <cons sem="G_NUMBER">16-fold</cons> (RIF ratio 0.79) and <cons sem="G_NUMBER">10-fold</cons> (RIF ratio 0.48) maximal <cons lex="induction" sem="G_MECHANISM">induction</cons>, respectively in the reporter-gene system.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(flutamide, testosterone 6beta-hydroxylation,DDI)">
<sentence><cons lex="flutamide" sem="G_DRUG">Flutamide</cons> and <cons lex="haloperidol" sem="G_DRUG">haloperidol</cons> were further demonstrated to cause <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons lex="induction" sem="G_MECHANISM">induction</cons> in human cryopreserved hepatocytes based on <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6beta-hydroxylation activity.</sentence>
</annotation>
<sentence>The <cons lex="induction" sem="G_MECHANISM">induction</cons> potential index calculated based on the maximum RIF ratio, <cons sem="G_IVITPARA">EC50</cons>, and in vivo <cons sem="G_IVITPARA">maximum plasma concentration</cons> was used to predict the likelihood of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons lex="induction" sem="G_MECHANISM">induction</cons> in humans.</sentence>
<sentence>When the <cons lex="induction" sem="G_MECHANISM">induction</cons> potential index is <cons sem="G_CHANGE">greater</cons> than <cons sem="G_NUMBER">0.08</cons>, the compound is likely to cause <cons lex="induction" sem="G_MECHANISM">induction</cons> in humans.</sentence>
<sentence>A high-throughput screening strategy was developed based on the validation results at <cons sem="G_NUMBER">1 microM</cons> and <cons sem="G_NUMBER">10 microM</cons> for the same set of drugs.</sentence>
<sentence>A RIF ratio of 0.4 was set as more practical screening cut-off to minimize the possibility of generating false positives.</sentence>
<sentence>Thus, a tiered approach was implemented to use the human PXR reporter-gene assay from early lead optimization to late lead characterization in drug discovery.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:18570159</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of <cons sem="G_DRUG">butylated hydroxytoluene</cons>, <cons sem="G_DRUG">curcumin</cons>, <cons sem="G_DRUG">propyl gallate</cons> and <cons lex="thiabendazole" sem="G_DRUG">thiabendazole</cons> on cytochrome P450 forms in cultured human hepatocytes.</sentence>
</title>
<abstract>
<sentence>1.</sentence>
<sentence>The objective of this study was to investigate the effects of four food chemicals, namely <cons sem="G_DRUG">butylated hydroxytoluene (BHT)</cons>, <cons sem="G_DRUG">curcumin(CC)</cons>, <cons sem="G_DRUG">propyl gallate (PG)</cons> and <cons lex="thiabendazole" sem="G_DRUG">thiabendazole (TB)</cons>, on cytochrome P450 (CYP) forms in cultured human hepatocytes.</sentence>
<sentence>2.</sentence>
<annotation sem="INVITROCDDIS" ddi="(thiabendazole, CYP1A2,DEI)(thiabendazole, CYP2B6,DEI)(thiabendazole, CYP3A4,DEI)(butylated hydroxytoluene, CYP2B6,DEI)(butylated hydroxytoluene, CYP3A4,DEI)">
<sentence>Treatment of human hepatocytes for 72 h with <cons sem="G_NUMBER">2-200 microM</cons> <cons sem="G_DRUG">TB</cons> produced concentration-dependent <cons sem="G_CHANGE">increases</cons> in <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> mRNA levels, whereas treatment with <cons sem="G_DRUG">BHT</cons> <cons sem="G_CHANGE">increased</cons> <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> mRNA levels.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(thiabendazole, CYP1A2,DEI)(thiabendazole, CYP2B6,DEI)(thiabendazole, CYP3A4,DEI)(butylated hydroxytoluene, CYP2B6,DEI)(butylated hydroxytoluene, CYP3A4,DEI)">
<sentence><cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> mRNA levels were <cons sem="G_MECHANISM">induced</cons> around <cons sem="G_NUMBER">48-</cons>, <cons sem="G_NUMBER">21-</cons> and <cons sem="G_NUMBER">9-fold</cons>, respectively, by <cons sem="G_NUMBER">200 microM</cons> <cons sem="G_DRUG">TB</cons>, with <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> and CYP <cons lex="3a4" sem="G_CYP">3A4</cons> mRNA levels being <cons sem="G_MECHANISM">induced</cons> around <cons sem="G_NUMBER">/12-</cons> and <cons sem="G_NUMBER">7-fold</cons>, respectively, by <cons sem="G_NUMBER">200 microM</cons> <cons sem="G_DRUG">BHT</cons>.</sentence>
</annotation>
<sentence>3.</sentence>
<annotation sem="INVITROCDDIS" ddi="(propyl gallate, CYP1A2,NDEI)(propyl gallate, CYP2B6,NDEI)(propyl gallate, CYP3A4,NDEI)(curcumin, CYP1A2,NDEI)(curcumin, CYP2B6,NDEI)(curcumin, CYP3A4,NDEI)">
<sentence>In contrast, the treatment of human hepatocytes for 72 h with <cons sem="G_DRUG">PG</cons> and <cons sem="G_DRUG">CC</cons> had <cons sem="G_CHANGE">little</cons> or <cons sem="G_NEGATIVEEFFECT">no</cons> effect on CYP mRNA levels.</sentence>
</annotation>
<sentence>4.</sentence>
<annotation sem="INVITROCDDIS" ddi="(thiabendazole, 7-ethoxyresorufin O-deethylase,DDI)(butylated hydroxytoluene, testosterone 6beta-hydroxylase,DDI)">
<sentence>The treatment of human hepatocytes with <cons sem="G_DRUG">TB</cons> also <cons sem="G_MECHANISM">induced</cons> <cons sem="G_CYP">CYP1A</cons>-dependent 7-ethoxyresorufin O-deethylase activity, whereas <cons sem="G_DRUG">BHT</cons> <cons sem="G_MECHANISM">induced</cons> <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>-dependent <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6beta-hydroxylase activity.</sentence>
</annotation>
<sentence>5.</sentence>
<annotation sem="INVITROCDDIS" ddi="(thiabendazole, CYP1A,DEI)(thiabendazole, CYP2B,DEI)(thiabendazole, CYP3A,DEI)(butylated hydroxytoluene, CYP2B,DEI)(butylated hydroxytoluene, CYP3A,DEI)">
<sentence>In summary, the results demonstrate that <cons sem="G_DRUG">TB</cons> is a mixed <cons sem="G_MECHANISM">inducer</cons> of CYP forms in human hepatocytes inducing <cons sem="G_CYP">CYP1A</cons>, <cons sem="G_CYP">CYP2B</cons> and <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> forms, whereas <cons sem="G_DRUG">BHT</cons> is an <cons sem="G_MECHANISM">inducer</cons> of <cons sem="G_CYP">CYP2B</cons> and <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> forms.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:18541695</bibliomisc>
</articleinfo>
<title>
<sentence>A novel bioactivation pathway for 2- [2-(2,6-dichlorophenyl)aminophenyl]ethanoic acid (<cons lex="diclofenac" sem="G_DRUG">diclofenac</cons>) initiated by cytochrome P450-mediated oxidative decarboxylation.</sentence>
</title>
<abstract>
<sentence><cons lex="diclofenac" sem="G_DRUG">Diclofenac</cons> (2- [2-(2,6-dichlorophenyl)aminophenyl]ethanoic acid), a nonsteroidal antiinflammatory drug, undergoes bioactivation by cytochrome P450 <cons lex="oxidation" sem="G_MECHANISM">oxidation</cons> to chemically reactive metabolites that are capable of reacting with endogenous nucleophiles such as glutathione (GSH) and proteins and that <cons sem="G_CHANGE">may</cons> play a role in the idiosyncratic hepatotoxicity associated with the drug.</sentence>
<sentence>Here, we investigated the ability of <cons lex="diclofenac" sem="G_DRUG">diclofenac</cons> to be <cons sem="G_MECHANISM">metabolized</cons> to 2-(2,6-dichloro-phenylamino)benzyl-S-thioether glutathione (DPAB-SG) in incubations with rat liver microsomes (RLMs) and human liver microsomes (HLMs) fortified with NADPH and GSH.</sentence>
<sentence>Thus, after incubation of <cons lex="diclofenac" sem="G_DRUG">diclofenac</cons> (<cons sem="G_NUMBER">50 microM</cons>) with liver microsomes (1 mg protein/ml), the presence of DPAB-SG was detected in both RLM and HLM incubation extracts by liquid chromatography-tandem mass spectrometry techniques.</sentence>
<sentence>The formation of DPAB-SG was NADPH-, concentration-, and time-dependent.</sentence>
<annotation sem="INVITROCDDIS" ddi="(diclofenac, DPAB-SG,DDI)(ketoconazole, DPAB-SG,DDI)">
<sentence>Coincubation of <cons lex="diclofenac" sem="G_DRUG">diclofenac</cons> (<cons sem="G_NUMBER">10 microM</cons>) with <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> (<cons sem="G_NUMBER">1 microM</cons>), an <cons sem="G_MECHANISM">inhibitor</cons> of cytochrome P450 (P450) <cons lex="3a4" sem="G_CYP">3A4</cons>, with HLMs led to a <cons sem="G_NUMBER">75%</cons> <cons sem="G_CHANGE">decrease</cons> in DPAB-SG <cons sem="G_MECHANISM">formation</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(sulfaphenazole, DPAB-SG,DDI)(quinidine, DPAB-SG,DDI)">
<sentence>However, in contrast, coincubation with the P450 <cons lex="2c9" sem="G_CYP">2C9</cons> <cons sem="G_MECHANISM">inhibitor</cons> sulfaphenazole (<cons sem="G_NUMBER">10 microM</cons>) or the P450 <cons lex="2d6" sem="G_CYP">2D6</cons> <cons sem="G_MECHANISM">inhibitor</cons> <cons lex="quinidine" sem="G_DRUG">quinidine</cons> (<cons sem="G_NUMBER">40 microM</cons>) led to a <cons sem="G_NUMBER">1.9</cons>- and <cons sem="G_NUMBER">1.6-fold</cons> <cons lex="increase" sem="G_CHANGE">increase</cons> in DPAB-SG production, respectively.</sentence>
</annotation>
<sentence>From these data, we propose that P450 <cons lex="3a4" sem="G_CYP">3A4</cons> mediates the oxidative decarboxylation of <cons lex="diclofenac" sem="G_DRUG">diclofenac</cons>, resulting in the formation of a transient benzylic carbon-centered free radical intermediate that partitions between elimination (o-imine methide production) and recombination (alcohol formation) pathways.</sentence>
<sentence>The benzyl alcohol intermediate, which was <cons sem="G_NEGATIVEEFFECT">not</cons> analyzed for in the present studies, if <cons sem="G_MECHANISM">formed</cons> could undergo dehydration to provide a reactive o-imine methide species.</sentence>
<sentence>The o-imine methide intermediate then is proposed to react covalently with GSH, forming DPAB-SG.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:18520073</bibliomisc>
</articleinfo>
<title>
<sentence>Stereoselective <cons lex="oxidation" sem="G_MECHANISM">oxidation</cons> and glucuronidation of <cons lex="carvedilol" sem="G_DRUG">carvedilol</cons> in human liver and intestinal microsomes.</sentence>
</title>
<abstract>
<sentence>The aim of the present study was to investigate the mechanism for the stereoselective presystemic <cons sem="G_IVITPARA">clearance</cons> of <cons lex="carvedilol" sem="G_DRUG">carvedilol</cons>.</sentence>
<sentence>We examined the <cons lex="oxidation" sem="G_MECHANISM">oxidation</cons> and glucuronidation of <cons lex="carvedilol" sem="G_DRUG">carvedilol</cons> in human liver microsomes (HLM) and human intestinal microsomes (HIM).</sentence>
<sentence>The <cons lex="oxidation" sem="G_MECHANISM">oxidation</cons> of <cons lex="carvedilol" sem="G_DRUG">carvedilol</cons> in HLM and HIM was evaluated in the presence of NADPH, whereas glucuronidation was evaluated in the presence of UDP-glucuronic acid.</sentence>
<sentence><cons lex="oxidation" sem="G_MECHANISM">Oxidation</cons> of S-<cons lex="carvedilol" sem="G_DRUG">carvedilol</cons> in HLM and HIM was <cons sem="G_CHANGE">greater</cons> than that of R-<cons lex="carvedilol" sem="G_DRUG">carvedilol</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(quinidine, R-carvedilol oxidation,DDI)(quinidine, S-carvedilol oxidation,DDI)(furafylline, S-carvedilol oxidation,DDI)">
<sentence>In addition, the <cons lex="oxidation" sem="G_MECHANISM">oxidation</cons> of R-<cons lex="carvedilol" sem="G_DRUG">carvedilol</cons> in HLM was <cons sem="G_MECHANISM">inhibited</cons> by <cons lex="quinidine" sem="G_DRUG">quinidine</cons>, whereas that of S-<cons lex="carvedilol" sem="G_DRUG">carvedilol</cons> was <cons sem="G_MECHANISM">inhibited</cons> by both <cons lex="quinidine" sem="G_DRUG">quinidine</cons> and <cons lex="furafylline" sem="G_DRUG">furafylline</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(ketoconazole, R- and S-carvedilol oxidation,DDI)">
<sentence>On the other hand, R- and S-<cons lex="carvedilol" sem="G_DRUG">carvedilol</cons> <cons lex="oxidation" sem="G_MECHANISM">oxidation</cons> in HIM was <cons sem="G_MECHANISM">inhibited</cons> by <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>.</sentence>
</annotation>
<sentence>Glucuronidation of S-<cons lex="carvedilol" sem="G_DRUG">carvedilol</cons> in HLM and HIM was also higher than that of R-<cons lex="carvedilol" sem="G_DRUG">carvedilol</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(carvedilol , 2D6 ,DEI)(carvedilol , CYP1A2 ,DEI)">
<sentence>These results suggested that cytochrome P450 (CYP) <cons lex="2d6" sem="G_CYP">2D6</cons> and <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> are involved in the stereoselective <cons lex="oxidation" sem="G_MECHANISM">oxidation</cons> of <cons lex="carvedilol" sem="G_DRUG">carvedilol</cons> in the liver, that <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> is involved in intestinal <cons lex="oxidation" sem="G_MECHANISM">oxidation</cons>, and that glucuronidation in the liver and intestine is at least partly responsible for stereoselective presystemic <cons sem="G_IVITPARA">clearance</cons>.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:18445989</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> is primarily responsible for the <cons sem="G_MECHANISM">metabolism</cons> of <cons sem="G_DRUG">clomiphene</cons>.</sentence>
</title>
<abstract>
<sentence><cons sem="G_DRUG">Clomiphene</cons> is a first line treatment for anovulation, a common cause of infertility.</sentence>
<sentence>Response to <cons sem="G_DRUG">clomiphene</cons> is variable and unpredictable.</sentence>
<sentence><cons lex="tamoxifen" sem="G_DRUG">Tamoxifen</cons> is structurally related to <cons sem="G_DRUG">clomiphene</cons>, and also shows considerable variation in response.</sentence>
<sentence><cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> are major contributors to the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="tamoxifen" sem="G_DRUG">tamoxifen</cons>.</sentence>
<sentence>The aim of the present work was to define the role of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> in the in vitro <cons sem="G_MECHANISM">metabolism</cons> of enclomiphene, regarded by some as the more active isomer of clomiphene.</sentence>
<sentence><cons sem="G_DRUG">Enclomiphene</cons> (<cons sem="G_NUMBER">25 microM</cons>) was incubated with human liver microsomes (from 4 extensive (EM) and 1 poor metaboliser with respect to <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>) and with microsomes from lymphoblastoid cells expressing <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>.</sentence>
<sentence>Microsomes from all the EM livers and recombinant <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> <cons sem="G_MECHANISM">metabolised</cons> enclomiphene (the disappearance of drug ranged from <cons sem="G_NUMBER">(40-60%)</cons>.</sentence>
<sentence><cons sem="G_NEGATIVEEFFECT">No</cons> <cons sem="G_MECHANISM">metabolism</cons> was detected in microsomes from the PM liver.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Quinidine, enclomiphene,DDI)">
<sentence><cons lex="quinidine" sem="G_DRUG">Quinidine</cons> (<cons sem="G_NUMBER">1 microM</cons>) completely <cons sem="G_MECHANISM">inhibited</cons> the <cons sem="G_MECHANISM">metabolism</cons> of enclomiphene by all the EM livers and by recombinant <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> (<cons sem="G_NUMBER">p&lt;0.001</cons>, one way ANOVA).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Ketoconazole, enclomiphene,NDDI)">
<sentence><cons lex="ketoconazole" sem="G_DRUG">Ketoconazole</cons> (<cons sem="G_NUMBER">2 microM</cons>) had <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem="G_CHANGE">significant</cons> effect on enclomiphene <cons sem="G_MECHANISM">metabolism</cons>in 3 out of the 4 EM livers.</sentence>
</annotation>
<sentence>The extent of enclomiphene <cons sem="G_MECHANISM">metabolism</cons> was <cons lex="correlated" sem="G_MECHANISM">correlated</cons> with the amount of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> present (<cons sem="G_NUMBER">p&lt;0.001</cons>, Pearson <cons lex="correlation" sem="G_MECHANISM">correlation</cons> test).</sentence>
<sentence>The findings indicate that <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> is primarily responsible for the <cons sem="G_MECHANISM">metabolism</cons> of enclomiphene.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:18348473</bibliomisc>
</articleinfo>
<title>
<sentence>Identification of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> as the primary cytochrome P450 responsible for the <cons sem="G_MECHANISM">metabolism</cons> of <cons sem="G_DRUG">tandospirone</cons> by human liver microsomes.</sentence>
</title>
<abstract>
<sentence>The present study was carried out to characterize the human P450 isoforms involved in the <cons sem="G_MECHANISM">metabolism</cons> of tandospirone, an anxiolytic agent known for its superior efficacy and safety.</sentence>
<sentence>Among 11 yeast-expressed recombinant P450 isoforms tested, <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> exhibited the highest <cons sem="G_DRUG">tandospirone</cons> metabolic activity.</sentence>
<sentence>Although there was <cons sem="G_NEGATIVEEFFECT">no</cons> qualitative difference between the two isoforms, a quantitative difference in metabolite profiling was found i.e., M4 (hydroxylation of the pyrimidine ring) was the major metabolite <cons sem="G_MECHANISM">formed</cons> with <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> while M2 (hydroxylation of the norbornan ring) and 1-PP (oxidative cleavage of the butyl chain) predominated with <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
<sentence>The metabolite profile on incubation with <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> was qualitatively and quantitatively similar to that obtained with human liver microsomes.</sentence>
<sentence>In vitro <cons sem="G_IVITPARA">intrinsic clearance (CLint)</cons> values derived from kinetic analysis using both P450 isoforms were similar (<cons sem="G_NUMBER">2.2</cons> and <cons sem="G_NUMBER">1.6 ml/min/nmol</cons> P450), but the hepatic content of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> was found to be more abundant than that of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(ketoconazole, tandospirone,DDI)(quinidine, tandospirone,NDDI)">
<sentence>The in vitro <cons sem="G_MECHANISM">metabolism</cons> of <cons sem="G_DRUG">tandospirone</cons> by human liver microsomes was <cons sem="G_CHANGE">markedly</cons> <cons sem="G_MECHANISM">inhibited</cons> by <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> (a <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitor</cons>) but <cons sem="G_NEGATIVEEFFECT">not</cons> by <cons lex="quinidine" sem="G_DRUG">quinidine</cons> (a <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> <cons sem="G_MECHANISM">inhibitor</cons>).</sentence>
</annotation>
<sentence>These results indicate that the <cons sem="G_MECHANISM">metabolism</cons> of <cons sem="G_DRUG">tandospirone</cons> by human liver microsomes primarily involves <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, and to a lesser extent <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:18332045</bibliomisc>
</articleinfo>
<title>
<sentence>Phthalate <cons lex="induction" sem="G_MECHANISM">induction</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> is dependent on glucocorticoid regulation of PXR expression.</sentence>
</title>
<abstract>
<sentence>Cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4</cons> (<cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>) is responsible for oxidative <cons sem="G_MECHANISM">metabolism</cons> of more than 60% of all pharmaceuticals.</sentence>
<sentence><cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> is inducible by xenobiotics that activate pregnane X receptor (PXR), and enhanced <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activity has been implicated in adverse drug interactions.</sentence>
<sentence>Recent evidence suggest that the widely used plasticizer, di-2-ethylhexyl phthalate (DEHP), and its primary metabolite mono-2-ethylhexyl phthalate (MEHP) <cons sem="G_CHANGE">may</cons> act as agonists for PXR.</sentence>
<sentence>Hospital patients are uniquely exposed to high levels of DEHP as well as being administered glucocorticoids.</sentence>
<sentence>Glucocorticoids positively regulate PXR expression in a glucocorticoid receptor (GR)-mediated mechanism.</sentence>
<annotation sem="INVITROCDDIS" ddi="(phthalates, CYP3A4,DEI)(glucocorticoids, CYP3A4,DEI)">
<sentence>We suggest that the magnitude of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons lex="induction" sem="G_MECHANISM">induction</cons> by phthalates is dependent on the expression of PXR and <cons sem="G_CHANGE">may</cons> be <cons sem="G_CHANGE">significantly</cons> higher in the presence of glucocorticoids.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(di-2-ethylhexyl phthalate, CYP3A4,DEI)(mono-2-ethylhexyl phthalate, CYP3A4,DEI)">
<sentence>DEHP and MEHP <cons lex="induced" sem="G_MECHANISM">induced</cons> PXR-mediated transcription of the <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> promoter in a dose-dependent fashion.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(phthalates, CYP3A4,DEI)(dexamethasone, CYP3A4,DEI)">
<sentence>Coexposure to phthalates and <cons lex="dexamethasone" sem="G_DRUG">dexamethasone</cons> (Dex) resulted in enhanced <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> promoter activity; furthermore, this <cons lex="induction" sem="G_MECHANISM">induction</cons> was abrogated by both the GR antagonist <cons sem="G_DRUG">RU486</cons> and GR small interfering ribonucleic acid.</sentence>
</annotation>
<sentence>Dex induced PXR protein expression in human hepatocytes and a liver-derived rat cell line.</sentence>
<annotation sem="INVITROCDDIS" ddi="(dexamethasone, CYP3A4,DEI)(di-2-ethylhexyl phthalate, CYP3A4,DEI)">
<sentence><cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> protein was highly <cons lex="induced" sem="G_MECHANISM">induced</cons> by <cons lex="dexamethasone" sem="G_DRUG">Dex</cons> and DEHP coadministration in human hepatocyte cultures.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(6beta-hydroxytestosterone  dexamethasone, CYP3A4,DEI)(6beta-hydroxytestosterone  phthalate, CYP3A4,DEI)">
<sentence>Finally, enhanced 6beta-hydroxytestosterone formation in  Dex and phthalate cotreated human hepatocytes confirmed <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> enzyme <cons lex="induction" sem="G_MECHANISM">induction</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(glucocorticoids, CYP3A4,DEI)(phthalates, CYP3A4,DEI)">
<sentence>Concomitant exposure to glucocorticoids and phthalates resulting in enhanced metabolic activity of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_CHANGE">may</cons> play a role in altered efficacy of pharmaceutical agents.</sentence>
</annotation>
<sentence>Understanding the role of glucocorticoid regulation of PXR as a key determinant in the magnitude of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons lex="induction" sem="G_MECHANISM">induction</cons> by xenobiotics <cons sem="G_CHANGE">may</cons> provide insight into adverse drug effects in a sensitive population.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:18322939</bibliomisc>
</articleinfo>
<title>
<sentence>Metabolic interactions of agrochemicals in humans.</sentence>
</title>
<abstract>
<sentence>Agrochemicals and other xenobiotics are <cons sem="G_MECHANISM">metabolized</cons> by xenobiotic-metabolizing enzymes (XMEs) to products that <cons sem="G_CHANGE">may</cons> be more or less toxic than the parent chemical.</sentence>
<sentence>In this regard, phase-I XMEs such as cytochrome P450s (CYPs) are of primary importance.</sentence>
<sentence>Interactions at the level of <cons sem="G_MECHANISM">metabolism</cons> <cons sem="G_CHANGE">may</cons> take place via either <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> or <cons lex="induction" sem="G_MECHANISM">induction</cons> of XMEs.</sentence>
<sentence>Such interactions have often been investigated, in vitro, in experimental animals, using subcellular fractions such as liver microsomes, but seldom in humans or at the level of individual XME isoforms.</sentence>
<sentence>The authors have been investigating the <cons sem="G_MECHANISM">metabolism</cons> of a number of agrochemicals by human liver microsomes and recombinant CYP isoforms and have recently embarked on studies of the <cons lex="induction" sem="G_MECHANISM">induction</cons> of XMEs in human hepatocytes.</sentence>
<sentence>The insecticides <cons sem="G_DRUG">chlorpyrifos</cons>, <cons sem="G_DRUG">carbaryl</cons>, <cons sem="G_DRUG">carbofuran</cons> and <cons sem="G_DRUG">fipronil</cons>, as well as the repellant DEET, are all extensively <cons lex="metabolized" sem="G_MECHANISM">metabolized</cons> by human liver microsomes and, although a number of CYP isoforms <cons sem="G_CHANGE">may</cons> be involved, <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> are usually the most important.</sentence>
<sentence><cons lex="permethrin" sem="G_DRUG">Permethrin</cons> is hydrolyzed by esterase(s) present in both human liver microsomes and cytosol.</sentence>
<sentence>A number of metabolic interactions have been observed.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Chlorpyrifos, testosterone,DDI)(Chlorpyrifos, estradiol,DDI)(Chlorpyrifos, carbaryl,DDI)">
<sentence><cons lex="chlorpyrifos" sem="G_DRUG">Chlorpyrifos</cons> and other phosphorothioates are potent <cons sem="G_MECHANISM">inhibitors</cons> of the CYP-dependent <cons sem="G_MECHANISM">metabolism</cons> of both endogenous substrates, such as <cons lex="testosterone" sem="G_DRUG">testosterone</cons> and <cons lex="estradiol" sem="G_DRUG">estradiol</cons>, and exogenous substrates, such as <cons sem="G_DRUG">carbaryl</cons>, presumably as a result of the interaction of highly reactive sulfur, released during the oxidative desulfuration reaction, with the heme iron of CYP.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(chlorpyrifos oxon, permethrin,DDI)(carbaryl, permethrin,DDI)">
<sentence>The hydrolysis of <cons lex="permethrin" sem="G_DRUG">permethrin</cons> in human liver can be <cons sem="G_MECHANISM">inhibited</cons> by <cons sem="G_DRUG">chlorpyrifos</cons> oxon and by <cons sem="G_DRUG">carbaryl</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Fipronil, testosterone,DDI)">
<sentence><cons sem="G_DRUG">Fipronil</cons> can <cons sem="G_MECHANISM">inhibit</cons> <cons lex="testosterone" sem="G_DRUG">testosterone</cons> <cons sem="G_MECHANISM">metabolism</cons> by <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and is an effective <cons sem="G_MECHANISM">inducer</cons> of CYP isoforms in human hepatocytes.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:18191104</bibliomisc>
</articleinfo>
<title>
<sentence>Flavonoids <cons sem="G_DRUG">diosmetin</cons> and <cons sem="G_DRUG">luteolin</cons> <cons sem="G_MECHANISM">inhibit</cons> <cons lex="midazolam" sem="G_DRUG">midazolam</cons> <cons sem="G_MECHANISM">metabolism</cons> by human liver microsomes and recombinant CYP <cons lex="3a4" sem="G_CYP">3A4</cons> and <cons lex="cyp3a5" sem="G_CYP">CYP3A5</cons> enzymes.</sentence>
</title>
<abstract>
<sentence>We evaluated the effects of <cons sem="G_CHANGE">increasing</cons> concentrations of the flavonoids <cons sem="G_DRUG">salvigenin</cons>, <cons sem="G_DRUG">diosmetin</cons> and <cons sem="G_DRUG">luteolin</cons> on the in vitro <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="midazolam" sem="G_DRUG">midazolam</cons> (MDZ), a probe substrate for cytochrome P450 (CYP) <cons lex="3a" sem="G_CYP">3A</cons> enzymes, which is converted into 1'-hydroxy-<cons lex="midazolam" sem="G_DRUG">midazolam</cons> (1'-OH-MDZ) and 4-hydroxy-<cons lex="midazolam" sem="G_DRUG">midazolam</cons> (4-OH-MDZ) by human liver microsomes.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Salvigenin, midazolam,ADDI)(diosmetin, 1'-OH-MDZ,ADDI)(diosmetin, 4'-OH-MDZ,ADDI)(luteolin, 1'-OH-MDZ,ADDI)(luteolin, 4'-OH-MDZ,ADDI)">
<sentence><cons sem="G_DRUG">Salvigenin</cons> had only a <cons sem="G_CHANGE">modest</cons> effect on <cons sem="G_DRUG">MDZ</cons> <cons sem="G_MECHANISM">metabolism</cons>, whereas <cons sem="G_DRUG">diosmetin</cons> and <cons sem="G_DRUG">luteolin</cons> <cons sem="G_MECHANISM">inhibited</cons> in a concentration-dependent manner the formation of both 1'-OH-MDZ and 4-OH-MDZ, with apparent <cons sem="G_IVITPARA">K(i)</cons> values in the <cons sem="G_NUMBER">30-50mumol</cons> range.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(diosmetin, 1'-OH-MDZ,DDI)(luteolin, 1'-OH-MDZ,DDI)(diosmetin, 4'-OH-MDZ,DDI)(luteolin, 4'-OH-MDZ,DDI)">
<sentence>Both <cons sem="G_DRUG">diosmetin</cons> and <cons sem="G_DRUG">luteolin</cons> <cons sem="G_CHANGE">decreased</cons> 1'-OH-MDZ formation by human recombinant <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, but <cons sem="G_NEGATIVEEFFECT">not</cons> <cons lex="cyp3a5" sem="G_CYP">CYP3A5</cons>, whereas they <cons sem="G_CHANGE">decreased</cons> 4-OH-MDZ formation by both recombinant enzymes.</sentence>
</annotation>
<sentence>To assess whether any relationship exists between the physico-chemical characteristics of flavones and their effects on <cons lex="midazolam" sem="G_DRUG">MDZ</cons> <cons sem="G_MECHANISM">metabolism</cons>, we tested the effects of three other flavones (flavone, tangeretin, chrysin) on <cons lex="midazolam" sem="G_DRUG">MDZ</cons> <cons sem="G_MECHANISM">metabolism</cons> by human liver microsomes.</sentence>
<annotation sem="INVITROCDDIS" ddi="(luteolin, MDZ biotransformation,DDI)(luteolin, flavones lacking hydroxyl,DDI)(diosmetin, MDZ biotransformation,DDI)(diosmetin, flavones lacking hydroxyl,DDI)">
<sentence>Whereas flavones possessing more than two hydroxyl groups (<cons sem="G_DRUG">luteolin</cons>, <cons sem="G_DRUG">diosmetin</cons>) <cons sem="G_MECHANISM">inhibited</cons> <cons sem="G_DRUG">MDZ</cons> biotransformation, flavones lacking hydroxyl groups in their A and B rings (<cons sem="G_DRUG">flavone</cons>, <cons sem="G_DRUG">tangeretin</cons>) <cons lex="stimulated" sem="G_MECHANISM">stimulated</cons> <cons sem="G_DRUG">MDZ</cons> <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
</annotation>
<sentence>We also found close relationships between the maximum <cons sem="G_MECHANISM">stimulatory</cons> or <cons sem="G_MECHANISM">inhibitory</cons> effects of flavones on 1'-OH-MDZ and 4-OH-MDZ formation rates and their log of octanol/water partition coefficients (logP) or their total number of hydroxyl groups.</sentence>
<annotation sem="INVITROCDDIS" ddi="(luteolin, CYP3A,DEI)(diosmetin, CYP3A,DEI)">
<sentence>The results of the study <cons sem="G_CHANGE">may</cons> be of clinical relevance since they suggest that luteolin and diosmetin <cons sem="G_CHANGE">may</cons> cause pharmacokinetic interactions with co-administered drugs <cons sem="G_MECHANISM">metabolized</cons> via <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:18022748</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of <cons sem="G_DRUG">Pyrethrins</cons> on cytochrome P450 forms in cultured rat and human hepatocytes.</sentence>
</title>
<abstract>
<sentence>High doses of <cons sem="G_DRUG">Pyrethrins</cons> produce liver and thyroid gland tumours in rats by modes of action involving the <cons lex="induction" sem="G_MECHANISM">induction</cons> of hepatic xenobiotic metabolising enzymes.</sentence>
<sentence>The aim of this study was to compare the effects of Pyrethrins with those of the rat liver and thyroid tumour promoter sodium <cons lex="phenobarbital" sem="G_DRUG">Phenobarbital</cons> on some cytochrome P450 (CYP) forms in cultured rat and human hepatocytes.</sentence>
<sentence>The treatment of female Sprague-Dawley rat and human (both male and female) hepatocytes for 72 h with <cons sem="G_NUMBER">0-1000 microM</cons> <cons sem="G_DRUG">Pyrethrins</cons> and <cons sem="G_NUMBER">0-1000 microM</cons> <cons lex="phenobarbital" sem="G_DRUG">Phenobarbital</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> result in any <cons sem="G_CHANGE">marked</cons> cytotoxicity.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Pyrethrins, 7-benzyloxy-4-trifluoromethylcoumarin O-debenzylase,DDI)(Phenobarbital, 7-benzyloxy-4-trifluoromethylcoumarin O-debenzylase,DDI)(Phenobarbital, CYP2B1,DEI)(Phenobarbital, CYP2B1/2,DEI)">
<sentence>In rat hepatocytes both <cons sem="G_DRUG">Pyrethrins</cons> and <cons lex="phenobarbital" sem="G_DRUG">Phenobarbital</cons> produced an <cons lex="induction" sem="G_MECHANISM">induction</cons> of 7-benzyloxy-4-trifluoromethylcoumarin O-debenzylase activity (a <cons sem="G_CYP">CYP1A/2B</cons> form marker) and <cons sem="G_CYP">CYP2B1</cons> and <cons sem="G_CYP">CYP2B1/2</cons> mRNA levels.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Pyrethrins, testosterone 6beta-hydroxylase,DDI)(Phenobarbital, testosterone 6beta-hydroxylase,DDI)">
<sentence><cons sem="G_DRUG">Pyrethrins</cons> and <cons lex="phenobarbital" sem="G_DRUG">Phenobarbital</cons> also <cons sem="G_MECHANISM">induced</cons> <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>-dependent <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6beta-hydroxylase activity in rat hepatocytes.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Pyrethrins, testosterone 6beta-hydroxylase,DDI)(Phenobarbital, testosterone 6beta-hydroxylase,DDI)(Pyrethrins, CYP3A,DEI)(Phenobarbital, CYP2B,DEI)">
<sentence>In human hepatocytes <cons sem="G_DRUG">Pyrethrins</cons> and <cons lex="phenobarbital" sem="G_DRUG">Phenobarbital</cons> <cons sem="G_MECHANISM">induced</cons> both <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6beta-hydroxylase activity and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> mRNA levels and also <cons sem="G_CHANGE">increased</cons> <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> mRNA levels.</sentence>
</annotation>
<sentence>The effects of <cons sem="G_DRUG">Pyrethrins</cons> and <cons lex="phenobarbital" sem="G_DRUG">Phenobarbital</cons> were concentration-dependent and exhibited a threshold.</sentence>
<sentence>These results demonstrate that the effects of <cons sem="G_DRUG">Pyrethrins</cons> on CYP forms in cultured rat and human hepatocytes are qualitatively similar to those of <cons lex="phenobarbital" sem="G_DRUG">Phenobarbital</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Pyrethrins, CYP2B,DEI)(Pyrethrins, CYP3A,DEI)">
<sentence><cons sem="G_DRUG">Pyrethrins</cons> <cons sem="G_MECHANISM">induce</cons> <cons sem="G_CYP">CYP2B</cons> and <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> forms in cultured rat hepatocytes and can <cons sem="G_MECHANISM">induce</cons> <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> and <cons sem="G_CYP">CYP2B</cons> forms in human hepatocytes.</sentence>
</annotation>
<sentence>While CYP form <cons lex="induction" sem="G_MECHANISM">induction</cons> by <cons sem="G_DRUG">Pyrethrins</cons>, <cons lex="phenobarbital" sem="G_DRUG">Phenobarbital</cons> and related compounds can be associated with liver and thyroid gland tumour formation in rodents, epidemiological data for <cons lex="phenobarbital" sem="G_DRUG">Phenobarbital</cons> suggests that such effects do <cons sem="G_NEGATIVEEFFECT">not</cons> occur in humans.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:17978169</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="dexamethasone" sem="G_DRUG">Dexamethasone</cons>-mediated up-regulation of human <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons> involves the glucocorticoid receptor and <cons sem="G_CHANGE">increased</cons> binding of hepatic nuclear factor 4 alpha to the proximal promoter.</sentence>
</title>
<abstract>
<sentence>Human cytochrome P450 <cons lex="2a6" sem="G_CYP">2A6</cons> (<cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons>) metabolizes various clinically relevant compounds, including <cons lex="nicotine" sem="G_DRUG">nicotine</cons>- and tobacco-specific procarcinogens; however, transcriptional regulation of this gene is poorly understood.</sentence>
<sentence>We investigated the role of the glucocorticoid receptor (GR) in transcriptional regulation of <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Dexamethasone, CYP2A6,DEI)">
<sentence><cons lex="dexamethasone" sem="G_DRUG">Dexamethasone (DEX)</cons> <cons sem="G_CHANGE">increased</cons> <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons> mRNA and protein levels in human hepatocytes in primary culture.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Dexamethasone, CYP2A6,DEI)">
<sentence>This effect was attenuated by the GR receptor antagonist <cons lex="mifepristone" sem="G_DRUG">mifepristone</cons> (<cons sem="G_DRUG">RU486</cons>; 17beta-hydroxy-11beta- [4-dimethylamino phenyl]-17alpha- [1-propynyl]estra-4,9-dien-3-one), suggesting that <cons lex="induction" sem="G_MECHANISM">induction</cons> of <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons> by <cons sem="G_DRUG">DEX</cons> was mediated by the GR.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Dexamethasone, luciferase,DDI)">
<sentence>In gene reporter assays, <cons sem="G_DRUG">DEX</cons> caused dose-dependent <cons sem="G_CHANGE">increases</cons> in luciferase activity that was also prevented by <cons sem="G_DRUG">RU486</cons> and progressive truncations of the <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons> promoter delineated <cons sem="G_DRUG">DEX</cons>-responsiveness to a -95 to +12 region containing an hepatic nuclear factor 4 (HNF4) alpha response element (HNF4-RE).</sentence>
</annotation>
<sentence>Mutation of the HNF4-RE abrogated HNF4alpha- and DEX-mediated transactivation of <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(HNF4alpha, CYP2A6,DEI)">
<sentence>In addition, overexpression of HNF4alpha <cons sem="G_CHANGE"></cons>increased <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons> transcriptional activity by <cons sem="G_NUMBER">3-fold</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Dexamethasone, HNF4alpha,DDI)">
<sentence> <cons sem="G_DRUG">DEX</cons> <cons sem="G_CHANGE">increased</cons> HNF4alpha mRNA levels by <cons sem="G_NUMBER">4-fold</cons>; however, the amount of HNF4alpha nuclear protein was unaltered.</sentence>
</annotation>
<sentence>Electrophoretic mobility shift, chromatin immunoprecipitation (ChIP), and streptavidin DNA binding assays revealed that <cons sem="G_DRUG">DEX</cons> <cons sem="G_CHANGE">increased</cons> binding of HNF4alpha to the HNF4-RE and that an interaction of GR and HNF4alpha occurred at this site.</sentence>
<sentence>Moreover, ChIP assays indicated that histone H4 acetylation of the <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons> proximal promoter chromatin was <cons sem="G_CHANGE">increased</cons> by DEX that <cons sem="G_CHANGE">may</cons> allow for increased binding of HNF4alpha to the HNF4-RE in human hepatocytes.</sentence>
<sentence>These findings indicate that <cons sem="G_CHANGE">increased</cons> expression of <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons> by <cons sem="G_DRUG">DEX</cons> is mediated by the GR via a nonconventional transcriptional mechanism involving interaction of HNF4alpha with an HNF4-RE rather than a glucocorticoid response element.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:17950511</bibliomisc>
</articleinfo>
<title>
<sentence>The <cons sem="G_MECHANISM">inhibitory</cons> effect of <cons sem="G_DRUG">tannic acid</cons> on cytochrome P450 enzymes and NADPH-CYP reductase in rat and human liver microsomes.</sentence>
</title>
<abstract>
<sentence><cons sem="G_DRUG">Tannic acid</cons> has been shown to <cons sem="G_CHANGE">decrease</cons> mutagenicity and/or carcinogenicity of several amine derivatives and polycyclic aromatic hydrocarbons in rodents.</sentence>
<sentence>The purpose of this study was to evaluate the effect of <cons sem="G_DRUG">tannic acid</cons> on cytochrome P450 (CYP)-<cons lex="catalyzed" sem="G_MECHANISM">catalyzed</cons> oxidations using rat liver microsomes (RLM) and human liver microsomes (HLM) as the enzyme sources.</sentence>
<annotation sem="INVITROCDDIS" ddi="(tannic acid, 7-methoxyresorufin O-demethylation,DDI)(tannic acid, 7-ethoxyresorufin O-deethylation,DDI)(tannic acid, tolbutamide hydroxylation,DDI)(tannic acid, p-nitrophenol hydroxylation,DDI)(tannic acid, testosterone 6beta-hydroxylation,DDI)">
<sentence>In RLM, <cons sem="G_DRUG">tannic acid</cons> showed a non-selective <cons sem="G_MECHANISM">inhibitory</cons> effect on 7-methoxyresorufin O-demethylation (<cons sem="G_DRUG">MROD</cons>), 7-ethoxyresorufin O-deethylation (EROD), <cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons> hydroxylation, p-nitrophenol hydroxylation and <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6beta-hydroxylation activities with <cons sem="G_IVITPARA">IC(50)</cons>values ranged from <cons sem="G_NUMBER">14.9</cons> to <cons sem="G_NUMBER">27.4 microM</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(tannic acid, 7-ethoxyresorufin O-deethylation,DDI)(tannic acid, 7-methoxyresorufin O-demethylation,DDI)(tannic acid, phenacetin O-deethylation,DDI)(tannic acid, diclofenac 4-hydroxylation,DDI)(tannic acid, dextromethorphan O-demethylation,DDI)(tannic acid, chlorzoxazone 6-hydroxylation,DDI)(tannic acid, testosterone 6beta-hydroxylation,DDI)">
<sentence>In HLM, <cons sem="G_DRUG">tannic acid</cons> <cons sem="G_MECHANISM">inhibited</cons> <cons sem="G_DRUG">EROD</cons>, <cons sem="G_DRUG">MROD</cons> and <cons lex="phenacetin" sem="G_DRUG">phenacetin</cons> O-deethylation activities with <cons sem="G_IVITPARA">IC(50)</cons> values ranged from <cons sem="G_NUMBER">5.1</cons> to <cons sem="G_NUMBER">7.5 microM</cons>, and <cons lex="diclofenac" sem="G_DRUG">diclofenac</cons> 4-hydroxylation, <cons lex="dextromethorphan" sem="G_DRUG">dextromethorphan</cons> O-demethylation, <cons lex="chlorzoxazone" sem="G_DRUG">chlorzoxazone</cons> 6-hydroxylation and <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6beta-hydroxylation with <cons sem="G_IVITPARA">IC(50)</cons> values ranged from <cons sem="G_NUMBER">20</cons> to <cons sem="G_NUMBER">77 microM</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(tannic acid, CYP1A2,DEI)">
<sentence>In baculovirus-insect cell-expressed human CYP <cons lex="1a1" sem="G_CYP">1A1</cons> and <cons lex="1a2" sem="G_CYP">1A2</cons>, the <cons sem="G_IVITPARA">IC(50)</cons> values of <cons sem="G_DRUG">tannic acid</cons> for CYP <cons lex="1a1" sem="G_CYP">1A1</cons>- and <cons lex="1a2" sem="G_CYP">1A2</cons>-<cons lex="catalyzed" sem="G_MECHANISM">catalyzed</cons> <cons sem="G_DRUG">EROD</cons> activities were <cons sem="G_NUMBER">23.1</cons> and <cons sem="G_NUMBER">2.3 microM</cons>, respectively, indicating that <cons sem="G_DRUG">tannic acid</cons> preferably <cons sem="G_MECHANISM">inhibited</cons> the activity of <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(tannic acid, CYP1A2,DEI)">
<sentence> <cons sem="G_DRUG">Tannic</cons> acid  <cons sem="G_MECHANISM">inhibited</cons> human <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> non-competitively with a <cons sem="G_IVITPARA">Ki</cons> value of <cons sem="G_NUMBER">4.8 microM</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(tannic acid, NADPH-CYP reductase,DEI)">
<sentence>Tannic acid was also found to <cons sem="G_MECHANISM">inhibit</cons> NADPH-CYP reductase in RLM and HLM with <cons sem="G_IVITPARA">IC(50)</cons> values of <cons sem="G_NUMBER">11.8 and 17.4 microM</cons>, respectively.</sentence>
</annotation>
<sentence>These results suggested that the <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of CYP enzyme activities by <cons sem="G_DRUG">tannic acid</cons> <cons sem="G_CHANGE">may</cons> be partially attributed to its <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of NADPH-CYP reductase activity.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:17827781</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem="G_MECHANISM">Inhibitory</cons> effects of angiotensin receptor blockers on <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> activity in human liver microsomes.</sentence>
</title>
<abstract>
<sentence>We investigated the <cons sem="G_MECHANISM">inhibitory</cons> effects of the angiotensin receptor blockers (ARBs), <cons lex="candesartan" sem="G_DRUG">candesartan</cons>, <cons lex="irbesartan" sem="G_DRUG">irbesartan</cons>, <cons lex="losartan" sem="G_DRUG">losartan</cons>, <cons lex="losartan" sem="G_DRUG">losartan</cons> active metabolite (EXP-3174), <cons lex="olmesartan" sem="G_DRUG">olmesartan</cons>, <cons lex="telmisartan" sem="G_DRUG">telmisartan</cons> and <cons lex="valsartan" sem="G_DRUG">valsartan</cons> (<cons sem="G_NUMBER">0.3-300 microM</cons>), on the <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> activity in human liver microsomes using (S)-(-)-<cons lex="warfarin" sem="G_DRUG">warfarin</cons> as a typical <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> substrate.</sentence>
<annotation sem="INVITROCDDIS" ddi="(candesartan, 7-hydroxylation (S)-(-)-warfarin,DDI)(irbesartan, 7-hydroxylation (S)-(-)-warfarin,DDI)(losartan, 7-hydroxylation (S)-(-)-warfarin,DDI)(telmisartan, 7-hydroxylation (S)-(-)-warfarin,DDI)">
<sentence><cons sem="G_NEGATIVEEFFECT">Except</cons> for <cons lex="olmesartan" sem="G_DRUG">olmesartan</cons> and <cons lex="valsartan" sem="G_DRUG">valsartan</cons>, these ARBs <cons sem="G_MECHANISM">inhibited</cons> the activity of 7-hydroxylation of (S)-(-)-<cons lex="warfarin" sem="G_DRUG">warfarin</cons> with <cons sem="G_IVITPARA">IC50</cons> values of <cons sem="G_NUMBER">39.5-116 microM</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(olmesartan, CYP2C9,DEI)">
<sentence>Of six synthetic derivatives of <cons lex="olmesartan" sem="G_DRUG">olmesartan</cons>, five compounds which possess either alkyl groups or a chloro group at the same position as that of the hydroxyisopropyl group in <cons lex="olmesartan" sem="G_DRUG">olmesartan</cons> <cons sem="G_MECHANISM">inhibited</cons> <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> activity with <cons sem="G_IVITPARA">IC50</cons> values of <cons sem="G_NUMBER">21.7-161 microM</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(olmesartan, CYP2C9,NDDI)(RNH-6272, CYP2C9,NDDI)">
<sentence><cons lex="olmesartan" sem="G_DRUG">Olmesartan</cons> and the <cons lex="olmesartan" sem="G_DRUG">olmesartan</cons> analogue, RNH-6272, both having a hydroxyisopropyl group, showed <cons sem="G_NEGATIVEEFFECT">no</cons> <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons>, indicating that the hydrophilicity of this group <cons sem="G_CHANGE">greatly</cons> contributes to the lack of <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> by these two compounds.</sentence>
</annotation>
<sentence>A three-dimensional model for docking between EXP-3174 and <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> indicated that the chloro group of EXP-3174 is oriented to a hydrophobic pocket in the <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> active site, indicating that the lipophilicity of the group present in ARBs at the position corresponding to that of the hydroxyisopropyl group in <cons lex="olmesartan" sem="G_DRUG">olmesartan</cons> is important in <cons sem="G_MECHANISM">inhibiting</cons> <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> activity.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:17827338</bibliomisc>
</articleinfo>
<title>
<sentence>Identification of human liver cytochrome P450 enzymes involved in biotransformation of <cons sem="G_DRUG">vicriviroc</cons>, a CCR5 receptor antagonist.</sentence>
</title>
<abstract>
<sentence><cons sem="G_DRUG">Vicriviroc</cons> (SCH 417690), a CCR5 receptor antagonist, is currently under investigation for the treatment of human immunodeficiency virus infection.</sentence>
<sentence>The objective of this study was to identify human liver cytochrome P450 enzyme(s) responsible for the <cons sem="G_MECHANISM">metabolism</cons> of vicriviroc.</sentence>
<sentence>Human liver microsomes <cons sem="G_MECHANISM">metabolism</cons> vicriviroc via N-<cons lex="oxidation" sem="G_MECHANISM">oxidation</cons> (M2/M3), O-demethylation (M15), N,N-dealkylation (M16), N-dealkylation (M41), and <cons lex="oxidation" sem="G_MECHANISM">oxidation</cons> to a carboxylic acid metabolite (M35b/M37a).</sentence>
<annotation sem="INVITROCDDIS" ddi="(CYP3A5, vicriviroc N-oxidation,DEI)(CYP3A5, vicriviroc O-demethylation,DEI)(CYP3A5, vicriviroc N-dealkylation,DEI)(CYP3A4, vicriviroc N-oxidation,DEI)(CYP3A4, vicriviroc O-demethylation,DEI)(CYP3A4, vicriviroc N,N-dealkylation,DEI)(CYP3A4, vicriviroc N-dealkylation,DEI)">
<sentence>Recombinant human <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons lex="catalyzed" sem="G_MECHANISM">catalyzed</cons> the formation of all these metabolites, whereas <cons lex="cyp3a5" sem="G_CYP">CYP3A5</cons> <cons lex="catalyzed" sem="G_MECHANISM">catalyzed</cons> the formation of M2/M3 and M41.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(CYP2C9, vicriviroc O-demethylation,DEI)">
<sentence><cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> only <cons lex="catalyzed" sem="G_MECHANISM">catalyzed</cons> the formation of M15.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(CYP3A4/5, testosterone 6beta-hydroxylation,DEI)">
<sentence>There was a high <cons lex="correlation" sem="G_MECHANISM">correlation</cons> between the rates of formation of M2/M3, M15, and M41, which was determined using 10 human liver microsomal samples and <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6beta-hydroxylation <cons lex="catalyzed" sem="G_MECHANISM">catalyzed</cons> by <cons lex="cyp3a4/5" sem="G_CYP">CYP3A4/5</cons> (<cons sem="G_NUMBER">r &gt; or = 0.91</cons>).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Ketoconazole, vicriviroc N-oxidation,DDI)(Ketoconazole, O-demethylation,DDI)(Ketoconazole, vicriviroc N-dealkylation,DDI)(Ketoconazole, vicriviroc oxidation to a carboxylic acid,DDI)(azamulin, vicriviroc N-oxidation,DDI)(azamulin, O-demethylation,DDI)(azamulin, vicriviroc N-dealkylation,DDI)(azamulin, vicriviroc oxidation to a carboxylic acid,DDI)">
<sentence><cons lex="ketoconazole" sem="G_DRUG">Ketoconazole</cons> and  <cons sem="G_DRUG">azamulin</cons> (<cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>) were potent <cons sem="G_MECHANISM">inhibitors</cons> of the <cons sem="G_MECHANISM">formation</cons> of M2/M3, M15, M41, and M35b/M37a from human liver microsomes.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(A CYP3A4/5-specific monoclonal antibody, vicriviroc N-oxidation,DDI)(A CYP3A4/5-specific monoclonal antibody, O-demethylation,DDI)(A CYP3A4/5-specific monoclonal antibody, vicriviroc N,N-dealkylation,DDI)(A CYP3A4/5-specific monoclonal antibody, vicriviroc N-dealkylation,DDI)(A CYP3A4/5-specific monoclonal antibody, vicriviroc oxidation to a carboxylic acid,DDI)">
<sentence>A <cons lex="cyp3a4/5" sem="G_CYP">CYP3A4/5</cons>-specific monoclonal antibody (<cons sem="G_NUMBER">1 microg/microg</cons> of protein) <cons sem="G_MECHANISM">inhibited</cons> the <cons sem="G_MECHANISM">formation</cons> of all metabolites from human liver microsomes by <cons sem="G_NUMBER">86 to 100%</cons>.</sentence>
</annotation>
<sentence>The results of this study suggest that <cons sem="G_MECHANISM">formation</cons> of the major <cons sem="G_DRUG">vicriviroc</cons> metabolites in human liver microsomes is primarily mediated via <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
<annotation sem="INVITROVDDIS" ddi="(vicriviroc, CYP2C9,NDEI)(vicriviroc, CYP3A5,NDEI)">
<sentence><cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> and <cons lex="cyp3a5" sem="G_CYP">CYP3A5</cons> most likely play a <cons sem="G_NEGATIVEEFFECT"> <cons sem="G_CHANGE">minor</cons></cons> role in the biotransformation of this compound.</sentence>
</annotation>
<sentence>These enzymology data will provide guidance to design clinical studies to address any potential drug-drug interactions.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:17387004</bibliomisc>
</articleinfo>
<title>
<sentence>Kinetics of the time-dependent <cons sem="G_MECHANISM">inactivation</cons> of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> in cryopreserved human hepatocytes by <cons sem="G_DRUG">methylenedioxymethamphetamine (MDMA)</cons>.</sentence>
</title>
<abstract>
<sentence><cons sem="G_DRUG">Methylenedioxymethamphetamine (MDMA)</cons> was investigated in cryopreserved human hepatocytes as a time-dependent <cons sem="G_MECHANISM">inactivator (TDI)</cons> of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> using <cons lex="dextromethorphan" sem="G_DRUG">dextromethorphan (DEX)</cons> as a probe <cons sem="G_MECHANISM">substrate</cons>.</sentence>
<sentence><cons lex="inhibition" sem="G_MECHANISM">Inhibition</cons> kinetic parameters <cons sem="G_IVITPARA">k(inact)</cons>, the maximal rate of <cons sem="G_MECHANISM">inactivation</cons>, and <cons sem="G_IVITPARA">K(I)</cons>, the <cons sem="G_MECHANISM">inhibitor</cons> concentration at half the maximal <cons sem="G_MECHANISM">activation</cons> rate, were determined.</sentence>
<sentence>Time- and concentration-dependent <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> were confirmed, and the influence of different elements of study design (e.g. cell number, stability of hepatocytes, dilution after preincubation) on estimated kinetic parameters were evaluated.</sentence>
<sentence>Dilution factors (DF) of 1.2, 5 or total removal of <cons sem="G_MECHANISM">inhibitor</cons> (by washing cells after preincubation, WR) resulted in <cons sem="G_IVITPARA">k(inact)</cons> and <cons sem="G_IVITPARA">K(I)</cons> (+/-S.E.) values of <cons sem="G_NUMBER">0.02+/-0.002 min(-1)</cons> and <cons sem="G_NUMBER">0.88+/-0.31 microM</cons>, <cons sem="G_NUMBER">0.01+/-0.001 min(-1)</cons> and <cons sem="G_NUMBER">1.23+/-0.70 microM</cons>, and <cons sem="G_NUMBER">0.01+/-0.001 min(-1)</cons> and <cons sem="G_NUMBER">2.10+/-1.32 microM</cons>, respectively; indicating that insufficient dilution <cons sem="G_CHANGE">may</cons> lead to overestimation of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> <cons sem="G_MECHANISM">inactivation</cons>.</sentence>
<annotation sem="INVITROVDDIS" ddi="(MDMA, CYP2D6,DEI)">
<sentence>Accounting for MDMA depletion during the preincubation, corrected <cons sem="G_IVITPARA">K(I)</cons> values were <cons sem="G_CHANGE">significantly</cons> lower (<cons sem="G_NUMBER">0.11+/-0.05 microM</cons> ,<cons sem="G_NUMBER">0.15+/-0.09 microM</cons>,<cons sem="G_NUMBER">0.24+/-0.16 microM</cons> for DF of 1.2, 5, and WR, respectively).</sentence>
</annotation>
<sentence><cons sem="G_MECHANISM">Inactivation</cons> efficiency in hepatocytes, as measured by <cons sem="G_IVITPARA">k(inact)/K(I)</cons>, was <cons sem="G_NUMBER">10-fold</cons> less than that previously reported in human liver microsomes or recombinantly expressed systems.</sentence>
<sentence>Possible causes for the observed differences between in vitro systems warrant further investigation.</sentence>
<sentence>These <cons sem="G_CHANGE">may</cons> include differences in metabolic consumption of MDMA in each system, non-specific binding and presence of active efflux in hepatocytes.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:17173379</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="inhibition" sem="G_MECHANISM">Inhibition</cons> of cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4</cons> by a pyrimidineimidazole: Evidence for complex <cons lex="heme" sem="G_DRUG">heme</cons> interactions.</sentence>
</title>
<abstract>
<sentence><cons sem="G_DRUG">PH-302</cons> <cons sem="G_MECHANISM">inhibits</cons> the inducible form of nitric oxide synthase (iNOS) by coordinating with the <cons lex="heme" sem="G_DRUG">heme</cons> of the monomeric form and preventing formation of the active dimer.</sentence>
<sentence>Inherent with the mechanism of pharmacology for this compound was the <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4</cons> (P450 <cons lex="3a4" sem="G_CYP">3A4</cons>), observed from early ADME screening.</sentence>
<annotation sem="INVITROCDDIS" ddi="(PH-302, midazolam hydroxylation,DDI)(PH-302, testosterone hydroxylation,DDI)">
<sentence>Further investigation showed that <cons sem="G_DRUG">PH-302</cons> <cons sem="G_MECHANISM">inhibited</cons> P450 <cons lex="3a4" sem="G_CYP">3A4</cons> competitively with a  <cons sem="G_IVITPARA">Ki</cons> of approximately <cons sem="G_NUMBER">2.0 microM</cons> against both <cons lex="midazolam" sem="G_DRUG">midazolam</cons> and <cons lex="testosterone" sem="G_DRUG">testosterone</cons> hydroxylation in human liver microsomes.</sentence>
</annotation>
<sentence>As expected, spectral binding analysis demonstrated that <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> was a result of type II coordination to the P450 <cons lex="heme" sem="G_DRUG">heme</cons> with the <cons lex="imidazole" sem="G_DRUG">imidazole</cons> moiety of <cons sem="G_DRUG">PH-302</cons>, although only 72% of the maximal absorbance difference was achievable with <cons sem="G_DRUG">PH-302</cons> compared to that of the smaller ligand <cons lex="imidazole" sem="G_DRUG">imidazole</cons>.</sentence>
<sentence>Time-dependent <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of P450 <cons lex="3a4" sem="G_CYP">3A4</cons> by <cons sem="G_DRUG">PH-302</cons> was also observed because of metabolite-<cons sem="G_MECHANISM">inhibitory</cons> (MI) complex formation via <cons sem="G_MECHANISM">metabolism</cons> of the methylenedioxyphenyl group.</sentence>
<annotation sem="INVITROCDDIS" ddi="(biphasic, CYP3A4,ADEI)">
<sentence>The profile for time-dependent <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> in recombinant P450 <cons lex="3a4" sem="G_CYP">3A4</cons> was biphasic, and was kinetically characterized by a <cons sem="G_IVITPARA">kinact</cons> of <cons sem="G_NUMBER">0.08 min-1</cons> and a <cons sem="G_IVITPARA">Ki</cons> of <cons sem="G_NUMBER">1.2 microM</cons> for the first phase (0-1.5 min) and a <cons sem="G_IVITPARA">kinact</cons> of <cons sem="G_NUMBER">0.06 min-1</cons> and a <cons sem="G_IVITPARA">Ki</cons> of <cons sem="G_NUMBER">23.8 microM</cons> for the second phase (1.5-10 min).</sentence>
</annotation>
<sentence>Spectral characterization of the <cons sem="G_DRUG">PH-302</cons> MI complex demonstrated that formation began to plateau within 3 min, consistent with the kinetic profile of <cons sem="G_MECHANISM">inactivation</cons> by <cons sem="G_DRUG">PH-302</cons>.</sentence>
<sentence>Meanwhile, spectral evidence for the <cons lex="imidazole" sem="G_DRUG">imidazole</cons>-derived type II difference spectrum of <cons sem="G_DRUG">PH-302</cons> was captured simultaneously with the formation of the MI complex.</sentence>
<sentence>The presence of simultaneously operable type II coordination and rapidly saturable MI complex formation with <cons lex="heme" sem="G_DRUG">heme</cons> by <cons sem="G_DRUG">PH-302</cons> indicates the presence of complex <cons lex="heme" sem="G_DRUG">heme</cons> interactions with this unique molecule.</sentence>
<sentence>Information from these mechanistic studies adds to our understanding of the nature of P450 <cons lex="3a4" sem="G_CYP">3A4</cons> <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> by <cons sem="G_DRUG">PH-302</cons> and provides a potentially useful tool compound for future studies investigating binding interactions in this important drug-metabolizing enzyme.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:16946512</bibliomisc>
</articleinfo>
<title>
<sentence>Effects of serotonin-3 receptor antagonists on cytochrome P450 activities in human liver microsomes.</sentence>
</title>
<abstract>
<sentence>The effects of three serotonin-3 (5-HT(3)) receptor antagonists,<cons sem="G_DRUG">azasetron</cons>, <cons lex="ondansetron" sem="G_DRUG">ondansetron</cons>, and <cons sem="G_DRUG">ramosetron</cons>, on cytochrome P450 (CYP) <cons lex="1a2" sem="G_CYP">1A2</cons>-mediated 7- <cons sem="G_DRUG">ethoxyresorufin</cons> O-deethylation, <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>-mediated <cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons> hydroxylation, <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>-mediated S-<cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons> 4'-hydroxylation, <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>-mediated <cons lex="debrisoquine" sem="G_DRUG">debrisoquine</cons> 4-hydroxylation, <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons>-mediated <cons lex="chlorzoxazone" sem="G_DRUG">chlorzoxazone</cons> 6-hydroxylation, <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>-mediated <cons lex="nifedipine" sem="G_DRUG">nifedipine</cons> <cons lex="oxidation" sem="G_MECHANISM">oxidation</cons>, and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>-mediated <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6beta-hydroxylation activities in human liver microsomes were compared.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Azasetron, CYP2C9,DEI)(Azasetron, CYP2C19,DEI)(Azasetron, CYP2D6,DEI)(Azasetron, CYP2E1,DEI)(Azasetron, CYP3A4,DEI)(ramosetron, CYP2C9,DEI)(ramosetron, CYP2C19,DEI)(ramosetron, CYP2D6,DEI)(ramosetron, CYP2E1,DEI)(ramosetron, CYP3A4,DEI)">
<sentence><cons sem="G_DRUG">Azasetron</cons> and <cons sem="G_IVITPARA">ramosetron</cons> at a concentration of 1 or 10 muM neither <cons sem="G_MECHANISM">inhibited</cons> nor <cons lex="stimulated" sem="G_MECHANISM">stimulated</cons> any of the metabolic activities.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(ondansetron, CYP1A2,DEI)(ondansetron, CYP2D6,ADEI)">
<sentence>On the other hand, <cons lex="ondansetron" sem="G_DRUG">ondansetron</cons> competitively <cons sem="G_MECHANISM">inhibited</cons> <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> and <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> activities, and the <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> constants <cons sem="G_IVITPARA">(K(i)</cons>) were <cons sem="G_NUMBER">3.2</cons> and <cons sem="G_NUMBER">21.0 muM</cons>, respectively, which are much higher than the reported plasma concentrations after clinical intravenous or oral dosing.</sentence>
</annotation>
<sentence>The free fractions of the three 5-HT(3) receptor antagonists in the incubation mixture estimated by ultracentrifugation were more than 68.6%.</sentence>
<sentence>These results suggest that azasetron, <cons lex="ondansetron" sem="G_DRUG">ondansetron</cons>, and ramosetron do <cons sem="G_NEGATIVEEFFECT">not</cons> cause clinically <cons sem="G_CHANGE">significant</cons> interactions with other drugs that are <cons sem="G_MECHANISM">metabolized</cons> by CYPs via the <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of <cons sem="G_IVITPARA">metabolism</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:16867169</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem="G_MECHANISM">Inhibitory</cons> effects of cytostatically active 6-aminobenzo [c]phenanthridines on cytochrome P450 enzymes in human hepatic microsomes.</sentence>
</title>
<abstract>
<sentence>Besides assays for the evaluation of efficacy new drug candidates have to undergo extensive testings for enhancement of pharmaceutical drug safety and optimization of application.</sentence>
<sentence>The objective of the present work was to investigate the pharmacokinetic drug drug interaction potential for the cytostatically active <cons sem="G_DRUG">6-aminobenzo [c]phenanthridines BP-11 (6-amino-11,12-dihydro-11-(4-hydroxy-3,5-dimethoxyphenyl)benzo [c]phenanthridine)</cons> and <cons sem="G_DRUG">BP-D7 (6-amino-11-(3,4,5-trimethoxyphenyl)benzo [c]phenanthridine)</cons> in vitro through incubation with human hepatic microsomes and marker substrates.</sentence>
<sentence>For these studies the cytochrome P-450 isoenzymes and corresponding marker substrates recommended by the EMEA (The European Agency for the Evaluation of Medicinal Products) were chosen.</sentence>
<sentence>In detail these selective substrates were <cons lex="caffeine" sem="G_DRUG">caffeine</cons> (<cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>),<cons sem="G_DRUG">coumarin</cons> (<cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons>), <cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons> (<cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>), S-(+)-<cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons> (<cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>), dextromethorphane (<cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>), <cons lex="chlorzoxazone" sem="G_DRUG">chlorzoxazone</cons> (<cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons>) and <cons lex="testosterone" sem="G_DRUG">testosterone</cons> (<cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>).</sentence>
<sentence>Incubations with each substrate were carried out without a possible <cons sem="G_MECHANISM">inhibitor</cons> and in the presence of a benzo [c]phenanthridine or a selective <cons sem="G_MECHANISM">inhibitor</cons> at varying concentrations.</sentence>
<sentence>Marker activities were determined by HPLC (high performance liquid chromatography).</sentence>
<sentence>For the isoenzymes showing more than <cons sem="G_NUMBER">50%</cons> <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> by the addition of <cons sem="G_NUMBER">20 microM</cons> <cons sem="G_DRUG">BP-11</cons> or <cons sem="G_DRUG">BP-D7</cons> additional concentrations of substrate and <cons sem="G_MECHANISM">inhibitor</cons> were tested for a characterization of the <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(BP-11, CYP1A2,ADEI)(BP-11, CYP2C9,ADEI)(BP-11, CYP2D6,ADEI)(BP-11, CYP3A4,ADEI)">
<sentence>The studies showed a <cons sem="G_CHANGE">moderate</cons> risk for <cons sem="G_MECHANISM">BP-11</cons> for interactions with the cytochrome P-450 isoenzymes <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(BP-D7, CYP3A4,ADEI)">
<sentence><cons sem="G_DRUG">BP-D7</cons>, the compound with the highest cytotstatic efficacy, showed only a <cons sem="G_CHANGE">moderate</cons> risk for interactions with drugs, also <cons sem="G_MECHANISM">metabolized</cons> by <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:16841513</bibliomisc>
</articleinfo>
<title>
<sentence>In vitro studies on <cons lex="quetiapine" sem="G_DRUG">quetiapine</cons> <cons sem="G_MECHANISM">metabolism</cons> using the substrate depletion approach with focus on drug-drug interactions.</sentence>
</title>
<abstract>
<sentence>The <cons sem="G_MECHANISM">metabolism</cons> of the atypical antipsychotic <cons lex="quetiapine" sem="G_DRUG">quetiapine</cons> was investigated by in vitro methods.</sentence>
<sentence>Pharmacokinetic parameters were determined in human liver microsomes and recombinant cytochrome P450 measuring substrate depletion and product formation.</sentence>
<annotation sem="INVITROCDDIS" ddi="(quetiapine, CYP3A4,DEI)(quetiapine, CYP2D6,DEI)">
<sentence>The cytochrome P450 isozymes <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> displayed activity towards <cons lex="quetiapine" sem="G_DRUG">quetiapine</cons>.</sentence>
</annotation>
<sentence>The isozyme <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> played a <cons sem="G_CHANGE">minor</cons> role in the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="quetiapine" sem="G_DRUG">quetiapine</cons> as <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> contributed <cons sem="G_NUMBER">89%</cons> to the overall <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
<sentence>A <cons sem="G_IVITPARA">Km</cons> value of <cons sem="G_NUMBER">18 microM</cons> was determined by substrate depletion, suggesting linear kinetics under therapeutic conditions.</sentence>
<annotation sem="INVITROCDDIS" ddi="(ketoconazole, CYP2D6,NDEInefazodone, CYP2D6,NDEI)(ketoconazole, CYP3A4,DEI)(nefazodone, CYP3A4,DEI)">
<sentence>Drugs known to <cons sem="G_MECHANISM">inhibit</cons> <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, such as <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> and <cons lex="nefazodone" sem="G_DRUG">nefazodone</cons>, displayed almost complete <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> at low concentrations, whereas <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> do <cons sem="G_NEGATIVEEFFECT">not</cons> seem to have a clinically relevant effect.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:16832679</bibliomisc>
</articleinfo>
<title>
<sentence>The <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> <cons sem="G_MECHANISM">inhibitor</cons> <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons> does <cons sem="G_NEGATIVEEFFECT">not</cons> <cons lex="increase" sem="G_CHANGE">increase</cons> the <cons sem="G_IVITPARA">plasma concentrations</cons> of <cons lex="zopiclone" sem="G_DRUG">zopiclone</cons>.</sentence>
</title>
<abstract>
<sentence><cons lex="zopiclone" sem="G_DRUG">Zopiclone</cons> is a short acting hypnotic, which is <cons sem="G_MECHANISM">metabolised</cons> by cytochrome P450 (CYP) <cons lex="3a4" sem="G_CYP">3A4</cons> and <cons lex="2c8" sem="G_CYP">2C8</cons> in vitro.</sentence>
<sentence>We studied the possible effect of <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons>, an <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons>, on the pharmacokinetics and pharmacodynamics of <cons lex="zopiclone" sem="G_DRUG">zopiclone</cons>.</sentence>
<sentence>In a randomised 2-phase crossover study, 10 healthy volunteers took <cons sem="G_NUMBER">600 mg</cons> <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons> or placebo orally twice daily for 3 days.</sentence>
<sentence>On day 3, each ingested a 7.5 mg dose of <cons lex="zopiclone" sem="G_DRUG">zopiclone</cons>.</sentence>
<sentence>Plasma concentrations and urinary excretion of <cons lex="zopiclone" sem="G_DRUG">zopiclone</cons> and its two primary metabolites, plasma <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons>, and psychomotor performance were measured.</sentence>
<sentence>The effects of <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons>, <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitors</cons> on the depletion of <cons lex="zopiclone" sem="G_DRUG">zopiclone</cons> (<cons sem="G_NUMBER">500 nM</cons>) were studied in vitro in human liver microsomes.</sentence>
<annotation sem="INVITROCDDIS" ddi="(gemfibrozil, zopiclone,NDDI)">
<sentence>The pharmacokinetic variables of the parent <cons lex="zopiclone" sem="G_DRUG">zopiclone</cons> were <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">significantly</cons> affected by <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(gemfibrozil, N-oxide-zopiclone,DDI)(gemfibrozil, N-desmethyl-zopiclone,ADDI)">
<sentence>However, <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons> raised the mean <cons sem="G_IVITPARA">peak plasma concentration (C(max))</cons> of N-oxide-<cons lex="zopiclone" sem="G_DRUG">zopiclone</cons> (<cons sem="G_NUMBER">1.6-fold; P&lt;0.001</cons>) and that of N-desmethyl-<cons lex="zopiclone" sem="G_DRUG">zopiclone</cons> (<cons sem="G_NUMBER">1.2-fold; P&lt;0.001</cons>).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(gemfibrozil, N-oxide-zopiclone,DDI)(gemfibrozil, N-desmethyl-zopiclone,ADDI)">
<sentence>The mean <cons sem="G_IVITPARA">area under the plasma concentration-time curve (AUC(0)-infinity)</cons> values of N-oxide-<cons lex="zopiclone" sem="G_DRUG">zopiclone</cons> and N-desmethyl-<cons lex="zopiclone" sem="G_DRUG">zopiclone</cons> were raised <cons sem="G_NUMBER">2-fold (P&lt;0.001)</cons> and <cons sem="G_NUMBER">1.2-fold (P&lt;0.01)</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(gemfibrozil, N-oxide zopiclone,ADDI)">
<sentence>The renal <cons sem="G_IVITPARA">clearance</cons> of N-oxide-<cons lex="zopiclone" sem="G_DRUG">zopiclone</cons> was <cons sem="G_CHANGE">reduced</cons> by <cons sem="G_NUMBER">48%</cons>/cons by <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons> (<cons sem="G_NUMBER">P&lt;0.001</cons>).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(gemfibrozil, zopiclone,NDDI)">
<sentence>The pharmacodynamic effects of <cons lex="zopiclone" sem="G_DRUG">zopiclone</cons>, measured using psychometric tests, were <cons sem="G_NEGATIVEEFFECT">not</cons> affected by <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(ketoconazole, zopiclone,DDI)(itraconazole, zopiclone,DDI)(montelukast, zopiclone,NDDI)(gemfibrozil, zopiclone,NDDI)(sulfaphenazole, zopiclone,NDDI)">
<sentence>In vitro, <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> (<cons sem="G_NUMBER">1 microM</cons>) and <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> (<cons sem="G_NUMBER">8 microM</cons>) <cons sem="G_CHANGE">decreased</cons> the elimination rate of <cons lex="zopiclone" sem="G_DRUG">zopiclone</cons> enantiomers by about <cons sem="G_NUMBER">65-95%</cons> while <cons lex="montelukast" sem="G_DRUG">montelukast</cons> (<cons sem="G_NUMBER">16 microM</cons>), <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons> (<cons sem="G_NUMBER">200 microM</cons>) and <cons sem="G_DRUG">sulfaphenazole</cons> (<cons sem="G_NUMBER">10 microM</cons>) had <cons sem="G_NEGATIVEEFFECT">no</cons> appreciable effect.</sentence> 
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Gemfibrozil, zopiclone,NDDI)">
<sentence><cons lex="gemfibrozil" sem="G_DRUG">Gemfibrozil</cons> does <cons sem="G_NEGATIVEEFFECT">not</cons> <cons lex="increase" sem="G_CHANGE">increase</cons> the plasma concentrations of the parent <cons lex="zopiclone" sem="G_DRUG">zopiclone</cons>.</sentence>
</annotation>
<sentence>Accordingly, <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> does <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">significantly</cons> metabolise <cons lex="zopiclone" sem="G_DRUG">zopiclone</cons> in vivo.</sentence>
<sentence>However, as <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons> raises the concentrations of two potentially active metabolites of <cons lex="zopiclone" sem="G_DRUG">zopiclone</cons>, slightly enhanced effects of <cons lex="zopiclone" sem="G_DRUG">zopiclone</cons> by <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons> can <cons sem="G_NEGATIVEEFFECT">not</cons> be excluded.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:16679385</bibliomisc>
</articleinfo>
<title>
<sentence>Evaluation of time-dependent cytochrome P450 <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> using cultured human hepatocytes.</sentence>
</title>
<abstract>
<sentence>Primary human hepatocytes in culture are commonly used to evaluate cytochrome P450 (P450) <cons lex="induction" sem="G_MECHANISM">induction</cons> via an enzyme activity endpoint.</sentence>
<sentence>However, other processes can confound data interpretation.</sentence>
<sentence>To this end, the impact of time-dependent P450 <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> in this system was evaluated.</sentence>
<sentence>Using a substrate-cassette approach, P450 activities were determined after incubation with the prototypic <cons sem="G_MECHANISM">inhibitors</cons> <cons sem="G_DRUG">tienilic acid</cons> (<cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>), <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons>, <cons lex="troleandomycin" sem="G_DRUG">troleandomycin</cons>, and <cons lex="fluoxetine" sem="G_DRUG">fluoxetine</cons> (<cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>).</sentence>
<sentence>Kinetic analysis of enzyme <cons sem="G_MECHANISM">inactivation</cons> in hepatocytes was used to describe the effect of these time-dependent <cons sem="G_MECHANISM">inhibitors</cons> and derive the <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> parameters <cons sem="G_IVITPARA">kinact</cons> and <cons sem="G_IVITPARA">KI</cons>) which generally were in good agreement with the values derived using recombinant P450s and human liver microsomes (HLMs).</sentence>
<annotation sem="INVITROCDDIS" ddi="(Tienilic acid, diclofenac 4'-hydroxylation,DDI)(erythromycin, midazolam 1'-hydroxylation,DDI)(troleandomycin, midazolam 1'-hydroxylation,DDI)(fluoxetine, midazolam 1'-hydroxylation,DDI)">
<sentence><cons sem="G_DRUG">Tienilic acid</cons> selectively <cons sem="G_MECHANISM">inhibited</cons> <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>-dependent <cons lex="diclofenac" sem="G_DRUG">diclofenac</cons> 4'-hydroxylation activity, and <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons>, <cons lex="troleandomycin" sem="G_DRUG">troleandomycin</cons>, and <cons lex="fluoxetine" sem="G_DRUG">fluoxetine</cons> inhibited <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>-dependent <cons lex="midazolam" sem="G_DRUG">midazolam</cons> 1'-hydroxylation in a time- and concentration-dependent manner.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Fluoxetine, S-mephenytoin 4'-hydroxylation,DDI)">
<sentence><cons lex="fluoxetine" sem="G_DRUG">Fluoxetine</cons> also <cons sem="G_MECHANISM">inhibited</cons> <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>-dependent S-<cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons> 4'-hydroxylation in a time- and concentration-dependent manner in hepatocytes, HLMs, and recombinant <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> (<cons sem="G_IVITPARA">KI</cons> <cons sem="G_NUMBER">0.4 microM</cons> and <cons sem="G_IVITPARA">kinact</cons> <cons sem="G_NUMBER">0.5 min(-1)</cons>).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Fluoxetine, CYP2D6,DEI)">
<sentence>As expected, the effect of <cons lex="fluoxetine" sem="G_DRUG">fluoxetine</cons> on <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> in hepatocytes was consistent with potent yet reversible <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(AZ1, CYP2C9,ADEI)">
<sentence>A very weak time-dependent <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> <cons sem="G_MECHANISM">inhibitor</cons> (<cons sem="G_DRUG">AZ1</cons>, a proprietary AstraZeneca compound;<cons sem="G_IVITPARA">KI</cons> <cons sem="G_NUMBER">30 microM</cons> and <cons sem="G_IVITPARA">kinact</cons> <cons sem="G_NUMBER">0.02 min(-1)</cons>) effectively  abolished <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> activity over 24 h at low (micromolar) concentrations in primary cultured human hepatocytes.</sentence>
</annotation>
<sentence>This work demonstrates that caution is warranted in the interpretation of enzyme <cons lex="induction" sem="G_MECHANISM">induction</cons> studies with metabolically stable, weak time-dependent <cons sem="G_MECHANISM">inhibitors</cons>, which <cons sem="G_CHANGE">may</cons> have dramatic <cons sem="G_MECHANISM">inhibitory</cons> effects on P450 activity in this system.</sentence>
<sentence>Therefore, in addition to enzyme activity, mRNA and/or protein levels should be measured to fully evaluate the P450 <cons lex="induction" sem="G_MECHANISM">induction</cons> potential of a drug candidate.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:16443667</bibliomisc>
</articleinfo>
<title>
<sentence>Identification of human liver cytochrome P450 enzymes responsible for the <cons sem="G_MECHANISM">metabolism</cons> of lonafarnib (Sarasar).</sentence>
</title>
<abstract>
<sentence><cons sem="G_DRUG">Lonafarnib (Sarasar)</cons>, a <cons lex="farnesyl" sem="G_DRUG">farnesyl</cons> transferase <cons sem="G_MECHANISM">inhibitor</cons>, is currently under development for the treatment of solid tumors.</sentence>
<sentence>Incubation of <cons sem="G_DRUG">lonafarnib</cons> with human liver microsomes resulted in the formation of four oxidative metabolites (M1, M2, M3, and M4).</sentence>
<sentence><cons sem="G_CHANGE">minor</cons> to trace levels of these metabolites were detected in humans after multiple-dose administration of <cons sem="G_DRUG">lonafarnib</cons>.</sentence>
<sentence>Liquid chromatography-mass spectrometry analyses exhibited a mass to charge ratio (m/z) for the (M+H)(+) ion of M1, M2, M3, and M4 at 653, 635, 669, and 653 Th, respectively.</sentence>
<sentence>These metabolites, respectively, resulted from changes of +O, -2H, +2O, and +O relative to <cons sem="G_DRUG">lonafarnib</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(CYP3A4, M1,DEI)(CYP3A4, M2,DEI)(CYP3A4, M3,DEI)(CYP3A5, M1,DEI)(CYP3A5, M2,DEI)(CYP3A5, M3,DEI)(CYP2C8, M4,DEI)">
<sentence>Recombinant human <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and <cons lex="cyp3a5" sem="G_CYP">CYP3A5</cons> exhibited catalytic activity with respect to the formation of M1, M2, and M3, whereas <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> exhibited catalytic activity with respect to the formation of M4.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(CYP3A4/5, testosterone 6beta-hydroxylation,DEI)">
<sentence>There was a high <cons lex="correlation" sem="G_MECHANISM">correlation</cons> between the formation of M1, determined in 10 human liver microsomal samples, and 6beta-hydroxylation of <cons lex="testosterone" sem="G_DRUG">testosterone</cons> <cons lex="catalyzed" sem="G_MECHANISM">catalyzed</cons> by <cons lex="cyp3a4/5" sem="G_CYP">CYP3A4/5</cons> (<cons sem="G_NUMBER">r = 0.93</cons>).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(ketoconazole, M1,DDI)(ketoconazole, M2,DDI)">
<sentence>The <cons sem="G_IVITPARA">IC(50)</cons> values of <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> for <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of M1 and M2 were <cons sem="G_NUMBER">0.61</cons> and <cons sem="G_NUMBER">0.92 microM</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(quercetin, M4,DDI)">
<sentence>The formation of M4 by human liver microsomes was <cons sem="G_MECHANISM">inhibited</cons> <cons sem="G_NUMBER">72%</cons> by <cons sem="G_NUMBER">50 microM</cons> <cons lex="quercetin" sem="G_DRUG">quercetin</cons>, suggesting that the formation of M4 was mediated via <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(A CYP3A4/5-specific inhibitory monoclonal antibody, M1,DDI)(A CYP3A4/5-specific inhibitory monoclonal antibody, M2,DDI)(A CYP3A4/5-specific inhibitory monoclonal antibody, M3,DDI)">
<sentence>A <cons lex="cyp3a4/5" sem="G_CYP">CYP3A4/5</cons>-specific <cons sem="G_MECHANISM">inhibitory</cons> monoclonal antibody <cons sem="G_MECHANISM">inhibited</cons> the formation of M1, M2, and M3 by <cons sem="G_NUMBER">85, 75, and 100%</cons>, respectively.</sentence>
</annotation>
<sentence>In conclusion, the formation of metabolites M1, M2, and M3 from <cons sem="G_IVITPARA">lonafarnib</cons> was mediated via <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and <cons lex="cyp3a5" sem="G_CYP">CYP3A5</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:16272753</bibliomisc>
</articleinfo>
<title>
<sentence>In vitro <cons sem="G_MECHANISM">inhibitory</cons> effect of <cons sem="G_DRUG">1-aminobenzotriazole</cons> on drug oxidations in human liver microsomes: a comparison with <cons sem="G_DRUG">SKF-525A</cons>.</sentence>
</title>
<abstract>
<sentence><cons sem="G_DRUG">1-Aminobenzotriazole (ABT)</cons> is extensively used as a non-specific cytochrome P450 (CYP) <cons sem="G_MECHANISM">inhibitor</cons>.</sentence>
<sentence>In this study, the <cons sem="G_MECHANISM">inhibitory</cons> effect of <cons sem="G_DRUG">ABT</cons> on CYP-dependent drug oxidations was investigated in human liver microsomes (HLM) and compared with that of SKF-525A, another non-specific <cons sem="G_MECHANISM">inhibitor</cons>.</sentence>
<sentence>The following probe activities for human CYP isoforms were determined using pooled HLM: <cons lex="phenacetin" sem="G_DRUG">phenacetin</cons> O-deethylation (<cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>); <cons lex="diclofenac" sem="G_DRUG">diclofenac</cons> 4'-hydroxylation (<cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>); S-<cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons> 4'-hydroxylation, (<cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>);<cons sem="G_DRUG">bufuralol</cons> 1'-hydroxylation (<cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>); <cons lex="chlorzoxazone" sem="G_DRUG">chlorzoxazone</cons> 6-hydroxylation (<cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons>); <cons lex="midazolam" sem="G_DRUG">midazolam</cons> 1'-hydroxylation, <cons lex="nifedipine" sem="G_DRUG">nifedipine</cons> <cons lex="oxidation" sem="G_MECHANISM">oxidation</cons>, and <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6beta-hydroxylation (<cons lex="cyp3a" sem="G_CYP">CYP3A</cons>).</sentence>
<annotation sem="INVITROCDDIS" ddi="(ABT, diclofenac 4'-hydroxylation,ADDI)">
<sentence><cons sem="G_DRUG">ABT</cons> had the strongest <cons sem="G_MECHANISM">inhibitory</cons> effect on the <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>-dependent drug oxidations and the weakest effect on the <cons lex="diclofenac" sem="G_DRUG">diclofenac</cons> 4'-hydroxylation.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(SKF-525A, bufuralol 1'-hydroxylation,DDI)(SKF-525A, chlorzoxazone 6-hydroxylation,ADDI)">
<sentence><cons sem="G_DRUG">SKF-525A</cons> potently <cons sem="G_MECHANISM">inhibited</cons> the <cons sem="G_DRUG">bufuralol</cons> 1'-hydroxylation, but weakly <cons sem="G_MECHANISM">inhibited</cons> <cons lex="chlorzoxazone" sem="G_DRUG">chlorzoxazone</cons> 6-hydroxylation.</sentence>
</annotation>
<sentence>The <cons sem="G_MECHANISM">inhibitory</cons> effects of <cons sem="G_MECHANISM">ABT</cons> and <cons sem="G_DRUG">SKF-525A</cons> were <cons sem="G_CHANGE">increased</cons> by preincubation in some probe reactions, and this preincubation effect was <cons sem="G_CHANGE">greater</cons> in <cons sem="G_DRUG">ABT</cons> than in <cons sem="G_IVITPARA">SKF-525A</cons> .</sentence>
<annotation sem="INVITROCDDIS" ddi="(ABT, phenacetin O-deethylation,DDI)(ABT, chlorzoxazone 6-hydroxylation,DDI)(ABT, midazolam 1'-hydroxylation,DDI)">
<sentence>The remarkable <cons sem="G_IVITPARA">IC50</cons> shift (&gt; 10 times) by preincubation with <cons sem="G_DRUG">ABT</cons> was observed on the <cons lex="phenacetin" sem="G_DRUG">phenacetin</cons> O-deethylation, <cons lex="chlorzoxazone" sem="G_DRUG">chlorzoxazone</cons> 6-hydroxylation, and <cons lex="midazolam" sem="G_DRUG">midazolam</cons> 1'-hydroxylation.</sentence>
</annotation>
<sentence>In conclusion,<cons sem="G_DRUG">ABT</cons> and <cons sem="G_DRUG">SKF-525A</cons> had a wide range of <cons sem="G_">IC50</cons> values in inhibiting the drug oxidations by HLM with and without preincubation.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:16203790</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of the <cons sem="G_DRUG">St. John's wort</cons> constituent <cons lex="hyperforin" sem="G_DRUG">hyperforin</cons> on <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons> <cons sem="G_MECHANISM">metabolism</cons> by human hepatocyte cultures.</sentence>
</title>
<abstract>
<sentence><cons sem="G_DRUG">St. John's wort</cons> is a commonly used herbal medication that increases cytochrome P450 <cons lex="3a" sem="G_CYP">3A</cons> (<cons lex="cyp3a" sem="G_CYP">CYP3A</cons>) activity.</sentence>
<sentence>Because <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons> is <cons sem="G_MECHANISM">inactivated</cons> by <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>, we studied the effects of the <cons sem="G_DRUG">St. John's wort</cons> constituent <cons lex="hyperforin" sem="G_DRUG">hyperforin</cons> on <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons> <cons sem="G_MECHANISM">metabolism</cons> in a human hepatocyte model.</sentence>
<sentence>Hepatocytes, isolated from three donor livers, were exposed to <cons lex="hyperforin" sem="G_DRUG">hyperforin</cons> (<cons sem="G_NUMBER">0.1, 0.5, or 1.5 micromol/L</cons>) or <cons lex="rifampin" sem="G_DRUG">rifampin</cons> (<cons sem="G_NUMBER">10 micromol/L</cons>) for 48 hours.</sentence>
<sentence>After 48 hours, <cons lex="hyperforin" sem="G_DRUG">hyperforin</cons>- or <cons lex="rifampin" sem="G_DRUG">rifampin</cons>-containing medium was replaced with medium containing 100 micromol/L <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons>.</sentence>
<sentence>After 1 hour, <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons> <cons sem="G_MECHANISM">metabolism</cons> was characterized by liquid chromatography-tandem mass spectrometry.</sentence>
<sentence>Subsequent incubations characterized the specific cytochrome P450s that produced the <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons> metabolites observed in hepatocyte incubations.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Rifampin, docetaxel,DDI)">
<sentence><cons lex="rifampin" sem="G_DRUG">Rifampin</cons> induced <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons> <cons sem="G_MECHANISM">metabolism</cons> <cons sem="G_NUMBER">6.8- to 32-fold</cons> above <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons> <cons sem="G_MECHANISM">metabolism</cons> in control cultures.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Hyperforin, docetaxel,DDI)">
<sentence><cons lex="hyperforin" sem="G_DRUG">Hyperforin</cons> induced <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons> <cons sem="G_MECHANISM">metabolism</cons> in all three hepatocyte preparations.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Hyperforin, docetaxel,DDI)">
<sentence><cons lex="hyperforin" sem="G_DRUG">Hyperforin</cons> <cons lex="induction" sem="G_MECHANISM">induction</cons> was dose-dependent and, at maximum, was <cons sem="G_NUMBER">2.6- to 7-fold</cons> <cons sem="G_CHANGE">greater</cons> than that in controls.</sentence>
</annotation>
<sentence><cons lex="docetaxel" sem="G_DRUG">Docetaxel</cons> metabolites identified in <cons lex="rifampin" sem="G_DRUG">rifampin</cons>- and <cons lex="hyperforin" sem="G_DRUG">hyperforin</cons>-treated hepatocyte preparations included the previously described tert-butyl-hydroxylated metabolite and two previously unidentified metabolites involving hydroxylation on the baccatin ring.</sentence>
<sentence><cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> produced the tert-butyl-hydroxylated metabolite and the two ring-hydroxylated metabolites.</sentence>
<sentence><cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> produced one of the newly described ring-hydroxylated metabolites.</sentence>
<annotation sem="INVITROCDDIS" ddi="(St. John's wort + hyperforin, docetaxel ,DDI)">
<sentence>Exposure to the <cons sem="G_DRUG">St. John's wort</cons> constituent <cons lex="hyperforin" sem="G_DRUG">hyperforin</cons> induces <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons> <cons sem="G_MECHANISM">metabolism</cons> in vitro.</sentence>
</annotation>
<sentence>This implies that subtherapeutic <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons> concentrations <cons sem="G_CHANGE">may</cons> result when <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons> is administered to patients using <cons sem="G_DRUG">St. John's wort</cons> on a chronic basis.</sentence>
<sentence>The results also show <cons lex="induction" sem="G_MECHANISM">induction</cons> of previously undescribed metabolic pathways for <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons>, one of which <cons sem="G_CHANGE">may</cons> be analogous to the known 6-alpha-hydroxylation of <cons lex="paclitaxel" sem="G_DRUG">paclitaxel</cons> by <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:16176562</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem="G_MECHANISM">Metabolism</cons> of <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons> by <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> in vitro: effect of fibrates and <cons sem="G_DRUG">rifampicin</cons>.</sentence>
</title>
<abstract>
<sentence><cons lex="repaglinide" sem="G_DRUG">Repaglinide</cons> is an antidiabetic drug <cons sem="G_MECHANISM">metabolised</cons> by cytochrome P450 (CYP) <cons lex="2c8" sem="G_CYP">2C8</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> enzymes.</sentence>
<sentence>To clarify the mechanisms of observed <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons> drug interactions, we determined the contribution of the two enzymes to <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons> <cons sem="G_MECHANISM">metabolism</cons> at different substrate concentrations, and examined the effect of fibrates and <cons sem="G_DRUG">rifampicin</cons> on <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons>, <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons> <cons sem="G_MECHANISM">metabolism</cons> in vitro.</sentence>
<sentence>We studied <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons> <cons sem="G_MECHANISM">metabolism</cons> using pooled human liver microsomes, recombinant <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> and recombinant <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> enzymes.</sentence>
<sentence>The effect of <cons lex="quercetin" sem="G_DRUG">quercetin</cons> and <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> on <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons> <cons sem="G_MECHANISM">metabolism</cons>, and of <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons>, <cons lex="bezafibrate" sem="G_DRUG">bezafibrate</cons>, <cons lex="fenofibrate" sem="G_DRUG">fenofibrate</cons> and rifampicin on <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> (<cons lex="paclitaxel" sem="G_DRUG">paclitaxel</cons> 6alpha-hydroxylation) and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> (<cons lex="midazolam" sem="G_DRUG">midazolam</cons> 1-hydroxylation) activities and <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons> <cons sem="G_MECHANISM">metabolism</cons> were studied using human liver microsomes.</sentence>
<sentence>At therapeutic <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons> concentrations (<cons sem="G_NUMBER">&lt;0.4 microM</cons>), <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons><cons sem="G_MECHANISM">metabolised</cons> <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons> at similar rates.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Quercetin, repaglinide,DDI)(itraconazole, repaglinide,DDI)">
<sentence><cons lex="quercetin" sem="G_DRUG">Quercetin</cons> (<cons sem="G_NUMBER">25 microM</cons>) and <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> (<cons sem="G_NUMBER">3 microM</cons>) <cons sem="G_MECHANISM">inhibited</cons> the <cons sem="G_MECHANISM">metabolism</cons> of <cons sem="G_NUMBER">0.2 microM</cons> <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons> by <cons sem="G_NUMBER">58% and 71%, and that of 2 microM</cons> <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons> by 56% and 59%, respectively.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(bezafibrate, CYP2C8,DEI)(gemfibrozil, CYP2C8,ADEI)(fenofibrate, CYP2C8,ADEI)(repaglinide, CYP2C8,ADEI)(bezafibrate, repaglinide ,ADEI)(fenofibrate, repaglinide ,ADEI)(repaglinide, repaglinide ,ADEI)(bezafibrate, CYP3A4,NDEI)(gemfibrozil, CYP3A4,NDEI)(fenofibrate, CYP3A4,NDEI)">
<sentence>The three fibrates <cons sem="G_MECHANISM">inhibited</cons> <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> (<cons sem="G_IVITPARA">Ki</cons>: <cons lex="bezafibrate" sem="G_DRUG">bezafibrate</cons> <cons sem="G_NUMBER">9.7 microM</cons>, <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons> <cons sem="G_NUMBER">30.4 microM</cons> and <cons lex="fenofibrate" sem="G_DRUG">fenofibrate</cons> <cons sem="G_NUMBER">92.6 microM</cons>) and <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons> <cons sem="G_MECHANISM">metabolism</cons> (<cons sem="G_IVITPARA">IC50</cons>: <cons lex="bezafibrate" sem="G_DRUG">bezafibrate</cons> <cons sem="G_NUMBER">37.7 microM</cons>, <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons> <cons sem="G_NUMBER">111 microM</cons> and <cons lex="fenofibrate" sem="G_DRUG">fenofibrate</cons> <cons sem="G_NUMBER">164 microM</cons>), but had <cons sem="G_NEGATIVEEFFECT">no</cons> effect on <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Rifampicin, CYP2C8,ADEI)(Rifampicin, CYP3A4,ADEI)(Rifampicin, repaglinide,DDI)">
<sentence><cons sem="G_DRUG">Rifampicin</cons> <cons sem="G_MECHANISM">inhibited</cons> <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> (<cons sem="G_IVITPARA">Ki</cons> <cons sem="G_NUMBER">30.2 microM</cons>), <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> (<cons sem="G_IVITPARA">Ki</cons> <cons sem="G_NUMBER">18.5 microM</cons>) and <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons> <cons sem="G_MECHANISM">metabolism</cons> (<cons sem="G_IVITPARA">IC50</cons>  <cons sem="G_NUMBER">13.7 microM</cons>).</sentence>
</annotation>
<sentence>In conclusion, both <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> are important in the <cons sem="G_MECHANISM">metabolism</cons> of therapeutic concentrations of <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons> in vitro, but their predicted contributions in vivo are highly dependent on the scaling factor used.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Gemfibrozil, CYP2C8,ADEI)(Gemfibrozil, CYP3A4,NDEI)">
<sentence><cons lex="gemfibrozil" sem="G_DRUG">Gemfibrozil</cons> is only a <cons sem="G_CHANGE">moderate</cons> <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> and does <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_MECHANISM">inhibit</cons> <cons sem="G_CYP">CYP3A4</cons>; <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of CYP-enzymes by parent <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons> alone does <cons sem="G_NEGATIVEEFFECT">not</cons> explain its interaction with <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons> in vivo.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Rifampicin, CYP2C8,DEI)(Rifampicin, CYP3A4,DEI)">
<sentence><cons sem="G_DRUG">Rifampicin</cons> competitively <cons sem="G_MECHANISM">inhibits</cons> both <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, which can counteract its inducing effect in humans.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:16141567</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of antifungal drugs on cytochrome P450 (CYP) <cons lex="2c9" sem="G_CYP">2C9</cons>, <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>, and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activities in human liver microsomes.</sentence>
</title>
<abstract>
<sentence>The effects of five antifungal drugs, <cons lex="fluconazole" sem="G_DRUG">fluconazole</cons>, <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>, <cons lex="micafungin" sem="G_DRUG">micafungin</cons>, <cons lex="miconazole" sem="G_DRUG">miconazole</cons>, and <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons>, on cytochrome P450 (CYP) <cons lex="2c9" sem="G_CYP">2C9</cons>-mediated <cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons> hydroxylation, <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>-mediated S-<cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons> 4'-hydroxylation, and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>-mediated <cons lex="nifedipine" sem="G_DRUG">nifedipine</cons> <cons lex="oxidation" sem="G_MECHANISM">oxidation</cons> activities in human liver microsomes were compared.</sentence>
<sentence>In addition, the effects of preincubation were estimated to investigate the mechanism-based <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(miconazole, tolbutamide hydroxylation,DDI)(voriconazole, tolbutamide hydroxylation,DDI)(fluconazole, tolbutamide hydroxylation,DDI)">
<sentence>The <cons sem="G_IVITPARA">IC50</cons> value against <cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons> hydroxylation was the lowest for <cons lex="miconazole" sem="G_DRUG">miconazole</cons>  <cons sem="G_NUMBER">(2.0 microM)</cons>, followed by <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> <cons sem="G_NUMBER">(8.4 microM)</cons> and <cons lex="fluconazole" sem="G_DRUG">fluconazole</cons> <cons sem="G_NUMBER">(30.3 microM)</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(miconazole, S-mephenytoin 4'-hydroxylation,DDI)(voriconazole, S-mephenytoin 4'-hydroxylation,DDI)(fluconazole, S-mephenytoin 4'-hydroxylation,DDI)">
<sentence>Similarly, the <cons sem="G_IVITPARA">IC50</cons> value against S-<cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons> 4'-hydroxylation was the lowest for <cons lex="miconazole" sem="G_DRUG">miconazole</cons> <cons sem="G_NUMBER">(0.33 microM)</cons>, followed by <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> <cons sem="G_NUMBER">(8.7 microM)</cons> and <cons lex="fluconazole" sem="G_DRUG">fluconazole</cons> <cons sem="G_NUMBER">(12.3 microM)</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(micafungin, tolbutamide hydroxylation,NDDI)(micafungin, S-mephenytoin 4'-hydroxylation,NDDI)(itraconazole, tolbutamide hydroxylation,DDI)(itraconazole, S-mephenytoin 4'-hydroxylation,DDI)">
<sentence>On the other hand, <cons lex="micafungin" sem="G_DRUG">micafungin</cons> at a concentration of <cons sem="G_NUMBER">10 or 25 microM</cons> neither <cons sem="G_MECHANISM">inhibited</cons> nor <cons lex="stimulated" sem="G_MECHANISM">stimulated</cons> <cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons> hydroxylation and S-<cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons> 4'-hydroxylation, and the <cons sem="G_IVITPARA">IC50</cons> values for <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> against these were <cons sem="G_CHANGE">greater</cons> than <cons sem="G_NUMBER">10 microM</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(miconazole, CYP2C9,DEI)(miconazole, CYP2C19,DEI)(voriconazole, CYP2C9,DEI)(voriconazole, CYP2C19,DEI)(fluconazole, CYP2C9,DEI)(fluconazole, CYP2C19,DEI)(micafungin, CYP2C9,NDEI)(micafungin, CYP2C19,NDEI)">
<sentence>These results suggest that <cons lex="miconazole" sem="G_DRUG">miconazole</cons> is the strongest <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> and <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>, followed by <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> and <cons lex="fluconazole" sem="G_DRUG">fluconazole</cons>, whereas <cons lex="micafungin" sem="G_DRUG">micafungin</cons> would <cons sem="G_NEGATIVEEFFECT">not</cons> cause clinically <cons sem="G_CHANGE">significant</cons> interactions with other drugs that are <cons sem="G_MECHANISM">metabolized</cons> by <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> or <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> via the <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
</annotation>
<sentence>The <cons sem="G_IVITPARA">IC50</cons> value of <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> against <cons lex="nifedipine" sem="G_DRUG">nifedipine</cons> <cons lex="oxidation" sem="G_MECHANISM">oxidation</cons> was comparable with that of <cons lex="fluconazole" sem="G_DRUG">fluconazole</cons> and <cons lex="micafungin" sem="G_DRUG">micafungin</cons> and higher than that of <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> and <cons lex="miconazole" sem="G_DRUG">miconazole</cons>.</sentence>
<sentence>The <cons sem="G_MECHANISM">stimulation</cons> of the <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>-, <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>-, or <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>-mediated reactions by 15-min preincubation was <cons sem="G_NEGATIVEEFFECT">not</cons> observed for any of the antifungal drugs, suggesting that these drugs are <cons sem="G_NEGATIVEEFFECT">not</cons> mechanism-based <cons sem="G_MECHANISM">inhibitors</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:16141545</bibliomisc>
</articleinfo>
<title>
<sentence>Contribution of human hepatic cytochrome p450 isoforms to the <cons sem="G_MECHANISM">metabolism</cons> of psychotropic drugs.</sentence>
</title>
<abstract>
<sentence>The metabolic activities of six psychotropic drugs, <cons lex="diazepam" sem="G_DRUG">diazepam</cons>, <cons lex="clotiazepam" sem="G_DRUG">clotiazepam</cons>,<cons sem="G_DRUG">tofisopam</cons>, <cons sem="G_DRUG">etizolam</cons>,<cons sem="G_DRUG">tandospirone</cons>, and <cons lex="imipramine" sem="G_DRUG">imipramine</cons>, were determined for 14 isoforms of recombinant human hepatic cytochrome P450s (CYPs) and human liver microsomes by measuring the disappearance rate of parent compounds.</sentence>
<sentence>In vitro kinetic studies revealed that <cons sem="G_IVITPARA">Vmax/Km</cons> values in human liver microsomes were the highest for <cons sem="G_DRUG">tofisopam</cons>, followed by <cons sem="G_DRUG">tandospirone</cons>&gt; <cons sem="G_DRUG">clotiazepam</cons>&gt; <cons sem="G_DRUG">imipramine</cons>, <cons lex="diazepam" sem="G_DRUG">diazepam</cons>, and <cons sem="G_DRUG">etizolam</cons>.</sentence>
<sentence>Among the recombinant CYPs, <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> exhibited the highest metabolic activities of all compounds except for <cons lex="clotiazepam" sem="G_DRUG">clotiazepam</cons> and <cons lex="imipramine" sem="G_DRUG">imipramine</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(clotiazepam, CYP2B6,DEI)(clotiazepam, CYP3A4,DEI)(clotiazepam, CYP2C18,DEI)(clotiazepam, CYP2C19,DEI)(imipramine, CYP2D6,DEI)">
<sentence>The <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="clotiazepam" sem="G_DRUG">clotiazepam</cons> was <cons lex="catalyzed" sem="G_MECHANISM">catalyzed</cons> by <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons>, <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, <cons lex="cyp2c18" sem="G_CYP">CYP2C18</cons>, and <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>, and <cons lex="imipramine" sem="G_DRUG">imipramine</cons> was <cons sem="G_MECHANISM">metabolized</cons> by <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> most efficiently.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(ketoconazole, diazepam,DDI)(ketoconazole, clotiazepam,DDI)(ketoconazole, etizolam,DDI)(quinidine, imipramine,NDDI)">
<sentence>In addition, the metabolic activities of <cons lex="diazepam" sem="G_DRUG">diazepam</cons>, <cons lex="clotiazepam" sem="G_DRUG">clotiazepam</cons>, and <cons sem="G_DRUG">etizolam</cons> in human liver microsomes were <cons sem="G_MECHANISM">inhibited</cons> by 2.5 microM <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>, a <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitor</cons>, by 97.5%, 65.1%, and 83.5%, respectively, and the <cons lex="imipramine" sem="G_DRUG">imipramine</cons> <cons sem="G_MECHANISM">metabolism</cons> was <cons sem="G_NEGATIVEEFFECT">not</cons> detected after the addition of <cons sem="G_NUMBER">1 or 10 microM</cons> <cons lex="quinidine" sem="G_DRUG">quinidine</cons>, a <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> <cons sem="G_MECHANISM">inhibitor</cons>.</sentence>
</annotation>
<sentence>These results suggest that the psychotropic drugs investigated are <cons sem="G_IVITPARA">metabolized</cons> predominantly by <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, except that <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> <cons sem="G_MECHANISM">catalyzes</cons> the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="imipramine" sem="G_DRUG">imipramine</cons>.</sentence>
<sentence>In addition, this approach based on the disappearance rate appears to be useful for the identification of the responsible CYP isoform(s) of older drugs, for which metabolic profiles have <cons sem="G_NEGATIVEEFFECT">not</cons> been reported.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:16035375</bibliomisc>
</articleinfo>
<title>
<sentence>Rate-limiting <cons sem="G_MECHANISM">biotransformation</cons> of <cons lex="triamterene" sem="G_DRUG">triamterene</cons> is mediated by <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>.</sentence>
</title>
<abstract>
<sentence><cons lex="triamterene" sem="G_DRUG">Triamterene</cons> (TA), a potassium-sparing diuretic, is extensively <cons sem="G_MECHANISM">metabolized</cons> by hydroxylation in 4'-position and subsequent conjugation by cytosolic sulfotransferases.</sentence>
<sentence>To identify the cytochrome P450 enzyme(s) <cons sem="G_MECHANISM">catalyzing</cons> hydroxylation of <cons lex="triamterene" sem="G_DRUG">triamterene</cons> (the rate-limiting step in the formation of the sulfate ester (STA)), in vitro incubation studies were performed with human liver microsomes.</sentence>
<sentence>Initial rates of <cons sem="G_DRUG">TA</cons> hydroxylation (<cons sem="G_NUMBER">0 - 300 microM</cons>) were determined during a ten-minute-incubation period with liver microsomes of two donors.</sentence>
<sentence>The role of individual CYP enzymes was determined by pre-incubation with selective <cons sem="G_MECHANISM">inhibitors/alternative substrates</cons>.</sentence>
<sentence>Vice versa, the effect of <cons sem="G_IVITPARA">TA</cons> (<cons sem="G_NUMBER">0 - 500 microM</cons>) on 3-demethylation of <cons lex="caffeine" sem="G_DRUG">caffeine</cons> (<cons sem="G_NUMBER">0 - 1,000 microM</cons>) was assessed.</sentence>
<sentence>Metabolite concentrations were estimated by reversed-phase HPLC methods.</sentence>
<sentence><cons sem="G_DRUG">TA</cons> <cons sem="G_IVITPARA">Km</cons> values without <cons sem="G_MECHANISM">inhibitors</cons> were <cons sem="G_NUMBER">60</cons> and <cons sem="G_NUMBER">142 microM</cons>, <cons sem="G_IVITPARA">Vmax</cons> was <cons sem="G_NUMBER">177 and 220 pmol/min/mg</cons> protein, respectively.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Furafylline, 4'-hydroxy-TA,DDI)(omeprazole, 4'-hydroxy-TA,ADDI)(quinidine, 4'-hydroxy-TA,ADDI)(ketoconazole, 4'-hydroxy-TA,ADDI)(erythromycin, 4'-hydroxy-TA,ADDI)">
<sentence>Mean <cons sem="G_MECHANISM">inhibitor</cons> <cons sem="G_MECHANISM">induced</cons> <cons sem="G_MECHANISM">changes</cons> of 4'-hydroxy-TA formation were as follows: <cons lex="furafylline" sem="G_DRUG">Furafylline</cons> <cons sem="G_NUMBER">25 microM</cons> (<cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>), complete <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> (<cons sem="G_NUMBER">-100%</cons>); <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> <cons sem="G_NUMBER">250 microM</cons> (<cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> <cons sem="G_MECHANISM">inhibitor</cons>/ <cons sem="G_CYP">CYP2C 19</cons>substrate), <cons sem="G_NUMBER">-30%</cons>;<cons sem="G_DRUG">coumarin</cons> <cons sem="G_NUMBER">25 microM</cons> (<cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons>), -11%; <cons lex="quinidine" sem="G_DRUG">quinidine</cons> <cons sem="G_NUMBER">25 microM</cons> (<cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>), <cons sem="G_NUMBER">-9%</cons>; <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> <cons sem="G_NUMBER">25 microM</cons> (<cons lex="cyp3a" sem="G_CYP">CYP3A</cons>), <cons sem="G_NUMBER">-18%</cons>; and <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> <cons sem="G_NUMBER">250 microM</cons> (<cons lex="cyp3a" sem="G_CYP">CYP3A</cons>), <cons sem="G_NUMBER">-8%</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(TA, caffeine 3-demethylation,ADDI)">
<sentence>In the reverse <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> studies,<cons sem="G_DRUG">TA</cons> competitively <cons sem="G_MECHANISM">inhibited</cons> <cons lex="caffeine" sem="G_DRUG">caffeine</cons> 3-demethylation with <cons sem="G_IVITPARA">Ki</cons> values of <cons sem="G_NUMBER">65</cons> and <cons sem="G_NUMBER">111 microM</cons>, respectively.</sentence>
</annotation>
<sentence>4'-hydroxylation of <cons sem="G_DRUG">TA</cons> in humans appears to be mediated exclusively by <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>.</sentence>
<sentence><cons lex="inhibition" sem="G_MECHANISM">Inhibition</cons> or <cons lex="induction" sem="G_MECHANISM">induction</cons> of <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> will <cons sem="G_MECHANISM">change</cons> the time course of both <cons sem="G_DRUG">TA</cons> and its active phase-II metabolite.</sentence>
<sentence>The net pharmacodynamic effect of such <cons sem="G_MECHANISM">changes</cons> is difficult to predict and needs to be evaluated in clinical studies.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15983905</bibliomisc>
</articleinfo>
<title>
<sentence>A potentially <cons sem="G_CHANGE">significant</cons> interaction between <cons lex="efavirenz" sem="G_DRUG">efavirenz</cons> and <cons sem="G_DRUG">phenytoin</cons>: a case report and review of the literature.</sentence>
</title>
<abstract>
<sentence>Although it has <cons sem="G_NEGATIVEEFFECT">not</cons> been demonstrated yet, <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons> is expected to <cons sem="G_CHANGE">reduce</cons> <cons lex="efavirenz" sem="G_DRUG">efavirenz</cons> exposure through coinduction of cytochrome P450 (CYP) <cons lex="3a4" sem="G_CYP">3A4</cons> and <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons>.</sentence>
<sentence>Conversely, <cons lex="efavirenz" sem="G_DRUG">efavirenz</cons> has been shown in vitro to <cons sem="G_MECHANISM">inhibit</cons> the enzymes responsible for <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons> <cons sem="G_IVITPARA">metabolism</cons>, <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> and <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>.</sentence>
<sentence>We report a case in which a potential bidirectional drug interaction between <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons> and <cons lex="efavirenz" sem="G_DRUG">efavirenz</cons> resulted in lower-than-expected <cons lex="efavirenz" sem="G_DRUG">efavirenz</cons> concentrations and elevated <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons> levels.</sentence>
<sentence>Therapeutic drug monitoring was used in this case to ensure adequate <cons lex="efavirenz" sem="G_DRUG">efavirenz</cons> exposure.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15842554</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="chlorpropamide" sem="G_DRUG">Chlorpropamide</cons> 2-hydroxylation is <cons sem="G_MECHANISM">catalysed</cons> by <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> and <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> in vitro: <cons lex="chlorpropamide" sem="G_DRUG">chlorpropamide</cons> disposition is <cons sem="G_MECHANISM">influenced</cons> by <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, but <cons sem="G_NEGATIVEEFFECT">not</cons> by <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> genetic polymorphism.</sentence>
</title>
<abstract>
<sentence>We evaluated the involvement of cytochrome P450 (CYP) isoforms <cons lex="2c9" sem="G_CYP">2C9</cons> and <cons lex="2c19" sem="G_CYP">2C19</cons> in <cons lex="chlorpropamide" sem="G_DRUG">chlorpropamide</cons> 2-hydroxylation in vitro and in <cons lex="chlorpropamide" sem="G_DRUG">chlorpropamide</cons> disposition in vivo.</sentence>
<sentence>To identify CYP isoforms(s) that <cons sem="G_MECHANISM">catalyse</cons> 2-hydroxylation of <cons lex="chlorpropamide" sem="G_DRUG">chlorpropamide</cons>, the incubation studies were conducted using human liver microsomes and recombinant CYP isoforms.</sentence>
<sentence>To evaluate whether genetic polymorphisms of <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> and/or <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> <cons sem="G_MECHANISM">influence</cons> the disposition of <cons lex="chlorpropamide" sem="G_DRUG">chlorpropamide</cons>, a single oral dose of <cons sem="G_NUMBER">250 mg</cons> <cons lex="chlorpropamide" sem="G_DRUG">chlorpropamide</cons> was administered to 21 healthy subjects pregenotyped for <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> and <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>.</sentence>
<sentence>In human liver microsomal incubation studies, the formation of 2-hydroxychlorpropamide (2-OH-<cons lex="chlorpropamide" sem="G_DRUG">chlorpropamide</cons>), a major <cons lex="chlorpropamide" sem="G_DRUG">chlorpropamide</cons> metabolite in human, has been best described by a one-enzyme model with estimated <cons sem="G_IVITPARA">K(m)</cons> and <cons sem="G_IVITPARA">V(max)</cons> of  <cons sem="G_NUMBER">121.7 +/- 19.9 microm</cons> and <cons sem="G_NUMBER">16.1 +/- 5.0 pmol min(-1) mg(-1)</cons> protein, respectively.</sentence>
<sentence>In incubation studies using human recombinant CYP isoforms, however, 2-OH-<cons lex="chlorpropamide" sem="G_DRUG">chlorpropamide</cons> was <cons sem="G_MECHANISM">formed</cons> by both <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> and <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> with similar <cons sem="G_IVITPARA">intrinsic clearances</cons> (<cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> vs. <cons sem="G_CYP">CYP2C19</cons>: <cons sem="G_NUMBER">0.26 vs. 0.22 microl min(-1) nmol(-1)</cons> protein).</sentence>
<annotation sem="INVITROCDDIS" ddi="(sulfaphenazole, 2-OH-chlorpropamide,DDI)(S-mephenytoin, 2-OH-chlorpropamide,NDDI)(ketoconazole, 2-OH-chlorpropamide,NDDI)(quinidine, 2-OH-chlorpropamide,NDDI)(furafylline, 2-OH-chlorpropamide,NDDI)">
<sentence>Formation of 2-OH-<cons lex="chlorpropamide" sem="G_DRUG">chlorpropamide</cons> in human liver microsomes was <cons sem="G_CHANGE">significantly</cons> <cons sem="G_MECHANISM">inhibited</cons> by <cons sem="G_IVITPARA">sulfaphenazole</cons>,but <cons sem="G_NEGATIVEEFFECT">not</cons> by S-<cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons>, <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>, <cons lex="quinidine" sem="G_DRUG">quinidine</cons>, or <cons lex="furafylline" sem="G_DRUG">furafylline</cons>.</sentence>
</annotation>
<sentence>In in vivo clinical trials, eight subjects with the CYP2C9*1/*3 genotype exhibited <cons sem="G_CHANGE">significantly</cons> lower nonrenal <cons sem="G_IVITPARA">clearance</cons>  <cons sem="G_NUMBER">[*1/*3 vs.*1/*1: 1.8 +/- 0.2 vs. 2.4 +/- 0.1 ml h(-1) kg(-1), P &lt; 0.05; 95%</cons> confidence interval (CI) on the difference 0.2, 1.0] and higher metabolic ratios (of chlorpropamide/2-OH-<cons lex="chlorpropamide" sem="G_DRUG">chlorpropamide</cons> in urine: <cons sem="G_NUMBER">*1/*3 vs.*1/*1: 1.01 +/- 0.19 vs. 0.56 +/- 0.08, P &lt; 0.05; 95% CI on the difference - 0.9, - 0.1</cons>) than did 13 subjects with <cons sem="G_CYP">CYP2C9*1/*1</cons> genotype.</sentence>
<sentence>In contrast, <cons sem="G_NEGATIVEEFFECT">no</cons> differences in <cons lex="chlorpropamide" sem="G_DRUG">chlorpropamide</cons> pharmacokinetics were observed for subjects with the <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> extensive metabolizer vs. poor metabolizer genotypes.</sentence>
<sentence>These results suggest that <cons lex="chlorpropamide" sem="G_DRUG">chlorpropamide</cons> disposition is principally determined by <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> activity in vivo, although both <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> and <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> have a <cons sem="G_MECHANISM">catalysing</cons> activity of <cons lex="chlorpropamide" sem="G_DRUG">chlorpropamide</cons> 2-hydroxylation pathway.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15802801</bibliomisc>
</articleinfo>
<title>
<sentence>Different effects of <cons lex="desipramine" sem="G_DRUG">desipramine</cons> on <cons sem="G_DRUG">bufuralol</cons> 1''-hydroxylation by rat and human <cons sem="G_CYP">CYP2D</cons> enzymes.</sentence>
</title>
<abstract>
<sentence><cons sem="G_MECHANISM">Inhibitory</cons> effects of <cons lex="desipramine" sem="G_DRUG">desipramine (DMI)</cons> on rat and human <cons sem="G_CYP">CYP2D</cons> enzymes were studied using <cons sem="G_DRUG">bufuralol (BF)</cons> 1''-hydroxylation as an index.</sentence>
<sentence><cons lex="inhibition" sem="G_MECHANISM">Inhibition</cons> was examined under the following two conditions: 1)<cons sem="G_DRUG">DMI</cons> was co-incubated with <cons sem="G_DRUG">BF</cons>  and NADPH in the reaction mixture containing rat or human liver microsomes or yeast cell microsomes expressing rat <cons sem="G_CYP">CYP2D1</cons>, <cons sem="G_CYP">CYP2D2</cons> or human <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> (co-incubation); 2) <cons sem="G_DRUG">DMI</cons> was preincubated with NADPH and the same enzyme sources prior to adding the substrate (preincubation).</sentence>
<sentence>When either rat liver microsomes or recombinant <cons sem="G_CYP">CYP2D2</cons> was employed, the preincubation with <cons sem="G_DRUG">DMI</cons> (<cons sem="G_NUMBER">0.3 microM</cons>) caused a <cons sem="G_CHANGE">greater</cons> <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of <cons sem="G_DRUG">BF</cons>1''-hydroxylation than the co-incubation did, whereas <cons sem="G_DRUG">BF</cons> 1''-hydroxylation by rat <cons sem="G_CYP">CYP2D1</cons> was <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">markedly</cons> affected under the same conditions.</sentence>
<annotation sem="INVITROCDDIS" ddi="(DMI, BF 1''-hydroxylation,DDI)">
<sentence>The <cons sem="G_MECHANISM">inhibitory</cons> effect of <cons sem="G_DRUG">DMI</cons> on <cons sem="G_DRUG">BF</cons> 1''-hydroxylation by human liver microsomal fractions or recombinant <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> was much lower than that on the hydroxylation by rat liver microsomes or <cons sem="G_CYP">CYP2D2</cons>.</sentence>
</annotation>
<sentence>Kinetic studies demonstrated that the <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons>-type changed from competitive for the co-incubation to noncompetitive for the preincubation in the case of <cons sem="G_CYP">CYP2D2</cons>, whereas the <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons>-type was competitive for both the co-incubation and the preincubation in the case of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>.</sentence>
<sentence>Furthermore, the loss of activity of rat <cons sem="G_CYP">CYP2D2</cons> under the preincubation conditions followed pseudo-first-order kinetics.</sentence>
<sentence>Binding experiments employing the recombinant enzymes and  [(3)H]-DMI revealed that <cons sem="G_CYP">CYP2D2</cons> and <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> were the only prominent proteins to which considerable radioactive <cons sem="G_DRUG">DMI</cons> metabolite(s) bound.</sentence>
<sentence>These results indicate that rat <cons sem="G_CYP">CYP2D2</cons> biotransforms <cons sem="G_DRUG">DMI</cons> into reactive metabolite(s), which covalently bind to <cons sem="G_CYP">CYP2D2</cons>, resulting in <cons sem="G_MECHANISM">inactivation</cons> of the enzyme.</sentence>
<sentence>In contrast, human <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> <cons sem="G_CHANGE">may</cons> also <cons sem="G_MECHANISM">biotransform</cons> <cons sem="G_DRUG">DMI</cons> into some metabolite(s) that covalently bind to <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>, but that do <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_MECHANISM">inactivate</cons> the enzyme.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15788367</bibliomisc>
</articleinfo>
<title>
<sentence>Cytochrome P450-dependent <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="gefitinib" sem="G_DRUG">gefitinib</cons>.</sentence>
</title>
<abstract>
<sentence>The in vitro <cons sem="G_MECHANISM">metabolism</cons> of  [(14)C]-<cons lex="gefitinib" sem="G_DRUG">gefitinib</cons> (<cons sem="G_NUMBER">1-3 microM</cons>) was investigated using human liver microsomes and a range of expressed human <cons sem="G_CYP">cytochrome P450</cons> enzymes, with particular focus on the formation of O-desmethyl-<cons lex="gefitinib" sem="G_DRUG">gefitinib</cons> <cons sem="G_DRUG">(M523595)</cons>, the major metabolite observed in human plasma.</sentence>
<sentence>High-performance liquid chromatography with ultraviolet light, radiochemical and mass spectral analysis, together with the availability of authentic standards, enabled quantification and structural identification of metabolites.</sentence>
<sentence>On incubation with pooled human liver microsomes,  [(14)C]-<cons lex="gefitinib" sem="G_DRUG">gefitinib</cons> underwent rapid and extensive <cons sem="G_MECHANISM">metabolism</cons> to a number of metabolites, although <cons sem="G_DRUG">M523595</cons> was only a <cons sem="G_CHANGE">minor</cons> microsomal product.</sentence>
<annotation sem="INVITROVDDIS" ddi="(ketoconazole, O-desmethyl-gefitinib,DDI)(quinidine, M523595,DDI)">
<sentence>Formation of most metabolites was <cons sem="G_CHANGE">markedly</cons> <cons sem="G_CHANGE">decreased</cons> by <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>, but <cons sem="G_DRUG">M523595</cons> production was <cons sem="G_MECHANISM">inhibited</cons> only by <cons lex="quinidine" sem="G_DRUG">quinidine</cons>.</sentence>
</annotation>
<sentence><cons lex="gefitinib" sem="G_DRUG">Gefitinib</cons> was <cons sem="G_MECHANISM">metabolized</cons> extensively by expressed <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, producing a similar range of metabolites to liver microsomes, but <cons sem="G_DRUG">M523595</cons> was <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_MECHANISM">formed</cons>.</sentence>
<sentence><cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, <cons lex="2c9" sem="G_CYP">2C9</cons> and <cons lex="2c19" sem="G_CYP">2C19</cons> produced <cons sem="G_NEGATIVEEFFECT">no</cons> measurable <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="gefitinib" sem="G_DRUG">gefitinib</cons> ,while <cons lex="cyp3a5" sem="G_CYP">CYP3A5</cons> produced a range of metabolites similar to <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, but to a much lower degree.</sentence>
<annotation sem="INVITROCDDIS" ddi="(CYP2D6, gefitinib,DEI)">
<sentence>In contrast, <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> <cons sem="G_MECHANISM">catalysed</cons> rapid and extensive <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="gefitinib" sem="G_DRUG">gefitinib</cons> to <cons sem="G_DRUG">M523595</cons>.</sentence>
</annotation>
<sentence>While formation of <cons sem="G_DRUG">M523595</cons> was <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> mediated, the overall <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="gefitinib" sem="G_DRUG">gefitinib</cons> was dependent primarily on <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, and this was <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">obviously</cons> diminished in liver microsomes from <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> poor metabolizers.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15771232</bibliomisc>
</articleinfo>
<title>
<sentence>Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes.</sentence>
</title>
<abstract>
<sentence>The <cons lex="induction" sem="G_MECHANISM">induction</cons> potential of different fibric acid derivatives on human drug metabolizing enzymes was evaluated to help assess the role of enzyme <cons lex="induction" sem="G_MECHANISM">induction</cons> on pharmacokinetic drug interactions.</sentence>
<sentence>Effects of <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons>, <cons sem="G_DRUG">fenofibric acid</cons>, and <cons sem="G_DRUG">clofibric acid</cons> on expression levels of cytochromes P450 (CYPs) <cons lex="3a4" sem="G_CYP">3A4</cons> and <cons lex="2c8" sem="G_CYP">2C8</cons> and UDP-glucuronyltransferase (UGT) <cons lex="1a1" sem="G_CYP">1A1</cons> were evaluated in primary human hepatocyte cultures.</sentence>
<sentence>The potential for these fibrates to <cons sem="G_MECHANISM">activate</cons> human pregnane X receptor (PXR) also was studied in a cell-based PXR reporter gene assay.</sentence>
<annotation sem="INVITROVDDIS" ddi="(gemfibrozil, CYP3A4,DEI)(gemfibrozil, CYP2C8,DEI)(gemfibrozil, UGT1A1,DEI)(fenofibric acid, CYP3A4,DEI)(fenofibric acid, CYP2C8,DEI)(fenofibric acid, UGT1A1,DEI)(clofibric acid, CYP3A4,DEI)(clofibric acid, CYP2C8,DEI)(clofibric acid, UGT1A1,DEI)">
<sentence>All three fibrates caused <cons sem="G_CHANGE">increases</cons> in mRNA levels of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> (<cons sem="G_NUMBER">2- to 5-fold</cons>), <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> (<cons sem="G_NUMBER">2- to 6-fold</cons>), and UGT1A1 (<cons sem="G_NUMBER">2- to 3-fold</cons>).</sentence>
</annotation>
<sentence>On average, the effects on <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> were less than (<cons sem="G_NUMBER">&lt; or =30%</cons> of <cons lex="rifampin" sem="G_DRUG">rifampin</cons>), while those on <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> and UGT1A1 were comparable to or <cons sem="G_CHANGE">slightly</cons> higher than (up to <cons sem="G_NUMBER">200%</cons> of <cons lex="rifampin" sem="G_DRUG">rifampin</cons>) the corresponding effects observed with <cons lex="rifampin" sem="G_DRUG">rifampin</cons> (<cons sem="G_NUMBER">10 microM</cons>).</sentence>
<annotation sem="INVITROCDDIS" ddi="(gemfibrozil, testosterone 6beta hydroxylase,ADDI)(fenofibric acid, testosterone 6beta hydroxylase,ADDI)(clofibric acid, testosterone 6beta hydroxylase,ADDI)">
<sentence>Consistent with the mRNA results, all fibrates caused <cons sem="G_CHANGE">moderate</cons> (approximately <cons sem="G_NUMBER">2- to 3-fold</cons>) <cons sem="G_CHANGE">increases</cons> in <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activity (measured by <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6beta hydroxylase), as compared to about a <cons sem="G_NUMBER">10-fold</cons> <cons lex="increase" sem="G_CHANGE">increase</cons> by <cons lex="rifampin" sem="G_DRUG">rifampin</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(clofibric acid, amodiaquine N-deethylase,DDI)(fenofibric acid, amodiaquine N-deethylase,DDI)(rifampin, amodiaquine N-deethylase,DDI)">
<sentence><cons sem="G_CHANGE">significant</cons> <cons sem="G_CHANGE">increases</cons> (<cons sem="G_NUMBER">3- to 6-fold</cons>) in <cons lex="amodiaquine" sem="G_DRUG">amodiaquine</cons> N-deethylase (a functional probe for <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> activity) also were observed with <cons sem="G_DRUG">clofibric acid</cons>,<cons sem="G_DRUG">fenofibric acid</cons>, and <cons lex="rifampin" sem="G_DRUG">rifampin</cons>, in agreement with the mRNA finding.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(gemfibrozil, CYP2C8,DEI)">
<sentence>However, in contrast to the mRNA <cons lex="induction" sem="G_MECHANISM">induction</cons>, <cons sem="G_CHANGE">marked</cons> <cons sem="G_CHANGE">decreases</cons> (<cons sem="G_NUMBER">&gt;60%</cons>) in <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> activity were obtained with <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons> treatment.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(gemfibrozil, amodiaquine N-deethylase,DDI)(fenofibric acid, amodiaquine N-deethylase,NDDI)(clofibric acid, amodiaquine N-deethylase,NDDI)(rifampin, amodiaquine N-deethylase,NDDI)">
<sentence>Consistent with this finding, co-incubation of <cons lex="amodiaquine" sem="G_DRUG">amodiaquine</cons> with <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons>  but <cons sem="G_NEGATIVEEFFECT">not</cons> with <cons sem="G_DRUG">fenofibric acid</cons>,<cons sem="G_DRUG">clofibric acid</cons>, or <cons lex="rifampin" sem="G_DRUG">rifampin</cons>,in human liver microsomes or hepatocytes resulted in <cons sem="G_CHANGE">significantly</cons>  <cons sem="G_CHANGE">decreased</cons> <cons lex="amodiaquine" sem="G_DRUG">amodiaquine</cons> N-deethylase activity (<cons sem="G_IVITPARA">IC50</cons> = <cons sem="G_NUMBER">80 microM</cons> for <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons>, <cons sem="G_NUMBER">&gt;500 microM</cons> for <cons sem="G_DRUG">fenofibric</cons> or <cons sem="G_DRUG">clofibric acid</cons>, and <cons sem="G_NUMBER">&gt;50 microM</cons> for <cons lex="rifampin" sem="G_DRUG">rifampin</cons>).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(gemfibrozil, glucuronidation of chrysin,ADDI)(fenofibric acid, glucuronidation of chrysin,ADDI)(clofibric acid, glucuronidation of chrysin,ADDI)">
<sentence>Similar to <cons lex="rifampin" sem="G_DRUG">rifampin</cons>, all three fibrates caused a <cons sem="G_CHANGE">modest</cons> change in the <cons sem="G_MECHANISM">glucuronidation</cons> of <cons sem="G_DRUG">chrysin</cons>, a nonspecific substrate of UGTs.</sentence>
</annotation>
<sentence><cons sem="G_NEGATIVEEFFECT">No</cons> <cons sem="G_CHANGE">significant</cons> <cons sem="G_MECHANISM">activation</cons> on human pregnane X receptor (PXR) was observed with the three fibrates in a PXR reporter gene assay.</sentence>
<annotation sem="INVITROCDDIS" ddi="(fenofibric acid, CYP3A4,DEI)(clofibric acid, CYP2C8,DEI)">
<sentence>In human hepatocytes, both <cons sem="G_DRUG">fenofibric acid</cons> and <cons sem="G_DRUG">clofibric acid</cons> are inducers of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Gemfibrozil, CYP3A4,DEI)(Gemfibrozil, CYP2C8,NDEI)">
<sentence><cons lex="gemfibrozil" sem="G_DRUG">Gemfibrozil</cons> is also an <cons sem="G_MECHANISM">inducer</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, but acts as both an <cons sem="G_MECHANISM">inducer</cons> and an <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons>.</sentence>
</annotation>
<sentence>In this system, all fibrates are weak inducers of UGT1A1.</sentence>
<sentence>The enzyme inducing effects of fibrates appear to be mediated via a mechanism(s) other than PXR <cons sem="G_MECHANISM">activation</cons>.</sentence>
<sentence>These results suggest that fibrates <cons sem="G_CHANGE">may</cons> have potential to cause various pharmacokinetic drug interactions via their differential effects on enzyme <cons lex="induction" sem="G_MECHANISM">induction</cons> and/or <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15684493</bibliomisc>
</articleinfo>
<title>
<sentence>Identification of human P450 isoforms involved in the <cons sem="G_MECHANISM">metabolism</cons> of the antiallergic drug,<cons sem="G_DRUG">oxatomide</cons>, and its kinetic parameters and <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> constants.</sentence>
</title>
<abstract>
<sentence><cons sem="G_DRUG">Oxatomide</cons> is an antiallergic drug used for the treatment of diseases mediated by type I allergy.</sentence>
<sentence>Recently, <cons lex="terfenadine" sem="G_DRUG">terfenadine</cons> and <cons lex="astemizole" sem="G_DRUG">astemizole</cons>, which have antiallergic actions similar to those of <cons sem="G_DRUG">oxatomide</cons>, showed side effects on the cardiovascular system.</sentence>
<sentence>This <cons sem="G_CHANGE">might</cons> be because concomitant drugs such as <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> <cons sem="G_MECHANISM">inhibit</cons> cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4</cons> (<cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>), the enzyme responsible for the degradation of <cons lex="terfenadine" sem="G_DRUG">terfenadine</cons> and <cons lex="astemizole" sem="G_DRUG">astemizole</cons>, and thus the blood concentrations of the drugs are abnormally <cons sem="G_CHANGE">increased</cons>.</sentence>
<sentence>In another article of this issue, we have reported that <cons sem="G_DRUG">oxatomide</cons> is <cons sem="G_MECHANISM">metabolized</cons> by <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>-Val and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, and simultaneously <cons sem="G_MECHANISM">inhibits</cons> the <cons sem="G_MECHANISM">metabolism</cons> of the model substrates for these enzymes.</sentence>
<sentence>In this study, we performed the kinetic analysis of <cons sem="G_DRUG">oxatomide</cons> <cons sem="G_DRUG">metabolism</cons> using microsomes prepared from human liver, and found that the<cons sem="G_IVITPARA">Km</cons> and <cons sem="G_IVITPARA">Vmax</cons> values were <cons sem="G_NUMBER">26.1 microM</cons> and <cons sem="G_NUMBER">1254.4 pmol/mg protein/min</cons>, respectively.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Ketoconazole, oxatomide,DDI)">
<sentence><cons lex="ketoconazole" sem="G_DRUG">Ketoconazole</cons>, one of the representative <cons sem="G_MECHANISM">inhibitors</cons> for <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, potently <cons sem="G_MECHANISM">inhibited</cons> the <cons sem="G_MECHANISM">metabolism</cons> of oxatomide,but other well-known CYP <cons sem="G_MECHANISM">inhibitor</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> show <cons sem="G_CHANGE">significant</cons> <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> .</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(CYP3A4, oxatomide,DEI)">
<sentence>These results suggest that the <cons sem="G_MECHANISM">metabolism</cons> of oxatomide is principally <cons lex="catalyzed" sem="G_MECHANISM">catalyzed</cons> by <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(oxatomide, (+/-) bufuralol,ADDI)(oxatomide, testosterone,ADDI)">
<sentence>Furthermore,<cons sem="G_DRUG">oxatomide</cons> <cons sem="G_MECHANISM">inhibited</cons> the <cons sem="G_MECHANISM">metabolism</cons> of (+/-) <cons sem="G_DRUG">bufuralol</cons> and <cons lex="testosterone" sem="G_DRUG">testosterone</cons>, model substrates for <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, respectively, in a dose-dependent manner with the <cons sem="G_IVITPARA">Ki</cons> values of <cons sem="G_NUMBER">57.4</cons> and <cons sem="G_NUMBER">24.3 microM</cons>, respectively.</sentence>
</annotation>
<sentence>These observations, together with the finding that the putative highest concentration of <cons sem="G_DRUG">oxatomide</cons> in blood was congruent with <cons sem="G_NUMBER">40 ng/ml</cons> ( congruent with <cons sem="G_NUMBER">93 nM</cons>) at 4 h after each dosage during consecutive 6-d administration, encouraged us to conclude that <cons sem="G_DRUG">oxatomide</cons> won't <cons sem="G_MECHANISM">inhibit</cons> <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> or <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> at clinical doses.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15640381</bibliomisc>
</articleinfo>
<title>
<sentence>Cytochrome P450 <cons lex="3a" sem="G_CYP">3A</cons>-mediated <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="buspirone" sem="G_DRUG">buspirone</cons> in human liver microsomes.</sentence>
</title>
<abstract>
<sentence>This study was carried out to determine the metabolic pathways of <cons lex="buspirone" sem="G_DRUG">buspirone</cons> and cytochrome P450 (P450) isoform(s) responsible for <cons lex="buspirone" sem="G_DRUG">buspirone</cons> <cons sem="G_MECHANISM">metabolism</cons> in human liver microsomes (HLMs).</sentence>
<sentence><cons lex="buspirone" sem="G_DRUG">Buspirone</cons> mainly underwent N-dealkylation to 1-pyrimidinylpiperazine (1-PP), N-<cons lex="oxidation" sem="G_MECHANISM">oxidation</cons> on the <cons lex="piperazine" sem="G_DRUG">piperazine</cons> ring to <cons lex="buspirone" sem="G_DRUG">buspirone</cons> N-oxide (Bu N-oxide), and hydroxylation to 3'-hydroxybuspirone (3'-OH-Bu), 5-hydroxybuspirone (5-OH-Bu), and 6'-hydroxybuspirone (6'-OH-Bu) in HLMs.</sentence>
<sentence>The apparent <cons sem="G_IVITPARA">K(m)</cons> values for <cons lex="buspirone" sem="G_DRUG">buspirone</cons> metabolite formation in pooled HLMs were <cons sem="G_NUMBER">8.7</cons> (1-PP), <cons sem="G_NUMBER">34.0</cons> (Bu N-oxide), <cons sem="G_NUMBER">4.3</cons> (3'-OH-Bu), 11.4/514 (5-OH-Bu), and <cons sem="G_NUMBER">8.8 microM</cons> (6'-OH-Bu).</sentence>
<annotation sem="INVITROCDDIS" ddi="(ketoconazole, Bu N-oxide,DDI)(ketoconazole, 3'-OH-Bu,DDI)(ketoconazole, 5-OH-Bu,DDI)(ketoconazole, 6'-OH-Bu,DDI)">
<sentence><cons lex="cyp3a" sem="G_CYP">CYP3A</cons> inhibitor <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> (<cons sem="G_NUMBER">1 microM</cons>) completely <cons sem="G_MECHANISM">inhibited</cons> the formation of all major metabolites in HLMs (<cons sem="G_NUMBER">0-16%</cons> of control),whereas the chemical <cons sem="G_MECHANISM">inhibitor</cons> selective to other P450 isoforms had <cons sem="G_CHANGE">little</cons> or <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem="G_MECHANISM">inhibitory</cons> effect.</sentence> 
</annotation>
<sentence>Recombinant <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, <cons lex="cyp3a5" sem="G_CYP">CYP3A5</cons>, and <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> exhibited <cons lex="buspirone" sem="G_DRUG">buspirone</cons> <cons lex="oxidation" sem="G_MECHANISM">oxidation</cons> activities among nine P450 isoforms tested.</sentence>
<sentence>The overall <cons sem="G_MECHANISM">metabolism</cons> rate of <cons sem="G_NUMBER">5 microM</cons> <cons lex="buspirone" sem="G_DRUG">buspirone</cons> by <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> was <cons sem="G_NUMBER">18-fold</cons> <cons sem="G_CHANGE">greater</cons> than that by <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> and <cons sem="G_NUMBER">35-fold</cons> <cons sem="G_CHANGE">greater</cons> than that by <cons lex="cyp3a5" sem="G_CYP">CYP3A5</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(buspirone, CYP3A,DEI)">
<sentence>In a panel of HLMs from 16 donors, <cons lex="buspirone" sem="G_DRUG">buspirone</cons> <cons sem="G_MECHANISM">metabolism</cons> <cons lex="correlated" sem="G_MECHANISM">correlated</cons> well <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> activity (<cons sem="G_NUMBER">r2 = 0.85-0.96, rho &lt; 0.0005</cons>),but <cons sem="G_NEGATIVEEFFECT">not</cons> the activities of other P450 isoforms.</sentence>
</annotation>
<sentence>The <cons sem="G_MECHANISM">metabolism</cons> rates of <cons lex="buspirone" sem="G_DRUG">buspirone</cons> in <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> poor-metabolizer genotype HLMs were comparable to those in pooled HLMs.</sentence>
<sentence>Taken together, these data suggest that <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>, mostly likely <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, is primarily responsible for the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="buspirone" sem="G_DRUG">buspirone</cons> in HLMs.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15619261</bibliomisc>
</articleinfo>
<title>
<sentence>Characterization of human cytochrome P450 enzymes involved in the in vitro <cons sem="G_MECHANISM">metabolism</cons> of <cons sem="G_DRUG">perospirone</cons>.</sentence>
</title>
<abstract>
<sentence>In vitro studies were carried out to identify the major contribution of <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons>, <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> to the <cons sem="G_MECHANISM">metabolism</cons> of <cons sem="G_DRUG">perospirone</cons> (cis-N- [4- [4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]cyclohexane-1,2-dicarboximide monohydrochloride dehydrate), a novel antipsychotic agent, using human liver microsomes and expressed P450 isoforms.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Quinidine, perospirone,DDI)(ketoconazole, perospirone,DDI)">
<sentence> <cons lex="quinidine" sem="G_DRUG">Quinidine</cons> (a specific <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>) did <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">markedly</cons> affect the <cons sem="G_MECHANISM">metabolism</cons> of <cons sem="G_DRUG">perospirone</cons>,whereas <cons lex="quercetin" sem="G_DRUG">quercetin</cons> (an <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons>) and <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> (an <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>) caused a <cons sem="G_CHANGE">decrease</cons> in the <cons sem="G_MECHANISM">metabolism</cons> with human liver microsomes in a concentration dependent fashion.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(quercetin, perospirone,DDI)(ketoconazole, perospirone,DDI)">
<sentence>With <cons sem="G_NUMBER">10 microM</cons> <cons lex="quercetin" sem="G_DRUG">quercetin</cons>, the <cons sem="G_MECHANISM">metabolism</cons> of <cons sem="G_DRUG">perospirone</cons> was <cons sem="G_MECHANISM">inhibited</cons> by <cons sem="G_NUMBER">60.0%</cons> and with <cons sem="G_NUMBER">1 microM</cons> <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> almost complete <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> was apparent.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Anti-CYP2C8 antisera, perospirone,NDDI)(anti-CYP2D6 antisera, perospirone,NDDI)(anti-CYP3A4 antisera, perospirone,DDI)">
<sentence>Anti-<cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> and anti-<cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> antisera did <cons sem="G_NEGATIVEEFFECT">not</cons> exert <cons sem="G_CHANGE">marked</cons> effects, whereas anti-<cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> antiserum caused almost complete <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons>.</sentence>
</annotation>
<sentence>With expressed P450s,<cons sem="G_IVITPARA">K(m)</cons> and <cons sem="G_IVITPARA">V(max)</cons> values were <cons sem="G_NUMBER">1.09 microM</cons> and <cons sem="G_NUMBER">1.93 pmol/min/pmol</cons> P450 for <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons>,<cons sem="G_NUMBER">1.38 microM</cons> and <cons sem="G_NUMBER">5.73  pmol/min/pmol</cons> P450 for <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>, and <cons sem="G_NUMBER">0.245 microM</cons> and <cons sem="G_NUMBER">61.3 pmol/min/pmol</cons> P450 for <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, respectively.</sentence>
<annotation sem="INVITROCDDIS" ddi="(CYP3A4, perospirone,DEI)(CYP2C8, perospirone,DEI)(CYP2D6, perospirone,DEI)">
<sentence>These results indicated that the <cons sem="G_MECHANISM">metabolism</cons> of perospirone in human liver was mainly catalysed by <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, and to a lesser extent <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> and <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> were responsible because kinetic data (<cons sem="G_IVITPARA">K(m)</cons> and <cons sem="G_IVITPARA">V(max)</cons>) of <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> and <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> suggested catalytic potential.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15618724</bibliomisc>
</articleinfo>
<title>
<sentence>CYP isoforms involved in the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="clarithromycin" sem="G_DRUG">clarithromycin</cons> in vitro: comparison between the identification from disappearance rate and that from formation rate of metabolites.</sentence>
</title>
<abstract>
<sentence>To clarify whether <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> is involved in the overall <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="clarithromycin" sem="G_DRUG">clarithromycin</cons> (CAM) or <cons sem="G_NEGATIVEEFFECT">not</cons>, in vitro studies using human liver microsomes and recombinant CYPs were performed by an approach based on the disappearance rate of parent compound from the incubation mixture.</sentence>
<sentence>In addition, the results of disappearance rate were compared with those obtained from the formation rates of the major metabolites of <cons sem="G_DRUG">CAM</cons>,<cons sem="G_DRUG">14-(R)-hydroxy-CAM</cons> and <cons sem="G_DRUG">N-demethyl-CAM</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(CAM, testosterone 6beta-hydroxylation,DDI)">
<sentence>The <cons sem="G_IVITPARA">intrinsic clearance (CL(int))</cons> values determined from the disappearance of <cons sem="G_DRUG">CAM</cons> in nine different human liver microsomes were highly <cons lex="correlated" sem="G_MECHANISM">correlated</cons> with the <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6beta-hydroxylation activity (<cons sem="G_NUMBER">r=0.957, p&lt;0.001</cons>).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(ketoconazole, CAM,DDI)(Anti-CYP3A4/5  antibodies, CAM,DDI)">  
<sentence>The <cons sem="G_IVITPARA">CL(int)</cons> of  <cons sem="G_DRUG">CAM</cons> was <cons sem="G_CHANGE">markedly</cons> <cons sem="G_CHANGE">reduced</cons> by selective <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> (<cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> and <cons lex="troleandomycin" sem="G_DRUG">troleandomycin</cons>) and by polyclonal antibodies raised against <cons lex="cyp3a4/5" sem="G_CYP">CYP3A4/5</cons> in human liver microsomes.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(CYP3A4, CAM,DEI)">
<sentence>Among the 11 isoforms of recombinant human CYP, only <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> revealed the metabolic activity for the disappearance of <cons sem="G_DRUG">CAM</cons>.</sentence>
</annotation>
<sentence>These results were fairly consistent with those obtained from the conventional approach based on the formation of major metabolites of CAM.</sentence>
<sentence>Comparison of the kinetic parameters estimated from the disappearance rate of <cons sem="G_DRUG">CAM</cons> and the formation rates of <cons sem="G_DRUG">14-(R)-hydroxy-CAM</cons> and <cons sem="G_DRUG">N-demethyl-CAM</cons> indicates that N-demethylation and 14-(R)-hydroxylation account for 65% of <cons sem="G_IVITPARA">CL(int)</cons> derived from the disappearance of <cons sem="G_DRUG">CAM</cons> in human liver microsomes.</sentence>
<annotation sem="INVITROCDDIS" ddi="(CYP3A4, 14-(R)-hydroxy-CAM,DEI)(CYP3A4, N-demethyl-CAM,DEI)">
<sentence>The findings suggest that <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> plays a predominant role in the overall metabolic <cons sem="G_IVITPARA">clearance</cons> of <cons sem="G_DRUG">CAM</cons> as well as in the formation of <cons sem="G_DRUG">14-(R)-hydroxy-CAM</cons> and <cons sem="G_DRUG">N-demethyl-CAM</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(CYP2C19, CAM,NDEI)">
<sentence><cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> does <cons sem="G_NEGATIVEEFFECT">not</cons> appear to be involved in the overall <cons sem="G_MECHANISM">metabolism</cons> of <cons sem="G_DRUG">CAM</cons> at least in human liver microsomes.</sentence>
</annotation>
<sentence>A combination of the disappearance rate of a parent compound and the formation rate of metabolites appears to be a useful approach for estimating the percentage contribution of the formation of metabolites to the overall metabolic <cons sem="G_IVITPARA">clearance</cons> of a parent compound in vitro.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15618695</bibliomisc>
</articleinfo>
<title>
<sentence>Application of microtiter plate assay to evaluate <cons sem="G_MECHANISM">inhibitory</cons> effects of various compounds on nine cytochrome P450 isoforms and to estimate their <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> patterns.</sentence>
</title>
<abstract>
<sentence>Using a microtiter plate (MTP) assay consists of recombinant cytochromes P450 and fluorescent probes, we evaluated <cons sem="G_MECHANISM">inhibitory</cons> effects of commercially available model-compounds, 18 typical substrates and 8 selective <cons sem="G_MECHANISM">inhibitors</cons>, on nine cytochromes P450 (CYPs) activities.</sentence>
<sentence>The <cons sem="G_IVITPARA">IC(50)</cons> values obtained from the assay were used to estimate <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> constant  <cons sem="G_IVITPARA">(Ki)</cons> values, assuming competitive <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons>.</sentence>
<sentence>The <cons sem="G_IVITPARA">Ki</cons> values calculated from  <cons sem="G_IVITPARA">IC(50)</cons> (the <cons sem="G_IVITPARA">Ki(-cal)</cons>) with the MTP assay using recombinant CYPs were compared with the <cons sem="G_IVITPARA">Ki</cons> values (the<cons sem="G_IVITPARA">Ki (-rep)</cons>), reported for human liver microsomes (HLM).</sentence>
<sentence>Regarding all the <cons sem="G_MECHANISM">inhibitory</cons> effects of the 26 test compounds on each CYP activity, a good <cons lex="correlation" sem="G_MECHANISM">correlation</cons> (<cons sem="G_NUMBER">r(2)=0.7306</cons>) was found between <cons sem="G_IVITPARA">Ki(-cal)</cons> and <cons sem="G_IVITPARA">Ki(-rep)</cons>.</sentence>
<sentence>The <cons sem="G_MECHANISM">inhibitory</cons> patterns of some compounds on the five major CYP isoforms were estimated, using the MTP assay with the preincubation method.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Furafylline, CYP1A2,DEI)(Furafylline, CYP3A4,DEI)(erythromycin, CYP1A2,DEI)(erythromycin, CYP3A4,DEI)">
<sentence><cons lex="furafylline" sem="G_DRUG">Furafylline</cons> and <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons>, both mechanism based <cons sem="G_MECHANISM">inhibitors</cons>, strongly <cons sem="G_MECHANISM">inhibited</cons> <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activity, respectively and their <cons sem="G_MECHANISM">inhibitory</cons> effects <cons sem="G_CHANGE">increased</cons> depending on the preincubation time.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(phenacetin, CYP1A2,DEI)(diclofenac, CYP1A2,DEI)(S-mephenytoin, CYP1A2,DEI)(dextromethorphan, CYP1A2,DEI)(bufuralol, CYP1A2,DEI)(terfenadine, CYP1A2,DEI)(phenacetin, CYP2C9,DEI)(diclofenac, CYP2C9,DEI)(S-mephenytoin, CYP2C9,DEI)(dextromethorphan, CYP2C9,DEI)(bufuralol, CYP2C9,DEI)(terfenadine, CYP2C9,DEI)(phenacetin, CYP2C19,DEI)(diclofenac, CYP2C19,DEI)(S-mephenytoin, CYP2C19,DEI)(dextromethorphan, CYP2C19,DEI)(bufuralol, CYP2C19,DEI)(terfenadine, CYP2C19,DEI)(phenacetin, CYP2D6,DEI)(diclofenac, CYP2D6,DEI)(S-mephenytoin, CYP2D6,DEI)(dextromethorphan, CYP2D6,DEI)(bufuralol, CYP2D6,DEI)(terfenadine, CYP2D6,DEI)(phenacetin, CYP3A4,DEI)(diclofenac, CYP3A4,DEI)(S-mephenytoin, CYP3A4,DEI)(dextromethorphan, CYP3A4,DEI)(bufuralol, CYP3A4,DEI)(terfenadine, CYP3A4,DEI)">
<sentence>In contrast, the <cons sem="G_MECHANISM">inhibitory</cons> effects of <cons lex="phenacetin" sem="G_DRUG">phenacetin</cons>, <cons lex="diclofenac" sem="G_DRUG">diclofenac</cons>, S-<cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons>, <cons lex="dextromethorphan" sem="G_DRUG">dextromethorphan</cons>,<cons sem="G_DRUG">bufuralol</cons> and <cons lex="terfenadine" sem="G_DRUG">terfenadine</cons>, typical substrates for <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>, <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, respectively, on each recombinant CYP activity <cons sem="G_CHANGE">decreased</cons> after preincubation.</sentence>
</annotation>
<sentence>Therefore, the MTP assay is a useful high throughput screening method to evaluate <cons sem="G_MECHANISM">inhibitory</cons> effects of new drug candidates on 9 CYP isoforms in HLM.</sentence>
<sentence>In addition, the MTP assay with the preincubation method <cons sem="G_CHANGE">might</cons> be beneficial to estimate <cons sem="G_MECHANISM">inhibitory</cons> patterns on CYP isoforms of new drug candidates and to estimate main CYP isoforms responsible for <cons sem="G_MECHANISM">metabolism</cons> of these compounds.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15560889</bibliomisc>
</articleinfo>
<title>
<sentence>In vitro <cons sem="G_MECHANISM">metabolism</cons> of <cons sem="G_DRUG">carbofuran</cons> by human, mouse, and rat cytochrome P450 and interactions with <cons sem="G_DRUG">chlorpyrifos</cons>, <cons lex="testosterone" sem="G_DRUG">testosterone</cons>, and <cons lex="estradiol" sem="G_DRUG">estradiol</cons>.</sentence>
</title>
<abstract>
<sentence>Carbofuran is a carbamate pesticide used in agricultural practice throughout the world.</sentence>
<sentence>Its effect as a pesticide is due to its ability to <cons sem="G_MECHANISM">inhibit</cons> acetylcholinesterase activity.</sentence>
<sentence>Though carbofuran has a long history of use, there is <cons sem="G_CHANGE">little</cons> information available with respect to its metabolic fate and disposition in mammals.</sentence>
<sentence>The present study was designed to investigate the comparative in vitro <cons sem="G_MECHANISM">metabolism</cons> of carbofuran from human, rat, and mouse liver microsomes (HLM, RLM, MLM, respectively), and characterize the specific enzymes involved in such <cons sem="G_MECHANISM">metabolism</cons>, with particular reference to human <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
<sentence>Carbofuran is <cons sem="G_MECHANISM">metabolism</cons> by cytochrome P450 (CYP) leading to the production of one major ring <cons lex="oxidation" sem="G_MECHANISM">oxidation</cons> metabolite, 3-hydroxycarbofuran, and two <cons sem="G_CHANGE">minor</cons> metabolites.</sentence>
<sentence>The affinity of carbofuran for CYP enzymes involved in the <cons lex="oxidation" sem="G_MECHANISM">oxidation</cons> to 3-hydroxycarbofuran is <cons sem="G_CHANGE">significantly</cons> less in HLM (<cons sem="G_IVITPARA">Km</cons>=<cons sem="G_NUMBER">1.950 mM</cons>) than in RLM (<cons sem="G_IVITPARA">Km</cons>=<cons sem="G_NUMBER">0.210 mM</cons>), or MLM (<cons sem="G_IVITPARA">Km</cons>=<cons sem="G_NUMBER">0.550 mM</cons>).</sentence>
<sentence><cons sem="G_IVITPARA">Intrinsic clearance</cons> rate calculations indicate that HLM are <cons sem="G_NUMBER">14-fold</cons> less efficient in the <cons sem="G_MECHANISM">metabolism</cons> of carbofuran to 3-hydroxycarbofuran than RLM or MLM.</sentence>
<sentence>A screen of 15 major human CYP isoforms for metabolic ability with respect to carbofuran <cons sem="G_MECHANISM">metabolism</cons> demonstrated that <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> is the major isoform responsible for carbofuran <cons lex="oxidation" sem="G_MECHANISM">oxidation</cons> in humans.</sentence>
<sentence><cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> and <cons lex="2c19" sem="G_CYP">2C19</cons> are much less active while other human CYP isoforms have minimal or <cons sem="G_NEGATIVEEFFECT">no</cons> activity toward carbofuran.</sentence>
<sentence>In contrast with the human isoforms, members of the <cons sem="G_CYP">CYP2C</cons> family in rats are likely to have a primary role in carbofuran <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
<sentence>Normalization of HLM data with the average levels of each CYP in native HLM, indicates that carbofuran <cons sem="G_MECHANISM">metabolism</cons> is primarily mediated by <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> (percent total normalized rate (<cons sem="G_NUMBER">% TNR)=77.5</cons>), although <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> and <cons lex="2c19" sem="G_CYP">2C19</cons> play ancillary roles (<cons sem="G_NUMBER">% TNR=9.0 and 6.0</cons>, respectively).</sentence>
<sentence>This is substantiated by the fact that <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>, a specific <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, is an excellent <cons sem="G_MECHANISM">inhibitor</cons> of 3-hydroxycarbofuran formation in HLM (<cons sem="G_IVITPARA">IC50</cons>: <cons sem="G_NUMBER">0.31 microM</cons>).</sentence>
<sentence>Chlorpyrifos, an irreversible non-competitive <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, <cons sem="G_MECHANISM">inhibits</cons> the <cons sem="G_MECHANISM">formation</cons> of 3-hydroxycarbofuran in HLM (<cons sem="G_IVITPARA">IC50</cons>: <cons sem="G_NUMBER">39 microM</cons>).</sentence>
<sentence>The use of phenotyped HLM demonstrated that individuals with high levels of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> have the <cons sem="G_CHANGE">greatest</cons> potential to <cons lex="metabolize" sem="G_MECHANISM">metabolize</cons> carbofuran to its major metabolite.</sentence>
<sentence>The variation in carbofuran <cons sem="G_MECHANISM">metabolism</cons> among 17 single-donor HLM samples is over 5-fold and the best <cons lex="correlation" sem="G_MECHANISM">correlation</cons> between CYP isoform activity and carbofuran <cons sem="G_MECHANISM">metabolism</cons> was observed with <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> (<cons sem="G_NUMBER">r2=0.96</cons>).</sentence>
<sentence>The interaction of carbofuran and the endogenous <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> substrates, <cons lex="testosterone" sem="G_DRUG">testosterone</cons> and <cons lex="estradiol" sem="G_DRUG">estradiol</cons>, were also investigated.</sentence>
<sentence><cons lex="testosterone" sem="G_DRUG">Testosterone</cons> <cons sem="G_MECHANISM">metabolism</cons> was <cons lex="activated" sem="G_MECHANISM">activated</cons> by carbofuran in HLM and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, however, less <cons sem="G_MECHANISM">activation</cons> was observed for carbofuran <cons sem="G_MECHANISM">metabolism</cons> by <cons lex="testosterone" sem="G_DRUG">testosterone</cons> in HLM and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
<sentence><cons sem="G_NEGATIVEEFFECT">No</cons> interactions between carbofuran and <cons lex="estradiol" sem="G_DRUG">estradiol</cons> <cons sem="G_MECHANISM">metabolism</cons> were observed.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15537834</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="lansoprazole" sem="G_DRUG">Lansoprazole</cons> enantiomer <cons sem="G_MECHANISM">activates</cons> human liver microsomal <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> catalytic activity in a stereospecific and substrate-specific manner.</sentence>
</title>
<abstract>
<sentence>We recently proposed a possible stereoselective <cons sem="G_MECHANISM">activation</cons> by <cons lex="lansoprazole" sem="G_DRUG">lansoprazole</cons> of <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>-<cons lex="catalyzed" sem="G_MECHANISM">catalyzed</cons> <cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons> hydroxylation, as well as stereoselective <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of several cytochrome P450 (P450) isoforms.</sentence>
<sentence>This study evaluated the effects of <cons lex="lansoprazole" sem="G_DRUG">lansoprazole</cons> enantiomers on <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> activity in vitro, using several probe substrates.</sentence>
<annotation sem="INVITROCDDIS" ddi="(R-lansoprazole, tolbutamide 4-methylhydroxylation,ADDI)(R-lansoprazole, phenytoin 4-hydroxylation,ADDI)">
<sentence>For <cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons> 4-methylhydroxylation and <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons> 4-hydroxylation, R-<cons lex="lansoprazole" sem="G_DRUG">lansoprazole</cons> was an <cons sem="G_MECHANISM">activator</cons> (<cons sem="G_NUMBER">140 and 550%</cons> of control at <cons sem="G_NUMBER">100 microM</cons> R-<cons lex="lansoprazole" sem="G_DRUG">lansoprazole</cons>,<cons sem="G_IVITPARA">EC50</cons> values of <cons sem="G_NUMBER">19.9  and  30.2 microM</cons>, respectively).</sentence>
</annotation>
<sentence>R-<cons lex="lansoprazole" sem="G_DRUG">Lansoprazole</cons>-mediated <cons sem="G_MECHANISM">activation</cons> of the formation of <cons sem="G_MECHANISM">4-hydroxyphenytoin</cons> was also seen with recombinant human <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(R-lansoprazole, phenytoin 4-hydroxylation,ADDI)">
<sentence>R-<cons lex="lansoprazole" sem="G_DRUG">Lansoprazole</cons> <cons sem="G_CHANGE">increased</cons> the Michaelis-Menten-derived <cons sem="G_IVITPARA">V(max)</cons> of <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons> 4-hydroxylation from <cons sem="G_NUMBER">0.024</cons> to <cons sem="G_NUMBER">0.121 pmol/min/pmol</cons> P450, and lowered its <cons sem="G_IVITPARA">K(m)</cons> from <cons sem="G_IVITPARA">20.5</cons> to <cons sem="G_IVITPARA">15.0 microM</cons>, suggesting that R-<cons lex="lansoprazole" sem="G_DRUG">lansoprazole</cons> <cons sem="G_MECHANISM">activates</cons> <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>-mediated <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons> <cons sem="G_MECHANISM">metabolism</cons> without displacing <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons> from the active site.</sentence>
</annotation>
<sentence>Kinetic parameters were also estimated using the two-site binding equation, with alpha values &lt;1 and beta values &gt;1, indicative of <cons sem="G_MECHANISM">activation</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(phenytoin, R-lansoprazole,NDDI)">
<sentence>Additionally, <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons> at <cons sem="G_NUMBER">10 to 200 microM</cons> had <cons sem="G_NEGATIVEEFFECT">no</cons> reciprocal effect on the <cons sem="G_MECHANISM">hydroxylation</cons> of R-<cons lex="lansoprazole" sem="G_DRUG">lansoprazole</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(R-lansoprazole, diclofenac,NDDI)(R-lansoprazole, S-warfarin,NDDI)">
<sentence>Meanwhile, R-<cons lex="lansoprazole" sem="G_DRUG">lansoprazole</cons> had <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem="G_MECHANISM">activation</cons> effect on <cons lex="diclofenac" sem="G_DRUG">diclofenac</cons> and S-<cons lex="warfarin" sem="G_DRUG">warfarin</cons> <cons sem="G_MECHANISM">metabolism</cons> in the incubation study using both recombinant <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> and human liver microsomes.</sentence>
</annotation>
<sentence>These substrate-dependent <cons sem="G_MECHANISM">activation</cons> effects suggest that <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons> has a different binding orientation compared with <cons lex="diclofenac" sem="G_DRUG">diclofenac</cons> and S-<cons lex="warfarin" sem="G_DRUG">warfarin</cons>.</sentence>
<sentence>Overall, these results suggest that R-<cons lex="lansoprazole" sem="G_DRUG">lansoprazole</cons> <cons sem="G_MECHANISM">activates</cons> <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> in a stereospecific and substrate-specific manner, possibly by binding within the active site and inducing positive cooperativity.</sentence>
<sentence>This is the first report to describe stereoselective <cons sem="G_MECHANISM">activation</cons> of this cytochrome P450 isoform.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15523003</bibliomisc>
</articleinfo>
<title>
<sentence>Mechanism-based <cons sem="G_MECHANISM">inactivation</cons> of <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> by HIV protease <cons sem="G_MECHANISM">inhibitors</cons>.</sentence>
</title>
<abstract>
<sentence>Human immunodeficiency virus (HIV) protease <cons sem="G_MECHANISM">inhibitors</cons> (PIs) are <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> enzymes, but the mechanism is poorly defined.</sentence>
<sentence>In this study, time- and concentration-dependent <cons sem="G_CHANGE">decreases</cons> in activity as defined by <cons sem="G_IVITPARA">maximum rate of <cons sem="G_MECHANISM">inactivation</cons>  (k(inact))</cons> and <cons sem="G_MECHANISM">inhibitor</cons> concentration that gives <cons sem="G_NUMBER">50%</cons> maximal <cons sem="G_MECHANISM">inactivation</cons> <cons sem="G_IVITPARA">(K(I))</cons> of <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> by <cons lex="amprenavir" sem="G_DRUG">amprenavir</cons>, <cons lex="indinavir" sem="G_DRUG">indinavir</cons>, <cons lex="lopinavir" sem="G_DRUG">lopinavir</cons>, <cons lex="nelfinavir" sem="G_DRUG">nelfinavir</cons>, <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons>, and <cons lex="saquinavir" sem="G_DRUG">saquinavir</cons> were quantified using <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6beta-hydroxylation as a marker for <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> activity with recombinant <cons sem="G_CYP">CYP3A4(+b(5))</cons>, recombinant <cons lex="cyp3a5" sem="G_CYP">CYP3A5</cons>, and pooled human liver microsomes (HLMs).</sentence>
<annotation sem="INVITROVDDIS" ddi="(amprenavir, CYP3A4,DEI)(lopinavir, CYP3A4,DEI)(nelfinavir, CYP3A4,DEI)(ritonavir, CYP3A4,DEI)(saquinavir, CYP3A4,DEI)(amprenavir, HLMs,DEI)(lopinavir, HLMs,DEI)(nelfinavir, HLMs,DEI)(ritonavir, HLMs,DEI)(saquinavir, HLMs,DEI)">
<sentence>All the PIs, except <cons lex="indinavir" sem="G_DRUG">indinavir</cons>, displayed <cons sem="G_MECHANISM">inactivation</cons> with <cons sem="G_CYP">CYP3A4(+b(5))</cons> and HLMs.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Ritonavir, CYP3A4,DEI)(Ritonavir, HLMs,DEI)">
<sentence><cons lex="ritonavir" sem="G_DRUG">Ritonavir</cons> was the most potent <cons sem="G_IVITPARA">(K(I)</cons> = <cons sem="G_NUMBER">0.10</cons> and <cons sem="G_NUMBER">0.17 microM</cons>) and demonstrated high  <cons sem="G_IVITPARA">k(inact)</cons> values ( <cons sem="G_NUMBER">0.32</cons> and <cons sem="G_NUMBER">0.40 min(-1))</cons> with both <cons sem="G_CYP">CYP3A4(+b(5))</cons> and HLMs.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Ritonavir, CYP3A4(+b(5)),ADEI)">
<sentence><cons lex="ritonavir" sem="G_DRUG">Ritonavir</cons> was <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_MECHANISM">depleted</cons> by high-affinity binding with <cons sem="G_CYP">CYP3A4(+b(5))</cons> and confirmed that estimation of reversible <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> was confounded with irreversible <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(nelfinavir, CYP3A5,DEI)(ritonavir, CYP3A5,DEI)">
<sentence>For <cons lex="cyp3a5" sem="G_CYP">CYP3A5</cons>, <cons lex="nelfinavir" sem="G_DRUG">nelfinavir</cons> exhibited the highest <cons sem="G_IVITPARA">k(inact)</cons> (<cons sem="G_NUMBER">0.47 min(-1)</cons>), but <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> was the most potent (<cons sem="G_IVITPARA">K(I)</cons> = <cons sem="G_NUMBER">0.12 microM</cons>).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Saquinavir, CYP3A5,NDEI)(indinavir, CYP3A5,NDEI)">
<sentence><cons lex="saquinavir" sem="G_DRUG">Saquinavir</cons> and <cons lex="indinavir" sem="G_DRUG">indinavir</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> show time- and concentration-dependent <cons sem="G_CHANGE">decreases</cons> in activity with <cons lex="cyp3a5" sem="G_CYP">CYP3A5</cons>.</sentence>
</annotation>
<sentence>Spectrophototmetrically determined metabolic intermediate complex formation was observed for all of the PIs with <cons sem="G_CYP">CYP3A4(+b(5))</cons>, except for <cons lex="lopinavir" sem="G_DRUG">lopinavir</cons> and <cons lex="saquinavir" sem="G_DRUG">saquinavir</cons>.</sentence>
<sentence>The addition of nucleophilic and free aldehyde trapping agents and free iron and reactive oxygen species scavengers did <cons sem="G_NEGATIVEEFFECT">not</cons> prevent <cons sem="G_MECHANISM">inactivation</cons> of <cons sem="G_CYP">CYP3A4(+b(5))</cons> by <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons>, <cons lex="amprenavir" sem="G_DRUG">amprenavir</cons>, or <cons lex="nelfinavir" sem="G_DRUG">nelfinavir</cons>, but glutathione <cons sem="G_CHANGE">decreased</cons> the <cons sem="G_MECHANISM">inactivation</cons> by <cons lex="saquinavir" sem="G_DRUG">saquinavir</cons> (<cons sem="G_NUMBER">17%</cons>) and catalase <cons sem="G_CHANGE">decreased</cons> the <cons sem="G_MECHANISM">inactivation</cons> by <cons lex="lopinavir" sem="G_DRUG">lopinavir</cons> (<cons sem="G_NUMBER">39%</cons>).</sentence>
<sentence>In conclusion, all the PIs exhibited mechanism-based <cons sem="G_MECHANISM">inactivation</cons>, and predictions of the extent and time course of drug interactions with PIs could be underestimated if based solely on reversible <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15507542</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="cyp2d6" sem="G_CYP">Cyp2D6</cons><cons sem="G_MECHANISM">catalyzes</cons> 5-hydroxylation of 1-(2-pyrimidinyl)-<cons lex="piperazine" sem="G_DRUG">piperazine</cons>, an active metabolite of several psychoactive drugs, in human liver microsomes.</sentence>
</title>
<abstract>
<sentence>1-(2-Pyrimidinyl)-<cons lex="piperazine" sem="G_DRUG">piperazine</cons> (1-PP) is an active metabolite of several psychoactive drugs including <cons lex="buspirone" sem="G_DRUG">buspirone</cons>.</sentence>
<sentence><cons sem="G_DRUG">1-PP</cons> is also the major metabolite in the human circulation and in rat brains following oral administration of <cons lex="buspirone" sem="G_DRUG">buspirone</cons>.</sentence>
<sentence>This study was conducted to identify the enzyme responsible for the metabolic conversion of <cons sem="G_DRUG">1-PP</cons> to <cons sem="G_DRUG">5-hydroxy-1-(2-pyrimidinyl)</cons>-<cons lex="piperazine" sem="G_DRUG">piperazine</cons> (HO-1-PP) in human liver microsomes (HLMs).</sentence>
<sentence>The product <cons sem="G_DRUG">HO-1-PP</cons> was quantified by a validated liquid chromatography-tandem mass spectrometry method.</sentence>
<sentence>In the presence of NADPH, <cons sem="G_DRUG">1-PP</cons> (<cons sem="G_NUMBER">100 microM</cons>) was incubated separately with human cDNA-expressed cytochrome P450 isozymes (including <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>, <cons lex="3a4" sem="G_CYP">3A4</cons>, <cons lex="1a2" sem="G_CYP">1A2</cons>, <cons lex="2a6" sem="G_CYP">2A6</cons>, <cons lex="2c9" sem="G_CYP">2C9</cons>, <cons lex="2c19" sem="G_CYP">2C19</cons>, <cons lex="2e1" sem="G_CYP">2E1</cons>, and <cons lex="2b6" sem="G_CYP">2B6</cons>) at 37 degrees C.</sentence>
<annotation sem="INVITROCDDIS" ddi="(HO-1-PP, CYP2D6,DEI)">
<sentence><cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> <cons lex="catalyzed" sem="G_MECHANISM">catalyzed</cons> the formation of <cons sem="G_DRUG">HO-1-PP</cons> from  <cons sem="G_DRUG">1-PP</cons> .</sentence></annotation>
<annotation sem="INVITROCDDIS" ddi="(quinidine, HO-1-PP,DDI)">
<sentence>This catalytic activity was <cons sem="G_NUMBER">&gt;95%</cons> <cons sem="G_MECHANISM">inhibited</cons> by <cons lex="quinidine" sem="G_DRUG">quinidine</cons>, a <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> inhibitor.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(HO-1-PP, bufuralol 1-hydroxylase,DDI)">
<sentence><cons sem="G_DRUG">HO-1-PP</cons> formation rates <cons lex="correlated" sem="G_MECHANISM">correlated</cons> well with the <cons sem="G_DRUG">bufuralol</cons> 1-hydroxylase (<cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>) activities of individual HLMs.</sentence>
</annotation>
<sentence>The formation of <cons sem="G_DRUG">HO-1-PP</cons> followed a Michaelis-Menten kinetics with a <cons sem="G_IVITPARA">K(m)</cons> of <cons sem="G_NUMBER">171 microM</cons> and <cons sem="G_IVITPARA">V(max)</cons> of <cons sem="G_NUMBER">313 pmol/min</cons> x mg protein in HLMs.</sentence>
<sentence>Collectively, these results indicate that polymorphic <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> is responsible for the conversion of 1-PP to HO-1-PP.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15451555</bibliomisc>
</articleinfo>
<title>
<sentence>Non-specific <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of human cytochrome P450-<cons lex="catalyzed" sem="G_MECHANISM">catalyzed</cons> reactions by hemin.</sentence>
</title>
<abstract>
<sentence>Hemin, a stable form of <cons lex="heme" sem="G_DRUG">heme</cons>, is known to have an antimutagenic effect.</sentence>
<sentence><cons sem="G_MECHANISM">Inhibitory</cons> effects of hemin on the cytochrome P450 (CYP)-<cons lex="catalyzed" sem="G_MECHANISM">catalyzed</cons> reactions of human liver microsomes and reconstituted systems containing purified CYP and NADPH-cytochrome P450 reductase (NPR) were seen.</sentence>
<sentence>Hemin non-specifically <cons sem="G_MECHANISM">inhibited</cons> all of the microsomal CYP activities examined.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Hemin, 7-ethoxyresorufin O-deethylation,DDI)(Hemin, 3-[2-(N,N-diethyl-N-methylammonium)ethyl]-7-methoxy-4-methylcoumarin O-demethylation,DDI)(Hemin, testosterone 6beta-hydroxylation,DDI)">
<sentence>Hemin also <cons sem="G_MECHANISM">inhibited</cons> 7-ethoxyresorufin O-deethylation, 3- [2-(N,N-diethyl-N-methylammonium)ethyl]-7-methoxy-4-methylcoumarin O-demethylation, and <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6beta-hydroxylation <cons lex="catalyzed" sem="G_MECHANISM">catalyzed</cons> by purified CYPs <cons lex="1a2" sem="G_CYP">1A2</cons>, <cons lex="2d6" sem="G_CYP">2D6</cons>, and <cons lex="3a4" sem="G_CYP">3A4</cons>, with <cons sem="G_IVITPARA">IC50</cons> values of <cons sem="G_NUMBER">27, 19, and 2.4 microM</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Hemin, cytochrome c,ADDI)(Hemin, ferricyanide,ADDI)">
<sentence>Hemin also <cons sem="G_MECHANISM">inhibited</cons> <cons sem="G_CHANGE">reduction</cons> of cytochrome c and ferricyanide by NPR, as much as <cons sem="G_NUMBER">47%</cons>.</sentence>
</annotation>
<sentence>Spectrally detectable CYP was destroyed in human liver microsomes and in a reconstituted system in the presence of hemin and an NADPH-generating system.</sentence>
<sentence>We propose that the antimutagenic effect of hemin <cons sem="G_CHANGE">might</cons> be due to <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of CYP and NPR enzymes involved in the bioactivation of mutagens.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15370959</bibliomisc>
</articleinfo>
<title>
<sentence>Potential of <cons lex="pranlukast" sem="G_DRUG">pranlukast</cons> and <cons lex="zafirlukast" sem="G_DRUG">zafirlukast</cons> in the <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of human liver cytochrome P450 enzymes.</sentence>
</title>
<abstract>
<sentence>1.</sentence>
<sentence>The potential of <cons lex="zafirlukast" sem="G_DRUG">zafirlukast</cons> to <cons sem="G_MECHANISM">inhibit</cons> several human cytochrome P450 enzymes is well known.</sentence>
<sentence>However, <cons lex="pranlukast" sem="G_DRUG">pranlukast</cons>, a structural analogue of <cons lex="zafirlukast" sem="G_DRUG">zafirlukast</cons>, has <cons sem="G_NEGATIVEEFFECT">not</cons> been studied.</sentence>
<sentence>Accordingly, the <cons sem="G_MECHANISM">inhibitory</cons> potential of <cons lex="pranlukast" sem="G_DRUG">pranlukast</cons> was evaluated and compared with that of <cons lex="zafirlukast" sem="G_DRUG">zafirlukast</cons>, a known <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons><cons sem="G_MECHANISM">inhibitor</cons>, in in vitro microsomal incubation studies.</sentence>
<sentence>2.</sentence>
<annotation sem="INVITROCDDIS" ddi="(pranlukast, tolbutamide 4-methylhydroxylation,DDI)(zafirlukast, tolbutamide 4-methylhydroxylation,DDI)">
<sentence>Both <cons lex="pranlukast" sem="G_DRUG">pranlukast</cons> and <cons lex="zafirlukast" sem="G_DRUG">zafirlukast</cons> showed <cons sem="G_CHANGE">moderate</cons> <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>-catalysed <cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons> 4-methylhydroxylation, competitively <cons sem="G_MECHANISM">inhibiting</cons> <cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons> 4-methylhydroxylation with estimated mean <cons sem="G_IVITPARA">K(i)</cons> values of <cons sem="G_NUMBER">3.82  +/- 0.50 and 5.86 +/- 0.08 microM</cons>, respectively.</sentence>
</annotation>
<sentence>3.</sentence>
<annotation sem="INVITROCDDIS" ddi="(pranlukast, S-mephenytoin 4'-hydroxylation,NDDI)(pranlukast, midazolam 1-hydroxylation,NDDI)">
<sentence><cons lex="pranlukast" sem="G_DRUG">Pranlukast</cons> had <cons sem="G_NEGATIVEEFFECT">no</cons> effect on <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>- <cons sem="G_MECHANISM">catalysed</cons> S-<cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons> 4'-hydroxylation or <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>-<cons sem="G_MECHANISM">catalysed</cons> <cons lex="midazolam" sem="G_DRUG">midazolam</cons> 1-hydroxylation.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(zafirlukast, S-mephenytoin 4'-hydroxylation,NDDI)(zafirlukast, midazolam 1-hydroxylation,NDDI)">  
<sentence>However, <cons lex="zafirlukast" sem="G_DRUG">zafirlukast</cons> showed <cons sem="G_CHANGE">minor</cons> <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of these reactions.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(pranlukast, phenacetin O-deethylation,NDDI)(pranlukast, dextromethorphan O-demethylation,NDDI)(zafirlukast, phenacetin O-deethylation,NDDI)(zafirlukast, dextromethorphan O-demethylation,NDDI)">
<sentence>Neither <cons lex="pranlukast" sem="G_DRUG">pranlukast</cons> nor <cons lex="zafirlukast" sem="G_DRUG">zafirlukast</cons> <cons sem="G_MECHANISM">inhibited</cons> <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>-<cons sem="G_MECHANISM">catalysed</cons> <cons lex="phenacetin" sem="G_DRUG">phenacetin</cons> O-deethylation, <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>-catalysed <cons lex="dextromethorphan" sem="G_DRUG">dextromethorphan</cons> O-demethylation or <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons>-<cons sem="G_MECHANISM">catalysed</cons> <cons lex="chlorzoxazone" sem="G_DRUG">chlorzoxazone</cons> 6-hydroxylation.</sentence>
</annotation>
<sentence>4.</sentence>
<annotation sem="INVITROCDDIS" ddi="(zafirlukast, tolbutamide 4-methylhydroxylation,DDI)(pranlukast, tolbutamide 4-methylhydroxylation,DDI)">
<sentence>The results suggest that like <cons lex="zafirlukast" sem="G_DRUG">zafirlukast</cons>, <cons lex="pranlukast" sem="G_DRUG">pranlukast</cons> also has the potential <cons sem="G_CHANGE">moderately</cons> to <cons sem="G_MECHANISM">inhibit</cons> <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>-<cons sem="G_MECHANISM">catalysed</cons> <cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons> 4-methylhydroxylation.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(pranlukast, S-warfarin,DDI)(pranlukast, phenytoin,DDI)">
<sentence>Therefore, the <cons sem="G_MECHANISM">inhibitory</cons> potential of <cons lex="pranlukast" sem="G_DRUG">pranlukast</cons> should be considered when it is co-administered with <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> substrates with narrow therapeutic ranges (e.g. S-<cons lex="warfarin" sem="G_DRUG">warfarin</cons>, <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons>).</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15319333</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons>, <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, and <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> are responsible for the in vitro N-demethylation of <cons lex="meperidine" sem="G_DRUG">meperidine</cons> in human liver microsomes.</sentence>
</title>
<abstract>
<sentence><cons lex="meperidine" sem="G_DRUG">Meperidine</cons> is an opioid analgesic <cons sem="G_MECHANISM">metabolized</cons> in the liver by N-demethylation to <cons sem="G_DRUG">normeperidine</cons>, a potent stimulant of the central nervous system.</sentence>
<sentence>The purpose of this study was to identify the human cytochrome P450 (P450) enzymes involved in normeperidine formation.</sentence>
<sentence>Our in vitro studies included 1) screening 16 expressed P450s for <cons sem="G_DRUG">normeperidine</cons> formation, 2) kinetic experiments on human liver microsomes and candidate P450s, and 3) <cons lex="correlation" sem="G_MECHANISM">correlation</cons> and <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> experiments using human hepatic microsomes.</sentence>
<sentence>After normalization by its relative abundance in human liver microsomes, <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons>, <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, and <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> accounted for <cons sem="G_NUMBER">57, 28, and 15%</cons> of the total <cons sem="G_IVITPARA">intrinsic clearance</cons> of <cons lex="meperidine" sem="G_DRUG">meperidine</cons>.</sentence>
<sentence><cons lex="cyp3a5" sem="G_CYP">CYP3A5</cons> and <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> contributed to <cons sem="G_NUMBER">&lt; 1%</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(normeperidine, S-mephenytoin N-demethylation,DDI)(normeperidine, midazolam 1'-hydroxylation,DDI)">
<sentence>Formation of <cons sem="G_DRUG">normeperidine</cons> <cons sem="G_CHANGE">significantly</cons> <cons lex="correlated" sem="G_MECHANISM">correlated</cons> with <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons>-selective S-<cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons> N-demethylation (<cons sem="G_NUMBER">r = 0.88, p &lt; 0.0001 at 75 &gt; microM</cons> <cons lex="meperidine" sem="G_DRUG">meperidine</cons>, and <cons sem="G_NUMBER">r = 0.89, p &lt; 0.0001 at 350 microM</cons> <cons lex="meperidine" sem="G_DRUG">meperidine</cons>, n = 21) and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>-selective <cons lex="midazolam" sem="G_DRUG">midazolam</cons> 1'-hydroxylation (<cons sem="G_NUMBER">r = 0.59, p &lt; 0.01 at 75 microM</cons> <cons lex="meperidine" sem="G_DRUG">meperidine</cons>, and <cons sem="G_NUMBER">r = 0.55, p &lt; 0.01 at 350 microM</cons> <cons lex="meperidine" sem="G_DRUG">meperidine</cons>, n = 23).</sentence>
</annotation>
<annotation sem="INVITROVDDIS" ddi="(normeperidine, S-mephenytoin 4'-hydroxylation,NDDI)">
<sentence><cons sem="G_NEGATIVEEFFECT">No</cons> <cons sem="G_CHANGE">significant</cons> <cons lex="correlation" sem="G_MECHANISM">correlation</cons> was observed with <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>-selective S-<cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons> 4'-hydroxylation (<cons sem="G_NUMBER">r = 0.36, p = 0.2 at 75 microM</cons> <cons lex="meperidine" sem="G_DRUG">meperidine</cons>, and <cons sem="G_NUMBER">r = 0.02, p = 0.9 at 350 microM</cons> <cons lex="meperidine" sem="G_DRUG">meperidine</cons>, n = 13).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(An anti-CYP2B6 antibody, normeperidine,ADDI)">
<sentence>An anti-<cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> antibody <cons sem="G_MECHANISM">inhibited</cons> normeperidine formation by <cons sem="G_NUMBER">46%</cons>.</sentence>
</annotation>
<sentence>In contrast, antibodies <cons sem="G_IVITPARA">inhibitory</cons> to <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and <cons sem="G_CYP">CYP2C8/9/18/19</cons> had <cons sem="G_CHANGE">little</cons> effect (<cons sem="G_NUMBER">&lt;14%</cons> <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons>).</sentence>
<annotation sem="INVITROCDDIS" ddi="(thiotepa, CYP2B6,DEI)(thiotepa, CYP3A4,DEI)(ketoconazole, CYP2B6,DEI)(ketoconazole, CYP3A4,DEI)">
<sentence>Experiments with <cons lex="thiotepa" sem="G_DRUG">thiotepa</cons> and <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> suggested <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of microsomal <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activity, whereas studies with <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> (a substrate of <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>) were inconclusive due to lack of specificity.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(normeperidine, CYP2B6,DEI)(normeperidine, CYP3A4,DEI)">
<sentence>We conclude that normeperidine formation in human liver microsomes is mainly <cons lex="catalyzed" sem="G_MECHANISM">catalyzed</cons> by <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, with a <cons sem="G_CHANGE">minor</cons> contribution from <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15258107</bibliomisc>
</articleinfo>
<title>
<sentence>Comparison of <cons sem="G_MECHANISM">inhibitory</cons> effects of the proton pump- <cons sem="G_MECHANISM">inhibiting</cons> drugs <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons>, <cons lex="esomeprazole" sem="G_DRUG">esomeprazole</cons>, <cons lex="lansoprazole" sem="G_DRUG">lansoprazole</cons>, <cons lex="pantoprazole" sem="G_DRUG">pantoprazole</cons>, and <cons lex="rabeprazole" sem="G_DRUG">rabeprazole</cons> on human cytochrome P450 activities.</sentence>
</title>
<abstract>
<sentence>The human <cons sem="G_IVITPARA">clearance</cons> of proton pump <cons sem="G_MECHANISM">inhibitors</cons> (PPIs) of the substituted <cons lex="benzimidazole" sem="G_DRUG">benzimidazole</cons> class is conducted primarily by the hepatic cytochrome P450 (P450) system.</sentence>
<sentence>To compare the potency and specificity of the currently used PPIs (i.e., <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons>, <cons lex="esomeprazole" sem="G_DRUG">esomeprazole</cons>, <cons lex="lansoprazole" sem="G_DRUG">lansoprazole</cons>, <cons lex="pantoprazole" sem="G_DRUG">pantoprazole</cons>, and <cons lex="rabeprazole" sem="G_DRUG">rabeprazole</cons>) as <cons sem="G_MECHANISM">inhibitors</cons> of four cytochrome P450 enzymes (<cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, <cons lex="2c19" sem="G_CYP">2C19</cons>, <cons lex="2d6" sem="G_CYP">2D6</cons>, and <cons lex="3a4" sem="G_CYP">3A4</cons>), we performed in vitro studies using human liver microsomal preparations and recombinant <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>.</sentence>
<sentence>Sample analysis was done using selected reaction monitoring liquid chromatography/tandem mass spectometry.</sentence>
<annotation sem="INVITROCDDIS" ddi="(lansoprazole, S-mephenytoin 4'-hydroxylation,DDI)(omeprazole, S-mephenytoin 4'-hydroxylation,DDI)(esomeprazole, S-mephenytoin 4'-hydroxylation,ADDI)(pantoprazole, S-mephenytoin 4'-hydroxylation,ADDI)(rabeprazole, S-mephenytoin 4'-hydroxylation,ADDI)">
<sentence>With several systems for <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> activity (two marker reactions, S-<cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons> 4'-hydroxylation and R-<cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> 5-hydroxylation, tested in either human liver microsomes or recombinant <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>), the five PPIs showed competitive <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> activity with <cons sem="G_IVITPARA">K(i)</cons> of <cons sem="G_NUMBER">0.4  to 1.5 microM</cons> for <cons lex="lansoprazole" sem="G_DRUG">lansoprazole</cons>,<cons sem="G_NUMBER">2 to 6 microM</cons> for <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons>, approximately <cons sem="G_NUMBER">8 microM</cons> for <cons lex="esomeprazole" sem="G_DRUG">esomeprazole</cons>,<cons sem="G_NUMBER">14 to 69 microM</cons> for <cons lex="pantoprazole" sem="G_DRUG">pantoprazole</cons>,<cons sem="G_NUMBER">and 17 to 21 microM</cons>  for <cons lex="rabeprazole" sem="G_DRUG">rabeprazole</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Pantoprazole, diclofenac 4'-hydroxylation,DDI)(Pantoprazole, midazolam 1'-hydroxylation,ADDI)">
<sentence><cons lex="pantoprazole" sem="G_DRUG">Pantoprazole</cons> was a competitive <cons sem="G_MECHANISM">inhibitor</cons> of both <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>-<cons lex="catalyzed" sem="G_MECHANISM">catalyzed</cons> <cons lex="diclofenac" sem="G_DRUG">diclofenac</cons> 4'-hydroxylation and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>-<cons lex="catalyzed" sem="G_MECHANISM">catalyzed</cons> <cons lex="midazolam" sem="G_DRUG">midazolam</cons> 1'-hydroxylation <cons sem="G_IVITPARA">(K(i)</cons> of <cons sem="G_NUMBER">6 and 22 microM</cons>, respectively), which were at least 2 times more potent than the other PPIs.</sentence>
</annotation>
<annotation sem="INVITROVDDIS" ddi="(lansoprazole, bufuralol 1'-hydroxylation,ADDI)(omeprazole, bufuralol 1'-hydroxylation,ADDI)(esomeprazole, bufuralol 1'-hydroxylation,ADDI)(Pantoprazole, bufuralol 1'-hydroxylation,ADDI)(rabeprazole, bufuralol 1'-hydroxylation,ADDI)">
<sentence>All PPIs were poor <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>-mediated <cons sem="G_DRUG">bufuralol</cons> 1'-hydroxylation with <cons sem="G_IVITPARA">IC(50)</cons> &gt;<cons sem="G_NUMBER">200 microM</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(rabeprazole, CYP2C9,DEI)(rabeprazole, CYP2C19,ADEI)(rabeprazole, CYP2D6,ADEI)(rabeprazole, CYP3A4,ADEI)">
<sentence>The <cons sem="G_MECHANISM">inhibitory</cons> potency of a nonenzymatically <cons sem="G_MECHANISM">formed</cons> product of <cons lex="rabeprazole" sem="G_DRUG">rabeprazole</cons>, <cons lex="rabeprazole" sem="G_DRUG">rabeprazole</cons> thioether, was also investigated and showed potent, competitive <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> with <cons sem="G_IVITPARA">K(i)</cons> values of <cons sem="G_NUMBER">6 microM</cons> for <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, <cons sem="G_NUMBER">2 to 8 microM</cons> for <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>,<cons sem="G_NUMBER">12 microM</cons> for <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>, and <cons sem="G_NUMBER">15 microM</cons> for <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(R-omeprazole, CYP2C9,DEI)(R-omeprazole, CYP2C19,DEI)">
<sentence>The <cons sem="G_MECHANISM">inhibitory</cons> potency of R-<cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> on the four studied P450 enzymes was also studied and showed higher <cons sem="G_MECHANISM">inhibitory</cons> potency than its S-isomer on <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> and <cons lex="2c19" sem="G_CYP">2C19</cons> activities.</sentence>
</annotation>
<sentence>Our data suggest that, although the <cons sem="G_MECHANISM">inhibitory</cons> profiles of the five studied PPIs were similar, <cons lex="lansoprazole" sem="G_DRUG">lansoprazole</cons> and <cons lex="pantoprazole" sem="G_DRUG">pantoprazole</cons> are the most potent in vitro <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> and <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, respectively.</sentence>
<sentence><cons lex="esomeprazole" sem="G_DRUG">Esomeprazole</cons> showed less <cons sem="G_MECHANISM">inhibitory</cons> potency compared with <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> and its R-enantiomer.</sentence>
<sentence>The <cons sem="G_MECHANISM">inhibitory</cons> potency of <cons lex="rabeprazole" sem="G_DRUG">rabeprazole</cons> was relatively lower than the other PPIs, but its thioether analog showed potent <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> on the P450 enzymes investigated, which <cons sem="G_CHANGE">may</cons> be clinically <cons sem="G_CHANGE">significant</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15175893</bibliomisc>
</articleinfo>
<title>
<sentence>Differences in the <cons lex="induction" sem="G_MECHANISM">induction</cons> of cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4</cons> by taxane anticancer drugs, <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons> and <cons lex="paclitaxel" sem="G_DRUG">paclitaxel</cons>, assessed employing primary human hepatocytes.</sentence>
</title>
<abstract>
<sentence>The <cons lex="induction" sem="G_MECHANISM">induction</cons> of cytochrome P450 (CYP) <cons lex="3a4" sem="G_CYP">3A4</cons> by drugs and other xenobiotics is a common cause of serious drug interactions.</sentence>
<sentence>The aim of this study was to comparatively examine the effects of <cons lex="paclitaxel" sem="G_DRUG">paclitaxel</cons> and <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons>, two structurally related taxane anticancer agents, on the activity and expression of hepatic <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
<sentence>Employing primary cultures of human hepatocytes from multiple donors, we investigated the differences in the magnitude of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons lex="induction" sem="G_MECHANISM">induction</cons> and relative accumulation of <cons lex="paclitaxel" sem="G_DRUG">paclitaxel</cons> and <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons>.</sentence>
<sentence>The <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activity of intact hepatocytes was measured as the rate of <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6beta-hydroxylation.</sentence>
<sentence>The <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>-specific immunoreactive protein and mRNA levels were measured employing Western blot and Northern blot analysis, respectively.</sentence>
<sentence>Furthermore, employing cell-based reporter gene assay in CV-1 cells, we evaluated the capacity of <cons lex="paclitaxel" sem="G_DRUG">paclitaxel</cons> and <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons> to <cons sem="G_MECHANISM">activate</cons> human pregnane X receptor (hPXR), an orphan nuclear receptor that plays a key role in the transcriptional regulation of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(paclitaxel, CYP3A4,DEI)">
<sentence>In concurrence with previous reports, we observed that <cons lex="paclitaxel" sem="G_DRUG">paclitaxel</cons> potently <cons sem="G_MECHANISM">induced</cons> <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activity and expression in hepatocytes treated for 48-96 h.</sentence> 
</annotation> 
<annotation sem="INVITROCDDIS" ddi="(docetaxel, CYP3A4,NDEI)">
<sentence>However, <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> <cons lex="increase" sem="G_CHANGE">increase</cons> the activity or the <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> immunoreactive protein levels for treatment periods up to 96 h.</sentence> 
</annotation>.
<annotation sem="INVITROCDDIS" ddi="(docetaxel, CYP3A4,ADEI)">
<sentence>A marginal <cons lex="increase" sem="G_CHANGE">increase</cons> in the <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> mRNA levels was observed in cells treated with higher levels (<cons sem="G_NUMBER">5 and 10 microM</cons>) of <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons>.</sentence></annotation>
<annotation sem="INVITROCDDIS" ddi="(paclitaxel, hPXR,DEI)(docetaxel, hPXR,ADEI)">
<sentence>Furthermore, while <cons lex="paclitaxel" sem="G_DRUG">paclitaxel</cons> effectively <cons lex="activated" sem="G_MECHANISM">activated</cons> hPXR (the half-maximal effective concentration, <cons sem="G_IVITPARA">EC50</cons>, being about <cons sem="G_NUMBER">5.2 microM</cons>), <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons> weakly <cons lex="activated" sem="G_MECHANISM">activated</cons> hPXR, and moreover the <cons sem="G_MECHANISM">activation</cons> occurred only at high concentrations relative to <cons lex="paclitaxel" sem="G_DRUG">paclitaxel</cons>.</sentence>
</annotation>
<sentence>A comparison of the cellular concentrations of <cons lex="paclitaxel" sem="G_DRUG">paclitaxel</cons> and <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons>, in the cell culture models employed for evaluating <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons lex="induction" sem="G_MECHANISM">induction</cons> and hPXR <cons sem="G_MECHANISM">activation</cons>, revealed that the intracellular <cons lex="paclitaxel" sem="G_DRUG">paclitaxel</cons> levels were three-fold higher than that of <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons>.</sentence>
<sentence>Thus, it appears that both pharmacokinetic (drug concentration) and pharmacodynamic differences (hPXR <cons sem="G_MECHANISM">activation</cons>) <cons sem="G_CHANGE">may</cons> account for the observed differences in <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> <cons lex="induction" sem="G_MECHANISM">induction</cons> by <cons lex="paclitaxel" sem="G_DRUG">paclitaxel</cons> and <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons>.</sentence>
<sentence>Our studies suggest that <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons> has <cons sem="G_CHANGE">markedly</cons> <cons sem="G_CHANGE">reduced</cons> propensity to cause drug interactions that <cons sem="G_CHANGE">may</cons> entail hepatic <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons lex="induction" sem="G_MECHANISM">induction</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15155554</bibliomisc>
</articleinfo>
<title>
<sentence>Selective <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons>-<cons lex="catalyzed" sem="G_MECHANISM">catalyzed</cons> <cons lex="bupropion" sem="G_DRUG">bupropion</cons> hydroxylation in human liver microsomes in vitro.</sentence>
</title>
<abstract>
<sentence>Some <cons sem="G_MECHANISM">inhibitory</cons> agents against <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> have been reported, but none of these has been extensively characterized or compared with others, as to the potency and selectivity of <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> toward <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons>.</sentence>
<sentence>The goal of this work was to find a selective and potent chemical in vitro <cons sem="G_MECHANISM">inhibitor</cons> toward <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> using <cons lex="bupropion" sem="G_DRUG">bupropion</cons> hydroxylation as a model reaction.</sentence>
<sentence>At the initial screening of more than 30 substances, <cons lex="ticlopidine" sem="G_DRUG">ticlopidine</cons>, triethylenethiophosphoramide (<cons lex="thiotepa" sem="G_DRUG">thioTEPA</cons>), <cons lex="metyrapone" sem="G_DRUG">metyrapone</cons>, <cons sem="G_DRUG">xanthate C8</cons>, and benzylisothiocyanate displayed <cons sem="G_IVITPARA">IC(50)</cons> values of <cons sem="G_NUMBER">&lt;10 microM</cons> and were selected for a more detailed analysis.</sentence>
<sentence><cons lex="metyrapone" sem="G_DRUG">Metyrapone</cons>, <cons sem="G_DRUG">xanthate C8</cons>, and <cons sem="G_DRUG">benzylisothiocyanate</cons> <cons sem="G_MECHANISM">inhibited</cons> several other cytochrome P450 activities rather effectively, some of them even more potently than <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons>, and consequently are unsuitable as <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons>-selective probes.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Ticlopidine, bupropion hydroxylation,DDI)(thioTEPA, bupropion hydroxylation,DDI)">
<sentence><cons lex="ticlopidine" sem="G_DRUG">Ticlopidine</cons> and <cons lex="thiotepa" sem="G_DRUG">thioTEPA</cons> were the most potent <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="bupropion" sem="G_DRUG">bupropion</cons> hydroxylation with <cons sem="G_IVITPARA">K(i)</cons> values of <cons sem="G_NUMBER">0.2</cons> and <cons sem="G_NUMBER">2.8 microM</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(thioTEPA, CYP2B6,DEI)">
<sentence>The <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> type of <cons lex="ticlopidine" sem="G_DRUG">ticlopidine</cons> was found to be mixed type, with a component of mechanism-based <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons>, whereas <cons lex="thiotepa" sem="G_DRUG">thioTEPA</cons><cons sem="G_MECHANISM">inhibited</cons> <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> in a competitive manner.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(ticlopidine, mephenytoin 4-hydroxylation,DDI)(ticlopidine, dextromethorphan O-demethylation,DDI)">
<sentence>In addition to <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons>, <cons lex="ticlopidine" sem="G_DRUG">ticlopidine</cons> also <cons sem="G_MECHANISM">inhibited</cons> both <cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons> 4-hydroxylation (<cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>) <cons sem="G_IVITPARA">(IC(50)</cons>, <cons sem="G_NUMBER">2.7 microM</cons>) and <cons lex="dextromethorphan" sem="G_DRUG">dextromethorphan</cons> O-demethylation (<cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>) (<cons sem="G_IVITPARA">IC(50)</cons>,<cons sem="G_NUMBER">4.4 microM</cons>).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(thioTEPA, coumarin 7-hydroxylation,DDI)">
<sentence>For <cons lex="thiotepa" sem="G_DRUG">thioTEPA</cons> the next sensitive P450 activity after <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> was <cons sem="G_DRUG">coumarin</cons> 7-hydroxylation ( <cons sem="G_IVITPARA">IC(50)</cons>, <cons sem="G_NUMBER">256 microM</cons>).</sentence>
</annotation>
<sentence>Thus, although both compounds proved to be relatively potent <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons>, <cons lex="thiotepa" sem="G_DRUG">thioTEPA</cons> was about 2 orders of magnitude more selective than <cons lex="ticlopidine" sem="G_DRUG">ticlopidine</cons>.</sentence>
<sentence>Thus, <cons lex="thiotepa" sem="G_DRUG">thioTEPA</cons> is a drug of choice when high <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> selectivity among major P450 enzymes is required.</sentence>
<sentence><cons lex="ticlopidine" sem="G_DRUG">Ticlopidine</cons> is a useful alternative under a controlled experimental setup and when higher potency is needed.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15133245</bibliomisc>
</articleinfo>
<title>
<sentence>Identification of human p450 isoforms involved in the <cons sem="G_MECHANISM">metabolism</cons> of the antiallergic drug,<cons sem="G_NUMBER">oxatomide</cons> , and its <cons sem="G_MECHANISM">inhibitory</cons> effect on enzyme activity.</sentence>
</title>
<abstract>
<sentence><cons sem="G_DRUG">Oxatomide</cons> is an antiallergic drug used for the treatment of diseases mediated by type I allergy.</sentence>
<sentence>Recently, it has been reported that <cons lex="terfenadine" sem="G_DRUG">terfenadine</cons> and <cons lex="astemizole" sem="G_DRUG">astemizole</cons>, which have antiallergic actions similar to those of oxatomide, show side effects on the cardiovascular system, such as QT prolongation, ventricular arrhythmia and cardiac arrest.</sentence>
<sentence>This <cons sem="G_CHANGE">might</cons> be because concomitant drugs such as <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> <cons sem="G_MECHANISM">inhibit</cons> cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4</cons> (<cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>), the enzyme responsible for degradation of <cons lex="terfenadine" sem="G_DRUG">terfenadine</cons> and <cons lex="astemizole" sem="G_DRUG">astemizole</cons>, and thus the blood concentrations of the drugs are abnormally <cons sem="G_CHANGE">increased</cons>.</sentence>
<sentence>On the other hand, isoforms of P450 involved in the <cons sem="G_MECHANISM">metabolism</cons> of <cons sem="G_DRUG">oxatomide</cons> have <cons sem="G_NEGATIVEEFFECT">not</cons> been clarified.</sentence>
<sentence>Therefore, we attempted to identify these isoforms using microsome preparations of in vitro expression systems derived from a human lymphoblastoid cell line.</sentence>
<sentence><cons sem="G_DRUG">Oxatomide</cons> was <cons sem="G_MECHANISM">metabolized</cons> by <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>-Val and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, but <cons sem="G_NEGATIVEEFFECT">not</cons> by <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>-Arg, <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>-Cys or <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> .</sentence>
<sentence>We also examined whether <cons sem="G_DRUG">oxatomide</cons> showed <cons sem="G_MECHANISM">inhibitory</cons> effects on metabolic activity of individual P450 isozymes using model substrates for each isozyme.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Oxatomide, CYP1A2,NDEI)(Oxatomide, CYP2C9-Arg,NDEI)(Oxatomide, CYP2C9-Cys,NDEI)(Oxatomide, CYP2C19,NDEI)(Oxatomide, CYP2D6-Val,DEI)(Oxatomide, CYP3A4,DEI)">
<sentence><cons sem="G_DRUG">Oxatomide</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_MECHANISM">inhibit</cons> the <cons sem="G_MECHANISM">metabolism</cons> of the model substrates for <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>-Arg, <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>-Cys and <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>, but <cons sem="G_MECHANISM">inhibited</cons> the degradation of those for <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>-Val and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> .</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Oxatomide, CYP2D6,DEI)(Oxatomide, CYP3A4,DEI)">
<sentence>It was found that <cons sem="G_DRUG">oxatomide</cons> is <cons sem="G_MECHANISM">metabolized</cons> by <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> in human liver microsomes, and simultaneously acts as an <cons sem="G_MECHANISM">inhibitor</cons> for these isoforms, responsible for the <cons sem="G_MECHANISM">metabolism</cons> of the drug itself.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15108219</bibliomisc>
</articleinfo>
<title>
<sentence>Interaction of <cons sem="G_DRUG">dexloxiglumide</cons>, a cholecystokinin type-1 receptor antagonist, with human cytochromes P450.</sentence>
</title>
<abstract>
<sentence><cons sem="G_DRUG">Dexloxiglumide (DEX)</cons> is a cholecystokinin type-1 receptor antagonist under development for the treatment of constipation-predominant irritable bowel syndrome.</sentence>
<sentence>Studies of the potential interaction of <cons sem="G_DRUG">DEX</cons> with human cytochromes P450 (CYPs) were conducted in vitro.</sentence>
<sentence><cons sem="G_NUMBER">DEX</cons> (<cons sem="G_NUMBER">300 micro M</cons>) , both with and without a 15-min pre-incubation, was incubated with pooled human liver microsomes and substrates selective for each of eight CYPs.</sentence>
<annotation sem="INVITROVDDIS" ddi="(Dexloxiglumide, tolbutamide 4-methyl-hydroxylase,DDI)(Dexloxiglumide, lauric acid 11-hydroxylase,DDI)">
<sentence>This resulted in <cons sem="G_NUMBER">&gt;30%</cons> <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of <cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons> 4-methyl-hydroxylase <cons sem="G_CYP">(CYP2C9/10)</cons> and <cons lex="lauric" sem="G_DRUG">lauric</cons> acid 11-hydroxylase (<cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons>) activities.</sentence>
</annotation>
<sentence>Mean <cons sem="G_IVITPARA">K(i)</cons> (SD) for <cons sem="G_CYP">CYP2C9/10</cons> and <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons> were <cons sem="G_NUMBER">69.0 (24.3)</cons> and <cons sem="G_NUMBER">426 (60) microM</cons>, respectively.</sentence>
<sentence>Incubations of  [(14)C]DEX with pooled human liver microsomes produced one major phase I metabolic fraction, with <cons sem="G_IVITPARA">V(max)</cons>=<cons sem="G_NUMBER">131 pmol/min/mg</cons> protein and <cons sem="G_IVITPARA">K(m)</cons>= <cons sem="G_NUMBER">23.7 microM</cons>.</sentence>
<sentence>Further incubations with (i) liver microsomes from 16 individual donors (<cons lex="correlation" sem="G_MECHANISM">correlation</cons> analysis), (ii) Supersomes trade mark and (iii) selective chemical <cons sem="G_MECHANISM">inhibitors</cons>, implicated <cons lex="cyp3a4/5" sem="G_CYP">CYP3A4/5</cons>, <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> and <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> in the formation of this component.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Dexloxiglumide, CYP2C9,ADEI)">
<sentence>Thus,<cons sem="G_DRUG">DEX</cons> interacts with <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> both as <cons sem="G_MECHANISM">inhibitor</cons> <cons sem="G_IVITPARA">(K(i)</cons>= <cons sem="G_NUMBER">69.0 microM</cons>) and as substrate in vitro.</sentence>
</annotation>
<sentence>However, based on the<cons sem="G_IVITPARA">maximum concentration</cons> (<cons sem="G_NUMBER">27 microM</cons>) after repeated oral doses of 200 mg t.i.d. and the unbound fraction (0.03) of <cons sem="G_DRUG">DEX</cons> in human plasma, <cons sem="G_NEGATIVEEFFECT">no</cons> clinically relevant metabolic interactions with other CYP substrates are predicted.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:14993813</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of <cons sem="G_DRUG">nilvadipine</cons>, a dihydropyridine calcium antagonist, on cytochrome P450 activities in human hepatic microsomes.</sentence>
</title>
<abstract>
<sentence>The effects of <cons sem="G_DRUG">nilvadipine</cons>, a dihydropyridine calcium antagonist, on cytochrome P450 (CYP) activities in human hepatic microsomes were investigated.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Nilvadipine, 7-ethoxyresorufin O-deethylase,ADDI)(Nilvadipine, coumarin 7-hydroxylase,ADDI)(Nilvadipine, tolbutamide methylhydroxylase,DDI)(Nilvadipine, S-mephenytoin 4'-hydroxylase,ADDI)(Nilvadipine, nifedipine oxidase,ADDI)">
<sentence><cons sem="G_DRUG">Nilvadipine</cons> competitively <cons sem="G_MECHANISM">inhibited</cons> <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>-mediated 7- <cons sem="G_DRUG">ethoxyresorufin</cons> O-deethylase, <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons>-mediated <cons sem="G_DRUG">coumarin</cons> 7-hydroxylase, <cons sem="G_CYP">CYP2C8/9</cons>-mediated <cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons> methylhydroxylase, <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>-mediated S-<cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons> 4'-hydroxylase, and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>-mediated <cons lex="nifedipine" sem="G_DRUG">nifedipine</cons> oxidase activities, and the <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> constant <cons sem="G_IVITPARA">(Ki)</cons> values were <cons sem="G_NUMBER">13.0, 35.8, 5.02, 24.5 and 44.3 microM</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Nilvadipine, 7-benzyloxyresorufin O-debenzylation,NDDI)(Nilvadipine, bufuralol 1'-hydroxylation,NDDI)(Nilvadipine, chlorzoxazone 6-hydroxylation,NDDI)">
<sentence>On the other hand, <cons sem="G_NEGATIVEEFFECT">no</cons> <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons>-mediated 7-<cons sem="G_DRUG">benzyloxyresorufin</cons> O-debenzylation, <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>-mediated <cons sem="G_DRUG">bufuralol</cons> 1'-hydroxylation, or <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons>-mediated <cons lex="chlorzoxazone" sem="G_DRUG">chlorzoxazone</cons> 6-hydroxylation by <cons sem="G_DRUG">nilvadipine</cons> at <cons sem="G_NUMBER">40 microM</cons> concentration was observed.</sentence>
</annotation>
<sentence>The free fractions of <cons sem="G_DRUG">nilvadipine</cons> in the incubation mixture estimated by ultracentrifugation were <cons sem="G_NUMBER">18.9-27.4%</cons>.</sentence>
<sentence>These results suggest that <cons sem="G_DRUG">nilvadipine</cons> would <cons sem="G_NEGATIVEEFFECT">not</cons> cause clinically <cons sem="G_CHANGE">significant</cons> interactions with other drugs, which are <cons sem="G_MECHANISM">metabolized</cons> by CYPs, via the <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:14977870</bibliomisc>
</articleinfo>
<title>
<sentence>Regulation of <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> in primary human hepatocytes by prototypical inducers.</sentence>
</title>
<abstract>
<sentence>The objectives of this study were to evaluate the ability of 14 compounds, which differentially <cons sem="G_MECHANISM">activate</cons> human pregnane X receptor (hPXR), to <cons sem="G_MECHANISM">induce</cons> <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> expression and to compare <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> concentration- and time-dependent <cons lex="induction" sem="G_MECHANISM">induction</cons> by select inducers.</sentence>
<sentence>Three primary human hepatocyte preparations were treated daily for 3 days with three concentrations of all compounds.</sentence>
<sentence>Additional concentration- and/or time-response studies were conducted with <cons lex="clotrimazole" sem="G_DRUG">clotrimazole</cons>, <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons>, <cons lex="phenobarbital" sem="G_DRUG">phenobarbital</cons>, and <cons lex="rifampin" sem="G_DRUG">rifampin</cons> in six preparations.</sentence>
<sentence><cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> protein and activities were assessed by Western blotting, <cons lex="bupropion" sem="G_DRUG">bupropion</cons> hydroxylation, and <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6beta-hydroxylation, respectively.</sentence>
<sentence>To evaluate hPXR <cons sem="G_MECHANISM">activation</cons> by the 14 compounds, reporter gene assays were conducted using Huh7 cells cotransfected with hPXR and a <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> (NR1)5-LUC reporter plasmid.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Clotrimazole, CYP2B6,DEI)(phenobarbital, CYP2B6,DEI)(rifampin, CYP2B6,DEI)(ritonavir, CYP2B6,DEI)(Clotrimazole, hPXR,DEI)(phenobarbital, hPXR,DEI)(rifampin, hPXR,DEI)(ritonavir, hPXR,DEI)(dexamethasone t-butylacetate, CYP2B6,ADEI)(sulfinpyrazone, CYP2B6,ADEI)(paclitaxel, CYP2B6,NDEI)(paclitaxel, hPXR,DEI)(carbamazepine, CYP2B6,ADEI)(carbamazepine, hPXR,NDEI)(phenytoin, CYP2B6,ADEI)(phenytoin, hPXR,NDEI)(dexamethasone, CYP2B6,NDEI)(dexamethasone, hPXR,NDEI)(methotrexate, CYP2B6,NDEI)(methotrexate, hPXR,NDEI)(probenecid, CYP2B6,NDEI)(probenecid, hPXR,NDEI)(sulfadimidine, CYP2B6,NDEI)(sulfadimidine, hPXR,NDEI)(troleandomycin, CYP2B6,NDEI)(troleandomycin, hPXR,NDEI)">
<sentence><cons lex="clotrimazole" sem="G_DRUG">Clotrimazole</cons>, <cons lex="phenobarbital" sem="G_DRUG">phenobarbital</cons>, <cons lex="rifampin" sem="G_DRUG">rifampin</cons>, and <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> strongly <cons sem="G_MECHANISM">induced</cons> <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> and <cons lex="activated" sem="G_MECHANISM">activated</cons> hPXR; <cons lex="dexamethasone" sem="G_DRUG">dexamethasone</cons> t-butylacetate and <cons lex="sulfinpyrazone" sem="G_DRUG">sulfinpyrazone</cons><cons sem="G_MECHANISM">induced</cons> <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> weakly and <cons lex="activated" sem="G_MECHANISM">activated</cons> hPXR <cons sem="G_CHANGE">moderately</cons>;<cons lex="paclitaxel" sem="G_DRUG">paclitaxel</cons> strongly <cons lex="activated" sem="G_MECHANISM">activated</cons> hPXR but did <cons sem="G_NEGATIVEEFFECT">not</cons> <cons lex="increase" sem="G_CHANGE">increase</cons> <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> expression <cons lex="carbamazepine" sem="G_DRUG">carbamazepine</cons> and <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons> <cons sem="G_CHANGE">moderately</cons> or strongly <cons sem="G_CHANGE">increased</cons> <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> expression but weakly <cons lex="activated" sem="G_MECHANISM">activated</cons> hPXR; and <cons lex="dexamethasone" sem="G_DRUG">dexamethasone</cons>, <cons lex="methotrexate" sem="G_DRUG">methotrexate</cons>, <cons lex="probenecid" sem="G_DRUG">probenecid</cons>,<cons sem="G_DRUG">sulfadimidine</cons>, and <cons lex="troleandomycin" sem="G_DRUG">troleandomycin</cons> demonstrated weak or <cons sem="G_CHANGE">negligible</cons> effects on <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> and hPXR.</sentence></annotation>
<sentence><cons sem="G_IVITPARA">EC50</cons> values for <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons lex="induction" sem="G_MECHANISM">induction</cons> by <cons lex="clotrimazole" sem="G_DRUG">clotrimazole</cons>, <cons lex="phenobarbital" sem="G_DRUG">phenobarbital</cons>, <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons>, and <cons lex="rifampin" sem="G_DRUG">rifampin</cons> were strongly <cons lex="correlated" sem="G_MECHANISM">correlated</cons> (<cons sem="G_NUMBER">r2 = 0.99</cons>) and were statistically indistinguishable for <cons lex="clotrimazole" sem="G_DRUG">clotrimazole</cons>, <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons>, and <cons lex="rifampin" sem="G_DRUG">rifampin</cons>.</sentence>
<sentence>Kinetic constants governing time-dependent <cons lex="induction" sem="G_MECHANISM">induction</cons> by <cons lex="phenobarbital" sem="G_DRUG">phenobarbital</cons> and <cons lex="rifampin" sem="G_DRUG">rifampin</cons> were also similar between <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
<sentence>These results indicate that <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> is highly <cons sem="G_MECHANISM">inducible</cons> by known <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> inducers and suggest that hPXR is a major determinant of <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons>-inducible expression for many, but <cons sem="G_NEGATIVEEFFECT">not</cons> all, compounds evaluated in this study.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:14709624</bibliomisc>
</articleinfo>
<title>
<sentence>The olivacine derivative <cons sem="G_DRUG">s 16020 (9-hydroxy-5,6-dimethyl-N- [2-(dimethylamino)ethyl)-6H-pyrido(4,3-B)-carbazole-1-carboxamide)</cons> <cons sem="G_MECHANISM">induces</cons> <cons sem="G_CYP">CYP1A</cons> and its own <cons sem="G_MECHANISM">metabolism</cons> in human hepatocytes in primary culture.</sentence>
</title>
<abstract>
<sentence>The olivacine derivative <cons sem="G_DRUG">9-hydroxy-5,6-dimethyl-N- [2-(dimethylamino)ethyl)-6H-pyrido(4,3-b)-carbazole-1-carboxamide (S 16020)</cons> exhibits a potent antitumor activity.</sentence>
<sentence>However, when administered in cancer patients, its blood <cons sem="G_IVITPARA">clearance</cons> <cons sem="G_CHANGE">increases</cons> after repeated administrations, whereas the <cons sem="G_IVITPARA">volume of distribution</cons> remains constant, suggesting that the drug is able to<cons sem="G_MECHANISM">induce</cons>  its own <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
<sentence>The aim of this work was to identify the enzymes involved in <cons sem="G_DRUG">S 16020</cons> <cons sem="G_MECHANISM">metabolism</cons> and determine whether this molecule is an enzyme inducer in human hepatocytes in primary cultures.</sentence>
<sentence>Among a battery of cDNA-expressed <cons sem="G_CYP">cytochromes P450 (P450s)</cons> and flavin monooxygenase (FMO), only <cons lex="cyp1a1" sem="G_CYP">CYP1A1</cons>, <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, and FMO3 were able to generate detectable amounts of metabolites of <cons sem="G_DRUG">S 16020</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(S 16020, CYP1A2,DEI)(S 16020, acetanilide 4-hydroxylation,DDI)(S 16020, ethoxyresorufin O-deethylation,DDI)(S 16020, chlorzoxazone 6-hydroxylation,DDI)(S 16020, 2,3,7,8-tetrachlorodibenzo-p-dioxin,DDI)">
<sentence>In primary hepatocytes,<cons sem="G_DRUG">S 16020</cons> behaved as a <cons sem="G_CYP">CYP1A</cons><cons sem="G_MECHANISM">inducer</cons>, producing an <cons lex="increase" sem="G_CHANGE">increase</cons> in <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> protein,<cons sem="G_DRUG">acetanilide</cons> 4-hydroxylation, <cons sem="G_DRUG">ethoxyresorufin</cons> O-deethylation, and <cons lex="chlorzoxazone" sem="G_DRUG">chlorzoxazone</cons> 6-hydroxylation to an extent similar to that of <cons sem="G_DRUG">2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)</cons>, a prototypical <cons sem="G_CYP">CYP1A</cons> inducer.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(S 16020, CYP2A6,NDEI)(S 16020, CYP2B6,NDEI)(S 16020, CYP2C9,NDEI)(S 16020, CYP2C19,NDEI)(S 16020, CYP2E1,NDEI)(S 16020, CYP3A4,NDEI)">
<sentence>The levels of other P450 proteins, including <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons>, <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons>, <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>, <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons>, and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, and related activities were <cons sem="G_NEGATIVEEFFECT">not</cons> affected by <cons sem="G_DRUG">S 16020</cons>.</sentence>
</annotation>
<sentence>In primary hepatocytes, pretreatment of cells with <cons sem="G_DRUG">S 16020</cons> or <cons sem="G_DRUG">TCDD</cons> produced a <cons sem="G_CHANGE">significant</cons> and similar <cons lex="increase" sem="G_CHANGE">increase</cons> of <cons sem="G_DRUG">S 16020</cons> <cons sem="G_MECHANISM">metabolism</cons>, consistent with the previous indications on the role of <cons sem="G_CYP">CYP1A</cons>s.</sentence>
<sentence>We conclude that <cons sem="G_CYP">CYP1A</cons>s and FMO3 are the major phase I enzymes involved in the <cons sem="G_MECHANISM">metabolism</cons> of <cons sem="G_DRUG">S 16020</cons> and that this molecule is a potent hydrocarbon-like inducer able to <cons sem="G_MECHANISM">stimulate</cons> its own <cons sem="G_MECHANISM">metabolism</cons> in primary human hepatocytes and liver.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:14636322</bibliomisc>
</articleinfo>
<title>
<sentence>Dose-dependent <cons lex="induction" sem="G_MECHANISM">induction</cons> of cytochrome P450 (CYP) <cons lex="3a4" sem="G_CYP">3A4</cons> and <cons sem="G_MECHANISM">activation</cons> of pregnane X receptor by <cons lex="topiramate" sem="G_DRUG">topiramate</cons>.</sentence>
</title>
<abstract>
<sentence>In clinical studies, <cons lex="topiramate" sem="G_DRUG">topiramate</cons> (<cons sem="G_DRUG">TPM</cons>) was shown to cause a dose-dependent <cons lex="increase" sem="G_CHANGE">increase</cons> in the <cons sem="G_IVITPARA">clearance</cons> of ethinyl <cons lex="estradiol" sem="G_DRUG">estradiol</cons>.</sentence>
<sentence>We hypothesized that this interaction results from <cons lex="induction" sem="G_MECHANISM">induction</cons> of hepatic cytochrome P450 (CYP) <cons lex="3a4" sem="G_CYP">3A4</cons> by <cons sem="G_DRUG">TPM</cons>.</sentence>
<sentence>Accordingly, we investigated whether<cons sem="G_DRUG">TPM</cons> <cons sem="G_MECHANISM">induces</cons> <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> in primary human hepatocytes and <cons sem="G_MECHANISM">activates</cons> the human pregnane X receptor (hPXR), a nuclear receptor that serves as a regulator of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> transcription.</sentence>
<sentence>Human hepatocytes were treated for 72 h with <cons sem="G_DRUG">TPM</cons> (<cons sem="G_NUMBER">10, 25, 50, 100, 250, and 500 microM</cons>) and known <cons sem="G_MECHANISM">inducers</cons>, <cons lex="phenobarbital" sem="G_DRUG">phenobarbital</cons> (PB; <cons sem="G_NUMBER">2 mM</cons>), and <cons sem="G_DRUG">rifampicin</cons> (<cons sem="G_NUMBER">10 microM</cons>).</sentence>
<sentence>The rate of <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6beta-hydroxylation by hepatocytes served as a marker for <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activity.</sentence>
<sentence>The <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>-specific protein and mRNA levels were determined by using Western and Northern blot analyses, respectively.</sentence>
<sentence>The hPXR <cons sem="G_MECHANISM">activation</cons> was assessed with cell-based reporter gene assay.</sentence>
<annotation sem="INVITROCDDIS" ddi="(TPM, CYP3A4,DEI)">
<sentence>Compared with controls,<cons sem="G_DRUG">TPM</cons> (<cons sem="G_NUMBER">50-500 microM</cons>)-treated hepatocytes exhibited a considerable <cons lex="increase" sem="G_CHANGE">increase</cons> in the <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activity (<cons sem="G_NUMBER">1.6- to 8.2-fold</cons>), protein levels (<cons sem="G_NUMBER">4.6- to 17.3-fold</cons>), and mRNA levels (<cons sem="G_NUMBER">1.9- to 13.3-fold</cons>).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(rifampicin, CYP3A4,DEI)">
<sentence>Comparatively,<cons sem="G_DRUG">rifampicin</cons> (<cons sem="G_NUMBER">10 microM</cons>) effected <cons sem="G_NUMBER">14.5-, 25.3-, and a 20.3-fold</cons> <cons lex="increase" sem="G_CHANGE">increase</cons> in <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activity, immunoreactive protein levels, and mRNA levels, respectively.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(TPM, hPXR,DEI)(rifampicin, hPXR,DEI)">
<sentence>TPM (<cons sem="G_NUMBER">50-500 microM</cons>) caused <cons sem="G_NUMBER">1.3- to 3-fold</cons> <cons sem="G_MECHANISM">activation</cons> of the hPXR, whereas <cons sem="G_DRUG">rifampicin</cons> (<cons sem="G_NUMBER">10 microM</cons>) caused a <cons sem="G_NUMBER">6-fold</cons> <cons sem="G_MECHANISM">activation</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(TPM, CYP3A4,DEI)(TPM, ethinyl estradiol,DDI)">
<sentence>The observed <cons lex="induction" sem="G_MECHANISM">induction</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> by <cons sem="G_DRUG">TPM</cons>, especially at the higher concentrations, provides a potential mechanistic explanation of the reported <cons lex="increase" sem="G_CHANGE">increase</cons> in the ethinyl <cons lex="estradiol" sem="G_DRUG">estradiol</cons> <cons sem="G_IVITPARA">clearance</cons> by <cons sem="G_DRUG">TPM</cons>.</sentence>
</annotation>
<sentence>It also is suggestive of other potential interactions when high-dose <cons sem="G_DRUG">TPM</cons> therapy is used.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:14570772</bibliomisc>
</articleinfo>
<title>
<sentence>Human cytochrome p450 <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> and metabolic-intermediate complex formation by  goldenseal extract and its methylenedioxyphenyl components.</sentence>
</title>
<abstract>
<sentence>The concurrent use of herbal medicinals with prescription and over-the-counter drugs carries a risk for unanticipated adverse drug-botanical pharmacokinetic interactions, particularly as a result of cytochrome P450 (P450) <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons>.</sentence>
<sentence>Extracts of goldenseal (Hydrastis canadensis) containing approximately equal concentrations ( approximately <cons sem="G_NUMBER">17 mM</cons>) of two methylenedioxyphenyl alkaloids, <cons lex="berberine" sem="G_DRUG">berberine</cons> and hydrastine, <cons sem="G_MECHANISM">inhibited</cons> with <cons sem="G_CHANGE">increasing</cons> potency (<cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>) <cons lex="diclofenac" sem="G_DRUG">diclofenac</cons> 4'-hydroxylation, (<cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>) bufuralol 1'-hydroxylation, and (<cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>) <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6beta-hydroxylation activities in human hepatic microsomes.</sentence>
<sentence>The <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6beta-hydroxylation activity was noncompetitive with an apparent <cons sem="G_IVITPARA">Ki</cons> of <cons sem="G_NUMBER">0.11%</cons> extract.</sentence>
<sentence>Of the methylenedioxyphenyl alkaloids, <cons lex="berberine" sem="G_DRUG">berberine</cons> (<cons sem="G_IVITPARA">IC50</cons> = <cons sem="G_NUMBER">45 microM</cons>) was the more <cons sem="G_MECHANISM">inhibitory</cons> toward bufuralol 1'-hydroxylation and hydrastine (<cons sem="G_IVITPARA">IC50</cons> approximately <cons sem="G_NUMBER">350 microM</cons> for both isomers), toward <cons lex="diclofenac" sem="G_DRUG">diclofenac</cons> 4'-hydroxylation.</sentence>
<sentence>For <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6beta-hydroxylation, <cons lex="berberine" sem="G_DRUG">berberine</cons> was the least <cons sem="G_MECHANISM">inhibitory</cons> component (<cons sem="G_IVITPARA">IC50</cons> approximately <cons sem="G_NUMBER">400 microM</cons>).</sentence>
<sentence>Hydrastine <cons sem="G_MECHANISM">inhibited</cons> <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6beta-hydroxylation with <cons sem="G_IVITPARA">IC50</cons> values for the (+)- and (-)-isomers of <cons sem="G_NUMBER">25 and 30 microM</cons>, respectively.</sentence>
<sentence>For (-)-hydrastine, an apparent <cons sem="G_IVITPARA">Ki</cons> value of <cons sem="G_NUMBER">18 microM</cons> without preincubation and an NADPH-dependent mechanism-based <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> with a kinactivation of <cons sem="G_NUMBER">0.23 min(-1)</cons> and a <cons sem="G_IVITPARA">KI</cons> of approximately <cons sem="G_NUMBER">110 microM</cons> were determined.</sentence>
<sentence>Cytochrome P450 metabolic-intermediate (MI) complex formation could be demonstrated for both hydrastine isomers.</sentence>
<sentence>With expressed P450 isoforms, hydrastine <cons sem="G_MECHANISM">formed</cons> a P450 MI complex with <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>, and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
<sentence>Coexpression of cytochrome b5 with the P450 isoforms enhanced the rate but <cons sem="G_NEGATIVEEFFECT">not</cons> the extent of P450 MI complex formation.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:14570767</bibliomisc>
</articleinfo>
<title>
<sentence>Mechanism-based <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of human liver microsomal cytochrome P450 <cons lex="1a2" sem="G_CYP">1A2</cons> by <cons lex="zileuton" sem="G_DRUG">zileuton</cons>, a 5-lipoxygenase <cons sem="G_MECHANISM">inhibitor</cons>.</sentence>
</title>
<abstract>
<sentence><cons lex="zileuton" sem="G_DRUG">Zileuton</cons>, a 5-lipoxygenase <cons sem="G_MECHANISM">inhibitor</cons>, was evaluated as an <cons sem="G_MECHANISM">inhibitor</cons> of cytochrome P450 activity in human liver microsomes.</sentence>
<annotation sem="INVITROCDDIS" ddi="(racemate, phenacetin O-deethylation,DDI)(racemate, paclitaxel 6alpha-hydroxylation,DDI)(racemate, diclofenac 4'-hydroxylation,DDI)(racemate, (S)-mephenytoin 4'-hydroxylation,DDI)(racemate, bufuralol 1'-hydroxylation,DDI)(racemate, testosterone 6beta-hydroxylation,DDI)(racemate, chlorzoxazone 6-hydroxylation,DDI)(racemate, bupropion hydroxylation,DDI)">
<sentence>In the absence of preincubation, the racemate was found to be a weak <cons sem="G_MECHANISM">inhibitor</cons> ( <cons sem="G_IVITPARA">IC50</cons> <cons sem="G_NUMBER">&gt; 100 microM</cons>) of <cons lex="phenacetin" sem="G_DRUG">phenacetin</cons> O-deethylation (POD) (<cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>), <cons lex="paclitaxel" sem="G_DRUG">paclitaxel</cons> 6alpha-hydroxylation (<cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons>), <cons lex="diclofenac" sem="G_DRUG">diclofenac</cons> 4'-hydroxylation (<cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>), (S)-<cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons> 4'-hydroxylation (<cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>),<cons sem="G_DRUG">bufuralol</cons> 1'-hydroxylation (<cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>), <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6beta-hydroxylation (<cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>), <cons lex="chlorzoxazone" sem="G_DRUG">chlorzoxazone</cons> 6-hydroxylation (<cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons>), and <cons lex="bupropion" sem="G_DRUG">bupropion</cons> hydroxylation (<cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons>).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(zileuton, phenacetin O-deethylation,DDI)">
<sentence>When preincubated with NADPH-fortified human liver microsomes in the absence of substrate, <cons lex="zileuton" sem="G_DRUG">zileuton</cons> (racemate) was shown to <cons sem="G_MECHANISM">inhibit</cons> POD.</sentence>
</annotation>
<sentence>The effect was NADPH-, time-, and concentration-dependent, and was characterized by a <cons sem="G_IVITPARA">kinact (maximal rate of enzyme <cons sem="G_MECHANISM">inactivation</cons>)</cons> and <cons sem="G_IVITPARA">apparent KI</cons>(<cons sem="G_MECHANISM">inhibitor</cons> concentration that supports half the <cons sem="G_IVITPARA">maximal rate of <cons sem="G_MECHANISM">inactivation</cons></cons>) of <cons sem="G_NUMBER">0.035 min(-1)</cons> and <cons sem="G_NUMBER">117 microM</cons>, respectively (<cons sem="G_IVITPARA">kinact/KIratio</cons> of <cons sem="G_NUMBER">0.0003 min-1 microM(-1)</cons>).</sentence>
<annotation sem="INVITROCDDIS" ddi="((S)-(-)- zileuton [(S)-(-)-zileuton, phenacetin O-deethylation,ADDI)((R)-(-)- zileuton [(S)-(-)-zileuton, phenacetin O-deethylation,ADDI)">
<sentence>Preincubation-dependent <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of <cons lex="zileuton" sem="G_DRUG">zileuton</cons>  [(S)-(-)-<cons sem="G_DRUG">zileuton</cons>;<cons sem="G_IVITPARA">kinact</cons>,<cons sem="G_NUMBER">0.037 min(-1)</cons>,<cons sem="G_IVITPARA">KI</cons>,<cons sem="G_NUMBER">98.2 microM</cons>,<cons sem="G_IVITPARA">kinact/KIratio</cons>,<cons sem="G_NUMBER">0.0004 min(-1) microM(-1)</cons>; (R)-(+)-<cons sem="G_DRUG">zileuton</cons>;<cons sem="G_IVITPARA">kinact</cons>,<cons sem="G_NUMBER">0.012 min(-1)</cons>,<cons sem="G_IVITPARA">KI</cons>,<cons sem="G_NUMBER">66.6 microM</cons>,<cons sem="G_IVITPARA">kinact/KIratio</cons>,<cons sem="G_NUMBER">0.0002 min(-1) microM(-1)</cons>].</sentence>
</annotation>
<sentence>In addition, the <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> was <cons sem="G_NEGATIVEEFFECT">not</cons> reversed in the presence of <cons sem="G_CHANGE">reduced</cons> glutathione, catalase, and superoxide dismutase and was refractory to dialysis.</sentence>
<annotation sem="INVITROCDDIS" ddi="(zileuton, CYP1A2,DEI)">
<sentence>Therefore, <cons lex="zileuton" sem="G_DRUG">zileuton</cons> was characterized as a mechanism-based <cons sem="G_MECHANISM">inhibitor</cons> of human liver microsomal <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(zileuton, antipyrine,DDI)(zileuton, propranolol,DDI)(zileuton, (R)-warfarin,DDI)(zileuton, theophylline,DDI)(zileuton, (S)-warfarin,NDDI)(zileuton, phenytoin,NDDI)(zileuton, terfenadine,NDDI)">
<sentence>Mechanism-based <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> <cons sem="G_CHANGE">may</cons> explain why <cons lex="zileuton" sem="G_DRUG">zileuton</cons> <cons sem="G_CHANGE">decreases</cons> the <cons sem="G_IVITPARA">oral clearance</cons> of <cons lex="antipyrine" sem="G_DRUG">antipyrine</cons>, <cons lex="propranolol" sem="G_DRUG">propranolol</cons>, (R)-<cons lex="warfarin" sem="G_DRUG">warfarin</cons>, and <cons lex="theophylline" sem="G_DRUG">theophylline</cons>, at doses that have a minimal effect on the pharmacokinetics of (S)-<cons lex="warfarin" sem="G_DRUG">warfarin</cons>, <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons>, and <cons lex="terfenadine" sem="G_DRUG">terfenadine</cons>.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:14555336</bibliomisc>
</articleinfo>
<title>
<sentence>Identification of cytochrome P450 enzymes involved in the <cons sem="G_MECHANISM">metabolism</cons> of <cons sem="G_DRUG">4'-methoxy-alpha-pyrrolidinopropiophenone (MOPPP)</cons>, a designer drug, in human liver microsomes.</sentence>
</title>
<abstract>
<sentence>1.</sentence>
<sentence>The <cons sem="G_MECHANISM">metabolism</cons> of <cons sem="G_IVITPARA">4'-methoxy-alpha-pyrrolidinopropiophenone (MOPPP)</cons>, a novel designer drug, to its demethylated major metabolite <cons sem="G_IVITPARA">4'-hydroxy-pyrrolidinopropio-phenone (HO-PPP)</cons> was studied in pooled human liver microsomes (HLM) and in cDNA-expressed human hepatic cytochrome P450 (CYP) enzymes.</sentence>
<sentence>2.</sentence>
<sentence><cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons><cons sem="G_MECHANISM">catalysed</cons> the demethylation with apparent <cons sem="G_IVITPARA">Km</cons> and <cons sem="G_IVITPARA">Vmax</cons> values of <cons sem="G_NUMBER">373.4 +/- 45.1 microM</cons> and <cons sem="G_NUMBER">6.0 +/- 0.3 pmol min(-1) pmol(-1)</cons> CYP, respectively (mean +/- SD).</sentence>
<sentence>Both <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> and HLM exhibited clear biphasic profiles with apparent <cons sem="G_IVITPARA">K(m,1)</cons> values of <cons sem="G_NUMBER">1.3 +/- 0.4 and 22.0 +/- 6.5 microM</cons>, respectively, and <cons sem="G_IVITPARA">V(max,1)</cons> values of <cons sem="G_NUMBER">1.1 +/- 0.1 pmol min(-1) pmol(-1)</cons> CYP and <cons sem="G_NUMBER">169.1 +/- 20.5 pmol min(-1) mg(-1)</cons> protein, respectively.</sentence>
<sentence>3.</sentence>
<sentence>Percentages of <cons sem="G_IVITPARA">intrinsic clearances</cons> of <cons sem="G_DRUG">MOPPP</cons> by particular CYPs were calculated using the relative activity factor (RAF) approach with (S)-<cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons>-4'-hydroxylation or <cons sem="G_DRUG">bufuralol</cons>-1'-hydroxylation as index reactions for <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> or <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>, respectively.</sentence>
<sentence>4.</sentence>
<sentence><cons sem="G_DRUG">MOPPP</cons>,<cons sem="G_DRUG">HO-PPP</cons> and the standard <cons sem="G_DRUG">3',4'-methylenedioxy-pyrrolidinopropio-phenone (MDPPP)</cons> were separated and analysed by liquid chromatography-mass spectrometry in the selected-ion monitoring (SIM) mode.</sentence>
<sentence>5.</sentence>
<annotation sem="INVITROCDDIS" ddi="(quinidine, HO-PPP,DDI)">
<sentence>The <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> specific chemical <cons sem="G_MECHANISM">inhibitor</cons> <cons lex="quinidine" sem="G_DRUG">quinidine</cons> (<cons sem="G_NUMBER">3 microM</cons>) <cons sem="G_CHANGE">significantly</cons> (<cons sem="G_NUMBER">p&lt;0.0001</cons>)<cons sem="G_MECHANISM">inhibited</cons> <cons sem="G_DRUG">HO-PPP</cons> formation by <cons sem="G_NUMBER">91.8 +/- 0.5% (mean +/- SEM)</cons> in incubation mixtures with HLM and <cons sem="G_NUMBER">2 microM</cons> MOPPP.</sentence>
</annotation>
<sentence>6.</sentence>
<sentence>It can be concluded from the data obtained from kinetic and <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> studies that polymorphically expressed <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> is the enzyme mainly responsible for <cons sem="G_DRUG">MOPPP</cons> demethylation.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:12967198</bibliomisc>
</articleinfo>
<title>
<sentence>Cytochrome P450 <cons lex="2c8" sem="G_CYP">2C8</cons> and <cons lex="cyp3a4/5" sem="G_CYP">CYP3A4/5</cons> are involved in <cons lex="chloroquine" sem="G_DRUG">chloroquine</cons><cons sem="G_MECHANISM">metabolism</cons> in human liver microsomes.</sentence>
</title>
<abstract>
<sentence><cons lex="chloroquine" sem="G_DRUG">Chloroquine</cons> has been used for many decades in the prophylaxis and treatment of malaria.</sentence>
<sentence>It is <cons sem="G_MECHANISM">metabolized</cons> in humans through the N-dealkylation pathway, to <cons sem="G_DRUG">desethylchloroquine (DCQ)</cons> and <cons sem="G_DRUG">bisdesethylchloroquine (BDCQ)</cons>, by cytochrome P450 (CYP).</sentence>
<sentence>However, until recently, <cons sem="G_NEGATIVEEFFECT">no</cons> data are available on the metabolic pathway of <cons lex="chloroquine" sem="G_DRUG">chloroquine</cons>.</sentence>
<sentence>Therefore, the metabolic pathway of <cons lex="chloroquine" sem="G_DRUG">chloroquine</cons> was evaluated using human liver microsomes and cDNA-expressed CYPs.</sentence>
<sentence><cons lex="chloroquine" sem="G_DRUG">Chloroquine</cons> is mainly <cons sem="G_MECHANISM">metabolized</cons> to <cons sem="G_DRUG">DCQ</cons>, and its Eadie-Hofstee plots were biphasic, indicating the involvement of multiple enzymes, with apparent <cons sem="G_IVITPARA">Km</cons> and <cons sem="G_IVITPARA">Vmax</cons> values of <cons sem="G_NUMBER">0.21 mM</cons> and <cons sem="G_NUMBER">1.02 nmol/min/mg protein 3.43 mM</cons> and <cons sem="G_NUMBER">10.47 nmol/min/mg protein</cons> for high and low affinity components, respectively.</sentence>
<sentence>Of the cDNA-expressing CYPs examined, <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, <cons lex="2c8" sem="G_CYP">2C8</cons>, <cons lex="2c19" sem="G_CYP">2C19</cons>, <cons lex="2d6" sem="G_CYP">2D6</cons> and <cons sem="G_CYP">3A4/5</cons> exhibited <cons sem="G_CHANGE">significant</cons> <cons sem="G_IVITPARA">DCQ</cons> formation.</sentence>
<annotation sem="INVITROCDDIS" ddi="(quercetin, DCQ,DDI)(ketoconazole, DCQ,DDI)">
<sentence>A study using chemical <cons sem="G_MECHANISM">inhibitors</cons> showed only <cons lex="quercetin" sem="G_DRUG">quercetin</cons> (a <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> <cons sem="G_MECHANISM">inhibitor</cons>) and <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> (a <cons lex="cyp3a4/5" sem="G_CYP">CYP3A4/5</cons><cons sem="G_MECHANISM">inhibitor</cons>)<cons sem="G_MECHANISM">inhibited</cons> the <cons sem="G_DRUG">DCQ</cons> formation.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(DCQ, midazolam 1-hydroxylation,DDI)(DCQ, paclitaxel 6alpha-hydroxylation,DDI)">
<sentence>In addition, the <cons sem="G_DRUG">DCQ</cons> formation <cons sem="G_CHANGE">significantly</cons> <cons lex="correlated" sem="G_MECHANISM">correlated</cons> with the <cons lex="cyp3a4/5" sem="G_CYP">CYP3A4/5</cons>-<cons lex="catalyzed" sem="G_MECHANISM">catalyzed</cons> <cons lex="midazolam" sem="G_DRUG">midazolam</cons> 1-hydroxylation (<cons sem="G_NUMBER">r = 0.868</cons>) and <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons>-<cons lex="catalyzed" sem="G_MECHANISM">catalyzed</cons> <cons lex="paclitaxel" sem="G_DRUG">paclitaxel</cons> 6alpha-hydroxylation (<cons sem="G_NUMBER">r = 0.900</cons>).</sentence>
</annotation>
<sentence>In conclusion, the results of the present study demonstrated that <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> and <cons lex="cyp3a4/5" sem="G_CYP">CYP3A4/5</cons> are the major enzymes responsible for the <cons lex="chloroquine" sem="G_DRUG">chloroquine</cons> N-deethylation to <cons sem="G_DRUG">DCQ</cons> in human liver microsomes.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:12899669</bibliomisc>
</articleinfo>
<title>
<sentence>A screening study on the liability of eight different female sex steroids to <cons sem="G_MECHANISM">inhibit</cons> <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, <cons lex="2c19" sem="G_CYP">2C19</cons> and <cons lex="3a4" sem="G_CYP">3A4</cons> activities in human liver microsomes.</sentence>
</title>
<abstract>
<sentence>The aim of this study was to screen the <cons sem="G_MECHANISM">inhibitory</cons> potential of different clinically used <cons sem="G_DRUG">oestrogen</cons> and <cons sem="G_DRUG">progestin</cons>  hormones on <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, <cons lex="2c19" sem="G_CYP">2C19</cons> and <cons lex="3a4" sem="G_CYP">3A4</cons> activities in human liver microsomes.</sentence>
<sentence>The degree of <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> by <cons lex="desogestrel" sem="G_DRUG">desogestrel</cons>,<cons sem="G_DRUG">3-ketodesogestrel</cons>,<cons sem="G_DRUG">17-beta-oestradiol</cons>,<cons sem="G_DRUG">gestodene</cons>,<cons sem="G_DRUG">aethinyloestradiol</cons>, <cons lex="medroxyprogesterone" sem="G_DRUG">medroxyprogesterone</cons> acetate, <cons sem="G_DRUG">norethisterone</cons> or L-<cons lex="norgestrel" sem="G_DRUG">norgestrel</cons> were studied at <cons sem="G_NUMBER">100 microM</cons> on <cons lex="losartan" sem="G_DRUG">losartan</cons> <cons lex="oxidation" sem="G_MECHANISM">oxidation</cons> (<cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>), R-<cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> 5'-hydroxylation (<cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>) and R-<cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> sulphoxidation (<cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>) with a 10-min preincubation with NADPH in human liver microsomes prepared from 6 individual genotyped donor livers.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Aethinyloestradiol, losartan oxidation,DDI)(Aethinyloestradiol, R-omeprazole 5-hydroxylation,DDI)(Aethinyloestradiol, R-omeprazole sulphoxidation,NDDI)">
<sentence><cons sem="G_DRUG">Aethinyloestradiol</cons> was found to be a potent <cons sem="G_MECHANISM">inhibitor</cons> (<cons sem="G_NUMBER">55%</cons> mean <cons sem="G_MECHANISM">inhibition</cons>; <cons sem="G_NUMBER">95% CI 32% to 79%)</cons> of <cons lex="losartan" sem="G_DRUG">losartan</cons> <cons lex="oxidation" sem="G_MECHANISM">oxidation</cons> (<cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>) and R-<cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> 5-hydroxylation (<cons sem="G_NUMBER">70%; 63% to 77%</cons>) (<cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>),while it had <cons sem="G_CHANGE">little</cons> effect on R-<cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> sulphoxidation (<cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>) activity.</sentence>
</annotation>
<annotation sem="INVITROVDDIS" ddi="(17-beta-Oestradiol, losartan oxidation,NDEI)(17-beta-Oestradiol, R-omeprazole 5-hydroxylation,NDEI)(17-beta-Oestradiol, R-omeprazole sulphoxidation,NDEI)">
<sentence><cons sem="G_DRUG">17-beta-Oestradiol</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> produce <cons sem="G_CHANGE">significant</cons> <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> on any of the studied enzyme activities.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(gestodene, CYP2C19,DEI)(3-ketodesogestrel, CYP2C19,DEI)(gestodene, CYP3A4,ADEI)(3-ketodesogestrel, CYP3A4,ADEI)(gestodene, CYP2C9,NDEI)(3-ketodesogestrel, CYP2C9,NDEI)">
<sentence>Of the <cons sem="G_DRUG">progestin</cons> hormones studied, <cons sem="G_DRUG">gestodene</cons> and <cons sem="G_DRUG">3-ketodesogestrel</cons> were potent <cons sem="G_DRUG">inhibitors</cons> of <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> (<cons sem="G_NUMBER">57%; 47% to 67% and 51%; 29% to 45%</cons>) and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> (<cons sem="G_NUMBER">45%; 30% to 59% and 40%; 19% to 62%</cons>),but had <cons sem="G_CHANGE">little</cons> effect on the <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> activity.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(medroxyprogesterone acetate, CYP2C9,DEI)(medroxyprogesterone acetate, CYP2C19,NDEI)(medroxyprogesterone acetate, CYP3A4,NDEI)">
<sentence>In addition, <cons lex="medroxyprogesterone" sem="G_DRUG">medroxyprogesterone</cons> acetate was found to <cons sem="G_MECHANISM">inhibit</cons> <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> (<cons sem="G_NUMBER">55%; 45% to 65%</cons>),while <cons sem="G_NEGATIVEEFFECT">not</cons> having <cons sem="G_CHANGE">significant</cons> effect on <cons lex="2c19" sem="G_CYP">2C19</cons> or <cons lex="3a4" sem="G_CYP">3A4</cons> .</sentence>
</annotation>
<sentence>In conclusion, the liability of clinically used female sex steroids to <cons sem="G_MECHANISM">inhibit</cons> <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, <cons lex="2c19" sem="G_CYP">2C19</cons> and <cons lex="3a4" sem="G_CYP">3A4</cons> activities in human liver microsomes is very distinctive and these differences among both the <cons sem="G_DRUG">oestrogen</cons> and <cons sem="G_DRUG">progestin</cons> hormones <cons sem="G_CHANGE">may</cons>, at least in part, explain the variable results from clinical trials examining <cons sem="G_MECHANISM">inhibitory</cons> effects of hormone replacement therapy and oral contraceptives on drug <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:12814970</bibliomisc>
</articleinfo>
<title>
<sentence>Identification of <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> as the main isoform for the phase I hydroxylated <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="genistein" sem="G_DRUG">genistein</cons> and a prodrug converting enzyme of methylated isoflavones.</sentence>
</title>
<abstract>
<sentence>This study determined the cytochrome P450 (P450) isoforms responsible for <cons sem="G_MECHANISM">metabolism</cons> of isoflavones using human liver microsomes (HLM) and expressed P450s.</sentence>
<sentence>The primary metabolite of <cons lex="genistein" sem="G_DRUG">genistein</cons> is 3'-OH-<cons lex="genistein" sem="G_DRUG">genistein</cons>, as identified with an authentic chemically synthesized standard.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Anti- CYP1A2 Antibody, 3'-OH-genistein,DDI)">
<sentence><cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> was predominantly responsible for 3'-OH-<cons lex="genistein" sem="G_DRUG">genistein</cons> <cons sem="G_MECHANISM">formation</cons> since its <cons sem="G_MECHANISM">formation</cons> was <cons sem="G_MECHANISM">inhibited</cons> (<cons sem="G_NUMBER">&gt;50%, p &lt; 0.05</cons>) by a monoclonal antibody specific for <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, was <cons lex="correlated" sem="G_MECHANISM">correlated</cons> with <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> activities of HLM, and was <cons lex="catalyzed" sem="G_MECHANISM">catalyzed</cons> by expressed <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>.</sentence>
</annotation>
<annotation sem="INVITROVDDIS" ddi="(CYP1A2, 3'-OH-genistein,DEI)(CYP2E1, 3'-OH-genistein,DEI)">
<sentence>In addition to <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons> also <cons lex="catalyzed" sem="G_MECHANISM">catalyzed</cons>, although to a lesser extent, its formation.</sentence>
</annotation>
<sentence>The contribution of these P450s to the formation of 3'-OH-<cons lex="genistein" sem="G_DRUG">genistein</cons> was also confirmed with a panel of expressed enzymes.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Methylated isoflavones biochanin A, HLM,DEI)(Methylated isoflavones prunetin, HLM,DEI)(Methylated isoflavones formononetin, HLM,DEI)">
<sentence>Methylated isoflavones biochanin A, prunetin, and formononetin (<cons sem="G_NUMBER">10-100 microM</cons>) were rapidly converted by HLM and expressed <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> to more active <cons lex="genistein" sem="G_DRUG">genistein</cons> and daidzein.</sentence>
</annotation>
<sentence>The conversion of biochanin A to <cons lex="genistein" sem="G_DRUG">genistein</cons> appears to be mainly mediated by <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> because of the strong <cons lex="correlation" sem="G_MECHANISM">correlation</cons> between the conversion rates and <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> activities in HLM.</sentence>
<sentence>Thus, <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> is an effective prodrug-converting enzyme for less active methylated isoflavones.</sentence>
<annotation sem="INVITROCDDIS" ddi="(biochanin A, CYP1A2,DEI)">
<sentence><cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>-<cons lex="catalyzed" sem="G_MECHANISM">catalyzed</cons> conversion of biochanin A to <cons lex="genistein" sem="G_DRUG">genistein</cons> (<cons sem="G_IVITPARA">Km</cons>, <cons sem="G_NUMBER">7.80 microM</cons>; <cons sem="G_IVITPARA">Vmax</cons>, <cons sem="G_NUMBER">903 pmol/min/mg</cons> of protein; <cons sem="G_IVITPARA">Vmax/Km</cons>, <cons sem="G_NUMBER">116 microl/min/mg</cons> of protein) was much faster than 3'-hydroxylation of <cons lex="genistein" sem="G_DRUG">genistein</cons> (<cons sem="G_IVITPARA">Km</cons>, <cons sem="G_NUMBER">12.7 microM</cons> and <cons sem="G_IVITPARA">Vmax</cons>, <cons sem="G_NUMBER">109 pmol/min/mg</cons> of protein; <cons sem="G_IVITPARA">Vmax/Km</cons>, <cons sem="G_NUMBER">8.6 microl/min/mg</cons> of protein).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(genistein , phenacetin,DDI)">
<sentence>The interaction studies showed that <cons lex="genistein" sem="G_DRUG">genistein</cons> <cons sem="G_MECHANISM">inhibited</cons> <cons sem="G_MECHANISM">formation</cons> of <cons lex="acetaminophen" sem="G_DRUG">acetaminophen</cons> from <cons lex="phenacetin" sem="G_DRUG">phenacetin</cons> with an <cons sem="G_IVITPARA">IC50</cons> value of <cons sem="G_NUMBER">16 microM</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(genistein , phenacetin,DDI)">
<sentence>Additional studies showed that <cons lex="phenacetin" sem="G_DRUG">phenacetin</cons> and <cons lex="genistein" sem="G_DRUG">genistein</cons> were mutually <cons sem="G_MECHANISM">inhibitory</cons>.</sentence>
</annotation>
<sentence>In conclusion, <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> and <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons> <cons sem="G_MECHANISM">metabolism</cons> <cons lex="genistein" sem="G_DRUG">genistein</cons> and <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> acted as prodrug-converting enzymes for other less active methylated isoflavones.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:12814962</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="eletriptan" sem="G_DRUG">Eletriptan</cons> <cons sem="G_MECHANISM">metabolism</cons> by human hepatic CYP450 enzymes and transport by human P-glycoprotein.</sentence>
</title>
<abstract>
<sentence>"Reaction phenotyping" studies were performed with <cons lex="eletriptan" sem="G_DRUG">eletriptan</cons> (ETT) to determine its propensity to interact with coadministered medications.</sentence>
<sentence>Its ability to serve as a <cons sem="G_MECHANISM">substrate</cons> for human P-glycoprotein (P-gp) was also investigated since a central mechanism of action has been proposed for this "triptan" class of drug.</sentence>
<annotation sem="INVITROVDDIS" ddi="(eletriptan, N-desmethyl eletriptan,DDI)(eletriptan, testosterone 6 beta-hydroxylation,DDI)">
<sentence>In studies with a characterized bank of human liver microsome preparations, a good <cons lex="correlation" sem="G_MECHANISM">correlation</cons> (<cons sem="G_NUMBER">r2 = 0.932</cons>) was obtained between formation of N-desmethyl <cons lex="eletriptan" sem="G_DRUG">eletriptan</cons> (DETT) and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>-<cons lex="catalyzed" sem="G_MECHANISM">catalyzed</cons> <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6 beta-hydroxylation.</sentence>
</annotation>
<sentence><cons sem="G_DRUG">DETT</cons> was selected to be monitored in our studies since it represents a <cons sem="G_CHANGE">significant</cons> <cons sem="G_DRUG">ETT</cons> metabolite in humans, circulating at concentrations <cons sem="G_NUMBER">10 to 20%</cons> of those observed for parent drug.</sentence>
<sentence><cons sem="G_DRUG">ETT</cons> was <cons sem="G_MECHANISM">metabolized</cons> to <cons sem="G_DRUG">DETT</cons> by recombinant <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> (<cons sem="G_CYP">rCYP2D6</cons>) and <cons sem="G_CYP">rCYP3A4</cons>, and to a lesser extent by <cons sem="G_CYP">rCYP2C9</cons> and <cons sem="G_CYP">rCYP2C19</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(troleandomycin, DETT,DDI)(erythromycin, DETT,DDI)(miconazole, DETT,DDI)(Anti-CYP3A4 antibody, DETT,DDI)">
<sentence>The <cons sem="G_MECHANISM">metabolism</cons> of <cons sem="G_DRUG">ETT</cons> to <cons sem="G_DRUG">DETT</cons> in human liver microsomes was <cons sem="G_CHANGE">markedly</cons> <cons sem="G_MECHANISM">inhibited</cons> by <cons lex="troleandomycin" sem="G_DRUG">troleandomycin</cons>, <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons>, <cons lex="miconazole" sem="G_DRUG">miconazole</cons>, and an <cons sem="G_MECHANISM">inhibitory</cons> antibody to <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> ,but <cons sem="G_NEGATIVEEFFECT">not</cons> by <cons sem="G_MECHANISM">inhibitors</cons> of other major P450 enzymes.</sentence>
</annotation>
<annotation sem="INVITROVDDIS" ddi="(ETT, CYP2D6,DEI)(ETT, CYP3A4,DEI)(ETT, CYP2C9,DEI)(ETT, CYP2C19,DEI)">
<sentence><cons sem="G_DRUG">ETT</cons> had <cons sem="G_CHANGE">little</cons> <cons sem="G_MECHANISM">inhibitory</cons> effect on any of the P450 enzymes investigated.</sentence>
</annotation>
<sentence><cons sem="G_DRUG">ETT</cons> was determined to be a good <cons sem="G_MECHANISM">substrate</cons> for human P-gp in vitro.</sentence>
<sentence>In bidirectional transport studies across LLC-MDR1 and LLC-Mdr1a cell monolayers, <cons sem="G_DRUG">ETT</cons> had a BA/AB transport ratio in the range 9 to 11.</sentence>
<sentence>This finding had <cons sem="G_CHANGE">significance</cons> in vivo since brain exposure to <cons sem="G_DRUG">ETT</cons> was <cons sem="G_CHANGE">reduced</cons> <cons sem="G_NUMBER">40-fold</cons> in Mdr1a+/+ relative to Mdr1a-/- mice.</sentence>
<annotation sem="INVITROCDDIS" ddi="(ETT, CYP3A4,DEI)">
<sentence><cons sem="G_DRUG">ETT</cons> <cons sem="G_MECHANISM">metabolism</cons> to <cons sem="G_DRUG">DETT</cons> is therefore <cons lex="catalyzed" sem="G_MECHANISM">catalyzed</cons> primarily by <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, and <cons sem="G_MECHANISM">plasma concentrations</cons> are expected to be <cons sem="G_CHANGE">increased</cons> when coadministered with inhibitors of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and P-gp activity.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:12766253</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem="G_DRUG">Avasimibe</cons> <cons sem="G_MECHANISM">induces</cons> <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and multiple drug resistance protein 1 gene expression through <cons sem="G_MECHANISM">activation</cons> of the pregnane X receptor.</sentence>
</title>
<abstract>
<sentence>In vitro and clinical studies were conducted to characterize the potential of <cons sem="G_DRUG">avasimibe</cons>, an acyl-CoA/cholesterol acyltransferase <cons sem="G_MECHANISM">inhibitor</cons> to cause drug-drug interactions.</sentence>
<sentence>Clinically, <cons sem="G_NUMBER">3- and 6-fold</cons> <cons sem="G_CHANGE">increases</cons> in <cons lex="midazolam" sem="G_DRUG">midazolam</cons> (<cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> substrate) <cons sem="G_IVITPARA">oral clearance</cons>  were observed after <cons sem="G_NUMBER">50 and 750 mg</cons> of avasimibe daily for 7 days, respectively.</sentence>
<sentence>A <cons sem="G_NUMBER">40%</cons> <cons sem="G_CHANGE">decrease</cons> in <cons lex="digoxin" sem="G_DRUG">digoxin</cons> (P-glycoprotein <cons sem="G_MECHANISM">substrate</cons>) <cons sem="G_IVITPARA">area under the curve</cons> was observed with <cons sem="G_NUMBER">750 mg</cons> of <cons sem="G_MECHANISM">avasimibe</cons> daily for 10 days.</sentence>
<sentence>In vitro studies were conducted to define the mechanisms of these interactions.</sentence>
<annotation sem="INVITROCDDIS" ddi="(avasimibe, CYP3A4,DEI)">
<sentence><cons lex="induction" sem="G_MECHANISM">Induction</cons> was observed in <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activity and immunoreactive protein (<cons sem="G_IVITPARA">EC50</cons> of <cons sem="G_NUMBER">200-400 nM</cons>) in primary human hepatocytes treated with <cons sem="G_DRUG">avasimibe</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Rifampin, CYP3A4,DEI)">
<sentence><cons lex="rifampin" sem="G_DRUG">Rifampin</cons> treatment yielded similar results.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(avasimibe, CYP3A4,DEI)">
<sentence>Microarray analysis revealed <cons sem="G_DRUG">avasimibe</cons> (<cons sem="G_NUMBER">1 microM</cons>) <cons sem="G_CHANGE">increased</cons> <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> mRNA <cons sem="G_NUMBER">20-fold</cons>, compared with a <cons sem="G_NUMBER">23-fold</cons> <cons lex="increase" sem="G_CHANGE">increase</cons> with <cons sem="G_NUMBER">50 microM</cons> <cons lex="rifampin" sem="G_DRUG">rifampin</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Avasimibe, P-glycoprotein,DEI)">
<sentence><cons sem="G_DRUG">Avasimibe</cons> <cons sem="G_MECHANISM">induced</cons> P-glycoprotein mRNA by about <cons sem="G_NUMBER">2-fold</cons> and immunoreactive protein in a dose-dependent manner.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Avasimibe, hPXR,DEI)">
<sentence>Transient transfection assays showed that <cons sem="G_DRUG">avasimibe</cons> is a potent <cons sem="G_MECHANISM">activator</cons> of the human pregnane X receptor (hPXR) and more active than <cons lex="rifampin" sem="G_DRUG">rifampin</cons> on an equimolar basis.</sentence>
</annotation>
<sentence>Drug-drug interaction studies for <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> using pooled human hepatic microsomes and <cons sem="G_DRUG">avasimibe</cons> at various concentrations, revealed <cons sem="G_IVITPARA">IC50</cons> values of <cons sem="G_NUMBER">20.7</cons>,<cons sem="G_NUMBER">1.6</cons>, and <cons sem="G_NUMBER">3.1 microM</cons> using <cons lex="testosterone" sem="G_DRUG">testosterone</cons>, <cons lex="midazolam" sem="G_DRUG">midazolam</cons>, and <cons lex="felodipine" sem="G_DRUG">felodipine</cons> as probe <cons sem="G_MECHANISM">substrates</cons>, respectively.</sentence>
<sentence>Our results indicate that <cons sem="G_DRUG">avasimibe</cons> causes clinically <cons sem="G_CHANGE">significant</cons> drug-drug interactions through direct <cons sem="G_MECHANISM">activation</cons> of hPXR and the subsequent <cons lex="induction" sem="G_MECHANISM">induction</cons> of its target genes <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and multiple drug resistance protein 1.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:12695341</bibliomisc>
</articleinfo>
<title>
<sentence>Identification of the cytochrome P450 enzymes involved in the N-<cons lex="oxidation" sem="G_MECHANISM">oxidation</cons> of <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons>.</sentence>
</title>
<abstract>
<sentence><cons lex="voriconazole" sem="G_DRUG">Voriconazole</cons> is a triazole antifungal agent with potent activity against a broad spectrum of clinically <cons sem="G_CHANGE">significant</cons> pathogens.</sentence>
<sentence>In vivo and in vitro studies have demonstrated that <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> is extensively <cons sem="G_MECHANISM">metabolized</cons>, with the major circulating metabolite resulting from N-<cons lex="oxidation" sem="G_MECHANISM">oxidation</cons>.</sentence>
<sentence>In the present study, we report on the human cytochrome P450 enzymes responsible for the generation of this metabolite.</sentence>
<sentence>In human liver microsomes <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> N-<cons lex="oxidation" sem="G_MECHANISM">oxidation</cons> exhibited biphasic kinetics with <cons sem="G_IVITPARA">K(m1)</cons> of <cons sem="G_NUMBER">8.1 microM</cons>, and <cons sem="G_IVITPARA">K(m2)</cons>  of  <cons sem="G_NUMBER">835 microM</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(voriconazole, CYP3A4,DEI)(ketoconazole, voriconazole,DDI)">
<sentence>Studies at <cons sem="G_NUMBER">2500 microM</cons> <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> identified <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> as the low-affinity component, with activity correlating strongly with <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activity in a bank of human liver microsomes (<cons sem="G_NUMBER">r = 0.90</cons>) and <cons sem="G_IVITPARA">inhibited</cons> by <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(voriconazole N-oxidation, CYP2C19,DEI)(voriconazole N-oxidation, CYP3A4,DEI)(sulfaphenazole, voriconazole N-oxidation,DDI)(ketoconazole, voriconazole N-oxidation,DDI)">
<sentence>At <cons sem="G_NUMBER">25 microM</cons>, <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> N-<cons lex="oxidation" sem="G_MECHANISM">oxidation</cons> showed strong <cons lex="correlation" sem="G_MECHANISM">correlation</cons> with <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activity (<cons sem="G_NUMBER">r = 0.77 and 0.74</cons>, respectively) and was <cons sem="G_MECHANISM">inhibited</cons> by both <cons sem="G_DRUG">sulfaphenazole</cons> and <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>.</sentence>
</annotation>
<sentence>Incubations with recombinant enzymes suggested both <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> and <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> as high-affinity enzymes ( <cons sem="G_IVITPARA">K(m)</cons> values of <cons sem="G_NUMBER">20 and 3.5 microM</cons>, respectively).</sentence>
<sentence>Further studies used chemical <cons sem="G_MECHANISM">inhibitors</cons> in human liver microsomes prepared from individual donors, including two <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> poor metabolizers.</sentence>
<annotation sem="INVITROCDDIS" ddi="(sulfaphenazole CYP2C9,NDEI)(ketoconazole CYP2C9,DEI)">
<sentence><cons sem="G_NEGATIVEEFFECT">No</cons> <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> was observed with <cons sem="G_IVITPARA">sulfaphenazole</cons>, indicating a <cons sem="G_CHANGE">minor</cons> role for <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> in human liver , but <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> by <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> was most potent in the <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> poor metabolizer livers, suggesting an <cons sem="G_CHANGE">increased</cons> role for <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> in individuals lacking <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>.</sentence> 
</annotation>
<sentence>These data indicate that <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> is a <cons sem="G_MECHANISM">substrate</cons> for <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>, and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, with <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> involvement being minimal in human liver microsomes.</sentence>
<sentence>Genotype status for <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> and/or coadministration of drugs that <cons sem="G_MECHANISM">modulate</cons> <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> or <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activities could effect <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> plasma levels.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:12642463</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="inhibition" sem="G_MECHANISM">Inhibition</cons> and <cons sem="G_MECHANISM">activation</cons> of the human liver microsomal and human cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4</cons> <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="testosterone" sem="G_DRUG">testosterone</cons> by deployment-related chemicals.</sentence>
</title>
<abstract>
<sentence>Cytochrome P450 (P450) enzymes are major catalysts involved in the <cons sem="G_MECHANISM">metabolism</cons> of xenobiotics and endogenous <cons sem="G_MECHANISM">substrates</cons> such as <cons lex="testosterone" sem="G_DRUG">testosterone</cons> (TST).</sentence>
<sentence>Major <cons sem="G_IVITPARA">TST</cons> metabolites <cons sem="G_MECHANISM">formed</cons> by human liver microsomes include <cons sem="G_DRUG">6beta-hydroxytestosterone (6beta-OHTST)</cons>,<cons sem="G_DRUG">2beta-hydroxytestosterone (2beta-OHTST)</cons>, and <cons sem="G_DRUG">15beta-hydroxytestosterone (15beta-OHTST)</cons>.</sentence>
<sentence>A screen of 16 cDNA-expressed human P450 isoforms demonstrated that <cons sem="G_NUMBER">94%</cons> of all <cons sem="G_DRUG">TST</cons> metabolites are produced by members of the <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> subfamily with 6beta-OHTST accounting for <cons sem="G_NUMBER">86%</cons> of all TST metabolites.</sentence>
<sentence>Similar <cons sem="G_IVITPARA">K(m)</cons> values were observed for production of 6beta-, 2beta-, and 15beta-OHTST with human liver microsomes (HLM) and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
<sentence>However,<cons sem="G_IVITPARA">V(max)</cons> and <cons sem="G_IVITPARA">CL(int)</cons> were <cons sem="G_CHANGE">significantly</cons> higher for <cons sem="G_DRUG">6beta-OHTST</cons> than <cons sem="G_DRUG">2beta-OHTST</cons> (approximately<cons sem="G_NUMBER">18-fold</cons>) and <cons sem="G_DRUG">15beta-OHTST</cons> (approximately <cons sem="G_NUMBER">40-fold</cons>).</sentence>
<sentence>Preincubation of HLM with a variety of ligands, including chemicals used in military deployments, resulted in varying levels of <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> or <cons sem="G_MECHANISM">activation</cons> of <cons sem="G_DRUG">TST</cons><cons sem="G_MECHANISM">metabolism</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(chlorpyrifos, TST,DDI)(phorate, TST,DDI)(fonofos, TST,DDI)">
<sentence>The <cons sem="G_CHANGE">greatest</cons> <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of <cons sem="G_DRUG">TST</cons> <cons sem="G_MECHANISM">metabolism</cons> in HLM was following preincubation with organophosphorus compounds, including <cons sem="G_DRUG">chlorpyrifos</cons>,<cons sem="G_DRUG">phorate</cons>, and <cons sem="G_DRUG">fonofos</cons>, with up to <cons sem="G_NUMBER">80%</cons> <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> noticed for several metabolites including <cons sem="G_DRUG">6beta-OHTST</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(chlorpyrifos, TST,DDI)">
<sentence>Preincubation of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> with <cons sem="G_DRUG">chlorpyrifos</cons>, but <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_DRUG">chlorpyrifos-oxon</cons>, resulted in <cons sem="G_NUMBER">98%</cons> <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of <cons sem="G_DRUG">TST</cons> <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Phorate, CYP3A4,DEI)(fonofos, CYP3A4,DEI)">
<sentence><cons sem="G_DRUG">Phorate</cons> and <cons sem="G_DRUG">fonofos</cons> also <cons sem="G_MECHANISM">inhibited</cons> the production of most primary metabolites of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Phorate, TST,DDI)(fonofos, TST,DDI)(phorate, TST,DDI)">
<sentence>Kinetic analysis indicated that <cons sem="G_DRUG">chlorpyrifos</cons> was one of the most potent <cons sem="G_MECHANISM">inhibitors</cons> of major <cons sem="G_DRUG">TST</cons> metabolites followed by <cons sem="G_DRUG">fonofos</cons> and phorate.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Phorate, TST,ADDI)(fonofos, TST,ADDI)(phorate, TST,ADDI)">
<sentence><cons sem="G_DRUG">Chlorpyrifos</cons>,<cons sem="G_DRUG">fonofos</cons>, and <cons sem="G_DRUG">phorate</cons> <cons sem="G_MECHANISM">inhibited</cons> major <cons sem="G_DRUG">TST</cons> metabolites noncompetitively and irreversibly.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(pyridostigmine bromide, 6beta-OHTST,DDI)(pyridostigmine bromide, 2beta-OHTST,DDI)">
<sentence>Conversely, preincubation of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> with <cons lex="pyridostigmine" sem="G_DRUG">pyridostigmine</cons> bromide <cons sem="G_CHANGE">increased</cons> metabolite levels of <cons sem="G_DRUG">6beta-OHTST</cons> and <cons sem="G_DRUG">2beta-OHTST</cons>.</sentence>
</annotation>
<annotation sem="INVITROVDDIS" ddi="(pyridostigmine bromide, 17beta-estradiol,DDI)">
<sentence>Preincubation of human aromatase (<cons sem="G_CYP">CYP19</cons>) with the test chemicals had <cons sem="G_NEGATIVEEFFECT">no</cons> effect on the production of the endogenous estrogen, 17beta-<cons lex="estradiol" sem="G_DRUG">estradiol</cons>.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:12584153</bibliomisc>
</articleinfo>
<title>
<sentence>Oxidative <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="amprenavir" sem="G_DRUG">amprenavir</cons> in the human liver. Effect of the <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> maturation.</sentence>
</title>
<abstract>
<sentence><cons lex="amprenavir" sem="G_DRUG">Amprenavir</cons> is a human immunodeficiency virus-1 (HIV-1) protease <cons sem="G_MECHANISM">inhibitor</cons> intended to be used to treat HIV-infected children.</sentence>
<sentence>Although a pediatric dosage is proposed by the manufacturer, <cons sem="G_NEGATIVEEFFECT">no</cons> data are currently available on the pharmacokinetics of <cons lex="amprenavir" sem="G_DRUG">amprenavir</cons> in neonates and infants.</sentence>
<sentence><cons lex="amprenavir" sem="G_DRUG">Amprenavir</cons> being primarily eliminated after oxidative biotransformation, we explored its in vitro <cons sem="G_MECHANISM">metabolism</cons> by cytochrome P450 (P450)-dependent monooxygenases.</sentence>
<sentence>In our conditions, five metabolites were <cons sem="G_MECHANISM">formed</cons> in vitro and subsequently analyzed by liquid chromatography-mass spectrometry; P450-dependent oxidations occurred either on the tetrahydrofuran ring (M3 and M4), the aniline ring (M5), and the aliphatic chain (M2) or resulted from the N-dealkylation and loss of the tetrahydrofuran ring (M1).</sentence>
<sentence>The two major metabolites, respectively M3 and M2 were <cons sem="G_MECHANISM">formed</cons> by human liver microsomes with <cons sem="G_IVITPARA">K(m)</cons> between <cons sem="G_NUMBER">10</cons> and <cons sem="G_NUMBER">70 microM</cons>.</sentence>
<sentence><cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and to a lesser extent <cons lex="cyp3a5" sem="G_CYP">CYP3A5</cons> were major contributors for the formation of M2, M3, and M5 metabolites,whereas <cons lex="cyp3a7" sem="G_CYP">CYP3A7</cons> had <cons sem="G_NEGATIVEEFFECT">no</cons> or <cons sem="G_CHANGE">little</cons> activity.</sentence>
<annotation sem="INVITROCDDIS" ddi="(ketoconazole, Amprenavir,DDI)(ritonavir, Amprenavir,DDI)(sulfaphenazole, Amprenavir,NDDI)(quinidine, Amprenavir,NDDI)">
<sentence>This assumption was confirmed by <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> with <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> and <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> (two potent <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>) whereas <cons sem="G_DRUG">sulfaphenazole</cons> (<cons lex="2c9" sem="G_CYP">2C9</cons> <cons sem="G_MECHANISM">inhibitor</cons>) and <cons lex="quinidine" sem="G_DRUG">quinidine</cons> (<cons lex="2d6" sem="G_CYP">2D6</cons> <cons sem="G_DRUG">inhibitor</cons>) were inefficient.</sentence>
</annotation>
<sentence>The <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="amprenavir" sem="G_DRUG">amprenavir</cons> was <cons sem="G_CHANGE">negligible</cons> in microsomes from either fetuses or neonates and steadily <cons sem="G_CHANGE">increased</cons>  after the first weeks of life in relation with the maturation of <cons lex="cyp3a4/5" sem="G_CYP">CYP3A4/5</cons>.</sentence>
<sentence>In conclusion, results demonstrated that the capacity of the human liver to oxidize <cons lex="amprenavir" sem="G_DRUG">amprenavir</cons> is low during the first weeks after birth and that dosage could be substantially <cons sem="G_CHANGE">reduced</cons> during the early neonatal period.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:12433826</bibliomisc>
</articleinfo>
<title>
<sentence>Effects of <cons lex="olopatadine" sem="G_DRUG">olopatadine</cons>, a new antiallergic agent, on human liver microsomal cytochrome P450 activities.</sentence>
</title>
<abstract>
<sentence><cons lex="olopatadine" sem="G_DRUG">Olopatadine</cons>, a new histamine H(1) receptor-selective antagonist, is a tricyclic drug containing an alkylamino moiety.</sentence>
<sentence>Some compounds containing a similar alkylamino group form a cytochrome p450 (p450) -iron (II)-nitrosoalkane metabolite complex  [metabolic intermediate complex (MIC)], thereby causing quasi-irreversible <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of the p450.</sentence>
<sentence>There was concern that <cons lex="olopatadine" sem="G_DRUG">olopatadine</cons> <cons sem="G_CHANGE">might</cons> also form MICs, therefore, the present investigation was undertaken to explore this possibility.</sentence>
<sentence>We identified the enzymes <cons sem="G_MECHANISM">catalyzing</cons> <cons lex="olopatadine" sem="G_DRUG">olopatadine</cons> <cons sem="G_MECHANISM">metabolism</cons> and investigated the effect of <cons lex="olopatadine" sem="G_DRUG">olopatadine</cons> on human p450 activities.</sentence>
<sentence>During incubation with human liver microsomes in the presence of a NADPH-generating system, <cons lex="olopatadine" sem="G_DRUG">olopatadine</cons> was <cons sem="G_MECHANISM">metabolized</cons> to two metabolites, M1 (N-monodemethylolopatadine) and M3 (<cons lex="olopatadine" sem="G_DRUG">olopatadine</cons> N-oxide) at rates of 0.330 and 2.50 pmol/min/mg protein, respectively.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Troleandomycin, N-monodemethylolopatadine,DDI)(ketoconazole, N-monodemethylolopatadine,DDI)">
<sentence><cons lex="troleandomycin" sem="G_DRUG">Troleandomycin</cons> and <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>, which are both selective <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>, <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">reduced</cons> M1 formation but specific <cons sem="G_MECHANISM">inhibitors</cons> of other p450 isozymes did <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">decrease</cons> M1 formation.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(N-monodemethylolopatadine, CYP3A4,DEI)">  
<sentence>Incubation of <cons lex="olopatadine" sem="G_DRUG">olopatadine</cons> with cDNA-expressed human p450 isozymes confirmed that M1 formation was almost exclusively <cons lex="catalyzed" sem="G_MECHANISM">catalyzed</cons> by <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(N-octylamine, olopatadine N-oxide,DDI)(thiourea, olopatadine N-oxide,DDI)">
<sentence>The formation of M3 was <cons sem="G_MECHANISM">enhanced</cons> by N-octylamine and was <cons sem="G_MECHANISM">inhibited</cons> by <cons sem="G_DRUG">thiourea</cons>.</sentence>
</annotation>
<sentence>High specific activity of M3 formation was exhibited by cDNA-expressed flavin-containing monooxygenase (FMO)1 and FMO3.</sentence>
<sentence><cons lex="olopatadine" sem="G_DRUG">Olopatadine</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_MECHANISM">inhibit</cons> p450 activities when it was simultaneously incubated with <cons sem="G_MECHANISM">substrates</cons> for different p450 isozymes.</sentence>
<sentence>Also, p450 activities in human liver microsomes were <cons sem="G_IVITPARA">unaffected</cons>  by pretreatment with <cons lex="olopatadine" sem="G_DRUG">olopatadine</cons> or M1.</sentence>
<sentence>Furthermore, spectral analysis revealed that neither <cons lex="olopatadine" sem="G_DRUG">olopatadine</cons> nor M1 <cons sem="G_MECHANISM">formed</cons> an MIC.</sentence>
<sentence>Therefore, it is unlikely that <cons lex="olopatadine" sem="G_DRUG">olopatadine</cons> will cause drug-drug interactions involving p450 isozymes.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:12386121</bibliomisc>
</articleinfo>
<title>
<sentence>Pathways of <cons lex="carbamazepine" sem="G_DRUG">carbamazepine</cons> bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites.</sentence>
</title>
<abstract>
<sentence>In vitro studies were conducted to identify the cytochromes P450 (P450s) involved in the formation of 2- and  <cons sem="G_DRUG">3-hydroxycarbamazepine</cons>, metabolites that <cons sem="G_CHANGE">may</cons> serve as precursors in the formation of protein-reactive metabolites.</sentence>
<sentence>Human liver microsomes (HLMs) converted <cons lex="carbamazepine" sem="G_DRUG">carbamazepine</cons> (<cons sem="G_NUMBER">30-300 microM</cons>) to 3-hydroxycarbamazepine at rates <cons sem="G_NUMBER">&gt;25</cons> times those of 2-hydroxycarbamazepine.</sentence>
<sentence>Both the 2- and 3-hydroxylation of <cons lex="carbamazepine" sem="G_DRUG">carbamazepine</cons> appeared to conform to monophasic Michaelis-Menten kinetics in HLMs (apparent <cons sem="G_IVITPARA">K(m)</cons> values, approximately <cons sem="G_NUMBER">1640</cons> and approximately <cons sem="G_NUMBER">217 microM</cons>; apparent <cons sem="G_IVITPARA">V(max)</cons> values, approximately <cons sem="G_NUMBER">5.71</cons> and approximately <cons sem="G_NUMBER">46.9 pmol/mg</cons> of protein/min, respectively).</sentence>
<annotation sem="INVITROCDDIS" ddi="(carbamazepine 2-hydroxylation, CYP2B6,DEI)(carbamazepine 3-hydroxylation, CYP2B6,DEI)">
<sentence>Rates of <cons lex="carbamazepine" sem="G_DRUG">carbamazepine</cons> 2- and 3-hydroxylation <cons lex="correlated" sem="G_MECHANISM">correlated</cons> strongly with <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> activity (<cons sem="G_NUMBER">r &gt;or= 0.757</cons>) in a panel of HLMs (n = 8).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(carbamazepine 3-hydroxylation, CYP2C8,DEI)">
<sentence><cons lex="carbamazepine" sem="G_DRUG">Carbamazepine</cons> <cons sem="G_MECHANISM">3-hydroxylation</cons>  also <cons lex="correlated" sem="G_MECHANISM">correlated</cons> <cons sem="G_CHANGE">significantly</cons> with <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> activity at a <cons lex="carbamazepine" sem="G_DRUG">carbamazepine</cons> concentration of <cons sem="G_NUMBER">30 microM</cons>.</sentence>
</annotation>
<sentence><cons sem="G_MECHANISM">Formation</cons> of <cons sem="G_DRUG">2- and 3-hydroxycarbamazepine</cons>  did <cons sem="G_NEGATIVEEFFECT">not</cons> correlate <cons sem="G_CHANGE">significantly</cons> with any other P450 activities.</sentence>
<annotation sem="INVITROCDDIS" ddi="(ketoconazole, carbamazepine 2-hydroxylation,DDI)(ketoconazole, carbamazepine 3-hydroxylation,DDI)(7-EFC, carbamazepine 2-hydroxylation,DDI)(7-EFC, carbamazepine 3-hydroxylation,DDI)(4-methylpyrazole, carbamazepine 2-hydroxycarbamazepine,DDI)">
<sentence>The chemical <cons sem="G_MECHANISM">inhibitors</cons> <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> (<cons lex="cyp3a" sem="G_CYP">CYP3A</cons>) and <cons sem="G_DRUG">7-EFC</cons> (<cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons>) <cons sem="G_MECHANISM">inhibited</cons> both 2- and <cons sem="G_DRUG">3-hydroxycarbamazepine</cons> <cons sem="G_MECHANISM">formation</cons> whereas <cons sem="G_DRUG">4-methylpyrazole</cons> (<cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons>) <cons sem="G_CHANGE">markedly</cons> <cons sem="G_CHANGE">decreased</cons> <cons sem="G_DRUG">2-hydroxycarbamazepine</cons> <cons sem="G_MECHANISM">formation</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(carbamazepine 2-hydroxylation, CYP3A4,DEI)(carbamazepine 3-hydroxylation, CYP3A4,DEI)(carbamazepine 2-hydroxylation, CYP2B6,DEI)(carbamazepine 3-hydroxylation, CYP2B6,DEI)(carbamazepine 2-hydroxylation, CYP2E1,ADEI)">
<sentence>Several recombinant P450s <cons lex="catalyzed" sem="G_MECHANISM">catalyzed</cons> <cons lex="carbamazepine" sem="G_DRUG">carbamazepine</cons> 2- and 3-hydroxylation, but after adjustment for relative hepatic abundance, <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> appeared to be the major catalysts of <cons lex="carbamazepine" sem="G_DRUG">carbamazepine</cons> 3-hydroxylase activity, and at least five P450s were <cons sem="G_CHANGE">significant</cons> contributors to 2-hydroxycarbamazepine formation; <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons> made the <cons sem="G_CHANGE">greatest</cons> contribution to the Cl(int) of <cons lex="carbamazepine" sem="G_DRUG">carbamazepine</cons> <cons sem="G_MECHANISM">2-hydroxylation</cons> (approximately 30%), but P450s <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, <cons lex="2a6" sem="G_CYP">2A6</cons>, <cons lex="2b6" sem="G_CYP">2B6</cons>, and <cons lex="3a4" sem="G_CYP">3A4</cons> also made <cons sem="G_CHANGE">significant</cons> contributions (approximately 13-18%).</sentence>
</annotation>
<sentence>These results suggest that <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> are largely responsible for the formation of 3-hyrdoxycarbamazepine, whereas multiple P450s (<cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, <cons lex="2a6" sem="G_CYP">2A6</cons>, <cons lex="2b6" sem="G_CYP">2B6</cons>, <cons lex="2e1" sem="G_CYP">2E1</cons>, and <cons lex="3a4" sem="G_CYP">3A4</cons>) contributed to 2-hydroxycarbamazepine formation.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:12234619</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="inhibition" sem="G_MECHANISM">Inhibition</cons> of cytochrome P450 <cons lex="2e1" sem="G_CYP">2E1</cons> by <cons lex="propofol" sem="G_DRUG">propofol</cons> in human and porcine liver microsomes.</sentence>
</title>
<abstract>
<sentence>While almost anesthetics are <cons sem="G_MECHANISM">metabolized</cons> by the cytochrome P450 (CYP) <cons lex="3a4" sem="G_CYP">3A4</cons>, some major volatile ones such as <cons lex="halothane" sem="G_DRUG">halothane</cons> and <cons lex="sevoflurane" sem="G_DRUG">sevoflurane</cons> are <cons sem="G_MECHANISM">metabolized</cons> by <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons> in humans.</sentence>
<annotation sem="INVITROCDDIS" ddi="(2,6-diisopropylphenol , CYP3A4,DEI)(2,6-diisopropylphenol , CYP1A2,DEI)(2,6-diisopropylphenol , CYP2E1,DEI)(2,6-diisopropylphenol , chlorzoxazone 6-OH hydroxylation,DDI)">
<sentence>To determine whether <cons sem="G_DRUG">2,6-diisopropylphenol</cons> (<cons lex="propofol" sem="G_DRUG">propofol</cons>), a widely used intravenous anesthetic agent, known to <cons sem="G_MECHANISM">inhibit</cons> <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, also <cons sem="G_MECHANISM">inhibits</cons> <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons>, 6-OH hydroxylation of <cons lex="chlorzoxazone" sem="G_DRUG">chlorzoxazone</cons>, a prototypical <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons> substrate, was estimated using two pools of human microsomes and one pool of porcine microsomes from seven livers.</sentence>
</annotation>
<sentence>Basal human enzyme activities were characterized by a <cons sem="G_IVITPARA">V(max)</cons>  of <cons sem="G_NUMBER">1426+/-230</cons> and <cons sem="G_MECHANISM">288+/-29 pmol min(-1)mg(-1)</cons> protein and a <cons sem="G_IVITPARA">K(m)</cons> of <cons sem="G_NUMBER">122+/-47</cons> and <cons sem="G_NUMBER">149+/-42 microM</cons>, while the corresponding porcine activities were associated with a <cons sem="G_IVITPARA">V(max)</cons> of <cons sem="G_NUMBER">352+/-42 pmol min(-1)mg(-1)</cons>  protein and a <cons sem="G_IVITPARA">K(m)</cons> of <cons sem="G_NUMBER">167+/-38 microM</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(propofol, CYP2E1,DEI)">
<sentence>A competitive <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons> by <cons lex="propofol" sem="G_DRUG">propofol</cons> was observed with low <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> constants in the therapeutic range in both porcine (<cons sem="G_NUMBER">19 microM</cons>) and human (<cons sem="G_NUMBER">48 microM</cons>) liver microsomes.</sentence>
</annotation>
<sentence>These in vitro results suggest that <cons lex="propofol" sem="G_DRUG">propofol</cons> could have a protective effect on toxic metabolite <cons sem="G_MECHANISM">activation</cons> of compounds <cons lex="catalyzed" sem="G_MECHANISM">catalyzed</cons> by <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:12228186</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem="G_MECHANISM">Inhibitory</cons> effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons>.</sentence>
</title>
<abstract>
<sentence>The ability of tricyclic antidepressants (TCAs) to <cons sem="G_MECHANISM">inhibit</cons> <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons> p-hydroxylation was evaluated in vitro by incubation studies of human liver microsomes and cDNA-expressed cytochrome p450s (p450s).</sentence>
<sentence>The TCAs tested were <cons lex="amitriptyline" sem="G_DRUG">amitriptyline</cons>, <cons lex="imipramine" sem="G_DRUG">imipramine</cons>, <cons lex="nortriptyline" sem="G_DRUG">nortriptyline</cons>, and <cons lex="desipramine" sem="G_DRUG">desipramine</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Amitriptyline, phenytoin p-hydroxylation,DDI)(imipramine, phenytoin p-hydroxylation,ADDI)">
<sentence><cons lex="amitriptyline" sem="G_DRUG">Amitriptyline</cons> and <cons lex="imipramine" sem="G_DRUG">imipramine</cons> strongly and competitively <cons sem="G_MECHANISM">inhibited</cons> <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons> p-hydroxylation in microsomal incubations (estimated <cons sem="G_IVITPARA">K(i)</cons> values of <cons sem="G_NUMBER">5.2 and 15.5 micro M</cons>, respectively).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(nortriptyline, phenytoin p-hydroxylation,NDDI)(desipramine, phenytoin p-hydroxylation,NDDI)">
<sentence>In contrast, <cons lex="nortriptyline" sem="G_DRUG">nortriptyline</cons> and <cons lex="desipramine" sem="G_DRUG">desipramine</cons> produced only weak <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(amitriptyline, phenytoin p-hydroxylation,DDI)(imipramine, phenytoin p-hydroxylation,DDI)(nortriptyline, phenytoin p-hydroxylation,DDI)(desipramine, phenytoin p-hydroxylation,DDI)">
<sentence>In the incubation study using cDNA-expressed P450s, both <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> and <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> <cons lex="catalyzed" sem="G_MECHANISM">catalyzed</cons> <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons> p-hydroxylation, whereas TCAs <cons sem="G_MECHANISM">inhibited</cons> only the <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> pathway.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(amitriptyline, phenytoin p-hydroxylation,ADDI)(imipramine, phenytoin p-hydroxylation,ADDI)(nortriptyline, phenytoin p-hydroxylation,DDI)(desipramine, phenytoin p-hydroxylation,ADDI)">
<sentence>All of the TCAs tested <cons sem="G_MECHANISM">inhibited</cons> <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>-<cons lex="catalyzed" sem="G_MECHANISM">catalyzed</cons> <cons lex="dextromethorphan" sem="G_DRUG">dextromethorphan</cons>-O-demethylation competitively, with estimated <cons sem="G_IVITPARA">K(i)</cons>  values of <cons sem="G_NUMBER">31.0</cons>,<cons sem="G_NUMBER">28.6</cons>,<cons sem="G_NUMBER">7.9</cons>, and <cons sem="G_NUMBER">12.5 micro M</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(amitriptyline, phenytoin p-hydroxylation,ADDI)(imipramine, phenytoin p-hydroxylation,ADDI)">
<sentence>The tertiary amine TCAs, <cons lex="amitriptyline" sem="G_DRUG">amitriptyline</cons> and <cons lex="imipramine" sem="G_DRUG">imipramine</cons>, also <cons sem="G_MECHANISM">inhibited</cons> <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>-<cons lex="catalyzed" sem="G_MECHANISM">catalyzed</cons> S-<cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons> 4'-<cons sem="G_MECHANISM">hydroxylation</cons> (estimated <cons sem="G_IVITPARA">K(i)</cons> of <cons sem="G_NUMBER">37.7</cons> and <cons sem="G_NUMBER">56.8 micro M</cons>, respectively).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(nortriptyline, phenytoin p-hydroxylation,NDDI)(desipramine, phenytoin p-hydroxylation,NDDI)">
<sentence>The secondary amine TCAs, <cons lex="nortriptyline" sem="G_DRUG">nortriptyline</cons> and <cons lex="desipramine" sem="G_DRUG">desipramine</cons>, however, showed minimal <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> (estimated <cons sem="G_IVITPARA">IC(50)</cons> of <cons sem="G_NUMBER">600</cons> and <cons sem="G_NUMBER">685 micro M</cons>, respectively).</sentence>
</annotation>
<sentence>None of the TCAs tested produced remarkable <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of any other p450 isoforms.</sentence>
<annotation sem="INVITROCDDIS" ddi="(amitriptyline, CYP2D6,DEI)(imipramine, CYP2D6,DEI)(nortriptyline, CYP2D6,DEI)(desipramine, CYP2D6,DEI)(amitriptyline, CYP2C19,DEI)(imipramine, CYP2C19,DEI)(nortriptyline, CYP2C19,DEI)(desipramine, CYP2C19,DEI)(amitriptyline, phenytoin p-hydroxylation,DDI)(imipramine, phenytoin p-hydroxylation,DDI)(nortriptyline, phenytoin p-hydroxylation,DDI)(desipramine, phenytoin p-hydroxylation,DDI)">
<sentence>These results suggest that TCAs <cons sem="G_MECHANISM">inhibit</cons> both <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> and <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> and that the interaction between TCAs and <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons> involves <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>-<cons lex="catalyzed" sem="G_MECHANISM">catalyzed</cons> <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons> p-hydroxylation.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:12167559</bibliomisc>
</articleinfo>
<title>
<sentence>The interactions of a selective protein kinase C beta <cons sem="G_MECHANISM">inhibitor</cons> with the human cytochromes P450.</sentence>
</title>
<abstract>
<sentence>Studies were performed to determine the cytochromes P450 (P450) responsible for the <cons sem="G_MECHANISM">biotransformation</cons> of <cons sem="G_DRUG">(S)-13 [(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16,21-dimetheno-1H</cons>,<cons sem="G_DRUG">13H-dibenzo [e,k]pyrrolo [3,4-h] [1,4,13]oxadiazacyclohexadecene-1,3(2H)-dione (LY333531)</cons> to its equipotent metabolite, N-desmethyl <cons sem="G_DRUG">LY333531</cons>, and to examine the ability of these two compounds to <cons sem="G_MECHANISM">inhibit</cons> P450-mediated <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
<sentence>Kinetic studies indicated that a single enzyme in human liver microsomes was able to form N-desmethyl <cons sem="G_DRUG">LY333531</cons> with an apparent <cons sem="G_IVITPARA">K(M)</cons> value of approximately <cons sem="G_NUMBER">1 microM</cons>.</sentence>
<sentence>The <cons sem="G_MECHANISM">formation</cons> rate of <cons sem="G_DRUG">N-desmethyl LY333531</cons> was <cons lex="correlated" sem="G_MECHANISM">correlated</cons> with markers of nine P450s in a bank of 20 human liver microsomes.</sentence>
<sentence>The only <cons sem="G_CHANGE">significant</cons> <cons lex="correlation" sem="G_MECHANISM">correlation</cons> observed was with the form-selective activity for <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>.</sentence>
<sentence>Of the nine cDNA-expressed P450s examined, only <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> <cons sem="G_MECHANISM">formed</cons>  <cons sem="G_DRUG">N-desmethyl LY333531</cons>.</sentence>
<sentence>However, <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">formed</cons> <cons sem="G_DRUG">N-desmethyl LY333531</cons> at a rate 57-fold <cons sem="G_CHANGE">greater</cons> than that observed with <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>.</sentence>
<annotation sem="INVITROVDDIS" ddi="(quinidine, N-desmethyl LY333531,NDDI)(ketoconazole, N-desmethyl LY333531,DDI)">
<sentence>In incubations with human liver microsomes, <cons lex="quinidine" sem="G_DRUG">quinidine</cons>, an <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>, demonstrated <cons sem="G_CHANGE">little</cons> <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of metabolite <cons sem="G_MECHANISM">formation</cons>  while <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>, an <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>, demonstrated almost complete <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons>.</sentence>
</annotation>
<sentence>Thus, <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> is responsible for the <cons sem="G_MECHANISM">formation</cons> of <cons sem="G_DRUG">N-desmethyl LY333531</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(LY333531, CYP2D6,DEI)(LY333531, CYP2C9,DEI)(LY333531, CYP3A,DEI)(LY333531, CYP1A2,DEI)(N-desmethyl LY333531, CYP2D6,DEI)(N-desmethyl LY333531, CYP2C9,DEI)(N-desmethyl LY333531, CYP3A,DEI)(N-desmethyl LY333531, CYP1A2,DEI)">
<sentence> <cons sem="G_DRUG">LY333531</cons> and <cons sem="G_DRUG">N-desmethyl LY333531</cons> were also examined for their ability to <cons sem="G_MECHANISM">inhibit</cons> <cons sem="G_MECHANISM">metabolism</cons> mediated by <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>, <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>, and <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(LY333531, CYP2D6,DEI)(N-desmethyl LY333531, CYP2D6,DEI)">
<sentence><cons sem="G_DRUG">LY333531</cons> and <cons sem="G_DRUG">N-desmethyl LY333531</cons> were found to competitively <cons sem="G_MECHANISM">inhibit</cons> <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> with calculated <cons sem="G_IVITPARA">K(i)</cons> values of <cons sem="G_NUMBER">0.17 and 1.0 microM</cons>, respectively.</sentence>
</annotation>
<sentence>Less potent <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> by these compounds of <cons sem="G_MECHANISM">metabolism</cons> mediated by the other three P450s examined was observed.</sentence>
<sentence>In conclusion, <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> is primarily responsible for forming <cons sem="G_DRUG">N-desmethyl LY333531</cons>.</sentence>
<sentence>Therefore, alterations in the activity of this enzyme have the potential to affect <cons sem="G_DRUG">LY333531</cons> <cons sem="G_IVITPARA">clearance</cons>.</sentence>
<sentence>In addition,<cons sem="G_DRUG">LY333531</cons> and its metabolite are predicted to be potential <cons sem="G_IVITPARA">inhibitors</cons> of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>-mediated reactions in vivo.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:12119000</bibliomisc>
</articleinfo>
<title>
<sentence>Cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4</cons>-mediated <cons sem="G_MECHANISM">bioactivation</cons> of <cons sem="G_DRUG">raloxifene</cons>: irreversible enzyme <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> and thiol adduct formation.</sentence>
</title>
<abstract>
<sentence><cons lex="raloxifene" sem="G_DRUG">Raloxifene</cons> is a selective <cons sem="G_DRUG">estrogen</cons> receptor modulator which is effective in the treatment of osteoporosis in postmenopausal women.</sentence>
<annotation sem="INVITROCDDIS" ddi="(raloxifene, CYP3A4,DEI)">
<sentence>We report herein that cytochrome P450 <cons sem="G_CYP">(P450)3A4</cons> is <cons sem="G_MECHANISM">inhibited</cons> by <cons lex="raloxifene" sem="G_DRUG">raloxifene</cons> in human liver microsomal incubations.</sentence>
</annotation>
<sentence>The nature of the <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> was irreversible and was NADPH- and preincubation time-dependent, with <cons sem="G_IVITPARA">K(I)</cons> and <cons sem="G_IVITPARA">k(inact)</cons> values estimated at <cons sem="G_NUMBER">9.9 microM</cons> and <cons sem="G_NUMBER">0.16 min(-1)</cons>, respectively.</sentence>
<annotation sem="INVITROCDDIS" ddi="(glutathione, CYP3A4,DEI)">
<sentence>The observed loss of P450 <cons lex="3a4" sem="G_CYP">3A4</cons> activity was <cons sem="G_MECHANISM">attenuated</cons> partially by <cons sem="G_DRUG">glutathione (GSH)</cons>, implying the involvement of a reactive metabolite(s) in the <cons sem="G_MECHANISM">inactivation</cons> process.</sentence>
</annotation>
<sentence>Subsequently,<cons sem="G_DRUG">GSH</cons> adducts of <cons lex="raloxifene" sem="G_DRUG">raloxifene</cons> were identified in incubations with human liver microsomes; substitution with <cons sem="G_DRUG">GSH</cons> occurred at the 5- or 7-position of the benzothiophene moiety or at the 3'-position of the <cons lex="phenol" sem="G_DRUG">phenol</cons> ring, with the 7-glutathionyl derivative being most abundant based on LC/MS and NMR analyses.</sentence>
<sentence>These adducts are postulated to derive from addition of <cons sem="G_DRUG">GSH</cons> to <cons lex="raloxifene" sem="G_DRUG">raloxifene</cons> arene oxides followed by dehydration and aromatization.</sentence>
<sentence>Alternatively, <cons lex="raloxifene" sem="G_DRUG">raloxifene</cons> <cons sem="G_CHANGE">may</cons> be <cons sem="G_MECHANISM">oxidized</cons> to an extended <cons sem="G_DRUG">quinone</cons> intermediate, which then is trapped by <cons sem="G_DRUG">GSH</cons> conjugation.</sentence>
<annotation sem="INVITROCDDIS" ddi="(raloxifene, CYP3A4,DEI)(ketoconazole, GSH adducts,DDI)(anti-P450 3A4 IgG, GSH adducts,DDI)">
<sentence>The bioactivation of <cons lex="raloxifene" sem="G_DRUG">raloxifene</cons> most likely is <cons lex="catalyzed" sem="G_MECHANISM">catalyzed</cons> by P450 <cons lex="3a4" sem="G_CYP">3A4</cons>, since the formation of GSH adducts was almost abolished when liver microsomes were pretreated with <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> or with an <cons sem="G_MECHANISM">inhibitory</cons> anti-P450 <cons lex="3a4" sem="G_CYP">3A4</cons> IgG.</sentence>
</annotation>
<sentence>The <cons sem="G_DRUG">GSH</cons> adducts also were detected in incubations of <cons lex="raloxifene" sem="G_DRUG">raloxifene</cons> with rat or human hepatocytes, while the corresponding N-<cons lex="acetylcysteine" sem="G_DRUG">acetylcysteine</cons> adducts were identified in the bile and urine from rats treated orally with the drug at <cons sem="G_NUMBER">5 mg/kg</cons>.</sentence>
<sentence>Taken together, these data indicate that P450 <cons lex="3a4" sem="G_CYP">3A4</cons>-mediated <cons sem="G_MECHANISM">bioactivation</cons> of <cons lex="raloxifene" sem="G_DRUG">raloxifene</cons> in vitro is accompanied by loss of enzyme activity.</sentence>
<sentence>The <cons sem="G_CHANGE">significance</cons> of these findings with respect to the clinical use of <cons lex="raloxifene" sem="G_DRUG">raloxifene</cons> remains to be determined.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:12065438</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons lex="induction" sem="G_MECHANISM">induction</cons> by drugs: <cons lex="correlation" sem="G_MECHANISM">correlation</cons> between a pregnane X receptor reporter gene assay and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> expression in human hepatocytes.</sentence>
</title>
<abstract>
<sentence><cons lex="induction" sem="G_MECHANISM">Induction</cons> of cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4</cons> (<cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>) is determined typically by employing primary culture of human hepatocytes and measuring <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> mRNA, protein and microsomal activity.</sentence>
<sentence>Recently a pregnane X receptor (PXR) reporter gene assay was established to screen <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inducers</cons>.</sentence>
<sentence>To evaluate results from the PXR reporter gene assay with those from the aforementioned conventional assays, 14 drugs were evaluated for their ability to <cons sem="G_MECHANISM">induce</cons> <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and <cons sem="G_MECHANISM">activate</cons> PXR.</sentence>
<sentence>Sandwiched primary cultures of human hepatocytes from six donors were used and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activity was assessed by measuring microsomal <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6beta-hydroxylase activity.</sentence>
<sentence>Hepatic <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> mRNA and protein levels were also analyzed using branched DNA technology/Northern blotting and Western blotting, respectively.</sentence>
<sentence>In general, PXR <cons sem="G_MECHANISM">activation</cons> <cons lex="correlated" sem="G_MECHANISM">correlated</cons> with the <cons lex="induction" sem="G_MECHANISM">induction</cons> potential observed in human hepatocyte cultures.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Clotrimazole, PXR,DEI)(phenobarbital, PXR,DEI)(rifampin, PXR,DEI)(sulfinpyrazone, PXR,DEI)(Clotrimazole, CYP3A4,DEI)(phenobarbital, CYP3A4,DEI)(rifampin, CYP3A4,DEI)(sulfinpyrazone, CYP3A4,DEI)(carbamazepine, CYP3A4,NDEI)(dexamethasone, CYP3A4,NDEI)(dexamethasone-t-butylacetate, CYP3A4,NDEI)(phenytoin, CYP3A4,NDEI)(sulfadimidine, CYP3A4,NDEI)(taxol, CYP3A4,NDEI)(carbamazepine, CYP3A4,NDEI)(dexamethasone, PXR,NDEI)(dexamethasone-t-butylacetate, PXR,NDEI)(phenytoin, PXR,NDEI)(sulfadimidine, PXR,NDEI)(taxol, PXR,NDEI)(methotrexate, PXR,DEI)(probenecid, PXR,DEI)(methotrexate, CYP3A4,DEI)(probenecid, CYP3A4,DEI)">
<sentence> <cons lex="clotrimazole" sem="G_DRUG">Clotrimazole</cons>, <cons lex="phenobarbital" sem="G_DRUG">phenobarbital</cons>, <cons lex="rifampin" sem="G_DRUG">rifampin</cons>, and <cons lex="sulfinpyrazone" sem="G_DRUG">sulfinpyrazone</cons> highly <cons lex="activated" sem="G_MECHANISM">activated</cons> PXR and <cons sem="G_CHANGE">increased</cons> <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activity;<cons lex="carbamazepine" sem="G_DRUG">carbamazepine</cons>, <cons lex="dexamethasone" sem="G_DRUG">dexamethasone</cons>, <cons lex="dexamethasone" sem="G_DRUG">dexamethasone</cons>-t-butylacetate, <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons>,<cons sem="G_DRUG">sulfadimidine</cons>, and <cons sem="G_DRUG">taxol</cons> weakly <cons lex="activated" sem="G_MECHANISM">activated</cons> PXR and induced <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activity, and <cons lex="methotrexate" sem="G_DRUG">methotrexate</cons> and <cons lex="probenecid" sem="G_DRUG">probenecid</cons> showed <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem="G_CHANGE">marked</cons> <cons sem="G_MECHANISM">activation</cons> in either system .</sentence> 
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Ritonavir, PXR,DEI)(troleandomycin, PXR,DEI)(Ritonavir, CYP3A4,NDEI)(troleandomycin, CYP3A4,NDEI)">
<sentence><cons lex="ritonavir" sem="G_DRUG">Ritonavir</cons> and <cons lex="troleandomycin" sem="G_DRUG">troleandomycin</cons> showed <cons sem="G_CHANGE">marked</cons> PXR activation but <cons sem="G_NEGATIVEEFFECT">no</cons> <cons lex="increase" sem="G_CHANGE">increase</cons> (in the case of <cons lex="troleandomycin" sem="G_DRUG">troleandomycin</cons>) or a <cons sem="G_CHANGE">significant</cons> <cons sem="G_CHANGE">decrease</cons> (in the case of <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons>) in microsomal <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activity.</sentence>
</annotation>
<sentence>It is concluded that the PXR reporter gene assay is a reliable and complementary method to assess the <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons lex="induction" sem="G_MECHANISM">induction</cons> potential of drugs and other xenobiotics.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:12060642</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="thalidomide" sem="G_DRUG">Thalidomide</cons> <cons sem="G_MECHANISM">metabolism</cons> by the <cons sem="G_CYP">CYP2C</cons> subfamily.</sentence>
</title>
<abstract>
<sentence>This research investigated the <cons sem="G_MECHANISM">biotransformation</cons> of <cons lex="thalidomide" sem="G_DRUG">thalidomide</cons> by cytochrome P-450 (CYP).</sentence>
<sentence>We used liver microsomes from humans and/or animals and the recombinant specific CYP isozymes to investigate CYP-mediated <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="thalidomide" sem="G_DRUG">thalidomide</cons>.</sentence>
<sentence><cons lex="thalidomide" sem="G_DRUG">Thalidomide</cons> was <cons sem="G_MECHANISM">biotransformed</cons> into <cons sem="G_DRUG">5-hydroxythalidomide (5-OH)</cons> and diastereomeric <cons sem="G_DRUG">5'-hydroxythalidomide (5'-OH)</cons> by liver microsomes.</sentence>
<sentence>The human liver microsomes with higher <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> activity <cons sem="G_MECHANISM">formed</cons> more metabolites than those with lower <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> activity and had less activity in metabolite <cons sem="G_MECHANISM">formations</cons> than those from rats.</sentence>
<sentence>Recombinant human <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> and rat <cons sem="G_CYP">CYP2C6</cons> isozymes were primarily responsible for forming these metabolites, and the male rat-specific <cons sem="G_CYP">CYP2C11</cons> <cons sem="G_MECHANISM">formed</cons> only  <cons sem="G_DRUG">5'-OH</cons>.</sentence>
<sentence><cons sem="G_DRUG">5-OH</cons> was subsequently <cons sem="G_MECHANISM">hydroxylated</cons> to <cons sem="G_DRUG">5,6-dihydroxythalidomide</cons>  by <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>, <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, and <cons lex="cyp1a1" sem="G_CYP">CYP1A1</cons> in humans and by <cons sem="G_CYP">CYP2C11</cons>, <cons lex="cyp1a1" sem="G_CYP">CYP1A1</cons>, <cons sem="G_CYP">CYP2C6</cons>, and <cons sem="G_CYP">CYP2C12</cons> in rats.</sentence>
<annotation sem="INVITROCDDIS" ddi="(S-mephenytoin, CYP2C19,DEI)(omeprazole, CYP2C19,DEI)">
<sentence>Incubations with S-<cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons> and <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons>, <cons sem="G_MECHANISM">substrates</cons> of <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>,<cons sem="G_MECHANISM">inhibited</cons> <cons sem="G_MECHANISM">metabolism</cons> by human liver microsomes, supporting the involvement of <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(alpha-Naphthoflavone, 5-OH,DDI)(alpha-Naphthoflavone, cis-5'-OH,DDI)">
<sentence><cons sem="G_DRUG">alpha-Naphthoflavone</cons>, an <cons sem="G_MECHANISM">inhibitor</cons> of <cons sem="G_CYP">CYP1A</cons>, simultaneously <cons lex="stimulated" sem="G_MECHANISM">stimulated</cons> the <cons sem="G_DRUG">5-OH</cons> formation and <cons sem="G_MECHANISM">inhibited</cons>  <cons sem="G_DRUG">cis-5'-OH</cons> formation <cons lex="catalyzed" sem="G_MECHANISM">catalyzed</cons> by human liver microsomes.</sentence>
</annotation>
<sentence>The contribution of the <cons sem="G_CYP">CYP2C</cons> subfamily was supported by the immunoinhibition study using human liver microsomes.</sentence>
<annotation sem="INVITROVDDIS" ddi="(CYP1A, 5-OH,DDI)(CYP1A, cis-5'-OH,DDI)(CYP2B, 5-OH,DDI)(CYP2B, cis-5'-OH,DDI)(CYP2E, 5-OH,DDI)(CYP2E, cis-5'-OH,DDI)(CYP3A, 5-OH,DDI)(CYP3A, cis-5'-OH,DDI)(CYP4A, 5-OH,DDI)(CYP4A, cis-5'-OH,DDI)">
<sentence>When we used the microsomes from treated rats, the metabolite formations did <cons sem="G_NEGATIVEEFFECT">not</cons> <cons lex="increase" sem="G_CHANGE">increase</cons> by <cons sem="G_MECHANISM">inducers</cons> for <cons sem="G_CYP">CYP1A</cons>,<cons sem="G_CYP">CYP2B</cons>,<cons sem="G_CYP">CYP2E</cons>, <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>, or <cons sem="G_CYP">CYP4A</cons>, suggesting that these could <cons sem="G_NEGATIVEEFFECT">not</cons> be involved in the main metabolic pathway in rats.</sentence>
</annotation>
<sentence>We discovered that the polymorphic enzyme <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> is responsible for 5- and 5'-hydroxylation of <cons lex="thalidomide" sem="G_DRUG">thalidomide</cons> in humans.</sentence>
<sentence>In rats, <cons lex="thalidomide" sem="G_DRUG">thalidomide</cons> was <cons sem="G_MECHANISM">hydroxylated</cons> extensively by <cons sem="G_CYP">CYP2C6</cons> as well as the sex-specific enzyme <cons sem="G_CYP">CYP2C11</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:12019187</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="trimethoprim" sem="G_DRUG">Trimethoprim</cons> and <cons lex="sulfamethoxazole" sem="G_DRUG">sulfamethoxazole</cons> are selective inhibitors of <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> and <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, respectively.</sentence>
</title>
<abstract>
<sentence>To evaluate the <cons sem="G_MECHANISM">inhibitory</cons> effects of <cons lex="trimethoprim" sem="G_DRUG">trimethoprim</cons> and <cons lex="sulfamethoxazole" sem="G_DRUG">sulfamethoxazole</cons> on cytochrome P450 (P450) isoforms, selective marker reactions for <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons>, <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons>, <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>, <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>, <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons>, and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> were examined in human liver microsomes and recombinant <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> and <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>.</sentence>
<sentence>The in vivo drug interactions of <cons lex="trimethoprim" sem="G_DRUG">trimethoprim</cons> and <cons lex="sulfamethoxazole" sem="G_DRUG">sulfamethoxazole</cons> were predicted in vitro using  [I]/( [I] + <cons sem="G_IVITPARA">K(i)</cons>) values.</sentence>
<annotation sem="INVITROCDDIS" ddi="(trimethoprim, paclitaxel 6alpha-hydroxylation,DDI)">
<sentence>With concentrations ranging from <cons sem="G_NUMBER">5 to 100 microM</cons>, <cons lex="trimethoprim" sem="G_DRUG">trimethoprim</cons> exhibited a selective <cons sem="G_MECHANISM">inhibitory</cons> effect on <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons>-mediated <cons lex="paclitaxel" sem="G_DRUG">paclitaxel</cons> 6alpha-hydroxylation in human liver microsomes and recombinant <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons>, with apparent <cons sem="G_IVITPARA">IC(50)</cons> <cons sem="G_IVITPARA">(K(i))</cons> values of <cons sem="G_NUMBER">54 microM (32 microM)</cons> and <cons sem="G_NUMBER">75 microM</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(sulfamethoxazole, tolbutamide hydroxylation,NDDI)">
<sentence>With concentrations ranging from <cons sem="G_NUMBER">50 to 500 microM</cons>, <cons lex="sulfamethoxazole" sem="G_DRUG">sulfamethoxazole</cons> was a selective <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>-mediated <cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons> hydroxylation in human liver microsomes and recombinant <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, with apparent <cons sem="G_IVITPARA">IC(50)</cons> <cons sem="G_IVITPARA">(K(i))</cons> values of <cons sem="G_NUMBER">544 microM (271 microM)</cons> and <cons sem="G_NUMBER">456 microM</cons>, respectively.</sentence>
</annotation>
<sentence>With concentrations higher than <cons sem="G_NUMBER">100 microM</cons> <cons lex="trimethoprim" sem="G_DRUG">trimethoprim</cons> and <cons sem="G_NUMBER">500 microM</cons> <cons lex="sulfamethoxazole" sem="G_DRUG">sulfamethoxazole</cons>, both drugs lost their selectivity for the P450 isoforms.</sentence>
<annotation sem="INVITROCDDIS" ddi="(trimethoprim, CYP2C8,ADEI)(sulfamethoxazole, CYP2C8,ADEI)(trimethoprim, CYP2C9,ADEI)(sulfamethoxazole, CYP2C9,ADEI)">
<sentence>Based on estimated total hepatic concentrations (or free plasma concentrations) of the drugs and the scaling model, one would expect in vivo in humans <cons sem="G_NUMBER">80% (26%) and 13% (24%)</cons> <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of the metabolic <cons sem="G_IVITPARA">clearance</cons> of <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> and <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> substrates by <cons lex="trimethoprim" sem="G_DRUG">trimethoprim</cons> and <cons lex="sulfamethoxazole" sem="G_DRUG">sulfamethoxazole</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(trimethoprim, CYP2C8,DEI)(sulfamethoxazole, CYP2C8,DEI)(trimethoprim, CYP2C9,DEI)(sulfamethoxazole, CYP2C9,DEI)">
<sentence>In conclusion, <cons lex="trimethoprim" sem="G_DRUG">trimethoprim</cons> and <cons lex="sulfamethoxazole" sem="G_DRUG">sulfamethoxazole</cons> can be used as selective <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> and <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> in in vitro studies.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(trimethoprim, CYP2C8,DEI)(sulfamethoxazole, CYP2C8,DEI)(trimethoprim, CYP2C9,DEI)(sulfamethoxazole, CYP2C9,DEI)">
<sentence>In humans, <cons lex="trimethoprim" sem="G_DRUG">trimethoprim</cons> and <cons lex="sulfamethoxazole" sem="G_DRUG">sulfamethoxazole</cons> <cons sem="G_CHANGE">may</cons> <cons sem="G_MECHANISM">inhibit</cons> the activities of <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> and <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, respectively.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:11950795</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="induction" sem="G_MECHANISM">Induction</cons> of cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4</cons> in primary human hepatocytes and activation of the human pregnane X receptor by <cons lex="tamoxifen" sem="G_DRUG">tamoxifen</cons> and <cons sem="G_DRUG">4-hydroxytamoxifen</cons>.</sentence>
</title>
<abstract>
<sentence><cons lex="tamoxifen" sem="G_DRUG">Tamoxifen</cons> is a widely utilized antiestrogen in the treatment and chemoprevention of breast cancer.</sentence>
<sentence>Clinical studies document that <cons lex="tamoxifen" sem="G_DRUG">tamoxifen</cons> administration <cons sem="G_CHANGE">markedly</cons> <cons sem="G_MECHANISM">enhances</cons> the <cons sem="G_MECHANISM">systemic elimination</cons> of other drugs.</sentence>
<sentence>Additionally, <cons lex="tamoxifen" sem="G_DRUG">tamoxifen</cons> <cons sem="G_MECHANISM">enhances</cons> its own <cons sem="G_IVITPARA">clearance</cons> following repeated dosing.</sentence>
<sentence>The mechanisms that underlie these clinically important events remain unresolved.</sentence>
<annotation sem="INVITROCDDIS" ddi="(tamoxifen, CYP3A4,DEI)(4-hydroxytamoxifen, CYP3A4,DEI)">
<sentence>Here, we report that <cons lex="tamoxifen" sem="G_DRUG">tamoxifen</cons> and its metabolite <cons sem="G_DRUG">4-hydroxytamoxifen</cons> <cons sem="G_CHANGE">markedly</cons> <cons sem="G_MECHANISM">induce</cons> cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4</cons>, a drug-<cons sem="G_MECHANISM">metabolizing</cons> enzyme of central importance, in primary cultures of human hepatocytes.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(tamoxifen, testosterone 6beta-hydroxylation,DDI)(4-hydroxytamoxifen, testosterone 6beta-hydroxylation,DDI)">
<sentence><cons lex="tamoxifen" sem="G_DRUG">Tamoxifen</cons> and <cons sem="G_DRUG">4-hydroxytamoxifen</cons> (<cons sem="G_NUMBER">1-10 microM</cons>) <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">increased</cons> the <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> expression and activity (measured as the rate of <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6beta-hydroxylation).</sentence>
</annotation>
<sentence>Maximal <cons lex="induction" sem="G_MECHANISM">induction</cons> was achieved at the <cons sem="G_NUMBER">5 microM</cons> level.</sentence>
<annotation sem="INVITROCDDIS" ddi="(tamoxifen, CYP3A4,DEI)(4-hydroxytamoxifen, CYP3A4,DEI)">
<sentence>At this level, <cons lex="tamoxifen" sem="G_DRUG">tamoxifen</cons> and <cons sem="G_DRUG">4-hydroxytamoxifen</cons> caused a <cons sem="G_NUMBER">1.5- to 3.3-fold (mean, 2.1-fold)</cons> and <cons sem="G_NUMBER">3.4- to 17-fold (mean, 7.5-fold)</cons> <cons lex="increase" sem="G_CHANGE">increase</cons> in the <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activity, respectively.</sentence>
</annotation>
<annotation sem="INVITROVDDIS" ddi="(rifampicin, CYP3A4,DEI)">
<sentence>In comparison,<cons sem="G_DRUG">rifampicin</cons> treatment resulted in a <cons sem="G_NUMBER">6- to 16-fold (mean, 10.5-fold)</cons> <cons lex="increase" sem="G_CHANGE">increase</cons>.</sentence>
</annotation>
<sentence>We also observed corresponding <cons lex="increase" sem="G_CHANGE">increase</cons> in the <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> immunoreactive protein and mRNA levels.</sentence>
<annotation sem="INVITROCDDIS" ddi="(tamoxifen, hPXR,DEI)(4-hydroxytamoxifen, hPXR,DEI)">
<sentence>Furthermore, <cons lex="tamoxifen" sem="G_DRUG">tamoxifen</cons> and <cons sem="G_DRUG">4-hydroxytamoxifen</cons> efficaciously <cons lex="activated" sem="G_MECHANISM">activated</cons> the human pregnane X receptor (hPXR; also known as the steroid xenobiotic receptor), a key regulator of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> expression.</sentence>
</annotation>
<sentence>The efficacy of <cons lex="tamoxifen" sem="G_DRUG">tamoxifen</cons> and <cons sem="G_DRUG">4-hydroxytamoxifen</cons> relative to <cons sem="G_DRUG">rifampicin</cons> for hPXR activation was approximately <cons sem="G_NUMBER">30 and 60%</cons>, respectively.</sentence>
<annotation sem="INVITROCDDIS" ddi="(tamoxifen, CYP3A4,DEI)(4-hydroxytamoxifen, CYP3A4,DEI)">
<sentence>Our results indicate that the mechanism of <cons lex="tamoxifen" sem="G_DRUG">tamoxifen</cons>-mediated <cons sem="G_MECHANISM">alteration</cons> in drug <cons sem="G_IVITPARA">clearance</cons> pathways in humans <cons sem="G_CHANGE">may</cons> involve <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons lex="induction" sem="G_MECHANISM">induction</cons> by the parent drug and/or its metabolite.</sentence>
</annotation>
<sentence>Furthermore, the <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons lex="induction" sem="G_MECHANISM">induction</cons> <cons sem="G_CHANGE">may</cons> be a result of hPXR <cons sem="G_MECHANISM">activation</cons>.</sentence>
<sentence>These findings have important implications for optimizing the use of <cons lex="tamoxifen" sem="G_DRUG">tamoxifen</cons> and in the development of newer antiestrogens.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:11936702</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem="G_MECHANISM">Inhibitory</cons> effects of H1-antihistamines on <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>- and <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>-mediated drug metabolic reactions in human liver microsomes.</sentence>
</title>
<abstract>
<sentence>To screen the <cons sem="G_MECHANISM">inhibitory</cons> effects of H1-antihistamines on hepatic <cons sem="G_DRUG">bufuralol</cons> <cons sem="G_MECHANISM">1'-hydroxylation</cons> and on <cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons> <cons sem="G_MECHANISM">4-methylhydroxylation</cons> in human liver microsomes.</sentence>
<sentence><cons sem="G_DRUG">Bufuralol</cons> 1'-<cons sem="G_MECHANISM">hydroxylation</cons> and <cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons> <cons sem="G_MECHANISM">4-methylhydroxylation</cons> were used as index reactions for <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> and <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, respectively.</sentence>
<sentence>The metabolites of both reactions were measured using high-performance liquid chromatography and were used as indicators of whether <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> or <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> activities were <cons sem="G_MECHANISM">inhibited</cons> or <cons sem="G_MECHANISM">unaffected</cons> by the agents.</sentence>
<annotation sem="INVITROCDDIS" ddi="(bufuralol 1'-hydroxylation, CYP2D6,DEI)">
<sentence>All five H1-antihistamines studied showed a concentration-dependent <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>-mediated <cons sem="G_DRUG">bufuralol</cons> <cons sem="G_MECHANISM">1'-hydroxylation</cons> with <cons sem="G_NUMBER">50%</cons>  <cons sem="G_MECHANISM">inhibitory</cons> concentration <cons sem="G_IVITPARA">(IC50)</cons> values of <cons sem="G_NUMBER">32-109 microM</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Cyclizine, tolbutamide  4-methylhydroxylation,DDI)(promethazine, tolbutamide  4-methylhydroxylation,DDI)">
<sentence><cons lex="cyclizine" sem="G_DRUG">Cyclizine</cons> and <cons lex="promethazine" sem="G_DRUG">promethazine</cons> showed <cons sem="G_MECHANISM">inhibitory</cons> effects on <cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons> <cons sem="G_MECHANISM">4-methylhydroxylation</cons> with <cons sem="G_IVITPARA">IC20</cons> values of <cons sem="G_NUMBER">85 microM</cons> and <cons sem="G_NUMBER">88 microM</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Tripelennamine, CYP2C9,NDEI)(chlorpheniramine, CYP2C9,NDEI)(diphenhydramine, CYP2C9,NDEI)">
<sentence><cons lex="tripelennamine" sem="G_DRUG">Tripelennamine</cons>, <cons lex="chlorpheniramine" sem="G_DRUG">chlorpheniramine</cons>, and <cons lex="diphenhydramine" sem="G_DRUG">diphenhydramine</cons> showed <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem="G_MECHANISM">inhibitory</cons> <cons sem="G_MECHANISM">effects</cons> on <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(cyclizine, cyp2c9,DEI)(promethazine, cyp2c9,DEI)">
<sentence>All five H1-antihistamines studied  <cons sem="G_MECHANISM">inhibited</cons> <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> <cons sem="G_CHANGE">markedly</cons>, but only <cons lex="cyclizine" sem="G_DRUG">cyclizine</cons> and <cons lex="promethazine" sem="G_DRUG">promethazine</cons> <cons sem="G_MECHANISM">inhibited</cons>  <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> at concentrations above that usually seen in plasma.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Promethazine, CYP2D6,DEI)(chlorpheniramine, CYP2D6,DEI)">
<sentence><cons lex="promethazine" sem="G_DRUG">Promethazine</cons> and <cons lex="chlorpheniramine" sem="G_DRUG">chlorpheniramine</cons> <cons sem="G_MECHANISM">inhibited</cons> <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> at concentrations that are very close to their therapeutic plasma concentrations.</sentence>
</annotation>
<sentence>Further studies in humans, especially in poor metabolizers of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>, will be required to confirm these findings.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:11936218</bibliomisc>
</articleinfo>
<title>
<sentence>Effects of flavonoids isolated from Scutellariae radix on cytochrome P-450 activities in human liver microsomes.</sentence>
</title>
<abstract>
<sentence>A series of flavonoids isolated from Scutellariae radix were evaluated for their effects on cytochrome P-450 (CYP) activities in human liver microsomes.</sentence>
<annotation sem="INVITROVDDIS" ddi="(Baicalein, pentoxyresorufin O-deethylation,NDDI)(Baicalein, mephenytoin 4-hydroxylation,NDDI)(Baicalein, dextromethorphan O-demethylation,NDDI)(Baicalein, chlorzoxazone 6-hydroxylation,NDDI)(2',5,6',7-tetrahydroxyflavone, pentoxyresorufin O-deethylation,NDDI)(2',5,6',7-tetrahydroxyflavone, mephenytoin 4-hydroxylation,NDDI)(2',5,6',7-tetrahydroxyflavone, dextromethorphan O-demethylation,NDDI)(2',5,6',7-tetrahydroxyflavone, chlorzoxazone 6-hydroxylation,NDDI)(Oroxylin A, pentoxyresorufin O-deethylation,NDDI)(Oroxylin A, mephenytoin 4-hydroxylation,NDDI)(Oroxylin A, dextromethorphan O-demethylation,NDDI)(Oroxylin A, chlorzoxazone 6-hydroxylation,NDDI)">
<sentence>All flavonoids did <cons sem="G_NEGATIVEEFFECT">not</cons> substantially <cons sem="G_MECHANISM">inhibit</cons> pentoxyresorufin O-deethylation (<cons sem="G_CYP">CYP2B 1</cons>), <cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons> 4-hydroxylation (<cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>), <cons lex="dextromethorphan" sem="G_DRUG">dextromethorphan</cons> O-demethylation (<cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>), and <cons lex="chlorzoxazone" sem="G_DRUG">chlorzoxazone</cons> 6-hydroxylation (<cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons>) activities (<cons sem="G_IVITPARA">IC50</cons>: <cons sem="G_NUMBER">&gt;50 microM</cons>).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Baicalein, testosterone 6beta-hydroxylation,DDI)(2',5,6',7-tetrahydroxyflavone, testosterone 6beta-hydroxylation,DDI)">
<sentence>Baicalein and 2',5,6',7-tetrahydroxyflavone <cons sem="G_MECHANISM">inhibited</cons> hepatic <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6beta-hydroxylation (<cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>) activity with a <cons sem="G_IVITPARA">IC50</cons> of <cons sem="G_NUMBER">17.4 and 7.8 microM</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Oroxylin A, diclofenac 4-hydroxylation,DDI)">
<sentence>Oroxylin A <cons sem="G_MECHANISM">inhibited</cons> <cons lex="diclofenac" sem="G_DRUG">diclofenac</cons> 4-hydroxylation (<cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>) activity with a <cons sem="G_IVITPARA">IC50</cons> of <cons sem="G_NUMBER">6.7 microM</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Baicalein, caffeine N'-demethylation,DDI)(2',5,6',7-tetrahydroxyflavone, caffeine N'-demethylation,DDI)(Oroxylin A, caffeine N'-demethylation,DDI)">
<sentence>In contrast, all flavonoids tested <cons sem="G_MECHANISM">inhibited</cons> hepatic <cons lex="caffeine" sem="G_DRUG">caffeine</cons> N'-demethylation (<cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>) with <cons sem="G_IVITPARA">IC50</cons> values ranging from <cons sem="G_NUMBER">0.7 to 51.3 microM</cons>.</sentence>
</annotation>
<sentence>Kinetic analysis revealed that the mechanism of <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> varied according to the flavonoids.</sentence>
<sentence>These results suggest that flavonoids tested are <cons sem="G_MECHANISM">inhibitors</cons> of hepatic <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> and that the extracts of Scutellariae radix, widely used as a hepatoprotective agent, <cons sem="G_CHANGE">may</cons> protect the liver through the prevention of <cons sem="G_CYP">CYPIA2</cons>-induced metabolic activation of protoxicants.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:11911845</bibliomisc>
</articleinfo>
<title>
<sentence>Human cytochrome P450s involved in the <cons sem="G_MECHANISM">metabolism</cons> of 9-cis- and <cons sem="G_DRUG">13-cis-retinoic acids</cons>.</sentence>
</title>
<abstract>
<sentence>The purpose of this work was to identify the principal human cytochrome P450s (CYPs) involved in the <cons sem="G_MECHANISM">metabolism</cons> of the retinoic acid (RA) isomers, 9-cis- and 13-cis-RA, by using a combination of techniques including human liver microsomes (<cons lex="correlation" sem="G_MECHANISM">correlation</cons> of activity and <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons>), and lymphoblast microsomes expressing a single CYP.</sentence>
<sentence>Concerning the <cons sem="G_DRUG">9-cis-RA</cons>,<cons sem="G_DRUG">4-OH-</cons> and <cons sem="G_DRUG">4-oxo-9-cis-RA</cons> were <cons sem="G_MECHANISM">formed</cons> with human liver microsomes, and their <cons sem="G_MECHANISM">formation</cons> <cons lex="correlated" sem="G_MECHANISM">correlated</cons> with activities linked to <cons sem="G_CYP">CYPs 3A4/5</cons>, <cons lex="2b6" sem="G_CYP">2B6</cons>, <cons lex="2c8" sem="G_CYP">2C8</cons>, <cons lex="2a6" sem="G_CYP">2A6</cons>, and <cons lex="2c9" sem="G_CYP">2C9</cons>.</sentence>
<sentence>The use of lymphoblast microsomes expressing a single human CYP identified CYPs <cons sem="G_CYP">2C9</cons>&gt;<cons sem="G_CYP">2C8</cons>&gt;<cons sem="G_CYP">3A7</cons> as the most active in the <cons sem="G_MECHANISM">formation</cons> of <cons sem="G_DRUG">4-OH-9-cis-RA</cons>.</sentence>
<sentence>With regard to <cons sem="G_DRUG">13-cis-RA</cons>, specific P450 activities linked to CYPs <cons lex="2b6" sem="G_CYP">2B6</cons>, <cons lex="2c8" sem="G_CYP">2C8</cons>,<cons sem="G_CYP">3A4/5</cons>, and <cons lex="2a6" sem="G_CYP">2A6</cons> were <cons lex="correlated" sem="G_MECHANISM">correlated</cons> with the <cons sem="G_MECHANISM">formation</cons> of <cons sem="G_DRUG">4-OH-</cons> and <cons sem="G_DRUG">4-oxo-13-cis-RA</cons>.</sentence>
<sentence>Microsomes expressing a single CYP identified CYPs <cons lex="3a7" sem="G_CYP">3A7</cons>, <cons lex="2c8" sem="G_CYP">2C8</cons>, <cons lex="4a11" sem="G_CYP">4A11</cons>, <cons lex="1b1" sem="G_CYP">1B1</cons>, <cons lex="2b6" sem="G_CYP">2B6</cons>, <cons lex="2c9" sem="G_CYP">2C9</cons>, <cons lex="2c19" sem="G_CYP">2C19</cons>, <cons lex="3a4" sem="G_CYP">3A4</cons> (<cons sem="G_CHANGE">decreasing</cons> activity) in the <cons sem="G_MECHANISM">formation</cons> of <cons sem="G_DRUG">4-OH-13-cis-RA</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(sulfaphenazole, 4-OH-9-cis-RA,DDI)(quercetin, 4-OH-9-cis-RA,DDI)(ketoconazole, 4-OH-9-cis-RA,DDI)(troleandomycin, 4-OH-9-cis-RA,ADDI)(troleandomycin, 4-OH-13-cis-RA,DDI)(ketoconazole, 4-OH-13-cis-RA,ADDI)(quercetin, 4-OH-13-cis-RA,NDDI)">
<sentence>The use of CYP-specific <cons sem="G_MECHANISM">inhibitors</cons> in human liver microsomes disclosed that the <cons sem="G_MECHANISM">formation</cons> of the <cons sem="G_DRUG">4-OH-9-cis-RA</cons> was best <cons sem="G_MECHANISM">inhibited</cons> by <cons sem="G_DRUG">sulfaphenazole</cons> (<cons sem="G_NUMBER">72%</cons>) and <cons lex="quercetin" sem="G_DRUG">quercetin</cons> (<cons sem="G_NUMBER">66%</cons>), whereas <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> and <cons lex="troleandomycin" sem="G_DRUG">troleandomycin</cons> <cons sem="G_MECHANISM">inhibited</cons> its <cons sem="G_MECHANISM">formation</cons> by <cons sem="G_NUMBER">55 and 38%</cons>, respectively; the formation of <cons sem="G_DRUG">4-OH-13-cis-RA</cons> was best <cons sem="G_MECHANISM">inhibited</cons> by <cons lex="troleandomycin" sem="G_DRUG">troleandomycin</cons> (<cons sem="G_NUMBER">54%</cons>) and <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> (<cons sem="G_NUMBER">46%</cons>), whereas <cons lex="quercetin" sem="G_DRUG">quercetin</cons> was a weak <cons sem="G_MECHANISM">inhibitor</cons> (<cons sem="G_NUMBER">14%</cons>).</sentence>
</annotation>
<sentence>In conclusion, adult human CYPs <cons lex="2c9" sem="G_CYP">2C9</cons>, <cons lex="2c8" sem="G_CYP">2C8</cons>, <cons lex="3a4" sem="G_CYP">3A4</cons> have been identified as active in the <cons sem="G_DRUG">9-cis-RA</cons> <cons sem="G_MECHANISM">metabolism</cons>, whereas CYPs <cons lex="3a4" sem="G_CYP">3A4</cons> and <cons lex="2c8" sem="G_CYP">2C8</cons> were active in <cons sem="G_DRUG">13-cis-RA</cons> <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
<sentence>The fetal form <cons lex="cyp3a7" sem="G_CYP">CYP3A7</cons> was also identified as very active in either 9-cis- or <cons sem="G_DRUG">13-cis-RA</cons> <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
<sentence>The role of these human CYPs in the biological response or resistance to <cons sem="G_DRUG">RA</cons> isomers remains to be determined.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:11854151</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="inhibition" sem="G_MECHANISM">Inhibition</cons> of <cons sem="G_CYP">cytochromes P450</cons> by antifungal <cons lex="imidazole" sem="G_DRUG">imidazole</cons> derivatives.</sentence>
</title>
<abstract>
<sentence>The interactions of a panel of antifungal agents with <cons sem="G_CYP">cytochromes P450 (P450s)</cons>, as a means of predicting potential drug-drug interactions, have <cons sem="G_NEGATIVEEFFECT">not</cons> yet been investigated.</sentence>
<sentence>The objective of this study was to evaluate the specificity and selectivity of five antifungal agents using selective probe reactions for each of the eight major <cons sem="G_CYP">P450s</cons>.</sentence>
<sentence>The index reactions used were <cons lex="phenacetin" sem="G_DRUG">phenacetin</cons> O-deethylation (for <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>),<cons sem="G_DRUG">coumarin</cons> 7-hydroxylation (<cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons>), <cons lex="diclofenac" sem="G_DRUG">diclofenac</cons> 4'-hydroxylation (<cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>), <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> 5-hydroxylation (<cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>), <cons lex="dextromethorphan" sem="G_DRUG">dextromethorphan</cons> O-demethylation (<cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>), 7-ethoxy-4- <cons sem="G_DRUG">trifluoromethylcoumarin</cons> deethylation (<cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons>), <cons lex="chlorzoxazone" sem="G_DRUG">chlorzoxazone</cons> 6-hydroxylation (<cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons>), and <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> sulfonation (<cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>).</sentence>
<sentence>Five antifungal agents that include an <cons lex="imidazole" sem="G_DRUG">imidazole</cons> moiety (<cons lex="clotrimazole" sem="G_DRUG">clotrimazole</cons>, <cons lex="miconazole" sem="G_DRUG">miconazole</cons>,<cons sem="G_DRUG">sulconazole</cons>, <cons lex="tioconazole" sem="G_DRUG">tioconazole</cons>, and <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>) were examined in cDNA-expressing microsomes from human lymphoblast cells or human liver microsomes.</sentence>
<sentence>All <cons sem="G_MECHANISM">inhibitors</cons> studied demonstrated nonselective <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of P450s.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Ketoconazole, CYP3A4,DEI)(Ketoconazole, CYP2C9,DEI)">
<sentence><cons lex="ketoconazole" sem="G_DRUG">Ketoconazole</cons> seemed to be the most selective for <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, although it also <cons sem="G_MECHANISM">inhibited</cons> <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(sulconazole, CYP1A2,DEI)(tioconazole, CYP1A2,DEI)(miconazole, CYP2B6,DEI)(sulconazole, CYP2B6,DEI)(miconazole, CYP2C19,DEI)(sulconazole, CYP2C19,DEI)(tioconazole, CYP2C19,DEI)(sulconazole, CYP2C9,DEI)(miconazole, CYP2D6,DEI)(sulconazole, CYP2D6,DEI)(tioconazole, CYP2E1,DEI)(clotrimazole, CYP3A4,DEI)(miconazole, CYP3A4,DEI)(tioconazole, CYP3A4,DEI)">
<sentence>High-affinity <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> was seen for <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> (<cons sem="G_DRUG">sulconazole</cons> and <cons lex="tioconazole" sem="G_DRUG">tioconazole</cons> <cons sem="G_IVITPARA">K(i)</cons>,<cons sem="G_NUMBER">0.4 microM</cons>), <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> (<cons lex="miconazole" sem="G_DRUG">miconazole</cons><cons sem="G_MECHANISM">K(i)</cons>,<cons sem="G_NUMBER">0.05 microM</cons>;<cons sem="G_DRUG">sulconazole</cons> <cons sem="G_IVITPARA">K(i)</cons>,<cons sem="G_NUMBER">0.04 microM</cons>), <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> (<cons lex="miconazole" sem="G_DRUG">miconazole</cons> <cons sem="G_IVITPARA">K(i)</cons>,<cons sem="G_NUMBER">0.05 microM</cons>; <cons sem="G_DRUG">sulconazole</cons> <cons sem="G_IVITPARA">K(i)</cons>,<cons sem="G_NUMBER">0.008 microM</cons>; <cons lex="tioconazole" sem="G_DRUG">tioconazole</cons> <cons sem="G_IVITPARA">K(i)</cons>,<cons sem="G_NUMBER">0.04 microM</cons>), <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> ( <cons sem="G_DRUG">sulconazole</cons> <cons sem="G_IVITPARA">K(i)</cons>, <cons sem="G_NUMBER">0.01 microM</cons>), <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> (<cons lex="miconazole" sem="G_DRUG">miconazole</cons> <cons sem="G_IVITPARA">K(i)</cons> ,<cons sem="G_NUMBER">0.70 microM</cons>; <cons sem="G_DRUG">sulconazole</cons> <cons sem="G_IVITPARA">K(i)</cons>,<cons sem="G_NUMBER">0.40 microM</cons>), <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons> (<cons lex="tioconazole" sem="G_DRUG">tioconazole</cons> <cons sem="G_IVITPARA">K(i)</cons>,<cons sem="G_NUMBER">0.4 microM</cons>), and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> (<cons lex="clotrimazole" sem="G_DRUG">clotrimazole</cons><cons sem="G_IVITPARA">K(i)</cons>,<cons sem="G_NUMBER">0.02 microM</cons>; <cons lex="miconazole" sem="G_DRUG">miconazole</cons> <cons sem="G_IVITPARA">K(i)</cons>, <cons sem="G_NUMBER">0.03 microM</cons>; <cons lex="tioconazole" sem="G_DRUG">tioconazole</cons> <cons sem="G_IVITPARA">K(i)</cons>, <cons sem="G_NUMBER">0.02 microM</cons>).</sentence>
</annotation>
<sentence>Therefore, this class of compounds is likely to result in <cons sem="G_CHANGE">significant</cons> drug-drug interactions in vivo.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:11741520</bibliomisc>
</articleinfo>
<title>
<sentence>Role of <cons sem="G_CYP">cytochrome P450</cons> in <cons lex="estradiol" sem="G_DRUG">estradiol</cons> <cons sem="G_MECHANISM">metabolism</cons> in vitro.</sentence>
</title>
<abstract>
<sentence>Catechol <cons sem="G_DRUG">estrogens</cons> and <cons sem="G_DRUG">16alpha-hydroxy estrogen</cons> are important metabolites that cause carcinogenesis.</sentence>
<sentence>This study was aimed to study the role of <cons sem="G_CYP">cytochrome P450</cons> in <cons lex="estradiol" sem="G_DRUG">estradiol</cons> <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
<sentence>The <cons lex="estradiol" sem="G_DRUG">estradiol</cons> metabolites were determined with HPLC-ECD.</sentence>
<sentence><cons lex="correlation" sem="G_MECHANISM">Correlation</cons> of <cons lex="estradiol" sem="G_DRUG">estradiol</cons> metabolites production between <cons sem="G_CYP">cytochrome P450</cons> activity, the <cons sem="G_MECHANISM">inhibitory</cons> effect of specific <cons sem="G_MECHANISM">inhibitors</cons> and enzyme catalyzing kinetics were studied in cDNA-expressed P450 or human liver microsomes.</sentence>
<annotation sem="INVITROCDDIS" ddi="(estradiol 2-hydroxylation, CYP1A2,DEI)(estradiol 2-hydroxylation, CYP3A4,DEI)(estradiol 2-hydroxylation, CYP2C9,DEI)">
<sentence><cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, and <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> catalyze the <cons lex="estradiol" sem="G_DRUG">estradiol</cons> 2-hydroxylation.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(17beta-hydroxy dehydrogenation, CYP2C9,DEI)(17beta-hydroxy dehydrogenation, CYP2C19,DEI)(17beta-hydroxy dehydrogenation, CYP2C8,DEI)">
<sentence><cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>, and <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> have high activity in catalyzing 17beta-hydroxy dehydrogenation in cDNA expressed P450, but <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> is the most important enzyme in catalyzing <cons lex="estradiol" sem="G_DRUG">estradiol</cons> 2-hydroxylation.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(furafyllin, CYP1A2,DEI)(furafyllin, CYP3A4,DEI)(troleandomycin, CYP1A2,DEI)(troleandomycin, CYP3A4,DEI)">
<sentence>Using <cons sem="G_DRUG">furafyllin</cons> and <cons lex="troleandomycin" sem="G_DRUG">troleandomycin</cons> to <cons sem="G_MECHANISM">inhibit</cons> <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> in liver microsomes, it was found that the 2-hydroxylation had been <cons sem="G_MECHANISM">inhibited</cons> about the same amount.</sentence>
</annotation>
<sentence>This result suggests that in human liver microsomes <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> play an important role in 2-hydroxy <cons lex="estradiol" sem="G_DRUG">estradiol</cons> formation.</sentence>
<sentence>At low substrate concentration, 17beta -hydroxy dehydrogenation dominated the <cons lex="estradiol" sem="G_DRUG">estradiol</cons> <cons sem="G_MECHANISM">metabolism</cons>, but at high substrate concentration, 2-hydroxylation exceeded 17beta-hydroxy dehydrogenation to become the important mechanism.</sentence>
<annotation sem="INVITROCDDIS" ddi="(estradiol 2-hydroxylation, CYP1A2,DEI)(estradiol 2-hydroxylation, CYP3A4,DEI)">
<sentence><cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> are two important enzymes catalyzing the main <cons lex="estradiol" sem="G_DRUG">estradiol</cons> 2-hydroxylation <cons sem="G_MECHANISM">metabolism</cons> pathway at high substrate concentrations.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(17beta-hydroxy dehydrogenation, CYP2C9,DEI)(17beta-hydroxy dehydrogenation, CYP2C19,DEI)(17beta-hydroxy dehydrogenation, CYP2C8,DEI)">
<sentence>17beta-hydroxy dehydrogenation is the main <cons sem="G_MECHANISM">metabolism</cons> pathway at low concentrations, and <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>, and <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> <cons sem="G_CHANGE">may</cons> have high <cons sem="G_MECHANISM">catalyzing</cons> activity.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:11741214</bibliomisc>
</articleinfo>
<title>
<sentence>Comparative studies to determine the selective <cons sem="G_MECHANISM">inhibitors</cons> for P-glycoprotein and <cons sem="G_CYP">cytochrome P4503A4</cons>.</sentence>
</title>
<abstract>
<sentence>It has been suggested that cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4 (CYP3A4)</cons> and MDR1 P-glycoprotein (P-gp) act synergistically to limit the <cons sem="G_IVITPARA">bioavailability</cons> of orally administered agents.</sentence>
<sentence>In order to determine the relative role of these proteins, it is essential to identify a selective <cons sem="G_MECHANISM">inhibitor</cons> for either P-gp or <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
<sentence>In the present investigation, comparative studies were performed to examine the effect of <cons sem="G_MECHANISM">inhibitors</cons> on the function of these proteins.</sentence>
<annotation sem="INVITROCDDIS" ddi="(PSC833, vinblastine,DEI)(ketoconazole, vinblastine,DEI)(verapamil, vinblastine,DEI)(L-754,394, vinblastine,DEI)">
<sentence>The <cons sem="G_IVITPARA">IC50</cons>of P-gp function, determined by examining the <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of the transcellular transport of <cons lex="vinblastine" sem="G_DRUG">vinblastine</cons> across Caco-2 monolayers, was in the order PSC833 &lt; <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>, <cons lex="verapamil" sem="G_DRUG">verapamil</cons> &lt; N-(2(R)-hydroxy-1(S)-indanyl)-5-(2(S)-(1,1-dimethylethylaminocarbonyl)-4-(furo(2,3-b)pyridin-5-yl)methyl)piperazin-1-yl)-4(S)-hydroxy-2(R)-phenylmethylpentanamide (L-754,394).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(L-754,384, midazolam,DDI)(ketoconazole, midazolam,DDI)(PSC 833, midazolam,DDI)(verapamil, midazolam,DDI)">
<sentence>In contrast, the <cons sem="G_IVITPARA">IC50</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> function, determined by examining the <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="midazolam" sem="G_DRUG">midazolam</cons> by intestinal and liver microsomes, was in the order L-754,384 &lt; <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> &lt; PSC 833 and <cons lex="verapamil" sem="G_DRUG">verapamil</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(L-754,384, CYP3A4,DEI)(ketoconazole, CYP3A4,DEI)(PSC 833, CYP3A4,DEI)(verapamil, CYP3A4,DEI)">
<sentence>The ratio of <cons sem="G_IVITPARA">IC50</cons> for P-gp to that for <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> was more than 200 for L-754,394, 60 ~ 150 for <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>, 1.5 for <cons lex="verapamil" sem="G_DRUG">verapamil</cons>, and 0.05 for PSC 833.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(PSC 833, P-gp,DEI)(L-754,394, P-gp,DEI)(PSC 833, CYP3A4,DEI)(L-754,394, CYP3A4,DEI)">
<sentence>Collectively, it was demonstrated that PSC 833 and L-754,394 can be used as selective <cons sem="G_MECHANISM">inhibitors</cons> of P-gp and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, respectively.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:11736863</bibliomisc>
</articleinfo>
<title>
<sentence>In vitro evaluation of <cons sem="G_IVITPARA">valproic acid</cons> as an <cons sem="G_MECHANISM">inhibitor</cons> of human cytochrome P450 isoforms: preferential <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of cytochrome P450 <cons lex="2c9" sem="G_CYP">2C9</cons> (<cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>).</sentence>
</title>
<abstract>
<sentence>To evaluate the potency and specificity of <cons sem="G_DRUG">valproic acid</cons> as an <cons sem="G_MECHANISM">inhibitor</cons> of the activity of different human CYP isoforms in liver microsomes.</sentence>
<sentence>Using pooled human liver microsomes, the effects of <cons sem="G_DRUG">valproic acid</cons> on seven CYP isoform specific marker reactions were measured: <cons lex="phenacetin" sem="G_DRUG">phenacetin</cons> O-deethylase (<cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>), <cons sem="G_DRUG">coumarin</cons> 7-hydroxylase (<cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons>), <cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons> hydroxylase (<cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>), S-<cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons> 4'-hydroxylase (<cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>), <cons lex="dextromethorphan" sem="G_DRUG">dextromethorphan</cons> O-demethylase (<cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>), <cons lex="chlorzoxazone" sem="G_DRUG">chlorzoxazone</cons> 6-hydroxylase (<cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons>) and <cons lex="midazolam" sem="G_DRUG">midazolam</cons> 1'-hydroxylase (<cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>).</sentence>
<annotation sem="INVITROCDDIS" ddi="(Valproic acid, CYP2C9,NDEI)">
<sentence><cons sem="G_DRUG">Valproic acid</cons> competitively <cons sem="G_MECHANISM">inhibited</cons> <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> activity with a <cons sem="G_CYP">Ki</cons> value of <cons sem="G_NUMBER">600 microM</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Valproic acid, CYP2C19,NDEI)">
<sentence>In addition,<cons sem="G_DRUG">valproic acid</cons> slightly <cons sem="G_MECHANISM">inhibited</cons> <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> activity (<cons sem="G_IVITPARA">Ki</cons> = <cons sem="G_NUMBER">8553 microM</cons>, mixed <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons>) and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activity (<cons sem="G_IVITPARA">Ki</cons> = <cons sem="G_NUMBER">7975 microM</cons>, competitive <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons>).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Valproic acid, CYP2A6,NDEI)">
<sentence>The <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons> activity by <cons sem="G_DRUG">valproic acid</cons> was time-, concentration- and NADPH-dependent (<cons sem="G_IVITPARA">KI</cons> = <cons sem="G_NUMBER">9150 microM</cons>, <cons sem="G_IVITPARA">Kinact</cons>=<cons sem="G_NUMBER">0.048 min(-1))</cons>, consistent with mechanism-based <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons>.</sentence>
</annotation>
<sentence>However, minimal <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> and <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons> activities was observed.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Valproic acid, CYP2C9,DEI)">
<sentence><cons sem="G_DRUG">Valproic acid</cons> <cons sem="G_MECHANISM">inhibits</cons> the activity of <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> at clinically relevant concentrations in human liver microsomes.</sentence>
</annotation>
<sentence><cons lex="inhibition" sem="G_MECHANISM">Inhibition</cons> of <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> can explain some of the effects of <cons sem="G_DRUG">valproic acid</cons> on the pharmacokinetics of other drugs, such as <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons>.</sentence>
<sentence>Co-administration of high doses of <cons sem="G_DRUG">valproic acid</cons> with drugs that are primarily <cons sem="G_MECHANISM">metabolized</cons> by <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> <cons sem="G_CHANGE">may</cons> result in <cons sem="G_CHANGE">significant</cons> drug interactions.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:11717174</bibliomisc>
</articleinfo>
<title>
<sentence>Characterization of the selectivity and mechanism of  <cons sem="G_CYP">cytochrome P450</cons> <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> by dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylenedioxybiphenyl-2,2'-dicarboxylate.</sentence>
</title>
<abstract>
<sentence>In vitro studies with human liver microsomes and <cons sem="G_CYP">cytochrome P450 (P450)</cons> prototype substrates were performed to characterize the selectivity and mechanism of <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of <cons sem="G_CYP">P450</cons> by dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylenedioxybiphenyl-2,2'-dicarboxylate (DDB).</sentence>
<annotation sem="INVITROCDDIS" ddi="(DDB, testosterone 6beta-hydroxylation,DDI)">
<sentence>DDB was found to be a strong <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6beta-hydroxylation activity (<cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>) with a <cons sem="G_IVITPARA">K(i)</cons> value of <cons sem="G_NUMBER">0.27 +/- 0.21 microM</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(DDB, caffeine N(3)-demethylation,DDI)(DDB, diclofenac 4'-hydroxylation,DDI)(DDB, dextromethorphan O-demethylation,DDI)">
<sentence>At higher concentrations, DDB marginally <cons sem="G_MECHANISM">inhibited</cons> <cons lex="caffeine" sem="G_DRUG">caffeine</cons> N(3)-demethylation (<cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>), <cons lex="diclofenac" sem="G_DRUG">diclofenac</cons> 4'-hydroxylation (<cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>), and <cons lex="dextromethorphan" sem="G_DRUG">dextromethorphan</cons> O-demethylation (<cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>) activities, but this compound had <cons sem="G_NEGATIVEEFFECT">no</cons> effect on <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons>-, <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>-, and <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons>-mediated reactions.</sentence>
</annotation>
<sentence>Spectral analysis indicated that the formation of metabolite-P450 complex having absorbance at <cons sem="G_NUMBER">456 nm</cons> was concentration-dependent; <cons sem="G_NUMBER">5 to 33%</cons> of the total P450 was complexed in rat and human liver microsomes after a 5-min incubation with <cons sem="G_DRUG">DDB</cons>.</sentence>
<sentence>In addition, microsomal incubations with DDB in the presence of NADPH resulted in a loss of spectral P450 content, which was restored after adding K(3)Fe(CN)(6).</sentence>
<sentence>This complex formation resulted in a time-dependent loss of <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>-<cons lex="catalyzed" sem="G_MECHANISM">catalyzed</cons> marker activity (<cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6beta-hydroxylation) in human liver microsomes.</sentence>
<sentence>The <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> was only partially restored upon dialysis.</sentence>
<sentence>These results collectively suggest that formation of a metabolite-<cons lex="cyp3a" sem="G_CYP">CYP3A</cons> complex with DDB was responsible for the <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>-selective time-dependent loss of catalytic function of <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:11708902</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem="G_DRUG">Diazinon</cons> is <cons lex="activated" sem="G_MECHANISM">activated</cons> by <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> in human liver.</sentence>
</title>
<abstract>
<sentence>Phosphorothioate compounds are used throughout the world as agricultural and domestic pesticides.</sentence>
<sentence>Here, the <cons sem="G_MECHANISM">activation</cons> of the phosphorothioate diazinon to diazoxon in human liver is described.</sentence>
<sentence>In an initial study using three human liver microsomal samples, <cons sem="G_IVITPARA">K(m)</cons> for diazoxon formation varied <cons sem="G_CHANGE">markedly</cons> (<cons sem="G_NUMBER">31, 208, and 660 microM</cons>; <cons sem="G_IVITPARA">V(max)</cons> <cons sem="G_NUMBER">1125, 685, and 1028 pmol/min/mg</cons> protein, respectively), suggesting the involvement of more than one P450 enzyme.</sentence>
<sentence>A wide variation in activity was found using <cons sem="G_NUMBER">50 microM</cons> <cons sem="G_DRUG">diazinon</cons> as substrate, (<cons sem="G_NUMBER">11-648 pmol/min/mg protein, n = 15</cons>), whereas, with <cons sem="G_NUMBER">500 microM</cons>, variation was less (<cons sem="G_NUMBER">164-978 pmol/min/mg</cons> protein).</sentence>
<annotation sem="INVITROCDDIS" ddi="(diazinon, S-mephenytoin 4'-hydroxylase,DDI)">
<sentence>Among eight P450-<cons lex="catalyzed" sem="G_MECHANISM">catalyzed</cons> reactions, the putative high-affinity component (<cons sem="G_NUMBER">50 microM</cons> <cons sem="G_DRUG">diazinon</cons>) <cons lex="correlated" sem="G_MECHANISM">correlated</cons> with S-<cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons> 4'-hydroxylase activity (<cons sem="G_NUMBER">r = 0.686, p &lt; 0.01</cons>), suggesting the involvement of <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>.</sentence>
</annotation>
<sentence>The putative low-affinity component (<cons sem="G_NUMBER">500 microM</cons> <cons sem="G_DRUG">diazinon</cons>) <cons lex="correlated" sem="G_MECHANISM">correlated</cons> with both S-<cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons> 4'-hydroxylase (<cons sem="G_NUMBER">r = 0.714; p &lt; 0.005</cons>) and high-affinity <cons lex="phenacetin" sem="G_DRUG">phenacetin</cons> O-deethylase activity (<cons sem="G_NUMBER">r = 0.625; p &lt; 0.05</cons>).</sentence>
<annotation sem="INVITROCDDIS" ddi="(furafylline, S-mephenytoin 4'-hydroxylase,DDI)(troleandomycin, S-mephenytoin 4'-hydroxylase,DDI)(ketoconazole, S-mephenytoin 4'-hydroxylase,DDI)">
<sentence>This activity was partially <cons sem="G_MECHANISM">inhibited</cons> by <cons lex="furafylline" sem="G_DRUG">furafylline</cons>, <cons lex="troleandomycin" sem="G_DRUG">troleandomycin</cons>, and <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>.</sentence>
</annotation>
<sentence>These data suggest contributions from <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>, <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
<sentence>None of the <cons sem="G_MECHANISM">inhibitors</cons> affected the high-affinity component.</sentence>
<annotation sem="INVITROCDDIS" ddi="(CYP2C19, diazinon,DEI)(CYP3A4, diazinon,DEI)(CYP1A2, diazinon,DEI)(CYP2C9, diazinon,DEI)">
<sentence>Of seven heterologously expressed human P450 enzymes, <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> <cons lex="activated" sem="G_MECHANISM">activated</cons> diazinon (<cons sem="G_NUMBER">500 microM</cons>) at the fastest rate, followed by <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, and <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(diazinon, S-mephenytoin 4'-hydroxylase,DDI)(diazinon, phenacetin O-deethylase,DDI)(diazinon, midazolam 1'-hydroxylase,NDDI)">
<sentence>Both hepatic microsomal S-<cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons> 4'-hydroxylase and high-affinity <cons lex="phenacetin" sem="G_DRUG">phenacetin</cons> O-deethylase activities were strongly <cons sem="G_MECHANISM">inhibited</cons> by diazinon (<cons sem="G_IVITPARA">IC50</cons> <cons sem="G_NUMBER">&lt; 2.5 microM</cons>), while <cons sem="G_NEGATIVEEFFECT">no</cons> effect was seen on <cons lex="midazolam" sem="G_DRUG">midazolam</cons> 1'-hydroxylase activity.</sentence>
</annotation>
<sentence>These data indicate that <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> is the major enzyme involved in diazinon <cons sem="G_MECHANISM">activation</cons> in human liver, while other enzymes including <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> <cons sem="G_CHANGE">may</cons> play a more <cons sem="G_CHANGE">minor</cons> role.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:11602509</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="gemfibrozil" sem="G_DRUG">Gemfibrozil</cons> is a potent <cons sem="G_MECHANISM">inhibitor</cons> of human cytochrome P450 <cons lex="2c9" sem="G_CYP">2C9</cons>.</sentence>
</title>
<abstract>
<sentence>The in vitro <cons  sem="G_MECHANISM">inhibitory</cons> effects of <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons> on cytochrome P450 (CYP) <cons lex="1a2" sem="G_CYP">1A2</cons> (<cons lex="phenacetin" sem="G_DRUG">phenacetin</cons> O-deethylation), <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons> (<cons lex="induced" sem="G_DRUG">coumarin</cons> 7-hydroxylation), <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> (<cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons> hydroxylation), <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> (S-<cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons> 4'-hydroxylation), <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> (<cons lex="dextromethorphan" sem="G_DRUG">dextromethorphan</cons> O-deethylation), <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons> (<cons lex="chlorzoxazone" sem="G_DRUG">chlorzoxazone</cons> 6-hydroxylation), and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> (<cons lex="midazolam" sem="G_DRUG">midazolam</cons> 1'-hydroxylation) activities were examined using pooled human liver microsomes.</sentence>
<sentence>The in vivo drug interactions of <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons> were predicted in vitro using the  [I]/( [I] + <cons sem="G_IVITPARA">K(i)</cons>) values.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Gemfibrozil, CYP2C9,DEI)">
<sentence><cons lex="gemfibrozil" sem="G_DRUG">Gemfibrozil</cons> strongly and competitively <cons sem="G_MECHANISM">inhibited</cons> <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> activity, with a <cons sem="G_IVITPARA">K(i)</cons> ( <cons sem="G_IVITPARA">IC(50)</cons>) value of <cons sem="G_NUMBER">5.8 (9.6) microM</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Gemfibrozil, CYP2C19,ADEI)(Gemfibrozil, CYP1A2,ADEI)">
<sentence>In addition, <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons> exhibited somewhat smaller <cons sem="G_MECHANISM">inhibitory</cons> effects on <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> and <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> activities, with <cons sem="G_IVITPARA">K(i)</cons> (<cons sem="G_IVITPARA">IC(50)</cons>) values of <cons sem="G_NUMBER">24 (47) microM</cons> and <cons sem="G_NUMBER">82 (136) microM</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Gemfibrozil, CYP2A6,NDEI)(Gemfibrozil, CYP2D6,NDEI)(Gemfibrozil, CYP2E1,NDEI)(Gemfibrozil, CYP3A4,NDEI)">
<sentence>With concentrations up to <cons sem="G_NUMBER">250 microM</cons>, <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons> showed <cons sem="G_NEGATIVEEFFECT">no</cons> appreciable effect on <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons>, <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>, <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons>, and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activities.</sentence>
</annotation>
<sentence>Based on  [I]/( [I] +  <cons sem="G_IVITPARA">K(i)</cons>) values calculated using <cons sem="G_IVITPARA">peak total (or unbound) plasma concentration</cons> of <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons>, <cons sem="G_NUMBER">96% (56%), 86% (24%), and 64% (8%)</cons> <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of the <cons sem="G_IVITPARA">clearance</cons> of <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>, and <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> substrates could be expected, respectively.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Gemfibrozil, warfarin,DDI)">
<sentence>In conclusion, <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons> <cons sem="G_MECHANISM">inhibits</cons> the activity of <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> at clinically relevant concentrations, and this is the likely mechanism by which <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons> interacts with <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> substrate drugs, such as <cons lex="warfarin" sem="G_DRUG">warfarin</cons> and <cons lex="glyburide" sem="G_DRUG">glyburide</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Gemfibrozil, CYP2C19,DEI)(Gemfibrozil, CYP1A2,DEI)">
<sentence><cons lex="gemfibrozil" sem="G_DRUG">Gemfibrozil</cons> <cons sem="G_CHANGE">may</cons> also <cons sem="G_MECHANISM">impair</cons> <cons sem="G_IVITPARA">clearance</cons> of <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> and <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> substrates, but <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of other CYP isoforms is unlikely.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:11560869</bibliomisc>
</articleinfo>
<title>
<sentence>In vitro <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="tegaserod" sem="G_DRUG">tegaserod</cons> in human liver and intestine: assessment of drug interactions.</sentence>
</title>
<abstract>
<sentence><cons lex="tegaserod" sem="G_DRUG">Tegaserod</cons> is a selective 5-HT(4) receptor partial agonist with promotile activity in the gastrointestinal tract.</sentence>
<sentence>This study was designed to describe the metabolic pathways of <cons lex="tegaserod" sem="G_DRUG">tegaserod</cons> in the human liver and small intestine in vitro, to identify the enzymes involved in <cons lex="tegaserod" sem="G_DRUG">tegaserod</cons> <cons sem="G_MECHANISM">metabolism</cons>, and to investigate the effect of <cons lex="tegaserod" sem="G_DRUG">tegaserod</cons> on CYP-<cons lex="catalyzed" sem="G_MECHANISM">catalyzed</cons> reactions involving other compounds.</sentence>
<sentence><cons lex="tegaserod" sem="G_DRUG">Tegaserod</cons> was <cons sem="G_MECHANISM">metabolism</cons> in human liver microsomes to O-desmethyl <cons lex="tegaserod" sem="G_DRUG">tegaserod</cons> at a low rate.</sentence>
<annotation sem="INVITROCDDIS" ddi="(quinidine, CYP2D6,DEI)">
<sentence>This metabolite was also <cons sem="G_MECHANISM">formed</cons> by cDNA expressed <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>, and the reaction in human liver microsomes was <cons sem="G_MECHANISM">inhibited</cons> by <cons lex="quinidine" sem="G_DRUG">quinidine</cons>.</sentence>
</annotation>
<sentence>In human liver slices, direct N-glucuronidation of <cons lex="tegaserod" sem="G_DRUG">tegaserod</cons> at the <cons lex="guanidine" sem="G_DRUG">guanidine</cons> nitrogens (M43.2, M43.8, and M45.3) was found, with M43.8 being the major metabolite.</sentence>
<sentence>Human small intestine slices also <cons sem="G_MECHANISM">metabolism</cons> <cons lex="tegaserod" sem="G_DRUG">tegaserod</cons> to the N-glucuronides, suggesting a contribution of the small intestine to the presystemic <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
<sentence>5-Methoxyindole-3-carboxylic acid (M29.0), the main metabolite in human plasma, was generated in vitro by a sequence of reactions starting with nonenzymatic acid-<cons lex="catalyzed" sem="G_MECHANISM">catalyzed</cons> hydrolysis, followed by enzymatic <cons lex="oxidation" sem="G_MECHANISM">oxidation</cons> and conjugation with glucuronic acid.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Tegaserod, CYP2C8,DEI)(Tegaserod, CYP2C9,DEI)(Tegaserod, CYP2C19,DEI)(Tegaserod, CYP2E1,DEI)(Tegaserod, CYP3A,DEI)">
<sentence><cons lex="tegaserod" sem="G_DRUG">Tegaserod</cons> <cons sem="G_MECHANISM">inhibited</cons> <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons>, <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>, <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons>, and <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> only to a small extent with <cons sem="G_IVITPARA">IC(50)</cons> values <cons sem="G_NUMBER">&gt;30 microM</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Tegaserod, CYP1A2,DEI)(Tegaserod, CYP2D6,DEI)">
<sentence><cons lex="tegaserod" sem="G_DRUG">Tegaserod</cons> more effectively <cons sem="G_MECHANISM">inhibited</cons> <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> and <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> with <cons sem="G_IVITPARA">K(i)</cons> values of <cons sem="G_NUMBER">0.84 and 0.85 microM</cons>, respectively.</sentence>
</annotation>
<sentence>However, these <cons sem="G_IVITPARA">K(i)</cons> values are approximately <cons sem="G_NUMBER">140-fold</cons> <cons sem="G_CHANGE">greater</cons> than the maximal <cons lex="tegaserod" sem="G_DRUG">tegaserod</cons> plasma concentrations following the clinically relevant <cons sem="G_NUMBER">6-mg</cons> oral dose given to healthy volunteers.</sentence>
<sentence>M29.0, the main circulating metabolite, did <cons sem="G_NEGATIVEEFFECT">not</cons> demonstrate any inhibitory potential toward cytochrome P450 enzymes in vitro.</sentence>
<sentence>Therefore, clinically relevant metabolic drug interactions with <cons lex="tegaserod" sem="G_DRUG">tegaserod</cons> seem unlikely.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:11560868</bibliomisc>
</articleinfo>
<title>
<sentence>Different enantioselective 9-hydroxylation of <cons lex="risperidone" sem="G_DRUG">risperidone</cons> by the two human <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> enzymes.</sentence>
</title>
<abstract>
<sentence>The antipsychotic agent <cons lex="risperidone" sem="G_DRUG">risperidone</cons>, is <cons sem="G_MECHANISM">metabolized</cons> by different cytochrome P-450 (CYP) enzymes, including <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>, to the active 9-hydroxyrisperidone, which is the major metabolite in plasma.</sentence>
<sentence>Two enantiomers, (+)- and (-)-9-hydroxyrisperidone <cons sem="G_CHANGE">might</cons> be <cons sem="G_MECHANISM">formed</cons>, and the aim of this study was to evaluate the importance of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> and <cons sem="G_CYP">CYP3A4/CYP3A5</cons> in the formation of these two enantiomers in human liver microsomes and in recombinantly expressed enzymes.</sentence>
<sentence>The enantiomers of 9-hydroxyrisperidone were analyzed with high pressure liquid chromatography using a chiral alpha-1 acid glycoprotein column.</sentence>
<sentence>A much higher formation rate was observed for (+)-9-hydroxyrisperidone than for (-)-9-hydroxyrisperidone in microsomes prepared from six individual livers.</sentence>
<annotation sem="INVITROCDDIS" ddi="(quinidine, (+)-9-hydroxyrisperidone,DDI)(ketoconazole, (+)-9-hydroxyrisperidone,DDI)">
<sentence>The formation of (+)-9-hydroxyrisperidone was <cons sem="G_CHANGE">strongly</cons> <cons sem="G_MECHANISM">inhibited</cons> by <cons lex="quinidine" sem="G_DRUG">quinidine</cons>, a potent <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> <cons sem="G_MECHANISM">inhibitor</cons>, whereas <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>, a <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitor</cons>, <cons sem="G_CHANGE">strongly</cons> <cons sem="G_MECHANISM">inhibited</cons> the formation of (-)-9-hydroxyrisperidone.</sentence>
</annotation>
<sentence>Recombinant human <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> <cons sem="G_MECHANISM">produced</cons> only (+)-9-hydroxyrisperidone, whereas a lower formation rate of both enantiomers was detected with expressed <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and <cons lex="cyp3a5" sem="G_CYP">CYP3A5</cons>.</sentence>
<sentence>In vivo data from 18 patients during treatment with <cons lex="risperidone" sem="G_DRUG">risperidone</cons> indicate that the plasma concentration of the (+)-enantiomer is higher than that of the (-)-enantiomer in extensive metabolizers of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>.</sentence>
<sentence>These findings clearly suggest that <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> plays a predominant role in (+)-9-<cons sem="G_MECHANISM">hydroxylation</cons> of <cons lex="risperidone" sem="G_DRUG">risperidone</cons>, the major metabolic pathway in clinical conditions, whereas <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> catalyzes the formation of the (-)-9-hydroxymetabolite.</sentence>
<sentence>Further studies are required to evaluate the pharmacological/toxic activity of both enantiomers.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:11502731</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem="G_MECHANISM">Metabolism</cons> of <cons lex="vanoxerine" sem="G_DRUG">vanoxerine</cons>, 1- [2- [bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine, by human cytochrome P450 enzymes.</sentence>
</title>
<abstract>
<sentence><cons lex="vanoxerine" sem="G_DRUG">Vanoxerine</cons> (1- [2- [bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine; GBR12909) is a promising agent for the treatment of <cons lex="cocaine" sem="G_DRUG">cocaine</cons> dependence.</sentence>
<sentence>Knowledge of the major pathway for <cons sem="G_DRUG">GBR12909</cons> <cons sem="G_MECHANISM">metabolism</cons> is important for prediction of the likelihood of drug-drug interactions, which <cons sem="G_CHANGE">may</cons> affect the therapeutic clinical outcome, when this agent is used in <cons lex="cocaine" sem="G_DRUG">cocaine</cons>-dependent individuals receiving multiple drug therapy.</sentence>
<sentence>We studied biotransformation of <cons sem="G_DRUG">GBR12909</cons> in human liver microsomes (n = 4), human hepatocytes, and microsomes containing cDNA-expressed human P450 isoforms with <cons sem="G_DRUG">GBR12909</cons> concentrations within the range of steady-state plasma concentrations detected in healthy volunteers.</sentence>
<sentence>A high-pressure liquid chromatography assay was used to measure parent GBR12909 and its primary metabolite.</sentence>
<sentence><cons sem="G_DRUG">GBR12909</cons> was <cons sem="G_MECHANISM">metabolized</cons> by human liver microsomes, hepatocytes, and cDNA-expressed human P450s to a single metabolite.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Ketoconazole, GBR12909,DDI)">
<sentence><cons lex="ketoconazole" sem="G_DRUG">Ketoconazole</cons>, a selective <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>, <cons sem="G_CHANGE">reduced</cons> <cons sem="G_DRUG">GBR12909</cons> <cons sem="G_IVITPARA">biotransformation</cons> in human liver microsomes and primary hepatocytes by <cons sem="G_NUMBER">92 +/- 2</cons> and <cons sem="G_NUMBER">92.4 +/- 0.4%</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Quercetin, GBR12909,DDI)">
<sentence><cons lex="quercetin" sem="G_DRUG">Quercetin</cons> (an <cons sem="G_MECHANISM">inhibitor</cons> of <cons sem="G_CYP">CYP2C8/3A4</cons>) was a <cons sem="G_CHANGE">less effective</cons> <cons sem="G_MECHANISM">inhibitor</cons> producing <cons sem="G_NUMBER">62 +/- 22%</cons> <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> in human liver microsomes and <cons sem="G_NUMBER">54 +/- 35%</cons> in hepatocytes.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(chlorzoxazone, GBR12909,DDI)">
<sentence>Other P450 selective <cons sem="G_MECHANISM">inhibitors</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">decrease</cons> <cons sem="G_DRUG">GBR12909</cons> <cons sem="G_IVITPARA">biotransformation</cons> more than <cons sem="G_NUMBER">29%</cons> in either human liver microsomes or hepatocytes with the exception of <cons lex="chlorzoxazone" sem="G_DRUG">chlorzoxazone</cons> (<cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons>), which <cons sem="G_MECHANISM">inhibited</cons> <cons sem="G_DRUG">GBR12909</cons> biotransformation by <cons sem="G_NUMBER">71.4 +/- 18.5%</cons> in primary human hepatocytes.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Ciprofloxacin, GBR12909,DDI)(sulfaphenazole, GBR12909,DDI)(quinidine, GBR12909,DDI)(chlorzoxazone, GBR12909,DDI)(mephenytoin, GBR12909,DDI)">
<sentence><cons lex="ciprofloxacin" sem="G_DRUG">Ciprofloxacin</cons> (<cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>), <cons sem="G_DRUG">sulfaphenazole</cons> (<cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>), <cons lex="quinidine" sem="G_DRUG">quinidine</cons> (<cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>), <cons lex="chlorzoxazone" sem="G_DRUG">chlorzoxazone</cons> (<cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons>), and <cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons> (<cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>) did <cons sem="G_NEGATIVEEFFECT">not</cons> demonstrate statistically <cons sem="G_CHANGE">significant</cons> <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> <cons sem="G_NUMBER">(p &gt; 0.05)</cons> of <cons sem="G_DRUG">GBR12909</cons> <cons sem="G_IVITPARA"></cons>biotransformation in liver microsomes.</sentence>
</annotation>
<sentence>cDNA-expressed P450 <cons lex="3a4" sem="G_CYP">3A4</cons> <cons sem="G_MECHANISM">metabolism</cons> <cons sem="G_DRUG">GBR12909</cons> to a <cons sem="G_CHANGE">greater</cons> extent than <cons lex="2c8" sem="G_CYP">2C8</cons> and <cons lex="2e1" sem="G_CYP">2E1</cons>.</sentence>
<sentence>These data suggest the possibility that multiple P450 isoforms <cons sem="G_CHANGE">may</cons> be involved in human <cons sem="G_DRUG">GBR12909</cons> <cons sem="G_MECHANISM">metabolism</cons> but that <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> appears to be the major enzyme responsible for human <cons sem="G_DRUG">GBR12909</cons> biotransformation.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:11465405</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem="G_MECHANISM">Metabolism</cons> of <cons sem="G_DRUG"></cons>2,5-bis(trifluoromethyl)-7-benzyloxy-4-trifluoromethylcoumarin by human hepatic CYP isoforms: evidence for selectivity towards <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
</title>
<abstract>
<sentence>1.</sentence>
<sentence>The <cons sem="G_MECHANISM">metabolism</cons> of <cons sem="G_DRUG">2,5-bis(trifluoromethyl)-7-benzyloxy-4-trifluoromethylcoumarin (BFBFC)</cons> to <cons sem="G_DRUG">7-hydroxy-4-trifluoromethylcoumarin (HFC)</cons> was studied in human liver microsomes and in cDNA-expressed human liver CYP isoforms.</sentence>
<sentence>For purposes of comparison, some limited studies were also performed with <cons sem="G_DRUG">7-benzyloxyquinoline (7BQ)</cons>.</sentence>
<sentence>2.</sentence>
<sentence>Initial interactive docking studies with a homology model of human <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> indicated that <cons sem="G_DRUG">BFBFC</cons> was likely to be a selective substrate for <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> with a relatively high binding affinity, due to the presence of several key hydrogen bonds with active site amino acid residues.</sentence>
<sentence>3.</sentence>
<sentence>Kinetic analysis of NADPH-dependent <cons sem="G_DRUG">BFBFC</cons> <cons sem="G_MECHANISM">metabolism</cons> to <cons sem="G_DRUG">HFC</cons> in three preparations of pooled human liver microsomes revealed mean (+/- TSEM) <cons sem="G_IVITPARA">Km</cons> and <cons sem="G_IVITPARA">Vmax</cons> = <cons sem="G_NUMBER">4.6 +/- 0.3 microM</cons> and <cons sem="G_NUMBER">20.0 +/- 3.8 pmol/min/mg</cons> protein, respectively.</sentence>
<sentence>4.</sentence>
<sentence>The <cons sem="G_MECHANISM">metabolism</cons> of <cons sem="G_DRUG">BFBFC</cons> to <cons sem="G_DRUG">HFC</cons> was determined in a characterized bank of 24 individual human liver microsomal preparations employing a <cons sem="G_DRUG">BFBFC</cons> substrate concentration of <cons sem="G_NUMBER">lO microM</cons> (i.e. around twice <cons sem="G_IVITPARA">Km</cons>).</sentence>
<annotation sem="INVITROCDDIS" ddi="(BFBFC, CYP3A,DEI)">
<sentence>Good <cons sem="G_MECHANISM">correlations</cons> <cons sem="G_NUMBER">(r2 = 0.736-0.904)</cons> were observed between <cons sem="G_DRUG">BFBFC</cons> <cons sem="G_MECHANISM">metabolism</cons> and markers of <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> isoforms.</sentence>
</annotation>
<sentence>5.</sentence>
<sentence>While <cons sem="G_NUMBER">10O microM</cons> <cons sem="G_DRUG">BFBFC</cons> was <cons sem="G_MECHANISM">metabolized</cons> to <cons sem="G_DRUG">HFC</cons> by cDNA-expressed <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, <cons sem="G_CHANGE">little</cons> or <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem="G_MECHANISM">metabolism</cons> was observed with cDNA-expressed <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons>, <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons>, <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons>, <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>, <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> and <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons>.</sentence>
<sentence>6.</sentence>
<annotation sem="INVITROCDDIS" ddi="(troleandomycin, BFBFC,DDI)(ketoconazole, BFBFC,DDI)(alpha-naphthoflavone, BFBFC,DDI)">
<sentence>The <cons sem="G_MECHANISM">metabolism</cons> of <cons sem="G_NUMBER">10 microM</cons> <cons sem="G_DRUG">BFBFC</cons> in human liver microsomes was <cons sem="G_CHANGE">markedly</cons> <cons sem="G_MECHANISM">inhibited</cons> by <cons sem="G_NUMBER">5-50 microM</cons> <cons lex="troleandomycin" sem="G_DRUG">troleandomycin</cons> and <cons sem="G_NUMBER">0.2-5 microM</cons> <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>, but <cons lex="stimulated" sem="G_MECHANISM">stimulated</cons> by <cons sem="G_NUMBER">0.2-10 microM</cons> alpha-naphthoflavone.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Anti-CYP3A4 antibody, BFBFC,DDI)">
<sentence>The <cons sem="G_MECHANISM">metabolism</cons> of <cons sem="G_NUMBER">10 microM</cons> <cons sem="G_DRUG">BFBFC</cons> in human liver microsomes was also <cons sem="G_CHANGE">markedly</cons> <cons sem="G_MECHANISM">inhibited</cons> by an antibody to <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
</annotation>
<sentence>7.</sentence>
<sentence>Kinetic analysis of NADPH-dependent <cons sem="G_DRUG">7BQ</cons> <cons sem="G_MECHANISM">metabolism</cons> to <cons sem="G_DRUG">7-hydroxyquinoline (7HQ)</cons> in human liver microsomes revealed <cons sem="G_IVITPARA">Km</cons> and <cons sem="G_IVITPARA">Vmax</cons> = <cons sem="G_NUMBER">70 microM</cons> and <cons sem="G_NUMBER">3.39 nmol/min/mg</cons> protein, respectively.</sentence>
<sentence>8.</sentence>
<sentence>While <cons sem="G_NUMBER">80 microM</cons> <cons sem="G_DRUG">7BQ</cons> was <cons sem="G_MECHANISM">metabolized</cons> to <cons sem="G_DRUG">7HQ</cons> by cDNA-expressed <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, only low rates of <cons sem="G_MECHANISM">metabolism</cons> were observed with cDNA-expressed <cons sem="G_CYP">CYPIA2</cons>, <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons>, <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons>, <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons>, <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>, <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> and <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons>.</sentence>
<sentence>9.</sentence>
<annotation sem="INVITROCDDIS" ddi="(CYP3A4, BFBFC,DEI)">
<sentence>In summary, by <cons lex="correlation" sem="G_MECHANISM">correlation</cons> analysis, the use of cDNA-expressed CYP isoforms, chemical <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> and <cons sem="G_MECHANISM">inhibitory</cons> antibodies, <cons sem="G_DRUG">BFBFC</cons> <cons sem="G_MECHANISM">metabolism</cons> in human liver microsomes appears to be primarily catalysed by <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
</annotation>
<sentence><cons sem="G_DRUG">BFBFC</cons> <cons sem="G_CHANGE">may</cons> be a useful fluorescent probe substrate for human hepatic <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, but compared with <cons sem="G_DRUG">7BQ</cons> has only a low rate of <cons sem="G_MECHANISM">metabolism</cons> in human liver microsomes.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:11465391</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="inhibition" sem="G_MECHANISM">Inhibition</cons> of human <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> activity in vitro by methylxanthines: potent competitive <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> by <cons sem="G_DRUG">8-phenyltheophylline</cons>.</sentence>
</title>
<abstract>
<sentence>1.</sentence>
<sentence>Humans are exposed in vivo to <cons sem="G_DRUG">methylxanthines</cons> by dietary ingestion, as well as from their use as therapeutic agents.</sentence>
<sentence>The <cons sem="G_MECHANISM">inhibitory</cons> effect of a series of these compounds on high-affinity <cons lex="phenacetin" sem="G_DRUG">phenacetin</cons> O-deethylase activity in the human liver microsomal fraction, a measure of <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> activity, has been evaluated.</sentence>
<sentence>2.</sentence>
<sentence><cons lex="paracetamol" sem="G_DRUG">Paracetamol</cons>, the product of <cons lex="phenacetin" sem="G_DRUG">phenacetin</cons> O-deethylase activity, was analysed by gas chromatography/negative-ion mass spectrometry using a novel bistrifluoromethylbenzoyl/ trimethylsilyl derivative, and incubation conditions for assessing high-affinity <cons lex="phenacetin" sem="G_DRUG">phenacetin</cons> O-deethylase activity were examined and optimized.</sentence>
<sentence>3.</sentence>
<annotation sem="INVITROVDDIS" ddi="(1-Methylxanthine, CYP1A2,DEI)(caffeine, CYP1A2,DEI)(theophylline, CYP1A2,DEI)(8-methylxanthine, CYP1A2,DEI)(pentoxyfylline, CYP1A2,DEI)(3isobutyl-1-methylxanthine, CYP1A2,DEI)">
<sentence><cons sem="G_DRUG">1-Methylxanthine</cons>, <cons lex="caffeine" sem="G_DRUG">caffeine</cons>, <cons lex="theophylline" sem="G_DRUG">theophylline</cons>, <cons sem="G_DRUG">8-methylxanthine</cons>, <cons sem="G_DRUG">pentoxyfylline</cons> and <cons sem="G_DRUG">3isobutyl-1-methylxanthine</cons> caused <cons sem="G_CHANGE"> <cons sem="G_CHANGE">moderate</cons></cons> <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> with <cons sem="G_IVITPARA">IC50</cons> = <cons sem="G_NUMBER">260</cons>, <cons sem="G_NUMBER">140</cons>, <cons sem="G_NUMBER">120</cons>, <cons sem="G_NUMBER">100</cons>, <cons sem="G_NUMBER">62</cons> and <cons sem="G_NUMBER">36 microM</cons> respectively.</sentence>
</annotation>
<sentence>4.</sentence>
<annotation sem="INVITROCDDIS" ddi="(8-Phenyltheophylline, phenacetin O-deethylase,DDI)">
<sentence><cons sem="G_DRUG">8-Phenyltheophylline</cons> was a potent competitive <cons sem="G_MECHANISM">inhibitor</cons> of high-affinity <cons lex="phenacetin" sem="G_DRUG">phenacetin</cons> O-deethylase activity with an <cons sem="G_IVITPARA">IC50</cons> = <cons sem="G_NUMBER">0.7 microM</cons> and <cons sem="G_IVITPARA">Ki</cons> = <cons sem="G_NUMBER">0.11 microM</cons>.</sentence>
</annotation>
<sentence>5.</sentence>
<annotation sem="INVITROCDDIS" ddi="(8-Phenyltheophylline, debrisoquine 4-hydroxylase,DDI)(8-Phenyltheophylline, terfenadine hydroxylase e,DDI)(8-Phenyltheophylline, chlorzoxazone 6-hydroxylase,DDI)(8-Phenyltheophylline, tolbutamide 4-hydroxylase,DDI)">
<sentence>The specificity of <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> by <cons sem="G_DRUG">8-phenyltheophylline</cons> was assessed by measuring its effect on <cons lex="debrisoquine" sem="G_DRUG">debrisoquine</cons> 4-hydroxylase (<cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>), <cons lex="terfenadine" sem="G_DRUG">terfenadine</cons> hydroxylase (<cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>), <cons lex="chlorzoxazone" sem="G_DRUG">chlorzoxazone</cons> 6-hydroxylase (<cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons>) and <cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons> 4-hydroxylase (<cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>) activities in human liver microsomal fraction.</sentence>
</annotation>
<sentence><cons sem="G_NEGATIVEEFFECT">No</cons> <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of any of these activities was observed.</sentence>
<sentence>6.</sentence>
<annotation sem="INVITROCDDIS" ddi="(8-Phenyltheophylline, CYP1A2,DEI)">
<sentence>The potency and specificity of <cons sem="G_DRUG">8-phenyltheophylline</cons> as an <cons sem="G_MECHANISM">inhibitor</cons> of human hepatic <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> indicate that the compound <cons sem="G_CHANGE">may</cons> be useful as a chemical <cons sem="G_MECHANISM">inhibitor</cons> of this enzyme for further in vitro studies.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:11422004</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem="G_MECHANISM">Inhibitory</cons> effects of <cons lex="verapamil" sem="G_DRUG">verapamil</cons> and <cons lex="diltiazem" sem="G_DRUG">diltiazem</cons> on <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons> <cons sem="G_MECHANISM">metabolism</cons> in human liver microsomes.</sentence>
</title>
<abstract>
<sentence>To determine the effects of <cons lex="verapamil" sem="G_DRUG">verapamil</cons> and <cons lex="diltiazem" sem="G_DRUG">diltiazem</cons> on <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons> <cons sem="G_MECHANISM">metabolism</cons> in human liver microsomes and to compare their <cons sem="G_MECHANISM">inhibitory</cons> potencies and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inactivation</cons> parameters with those reported previously for <cons sem="G_DRUG">mibefradil</cons>.</sentence>
<sentence><cons lex="simvastatin" sem="G_DRUG">Simvastatin</cons> <cons sem="G_MECHANISM">metabolism</cons> was investigated in human liver microsomes in the presence and absence of <cons lex="verapamil" sem="G_DRUG">verapamil</cons> or <cons lex="diltiazem" sem="G_DRUG">diltiazem</cons> (<cons sem="G_NUMBER">0.1-250 microM</cons>).</sentence>
<sentence>Kinetics of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inactivation</cons> by <cons lex="verapamil" sem="G_DRUG">verapamil</cons> and <cons lex="diltiazem" sem="G_DRUG">diltiazem</cons> were determined using <cons lex="testosterone" sem="G_DRUG">testosterone</cons> as the substrate.</sentence>
<annotation sem="INVITROCDDIS" ddi="(verapamil, simvastatin,DDI)">
<sentence>When <cons lex="verapamil" sem="G_DRUG">verapamil</cons> was coincubated with <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons>, <cons sem="G_IVITPARA">IC50</cons> values ranged from <cons sem="G_NUMBER">23 to 26 microM</cons> for all major metabolites.</sentence>
</annotation>
<sentence>The <cons sem="G_IVITPARA">IC50</cons> values ranged from <cons sem="G_NUMBER">4.8 to 5.6 microM</cons> on preincubation of <cons lex="verapamil" sem="G_DRUG">verapamil</cons> for 30 min in the presence of an NADPH-generating system.</sentence>
<sentence>Corresponding <cons sem="G_IVITPARA">IC50</cons> values for <cons lex="diltiazem" sem="G_DRUG">diltiazem</cons> ranged from <cons sem="G_NUMBER">110-127 microM</cons> and from <cons sem="G_NUMBER">21-27 microM</cons>, respectively.</sentence>
<annotation sem="INVITROCDDIS" ddi="(verapamil, testosterone 6beta-hydroxylation,DDI)(diltiazem, testosterone 6beta-hydroxylation,DDI)">
<sentence><cons lex="verapamil" sem="G_DRUG">Verapamil</cons> and <cons lex="diltiazem" sem="G_DRUG">diltiazem</cons> <cons sem="G_MECHANISM">inhibited</cons> <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6beta-hydroxylation in a time- and concentration-dependent manner, key features of mechanism-based <cons sem="G_MECHANISM">inactivation</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(verapamil, testosterone 6beta-hydroxylation,DDI)(diltiazem, testosterone 6beta-hydroxylation,DDI)">
<sentence>Values for the <cons sem="G_MECHANISM">inactivation</cons> parameters <cons sem="G_IVITPARA">kinact</cons> and <cons sem="G_IVITPARA">KI</cons> were <cons sem="G_NUMBER">0.15 +/- 0.04 min-1 (mean +/- s.d.)</cons> and <cons sem="G_NUMBER">2.9 +/- 0.6 microM</cons>, respectively, for <cons lex="verapamil" sem="G_DRUG">verapamil</cons> and <cons sem="G_NUMBER">0.07 +/- 0.01 min-1</cons> and <cons sem="G_NUMBER">3.3 +/- 1.5 microM</cons>, respectively, for <cons lex="diltiazem" sem="G_DRUG">diltiazem</cons>.</sentence>
</annotation>
<sentence>The <cons sem="G_IVITPARA">IC50</cons> values for coincubation of <cons lex="verapamil" sem="G_DRUG">verapamil</cons> and <cons lex="diltiazem" sem="G_DRUG">diltiazem</cons> were <cons sem="G_NUMBER">46- and 220-fold</cons> <cons sem="G_CHANGE">higher</cons>, respectively, than those reported previously for <cons sem="G_DRUG">mibefradil</cons>, and <cons sem="G_NUMBER">16- and 71-fold</cons> <cons sem="G_CHANGE">higher</cons>, respectively, for preincubation.</sentence>
<sentence>Thus, the results of this study suggest that <cons lex="verapamil" sem="G_DRUG">verapamil</cons> and <cons lex="diltiazem" sem="G_DRUG">diltiazem</cons> are less likely than <cons sem="G_DRUG">mibefradil</cons> to cause acute drug interactions with <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons> in vivo.</sentence>
<annotation sem="INVITROCDDIS" ddi="(verapamil, CYP3A4,DEI)(diltiazem, CYP3A4,DEI)(verapamil, simvastatin,DDI)(diltiazem, simvastatin,DDI)">
<sentence>However, <cons lex="verapamil" sem="G_DRUG">verapamil</cons> and <cons lex="diltiazem" sem="G_DRUG">diltiazem</cons> are <cons sem="G_CHANGE">moderate</cons> mechanism-based <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and therefore <cons sem="G_CHANGE">may</cons> still cause <cons sem="G_CHANGE">significant</cons> <cons lex="inhibition" sem="G_MECHANISM">inhibition</cons> of <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons> <cons sem="G_MECHANISM">metabolism</cons> in vivo during chronic therapy.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:11408373</bibliomisc>
</articleinfo>
<title>
<sentence>Role of <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> polymorphism in <cons lex="losartan" sem="G_DRUG">losartan</cons> <cons sem="G_MECHANISM">oxidation</cons>.</sentence>
</title>
<abstract>
<sentence><cons lex="losartan" sem="G_DRUG">Losartan</cons>, an angiotensin II receptor antagonist, is <cons sem="G_MECHANISM">oxidized</cons> by hepatic cytochromes P450 to an active carboxylic acid metabolite, E-3174.</sentence>
<sentence>The aim of the present investigation was to study the contribution of <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> in <cons lex="losartan" sem="G_DRUG">losartan</cons> <cons sem="G_MECHANISM">oxidation</cons> in vitro and to evaluate the role of <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> polymorphism.</sentence>
<sentence>Kinetic properties of different genetic <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> variants were compared both in a yeast expression system and in 25 different samples of human liver microsomes where all known genotypes of <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> were represented.</sentence>
<sentence>Microsomes were incubated with <cons lex="losartan" sem="G_DRUG">losartan</cons> (<cons sem="G_NUMBER">0.05-50 microM</cons>), and the <cons sem="G_MECHANISM">formation</cons> of <cons sem="G_DRUG">E-3174</cons> was analyzed by high-performance liquid chromatography to estimate V(max), <cons sem="G_IVITPARA">K(m)</cons>, and <cons sem="G_IVITPARA">intrinsic clearance</cons> for all individual samples.</sentence>
<annotation  sem="INVITROCDDIS" ddi="(Sulfaphenazole, E-3174,DDI)(triacetyloleandomycin, E-3174,DDI)">
<sentence><cons sem="G_DRUG">Sulfaphenazole</cons>, a <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> <cons sem="G_MECHANISM">inhibitor</cons>, <cons sem="G_MECHANISM">blocked</cons> the <cons sem="G_MECHANISM">formation</cons> of <cons sem="G_DRUG">E-3174</cons> at low <cons lex="losartan" sem="G_DRUG">losartan</cons> concentrations (<cons sem="G_NUMBER">&lt;1 microM</cons>), whereas the <cons sem="G_MECHANISM">inhibitory</cons> effect of <cons sem="G_DRUG">triacetyloleandomycin</cons>, a <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitor</cons>, was <cons sem="G_CHANGE">significant</cons> only at high concentrations of <cons lex="losartan" sem="G_DRUG">losartan</cons> (<cons sem="G_NUMBER">&gt;25 microM</cons>).</sentence>
</annotation>
<sentence>In comparison to the <cons lex="cyp2c9" sem="G_CYP">CYP2C9.1 variant</cons>, <cons sem="G_MECHANISM">oxidation</cons> of <cons lex="losartan" sem="G_DRUG">losartan</cons> was <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">reduced</cons> in yeast expressing the rare <cons lex="cyp2c9" sem="G_CYP">CYP2C9.2</cons> or <cons lex="cyp2c9" sem="G_CYP">CYP2C9.3 variants</cons>.</sentence>
<sentence>Moreover, the rate of <cons lex="losartan" sem="G_DRUG">losartan</cons> <cons sem="G_MECHANISM">oxidation</cons> was lower in liver microsomes from individuals hetero- or homozygous for the <cons sem="G_CYP">CYP2C9*3 allele</cons>, or homozygous for the <cons sem="G_CYP">CYP2C9*2 allele</cons>.</sentence>
<sentence>The difference between the common and rare <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> variants was mainly explained by a lower <cons sem="G_IVITPARA">V(max)</cons>, both in yeast and human liver microsomes.</sentence>
<sentence>In summary, these in vitro results indicate that <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> is the major human P450 isoenzyme responsible for <cons lex="losartan" sem="G_DRUG">losartan</cons> <cons sem="G_MECHANISM">oxidation</cons> and that the <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> genotype contributes to interindividual differences in <cons lex="losartan" sem="G_DRUG">losartan</cons> <cons sem="G_MECHANISM">oxidation</cons> and activation.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:11407536</bibliomisc>
</articleinfo>
<title>
<sentence>Species difference in stereoselective involvement of <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> in the mono-N-dealkylation of <cons lex="disopyramide" sem="G_DRUG">disopyramide</cons>.</sentence>
</title>
<abstract>
<sentence>1.</sentence>
<sentence>To determine which CYP isoenzyme is involved in the N-dealkylation of <cons lex="disopyramide" sem="G_DRUG">disopyramide (DP)</cons> <cons sem="G_MECHANISM">metabolism</cons> in human and dog, and to determine the stereoselectivity of <cons sem="G_DRUG">DP</cons> <cons sem="G_MECHANISM">metabolism</cons> with human CYP and dog CYP isoenzymes, the following in vitro <cons sem="G_MECHANISM">metabolism</cons> studies of DP were conducted: <cons sem="G_MECHANISM">correlation</cons> between human CYP isoenzyme activities and <cons sem="G_DRUG">DP</cons> <cons sem="G_MECHANISM">metabolism</cons> with human liver microsomes; <cons sem="G_MECHANISM">inhibition</cons> of <cons sem="G_DRUG">DP</cons> <cons sem="G_MECHANISM">metabolism</cons> in human and dog liver microsomes with chemical <cons sem="G_MECHANISM">inhibitors</cons> of CYP isoenzymes; <cons sem="G_MECHANISM">inhibition</cons> of DP <cons sem="G_MECHANISM">metabolism</cons> in human microsomes with human CYP antibodies; <cons sem="G_MECHANISM">inhibition</cons> of DP <cons sem="G_MECHANISM">metabolism</cons> in dog liver microsomes with human and dog CYP antibodies; <cons sem="G_MECHANISM">metabolism</cons> of DP with human (<cons sem="G_CYP">CYP3A4</cons>) and dog (<cons sem="G_CYP">CYP3A12</cons>) cDNA-expressed isoenzymes; determination of <cons sem="G_IVITPARA">Km</cons> and <cons sem="G_IVITPARA">Vmax</cons> of <cons sem="G_DRUG">DP</cons> enantiomers by using cDNA-expressed <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and <cons sem="G_CYP">CYP3A12</cons>.</sentence>
<sentence>2.</sentence>
<annotation sem="INVITROCDDIS" ddi="(mono-N-dealkylated disopyramide, CYP3A4,DEI)">
<sentence>In human liver microsomes, the <cons sem="G_MECHANISM">formation</cons> of the <cons lex="disopyramide" sem="G_DRUG">mono-N-dealkylated disopyramide (MNDP)</cons> metabolite was best <cons sem="G_MECHANISM">correlated</cons> with <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activities.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(ketoconazole, DP,DDI)(troleandomycin, DP,DDI)(Anti-CYP3A4 antibody, DP,DDI)">
<sentence><cons sem="G_DRUG">DP</cons> <cons sem="G_MECHANISM">metabolism</cons> was <cons sem="G_CHANGE"></cons>substantially <cons sem="G_MECHANISM">inhibited</cons> by <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>, <cons lex="troleandomycin" sem="G_DRUG">troleandomycin (TA)</cons>; and human <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> antibody.</sentence>
</annotation>
<sentence><cons sem="G_DRUG">DP</cons> was <cons sem="G_MECHANISM">metabolized</cons> by cDNA-expressed <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> isoenzymes.</sentence>
<sentence>In dog liver microsomes, <cons sem="G_DRUG">DP</cons> <cons sem="G_MECHANISM">metabolism</cons> was <cons sem="G_MECHANISM">inhibited</cons> by <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>, TA and dog anti-<cons sem="G_CYP">CYP3A12</cons>.</sentence>
<sentence><cons sem="G_DRUG">DP</cons> was also <cons sem="G_MECHANISM">metabolized</cons> by cDNA-expressed <cons sem="G_CYP">CYP3A12</cons>.</sentence>
<sentence>3.</sentence>
<sentence><cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and <cons sem="G_CYP">CYP3A12</cons> are the principal isoenzymes involved in <cons sem="G_DRUG">DP</cons> <cons sem="G_MECHANISM">metabolism</cons> in human and dog respectively.</sentence>
<sentence>There was <cons sem="G_NEGATIVEEFFECT">no</cons> stereoselectivity in N-dealkylation of <cons sem="G_DRUG">DP</cons> by human <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
<sentence>However, there was notable stereoselectivity in the N-dealkylation by dog <cons sem="G_CYP">CYP3A12</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:11368292</bibliomisc>
</articleinfo>
<title>
<sentence>Clinical pharmacokinetics of <cons lex="fluvastatin" sem="G_DRUG">fluvastatin</cons>.</sentence>
</title>
<abstract>
<sentence><cons lex="fluvastatin" sem="G_DRUG">Fluvastatin</cons>, the first fully synthetic HMG-CoA reductase <cons sem="G_MECHANISM">inhibitor</cons>, has been shown to <cons sem="G_CHANGE">reduce</cons> <cons lex="cholesterol" sem="G_DRUG">cholesterol</cons> in patients with hyperlipidaemia, to prevent subsequent coronary events in patients with established coronary heart disease, and to alter endothelial function and plaque stability in animal models.</sentence>
<sentence><cons lex="fluvastatin" sem="G_DRUG">Fluvastatin</cons> is relatively hydrophilic, compared with the semisynthetic HMG-CoA reductase <cons sem="G_MECHANISM">inhibitors</cons>, and, therefore, it is extensively absorbed from the gastrointestinal tract.</sentence>
<sentence>After absorption, it is nearly completely extracted and <cons sem="G_MECHANISM">metabolised</cons> in the liver to 2 hydroxylated metabolites and an N-desisopropyl metabolite, which are excreted in the bile.</sentence>
<sentence>Approximately <cons sem="G_NUMBER">95%</cons> of a dose is recovered in the faeces, with <cons sem="G_NUMBER">60%</cons> of a dose recovered as the 3 metabolites.</sentence>
<sentence>The 6-hydroxy and N-desisopropyl <cons lex="fluvastatin" sem="G_DRUG">fluvastatin</cons> metabolites are exclusively generated by cytochrome P450 (CYP) <cons lex="2c9" sem="G_CYP">2C9</cons> and do <cons sem="G_NEGATIVEEFFECT">not</cons> accumulate in the blood.</sentence>
<sentence><cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> and <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> form the 5-hydroxy <cons lex="fluvastatin" sem="G_DRUG">fluvastatin</cons> metabolite.</sentence>
<sentence>Because of its hydrophilic nature and extensive plasma protein binding, <cons lex="fluvastatin" sem="G_DRUG">fluvastatin</cons> has a small volume of distribution with minimal concentrations in extrahepatic tissues.</sentence>
<sentence>The pharmacokinetics of <cons lex="fluvastatin" sem="G_DRUG">fluvastatin</cons> are <cons sem="G_NEGATIVEEFFECT">not</cons> influenced by renal function, due to its extensive <cons sem="G_MECHANISM">metabolism</cons> and biliary excretion; limited data in patients with cirrhosis suggest a <cons sem="G_NUMBER">30%</cons> <cons sem="G_CHANGE">reduction</cons> in <cons sem="G_IVITPARA">oral clearance</cons>.</sentence>
<sentence>Age and gender do <cons sem="G_NEGATIVEEFFECT">not</cons> appear to affect the disposition of <cons lex="fluvastatin" sem="G_DRUG">fluvastatin</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(erythromycin, fluvastatin,NDDI)(ketoconazole, fluvastatin,NDDI)(itraconazole, fluvastatin,NDDI)">
<sentence><cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitors</cons> (<cons sem="G_DRUG">erythromycin</cons>, <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> and <cons sem="G_DRUG">itraconazole</cons>) have <cons sem="G_NEGATIVEEFFECT">no</cons> effect on <cons lex="fluvastatin" sem="G_DRUG">fluvastatin</cons> pharmacokinetics, in contrast to other HMG-CoA reductase <cons sem="G_MECHANISM">inhibitors</cons> which are primarily <cons sem="G_MECHANISM">metabolised</cons> by <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> and are subject to potential drug interactions with <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> <cons sem="G_MECHANISM">inhibitors</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(cholestyramine, fluvastatin,DDI)(gastric acid, fluvastatin,DDI)">
<sentence>Coadministration of <cons lex="fluvastatin" sem="G_DRUG">fluvastatin</cons> with gastrointestinal agents such as <cons lex="cholestyramine" sem="G_DRUG">cholestyramine</cons>, and gastric acid regulating agents (H2 receptor antagonists and proton pump inhibitors), <cons sem="G_CHANGE">significantly</cons> alters <cons lex="fluvastatin" sem="G_DRUG">fluvastatin</cons> disposition by <cons sem="G_CHANGE">decreasing</cons> and <cons sem="G_CHANGE">increasing</cons> <cons sem="G_IVITPARA">bioavailability</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(rifampicin, fluvastatin,DDI)">
<sentence>The nonspecific CYP <cons sem="G_MECHANISM">inducer</cons> <cons sem="G_DRUG">rifampicin (rifampin)</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">increases</cons> <cons lex="fluvastatin" sem="G_DRUG">fluvastatin</cons> <cons sem="G_IVITPARA">oral clearance</cons>.</sentence>
</annotation>
<sentence>In addition to being a <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> <cons sem="G_MECHANISM"></cons>substrate, <cons lex="fluvastatin" sem="G_DRUG">fluvastatin</cons> demonstrates <cons sem="G_MECHANISM">inhibitory</cons> effects on this isoenzyme in vitro and in vivo.</sentence>
<annotation sem="INVITROCDDIS" ddi="(fluvastatin, tolbutamide,DDI)(fluvastatin, diclofenac,DDI)">
<sentence>In human liver microsomes, <cons lex="fluvastatin" sem="G_DRUG">fluvastatin</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_MECHANISM">inhibits</cons> the hydroxylation of 2 <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> substrates, <cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons> and <cons lex="diclofenac" sem="G_DRUG">diclofenac</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(fluvastatin, diclofenac,ADDI)(fluvastatin, tolbutamide,ADDI)(fluvastatin, glibenclamide,ADDI)(fluvastatin, losartan,ADDI)">
<sentence>The <cons sem="G_IVITPARA">oral clearances</cons> of the <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> substrates <cons lex="diclofenac" sem="G_DRUG">diclofenac</cons>, <cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons>, <cons lex="glibenclamide" sem="G_DRUG">glibenclamide (glyburide)</cons> and <cons lex="losartan" sem="G_DRUG">losartan</cons> are <cons sem="G_CHANGE">reduced</cons> by <cons sem="G_NUMBER">15 to 25%</cons> when coadministered with <cons lex="fluvastatin" sem="G_DRUG">fluvastatin</cons>.</sentence>
</annotation>
<sentence>These alterations have <cons sem="G_NEGATIVEEFFECT">not</cons> been shown to be clinically <cons sem="G_CHANGE">significant</cons>.</sentence>
<sentence>There are inadequate data evaluating the potential interaction of <cons lex="fluvastatin" sem="G_DRUG">fluvastatin</cons> with <cons lex="warfarin" sem="G_DRUG">warfarin</cons> and <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons>, 2 <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> substrates with a narrow therapeutic index, and caution is recommended when using <cons lex="fluvastatin" sem="G_DRUG">fluvastatin</cons> with these agents.</sentence>
<sentence><cons lex="fluvastatin" sem="G_DRUG">Fluvastatin</cons> does <cons sem="G_NEGATIVEEFFECT">not</cons> appear to have a <cons sem="G_CHANGE">significant</cons> effect on other CYP isoenzymes or P-glycoprotein-mediated transport in vivo.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:11353760</bibliomisc>
</articleinfo>
<title>
<sentence>Evaluation of <cons lex="methoxsalen" sem="G_DRUG">methoxsalen</cons>, <cons lex="tranylcypromine" sem="G_DRUG">tranylcypromine</cons>, and <cons sem="G_DRUG">tryptamine</cons> as specific and selective <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons> <cons sem="G_MECHANISM">inhibitors</cons> in vitro.</sentence>
</title>
<abstract>
<sentence><cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons> is the principle enzyme <cons sem="G_MECHANISM">metabolizing</cons> <cons lex="nicotine" sem="G_DRUG">nicotine</cons> to its inactive metabolite cotinine.</sentence>
<sentence>In this study, the selective probe reactions for each major cytochrome P450 (P450) were used to evaluate the specificity and selectivity of the <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons> <cons sem="G_MECHANISM">inhibitors</cons> <cons lex="methoxsalen" sem="G_DRUG">methoxsalen</cons>, <cons lex="tranylcypromine" sem="G_DRUG">tranylcypromine</cons>, and tryptamine in cDNA-expressing and human liver microsomes.</sentence>
<sentence><cons lex="phenacetin" sem="G_DRUG">Phenacetin</cons> O-deethylation (<cons sem="G_CYP">CYP1A2</cons>), <cons sem="G_DRUG">coumarin</cons> 7-hydroxylation (<cons sem="G_CYP">CYP2A6</cons>), <cons lex="diclofenac" sem="G_DRUG">diclofenac</cons> 4'-hydroxylation (<cons sem="G_CYP">CYP2C9</cons>), <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> 5-hydroxylation (<cons sem="G_CYP">CYP2C19</cons>), <cons lex="dextromethorphan" sem="G_DRUG">dextromethorphan</cons> O-demethylation (<cons sem="G_CYP">CYP2D6</cons>), 7-ethoxy-4-trifluoromethylcoumarin deethylation (<cons sem="G_CYP">CYP2B6</cons>), p-nitrophenol hydroxylation (<cons sem="G_CYP">CYP2E1</cons>), and <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> sulfonation (<cons sem="G_CYP">CYP3A4</cons>) were used as index reactions.</sentence>
<annotation sem="INVITROCDDIS" ddi="(tranylcypromine, CYP2A6,DEI)(methoxsalen, CYP2A6,DEI)(tryptamine, CYP2A6,DEI)">
   <sentence>Apparent <cons sem="G_IVITPARA">K(i)</cons> values for <cons sem="G_MECHANISM">inhibition</cons> of P450s' (<cons sem="G_CYP">1A2</cons>, <cons lex="2a6" sem="G_CYP">2A6</cons>, <cons lex="2b6" sem="G_CYP">2B6</cons>, <cons lex="2c9" sem="G_CYP">2C9</cons>, <cons lex="2c19" sem="G_CYP">2C19</cons>, <cons lex="2d6" sem="G_CYP">2D6</cons>, <cons lex="2e1" sem="G_CYP">2E1</cons>, and <cons sem="G_CYP">3A4</cons>) activities showed that <cons lex="tranylcypromine" sem="G_DRUG">tranylcypromine</cons>, <cons lex="methoxsalen" sem="G_DRUG">methoxsalen</cons>, and <cons sem="G_DRUG">tryptamine</cons> have high specificity and relative selectivity for <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(tranylcypromine, CYP2A6,DEI)">
<sentence>In cDNA-expressing microsomes, <cons lex="tranylcypromine" sem="G_DRUG">tranylcypromine</cons> <cons sem="G_MECHANISM">inhibited</cons> <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons> (<cons sem="G_IVITPARA">K(i)</cons> = <cons sem="G_NUMBER">0.08 microM</cons>) with about <cons sem="G_NUMBER">60- to 5000-fold</cons> <cons sem="G_CHANGE">greater</cons> potency relative to other P450s.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Methoxsalen, CYP2A6,DEI)(Methoxsalen, CYP1A2,DEI)">
<sentence><cons lex="methoxsalen" sem="G_DRUG">Methoxsalen</cons> <cons sem="G_MECHANISM">inhibited</cons> <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons> (<cons sem="G_IVITPARA">K(i)</cons> = <cons sem="G_NUMBER">0.8 microM</cons>) with about <cons sem="G_NUMBER">3.5- 94-fold</cons> <cons sem="G_CHANGE">greater</cons> potency than other P450s, except for <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> (<cons sem="G_IVITPARA">K(i)</cons> = <cons sem="G_NUMBER">0.2 microM</cons>).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Tryptamine, CYP2A6,DEI)">
<sentence>Tryptamine <cons sem="G_MECHANISM">inhibited</cons> <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons> (<cons sem="G_IVITPARA">K(i)</cons> = <cons sem="G_NUMBER">1.7 microM</cons>) with about <cons sem="G_NUMBER">6.5- 213-fold</cons> <cons sem="G_CHANGE">greater</cons> potency relative to other P450s, except for <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> (<cons sem="G_IVITPARA">K(i)</cons> = <cons sem="G_NUMBER">1.7 microM</cons>).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(methoxsalen, human liver microsomes,DEI)(tranylcypromine, human liver microsomes,DEI)">
<sentence>Similar results were also obtained with <cons lex="methoxsalen" sem="G_DRUG">methoxsalen</cons> and <cons lex="tranylcypromine" sem="G_DRUG">tranylcypromine</cons> in human liver microsomes.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(R-(+)-Tranylcypromine, nicotine,DDI)((+/-)-tranylcypromine, nicotine,DDI)(S-(-)-tranylcypromine, nicotine,DDI)">
<sentence>R-(+)-<cons lex="tranylcypromine" sem="G_DRUG">Tranylcypromine</cons>, (+/-)-<cons lex="tranylcypromine" sem="G_DRUG">tranylcypromine</cons>, and S-(-)-<cons lex="tranylcypromine" sem="G_DRUG">tranylcypromine</cons> competitively <cons sem="G_MECHANISM">inhibited</cons> <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons>-mediated <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="nicotine" sem="G_DRUG">nicotine</cons> with apparent <cons sem="G_IVITPARA">K(i)</cons> values of <cons sem="G_NUMBER">0.05, 0.08, and 2.0 microM</cons>, respectively.</sentence>
</annotation>
<sentence><cons lex="tranylcypromine" sem="G_DRUG">Tranylcypromine</cons>  [particularly R-(+) isomer], tryptamine, and <cons lex="methoxsalen" sem="G_DRUG">methoxsalen</cons> are specific and relatively selective for <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons> and <cons sem="G_CHANGE">may</cons> be useful in vivo to <cons sem="G_CHANGE">increase</cons> smoking by inhibiting <cons lex="nicotine" sem="G_DRUG">nicotine</cons> <cons sem="G_MECHANISM">metabolism</cons> with a low risk of metabolic drug interactions.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:11353758</bibliomisc>
</articleinfo>
<title>
<sentence>Involvement of <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> in n-demethylation of <cons lex="ketamine" sem="G_DRUG">ketamine</cons> in human liver microsomes.</sentence>
</title>
<abstract>
<sentence><cons lex="ketamine" sem="G_DRUG">Ketamine</cons> is <cons sem="G_MECHANISM">metabolized</cons> by cytochrome P450 (CYP) leading to production of pharmacologically active products and contributing to drug excretion.</sentence>
<sentence>We identified the CYP enzymes involved in the N-demethylation of <cons lex="ketamine" sem="G_DRUG">ketamine</cons> enantiomers using pooled human liver microsomes and microsomes from human B-lymphoblastoid cells that expressed CYP enzymes.</sentence>
<sentence>The kinetic data in human liver microsomes for the (R)- and (S)-<cons lex="ketamine" sem="G_DRUG">ketamine</cons> N-demethylase activities could be analyzed as two-enzyme systems.</sentence>
<sentence>The <cons sem="G_IVITPARA"> <cons sem="G_IVITPARA">K(m)</cons></cons> values were <cons sem="G_NUMBER">31 and 496 microM</cons> for (R)-<cons lex="ketamine" sem="G_DRUG">ketamine</cons>, and <cons sem="G_NUMBER">24 and 444 microM</cons> for (S)-<cons lex="ketamine" sem="G_DRUG">ketamine</cons>.</sentence>
<sentence>Among the 12 cDNA-expressed CYP enzymes examined, <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons>, <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> showed high activities for the N-demethylation of both enantiomers at the substrate concentration of <cons sem="G_NUMBER">1 mM</cons>.</sentence>
<sentence><cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> had the lowest <cons sem="G_IVITPARA"> <cons sem="G_IVITPARA">K(m)</cons></cons> value for the N-demethylation of (R)- and (S)-<cons lex="ketamine" sem="G_DRUG">ketamine</cons> (<cons sem="G_NUMBER">74 and 44 microM</cons>, respectively).</sentence>
<sentence>Also, the <cons sem="G_IVITPARA">intrinsic clearance (CL(int): V(max)/<cons sem="G_IVITPARA">K(m)</cons>)</cons> of <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> for the N-demethylation of both enantiomers were 7 to 13 times higher than those of <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Orphenadrine, Ketamine N-demethylase,DDI)(sulfaphenazole, Ketamine N-demethylase,DDI)(cyclosporin A, Ketamine N-demethylase,NDDI)">
<sentence><cons lex="orphenadrine" sem="G_DRUG">Orphenadrine</cons> (<cons sem="G_CYP">CYP2B6</cons> <cons sem="G_MECHANISM">inhibitor</cons>, <cons sem="G_NUMBER">500 microM</cons>) and <cons sem="G_DRUG">sulfaphenazole</cons> (<cons sem="G_CYP">CYP2C9</cons> <cons sem="G_MECHANISM">inhibitor</cons>, <cons sem="G_NUMBER">100 microM</cons>) <cons sem="G_MECHANISM">inhibited</cons> the N-demethylase activities for both enantiomers (<cons sem="G_NUMBER">5 microM</cons>) in human liver microsomes by <cons sem="G_NUMBER">60 to 70%</cons>, whereas <cons sem="G_DRUG">cyclosporin A</cons> (<cons sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitor</cons>, <cons sem="G_NUMBER">100 microM</cons>) failed to <cons sem="G_MECHANISM">inhibit</cons> these activities.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(anti-CYP2B6 antibody, Ketamine N-demethylase,DDI)(anti-CYP2C antibody, Ketamine N-demethylase,NDDI)(anti-CYP3A4 antibody, Ketamine N-demethylase,NDDI)">
<sentence>In addition, the anti-<cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> antibody <cons sem="G_MECHANISM">inhibited</cons> these activities in human liver microsomes by <cons sem="G_NUMBER">80%</cons>, whereas anti-<cons sem="G_CYP">CYP2C</cons> antibody and anti-<cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> antibody failed to <cons sem="G_MECHANISM">inhibit</cons> these activities.</sentence>
</annotation>
<sentence>These results suggest that the high affinity/low capacity enzyme in human liver microsomes is mediated by <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons>, and the low affinity/high capacity enzyme is mediated by <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
<sentence><cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> mainly mediates the N-demethylation of (R)- and (S)-<cons lex="ketamine" sem="G_DRUG">ketamine</cons> in human liver microsomes at therapeutic concentrations (<cons sem="G_NUMBER">5 microM</cons>).</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:11334262</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem="G_MECHANISM">Inhibition</cons> of drug <cons sem="G_MECHANISM">metabolism</cons> in human liver microsomes by <cons lex="nizatidine" sem="G_DRUG">nizatidine</cons>, <cons lex="cimetidine" sem="G_DRUG">cimetidine</cons> and <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons>.</sentence>
</title>
<abstract>
<sentence>1.</sentence>
<sentence>The <cons sem="G_MECHANISM">inhibitory</cons> effects of <cons lex="cimetidine" sem="G_DRUG">cimetidine</cons>, <cons lex="nizatidine" sem="G_DRUG">nizatidine</cons> and <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> on the metabolic activity of <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, <cons lex="2c19" sem="G_CYP">2C19</cons>, <cons lex="2d6" sem="G_CYP">2D6</cons> and <cons lex="3a" sem="G_CYP">3A</cons> were investigated in human liver microsomes.</sentence>
<annotation sem="INVITROCDDIS" ddi="(cimetidine, CYP2C9,DEI)(cimetidine, CYP2C19,DEI)(cimetidine, CYP2D6,DEI)(cimetidine, CYP3A,DEI)(omeprazole, CYP2C9,DEI)(omeprazole, CYP2C19,DEI)(omeprazole, CYP2D6,DEI)(omeprazole, CYP3A,DEI)(omeprazole, S-mephenytoin,DDI)">
<sentence>Both <cons lex="cimetidine" sem="G_DRUG">cimetidine</cons> and <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> <cons sem="G_MECHANISM">inhibited</cons> each of the CYP subfamily enzymes; in particular, <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> extensively <cons sem="G_MECHANISM">inhibited</cons> the hydroxylation of S-<cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons> (<cons sem="G_CYP">CYP2C19</cons>, <cons sem="G_IVITPARA">Ki</cons> = <cons sem="G_NUMBER">7.1 microM</cons>).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Nizatidine, CYP2C9,NDEI)(Nizatidine, CYP2C19,NDEI)(Nizatidine, CYP2D6,NDEI)(Nizatidine, CYP3A,NDEI)">
<sentence><cons lex="nizatidine" sem="G_DRUG">Nizatidine</cons> exhibited <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem="G_MECHANISM">inhibition</cons> of any of the CYP isoforms examined.</sentence>
</annotation>
<sentence>2.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Cimetidine, tolbutamide,DDI)(Cimetidine, diclofenac,NDDI)(omeprazole, diclofenac,DDI)(omeprazole, tolbutamide,NDDI)">
<sentence><cons lex="cimetidine" sem="G_DRUG">Cimetidine</cons> <cons sem="G_MECHANISM">inhibited</cons> the hydroxylation of <cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons> but <cons sem="G_NEGATIVEEFFECT">not</cons> of <cons lex="diclofenac" sem="G_DRUG">diclofenac</cons>, whereas <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> <cons sem="G_MECHANISM">inhibited</cons> the hydroxylation of <cons lex="diclofenac" sem="G_DRUG">diclofenac</cons> but <cons sem="G_NEGATIVEEFFECT">not</cons> that of <cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons>.</sentence>
</annotation>
<sentence>The ability to <cons sem="G_MECHANISM">inhibit</cons> <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> varied with incubation time, as measured by the metabolic rate constant for the substrates.</sentence>
<sentence>Therefore, suitable substrates and incubation times must be selected in <cons sem="G_MECHANISM">inhibition</cons> studies examining metabolic <cons sem="G_IVITPARA">clearance</cons> and the mechanism of <cons sem="G_MECHANISM">inhibition</cons> of these drugs.</sentence>
<sentence>3.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Nizatidine, cisapride,NDDI)(Nizatidine, glibenclamide,NDDI)(Nizatidine, benidipine,NDDI)(Nizatidine, simvastatin,NDDI)">
<sentence><cons lex="nizatidine" sem="G_DRUG">Nizatidine</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_MECHANISM">inhibit</cons> the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="cisapride" sem="G_DRUG">cisapride</cons>, <cons lex="glibenclamide" sem="G_DRUG">glibenclamide</cons>, <cons lex="benidipine" sem="G_DRUG">benidipine</cons> and <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Omeprazole, cisapride,DDI)(Omeprazole, glibenclamide,ADDI)(Omeprazole, benidipine,DDI)(cimetidine, glibenclamide,ADDI)">
<sentence><cons lex="omeprazole" sem="G_DRUG">Omeprazole</cons> <cons sem="G_MECHANISM">inhibited</cons> the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="cisapride" sem="G_DRUG">cisapride</cons> (<cons sem="G_IVITPARA">Ki</cons> = <cons sem="G_NUMBER">0.4 microM</cons>), <cons lex="glibenclamide" sem="G_DRUG">glibenclamide</cons> (<cons sem="G_NUMBER">11.7 microM</cons>) and <cons lex="benidipine" sem="G_DRUG">benidipine</cons> (<cons sem="G_NUMBER">6.5 microM</cons>), whereas <cons lex="cimetidine" sem="G_DRUG">cimetidine</cons> <cons sem="G_MECHANISM">inhibited</cons> the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="glibenclamide" sem="G_DRUG">glibenclamide</cons> (<cons sem="G_NUMBER">11.6 microM</cons>).</sentence>
</annotation>
<sentence>To avoid drug-drug interactions, care needs to be taken to select suitable medicines for co-administration with anti-ulcer drugs.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9864282</bibliomisc>
</articleinfo>
<title>
<sentence>The role of <cons sem="G_CYP">CYP2C</cons> in the in vitro bioactivation of the contraceptive steroid <cons lex="desogestrel" sem="G_DRUG">desogestrel</cons>.</sentence>
</title>
<abstract>
<sentence><cons lex="desogestrel" sem="G_DRUG">Desogestrel</cons> is a 3-deoxo progestogenic steroid that requires bioactivation to 3-ketodesogestrel.</sentence>
<sentence>In these studies we have attempted to define the pathway of 3-ketodesogestrel <cons sem="G_MECHANISM">formation</cons> and characterise the enzymes responsible for this biotransformation in vitro.</sentence>
<sentence>Initial studies using deuterated <cons lex="desogestrel" sem="G_DRUG">desogestrel</cons> confirmed that <cons lex="desogestrel" sem="G_DRUG">desogestrel</cons> is <cons sem="G_MECHANISM">metabolised</cons> by human liver microsomes via 3alpha-hydroxy and 3beta-hydroxydesogestrel to 3-ketodesogestrel.</sentence>
<sentence>Metabolites were analysed by radiometric high-performance liquid chromatography and were identified by liquid chromatography-mass spectrometry and by cochromatography with authentic standards.</sentence>
<sentence><cons lex="desogestrel" sem="G_DRUG">Desogestrel</cons> was <cons sem="G_MECHANISM">metabolised</cons> by microsomes from lymphoblasts containing cDNA-expressed <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> and <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> to 3alpha-hydroxydesogestrel with small amounts of 3beta-hydroxydesogestrel also being observed.</sentence>
<sentence>The <cons sem="G_IVITPARA">Km</cons> value for 3alpha-hydroxylation by <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> cell line microsomes was <cons sem="G_NUMBER">6.5 microM</cons> and the corresponding <cons sem="G_IVITPARA">Vmax</cons> value was <cons sem="G_NUMBER">1269 pmole. mg-1.min-1.</cons></sentence>
<annotation sem="INVITROCDDIS" ddi="(Sulfaphenazole, 3alpha-hydroxydesogestrel,DDI)">
<sentence><cons sem="G_DRUG">Sulfaphenazole</cons> potently <cons sem="G_MECHANISM">inhibited</cons> 3alpha-hydroxydesogestrel <cons sem="G_MECHANISM">formation</cons> by <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> microsomes with a <cons sem="G_IVITPARA">Ki</cons> value of <cons sem="G_NUMBER">0.91 microM</cons>.</sentence>
</annotation>
<sentence>There was a <cons sem="G_CHANGE">significant</cons> negative <cons sem="G_MECHANISM">correlation</cons> between 3-ketodesogestrel and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> content/activity in a panel of human livers suggesting that the further <cons sem="G_MECHANISM">metabolism</cons> of 3-ketodesogestrel is mediated by <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Sulfaphenazole, 3alpha-hydroxydesogestrel,DDI)(Sulfaphenazole, 3-ketodesogestrel,DDI)">
<sentence><cons sem="G_DRUG">Sulfaphenazole</cons> partially <cons sem="G_MECHANISM">inhibited</cons> 3alpha-hydroxydesogestrel and 3-ketodesogestrel <cons sem="G_MECHANISM">formation</cons> in human liver microsomes indicating a possible in vivo role for <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Sulfaphenazole + S-mephenytoin, 3alpha-hydroxydesogestrel,DDI)">
<sentence>In addition, when sulfaphenazole was combined with S-<cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons>, further <cons sem="G_MECHANISM">inhibition</cons> of 3alpha-hydroxydesogestrel <cons sem="G_MECHANISM">formation</cons> was observed suggesting a possible role for <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>.</sentence>
</annotation>
<sentence>This was confirmed in incubations with <cons sem="G_MECHANISM">inhibitory</cons> antibodies.</sentence>
<sentence>Whereas an anti-<cons sem="G_CYP">CYP2C9/2C19</cons> antibody completely abolished <cons lex="desogestrel" sem="G_DRUG">desogestrel</cons> <cons sem="G_MECHANISM">metabolism</cons>, anti-<cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and anti-<cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons> were <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_MECHANISM">inhibitory</cons>.</sentence>
<sentence>We conclude that <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> and possibly <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> and important isoforms catalysing the initial hydroxylation of <cons lex="desogestrel" sem="G_DRUG">desogestrel</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9825830</bibliomisc>
</articleinfo>
<title>
<sentence>In-vitro characterization of the cytochrome P450 isoenzymes involved in the back <cons sem="G_MECHANISM">oxidation</cons> and N-dealkylation of <cons sem="G_CHANGE">reduced</cons> <cons lex="haloperidol" sem="G_DRUG">haloperidol</cons>.</sentence>
</title>
<abstract>
<sentence>In-vitro studies were performed using human liver microsomes and c-DNA-expressed human P450 isoforms to identify the cytochrome P450 isoenzyme(s) involved in the back <cons sem="G_MECHANISM">oxidation</cons> and N-dealkylation of <cons sem="G_CHANGE">reduced</cons> <cons lex="haloperidol" sem="G_DRUG">haloperidol</cons>.</sentence>
<sentence>Back <cons sem="G_MECHANISM">oxidation</cons> and N-dealkylation of <cons sem="G_CHANGE">reduced</cons> <cons lex="haloperidol" sem="G_DRUG">haloperidol</cons> were assessed by measuring the <cons sem="G_MECHANISM">formation</cons> of <cons lex="haloperidol" sem="G_DRUG">haloperidol</cons> and 4-(4-chlorophenyl)-4-hydroxypiperidine (<cons sem="G_DRUG">CPHP</cons>), respectively.</sentence>
<sentence>The <cons lex="haloperidol" sem="G_DRUG">haloperidol</cons> and <cons sem="G_DRUG">CPHP</cons> <cons sem="G_MECHANISM">formation</cons> rates as a function of substrate concentration, measured in three livers, followed monophasic enzyme kinetics.</sentence>
<sentence>For <cons lex="haloperidol" sem="G_DRUG">haloperidol</cons> <cons sem="G_MECHANISM">formation</cons> <cons sem="G_IVITPARA">Km</cons> values ranged from <cons sem="G_NUMBER">51-59 microM</cons>, and <cons sem="G_IVITPARA">Vmax</cons> values from <cons sem="G_NUMBER">190-334 pmol mg(-1) min(-1)</cons>; for <cons sem="G_DRUG">CPHP</cons> <cons sem="G_MECHANISM">formation</cons> <cons sem="G_IVITPARA">Km</cons> values were <cons sem="G_NUMBER">44-49 microM</cons>, and <cons sem="G_IVITPARA">Vmax</cons> values <cons sem="G_NUMBER">74-110 pmol mg(-1) min(-1)</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Haloperidol, dextromethorphan N-demethylase,DDI)(CPHP, dextromethorphan N-demethylase,DDI)">
<sentence><cons lex="haloperidol" sem="G_DRUG">Haloperidol</cons> and <cons sem="G_DRUG">CPHP</cons> <cons sem="G_MECHANISM">formation</cons> rates in the nine liver preparations were <cons sem="G_CHANGE">significantly</cons> <cons sem="G_MECHANISM">correlated</cons> with <cons lex="dextromethorphan" sem="G_DRUG">dextromethorphan</cons> N-demethylase activity (a marker of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activity), but <cons sem="G_NEGATIVEEFFECT">not</cons> with the <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>, <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> and <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> activity.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Ketoconazole, haloperidol,DDI)(troleandomycin, haloperidol,DDI)(Ketoconazole, CPHP,DDI)(troleandomycin, CPHP,DDI)">
<sentence><cons lex="ketoconazole" sem="G_DRUG">Ketoconazole</cons> and <cons lex="troleandomycin" sem="G_DRUG">troleandomycin</cons>, <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, <cons sem="G_MECHANISM">inhibited</cons> competitively both <cons lex="haloperidol" sem="G_DRUG">haloperidol</cons> and <cons sem="G_DRUG">CPHP</cons> <cons sem="G_MECHANISM">formation</cons>, with a <cons sem="G_IVITPARA">Ki</cons> value lower than <cons sem="G_NUMBER">0.2 microM</cons> for <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> and lower than <cons sem="G_NUMBER">0.3 microM</cons> for <cons lex="troleandomycin" sem="G_DRUG">troleandomycin</cons>.</sentence>
</annotation>
<annotation sem="INVITROVDDIS" ddi="(Sulphaphenazole, haloperidol,ADDI)(furafylline, haloperidol,ADDI)(quinidine, haloperidol,ADDI)(paroxetine, haloperidol,ADDI)">
<sentence><cons sem="G_DRUG">Sulphaphenazole</cons> (<cons sem="G_CYP">CYP2C9</cons>), <cons lex="furafylline" sem="G_DRUG">furafylline</cons> (<cons sem="G_CYP">CYP1A2</cons>) and <cons lex="quinidine" sem="G_DRUG">quinidine</cons> and <cons lex="paroxetine" sem="G_DRUG">paroxetine</cons> (<cons sem="G_CYP">CYP2D6</cons>) gave only <cons sem="G_CHANGE">little</cons> <cons sem="G_MECHANISM">inhibition</cons> (<cons sem="G_IVITPARA">IC50</cons> <cons sem="G_NUMBER">&gt; 60 microM</cons>).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(alpha-naphthoflavone, haloperidol,DDI)(alpha-naphthoflavone, CPHP,DDI)">
<sentence><cons sem="G_DRUG">CPHP</cons> and <cons lex="haloperidol" sem="G_DRUG">haloperidol</cons> <cons sem="G_MECHANISM">formation</cons> were, moreover, enhanced by alpha-naphthoflavone, an effect known for <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> mediated reactions.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Anti-CYP3A4 antibodies, haloperidol,DDI)(Anti-CYP3A4 antibodies, CPHP,DDI)(Anti-CYP2D6 antibodies, haloperidol,NDDI)(Anti-CYP2D6 antibodies, CPHP,NDDI)">
<sentence>Anti-<cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> antibodies strongly <cons sem="G_MECHANISM">inhibited</cons> <cons lex="haloperidol" sem="G_DRUG">haloperidol</cons> and <cons sem="G_DRUG">CPHP</cons> <cons sem="G_MECHANISM">formation</cons>, whereas <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> antibodies did <cons sem="G_NEGATIVEEFFECT">not</cons>.</sentence>
</annotation>
<sentence>Among the recombinant human CYP isoforms tested, <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> exhibited the highest activity with respect to <cons lex="haloperidol" sem="G_DRUG">haloperidol</cons> and <cons sem="G_DRUG">CPHP</cons> <cons sem="G_MECHANISM">formation</cons> rates, with <cons sem="G_NEGATIVEEFFECT">no</cons> detectable effect of <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> and <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>.</sentence>
<sentence>These results strongly suggest that back <cons sem="G_MECHANISM">oxidation</cons> and N-dealkylation of <cons sem="G_CHANGE">reduced</cons> <cons lex="haloperidol" sem="G_DRUG">haloperidol</cons> in human liver microsomal preparations are mediated by <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9765359</bibliomisc>
</articleinfo>
<title>
<sentence>Microsomal <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="delavirdine" sem="G_DRUG">delavirdine</cons>: evidence for mechanism-based <cons sem="G_MECHANISM">inactivation</cons> of human cytochrome P450 <cons lex="3a" sem="G_CYP">3A</cons>.</sentence>
</title>
<abstract>
<sentence>Administration of <cons lex="delavirdine" sem="G_DRUG">delavirdine</cons>, an HIV-1 reverse transcriptase <cons sem="G_MECHANISM">inhibitor</cons>, to rats or monkeys resulted in apparent loss of hepatic microsomal <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> and <cons lex="delavirdine" sem="G_DRUG">delavirdine</cons> desalkylation activity.</sentence>
<annotation sem="INVITROCDDIS" ddi="(CYP3A, desalkyl delavirdine,DEI)(CYP3A, 6'-hydroxy delavirdine,DEI)(CYP2D6, desalkyl delavirdine,ADEI)">
<sentence>Human <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> catalyzes the <cons sem="G_MECHANISM">formation</cons> of desalkyl <cons lex="delavirdine" sem="G_DRUG">delavirdine</cons> and 6'-hydroxy <cons lex="delavirdine" sem="G_DRUG">delavirdine</cons>, an unstable metabolite, while <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> catalyzes only desalkyl <cons lex="delavirdine" sem="G_DRUG">delavirdine</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(CYP2D6, desalkyl delavirdine,DEI)">
<sentence><cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> <cons sem="G_MECHANISM">catalyzed</cons> desalkyl <cons lex="delavirdine" sem="G_DRUG">delavirdine</cons> <cons sem="G_MECHANISM">formation</cons> was linear with time (up to 30 min) but when <cons sem="G_MECHANISM">catalyzed</cons> by cDNA expressed <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> or human liver microsomes the reaction rate declined progressively with time.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(delavirdine, triazolam 1'-hydroxylation,DDI)">
<sentence>Coincubation with <cons lex="triazolam" sem="G_DRUG">triazolam</cons> showed that <cons lex="delavirdine" sem="G_DRUG">delavirdine</cons> caused a time- and NADPH-dependent loss of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activity in human liver microsomes as measured by <cons lex="triazolam" sem="G_DRUG">triazolam</cons> 1'-hydroxylation.</sentence>
</annotation>
<sentence>The catalytic activity loss was saturable and was characterized by a <cons sem="G_IVITPARA">Ki</cons> of <cons sem="G_NUMBER">21.6 +/- 8.9 microM</cons> and a <cons sem="G_IVITPARA">kinact</cons> of <cons sem="G_NUMBER">0.59 +/- 0.08 min-1</cons>.</sentence>
<sentence>An apparent partition ratio of 41 was determined with cDNA expressed <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, based on the substrate depletion method.</sentence>
<sentence>Incubation of  [14C]delavirdine with microsomes from several species resulted in irreversible association with an approximately 50 kDa protein, as demonstrated by SDS-PAGE/autoradiography.</sentence>
<sentence>Binding to the protein was NADPH dependent, glutathione insensitive, proportional to the level of <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> expression and was <cons sem="G_MECHANISM">inhibited</cons> by <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>, a specific <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> <cons sem="G_MECHANISM">inhibitor</cons>.</sentence>
<sentence>NADPH-dependent irreversible binding to human and rat total microsomal protein was demonstrated following exhaustive extraction of microsomal protein.</sentence>
<annotation sem="INVITROCDDIS" ddi="(ketoconazole, glutathione,DDI)">
<sentence>Binding was <cons sem="G_CHANGE">decreased</cons> in the presence of glutathione and appeared to be related to expression level of <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>.</sentence>
</annotation>
<sentence>These results suggest that <cons lex="delavirdine" sem="G_DRUG">delavirdine</cons> can <cons sem="G_MECHANISM">inactivate</cons> <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> and has the potential to slow the <cons sem="G_MECHANISM">metabolism</cons> of coadministered <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> substrates.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9758674</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem="G_MECHANISM">Inhibition</cons> of <cons lex="desipramine" sem="G_DRUG">desipramine</cons> hydroxylation (Cytochrome <cons sem="G_CYP">P450-2D6</cons>) in vitro by <cons lex="quinidine" sem="G_DRUG">quinidine</cons> and by viral protease <cons sem="G_MECHANISM">inhibitors</cons>: relation to drug interactions in vivo.</sentence>
</title>
<abstract>
<sentence>Pharmacokinetic drug interactions with viral protease <cons sem="G_MECHANISM">inhibitors</cons> are of potential clinical importance.</sentence>
<sentence>An in vitro model was applied to the quantitative identification of possible interactions of protease <cons sem="G_MECHANISM">inhibitors</cons> with substrates of cytochrome P450-<cons lex="2d6" sem="G_CYP">2D6</cons>.</sentence>
<sentence>Biotransformation of <cons lex="desipramine" sem="G_DRUG">desipramine (DMI)</cons> to <cons sem="G_DRUG">hydroxydesipramine (OH-DMI)</cons>, an index reaction used to profile activity of human cytochrome P450-<cons lex="2d6" sem="G_CYP">2D6</cons>, was studied in vitro using human liver microsomes.</sentence>
<sentence><cons lex="quinidine" sem="G_DRUG">Quinidine</cons> and four viral protease <cons sem="G_MECHANISM">inhibitors</cons> currently used to treat human immunodeficiency virus infection were tested as chemical <cons sem="G_MECHANISM">inhibitors</cons> in this system.</sentence>
<sentence><cons sem="G_MECHANISM">Formation</cons> of <cons sem="G_DRUG">OH-DMI</cons> from <cons sem="G_DRUG">DMI</cons> was consistent with Michaelis-Menten kinetics, having a mean <cons sem="G_IVITPARA">Km</cons> value of <cons sem="G_NUMBER">11.7 microM (range: 9.9-15.3 microM)</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Quinidine, OH-DMI,DDI)">
<sentence><cons lex="quinidine" sem="G_DRUG">Quinidine</cons>, a highly potent and relatively selective <cons sem="G_MECHANISM">inhibitor</cons> of P450-<cons lex="2d6" sem="G_CYP">2D6</cons>, strongly <cons sem="G_MECHANISM">inhibited</cons> OH-DMI <cons sem="G_MECHANISM">formation</cons> with an apparent competitive mechanism, having a mean <cons sem="G_MECHANISM">inhibition</cons> constant of <cons sem="G_NUMBER">0.16 microM (range: 0.13-0.18 microM)</cons>.</sentence>
</annotation>
<annotation sem="INVITROVDDIS" ddi="(ritonavir, OH-DMI,DDI)(indinavir, OH-DMI,DDI)(saquinavir, OH-DMI,DDI)(nelfinavir, OH-DMI,DDI)">
<sentence>All four protease <cons sem="G_MECHANISM">inhibitors</cons> impaired OH-DMI formation; the pattern was consistent with a mixed competitive-noncompetitive mechanism.</sentence>
</annotation>
<annotation sem="INVITROVDDIS" ddi="(ritonavir, OH-DMI,DDI)(indinavir, OH-DMI,ADDI)(saquinavir, OH-DMI,ADDI)(nelfinavir, OH-DMI,ADDI)">
<sentence>Mean <cons sem="G_MECHANISM">inhibition</cons> constants (small numbers indicating <cons sem="G_CHANGE">greater</cons> <cons sem="G_MECHANISM">inhibiting</cons> potency) were as follows: <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons>, <cons sem="G_NUMBER">4.8 microM</cons>; <cons lex="indinavir" sem="G_DRUG">indinavir</cons>, <cons sem="G_NUMBER">15.6 microM</cons>; <cons lex="saquinavir" sem="G_DRUG">saquinavir</cons>, <cons sem="G_NUMBER">24.0 microM</cons>; <cons lex="nelfinavir" sem="G_DRUG">nelfinavir</cons>, <cons sem="G_NUMBER">51.9 microM</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(ritonavir, OH-DMI,DDI)">
<sentence>In a clinical pharmacokinetic study, coadministration of <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> with <cons sem="G_DRUG">DMI</cons> <cons sem="G_MECHANISM">inhibited</cons> <cons sem="G_DRUG">DMI</cons> <cons sem="G_IVITPARA">clearance</cons> by an average of <cons sem="G_NUMBER">59%</cons>.</sentence>
</annotation>
<sentence>The in vitro findings, together with observed plasma <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> concentrations, provided a reasonable quantitative forecast of this interaction, whereas estimated unbound plasma or intrahepatic <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> concentrations yielded poor quantitative forecasts.</sentence>
<sentence>Thus the in vitro model correctly identifies <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> as a potent and clinically important <cons sem="G_MECHANISM">inhibitor</cons> of human P450-<cons lex="2d6" sem="G_CYP">2D6</cons>.</sentence>
<sentence>Other protease <cons sem="G_MECHANISM">inhibitors</cons> <cons sem="G_CHANGE">may</cons> also <cons sem="G_MECHANISM">inhibit</cons> <cons lex="2d6" sem="G_CYP">2D6</cons> activity in humans, but with lower potency than <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9741959</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem="G_DRUG">3,3'-diindolylmethane</cons> induces <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> in cultured precision-cut human liver slices.</sentence>
</title>
<abstract>
<sentence>1.</sentence>
<sentence>The effect of <cons sem="G_DRUG">3,3'-diindolylmethane</cons> (<cons sem="G_DRUG">DIM</cons>), an <cons lex="indole" sem="G_DRUG">indole</cons> derivative derived from cruciferous vegetables, on cytochrome P450 (CYP) isoforms in the CYP1A and <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> subfamilies has been studied in 72-h cultured human liver slices.</sentence>
<sentence>2.</sentence>
<sentence>In cultured human liver slices <cons sem="G_NUMBER">50 microM</cons> <cons sem="G_DRUG">DIM</cons> <cons sem="G_MECHANISM">induced</cons> 7-ethoxyresorufin O-deethylase and to a lesser extent 7-methoxyresorufin O-demethylase activities.</sentence>
<sentence>3.</sentence>
<sentence>Western immunoblotting of liver slice microsomes was performed with antibodies to rat <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> and human <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(DIM, CYP1A2,DEI)(DIM, CYP3A4,NDEI)">
<sentence>Compared with control liver slice microsomes (dimethyl sulphoxide-only treated), <cons sem="G_DRUG">DIM</cons> <cons sem="G_MECHANISM">induced</cons> levels of <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> but had <cons sem="G_CHANGE">little</cons> effect on levels of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(polycholorinated biphenyl mixture Aroclor 1254, CYP1A2,DEI)(polycholorinated biphenyl mixture Aroclor 1254, CYP3A4,NDEI)">
<sentence>The treatment of human liver slices with <cons sem="G_NUMBER">2 microg/ml</cons> of the polycholorinated biphenyl mixture <cons sem="G_DRUG">Aroclor 1254</cons> also resulted in an <cons sem="G_MECHANISM">induction</cons> of levels of <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, but had <cons sem="G_NEGATIVEEFFECT">no</cons> effect on <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
</annotation>
<sentence>4.</sentence>
<annotation sem="INVITROCDDIS" ddi="(DIM, CYP1A,DEI)">
<sentence>These results demonstrate that <cons sem="G_DRUG">DIM</cons> induces <cons sem="G_CYP">CYP1A</cons> isoforms in cultured human liver slices.</sentence>
</annotation>
<sentence>Some variability in the magnitude of <cons sem="G_MECHANISM">induction</cons> of enzyme activities by <cons sem="G_DRUG">DIM</cons> was observed in four human liver samples examined.</sentence>
<annotation sem="INVITROCDDIS" ddi="(DIM, 7-ethoxyresorufin O-deethylase,DDI)">
<sentence>For <cons sem="G_DRUG">7-ethoxyresorufin</cons> O-deethylase, the magnitude of <cons sem="G_MECHANISM">induction</cons> by <cons sem="G_NUMBER">50 microM</cons> <cons sem="G_DRUG">DIM</cons> ranged from <cons sem="G_NUMBER">2.3- to 19.3-fold</cons>.</sentence>
</annotation>
<sentence>5.</sentence>
<sentence>These results demonstrate that cultured human liver slices can be used to evaluate the effect of chemicals derived from cruciferous and other vegetables on CYP isoforms.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9690950</bibliomisc>
</articleinfo>
<title>
<sentence>Involvement of <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> in <cons lex="mexiletine" sem="G_DRUG">mexiletine</cons> <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
</title>
<abstract>
<sentence><cons lex="mexiletine" sem="G_DRUG">Mexiletine</cons> has been reported to be hydroxylated by cytochrome P450 <cons lex="2d6" sem="G_CYP">2D6</cons> (<cons sem="G_CYP">CYP2D6</cons>) in humans.</sentence>
<sentence>However, the involvement of <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> in the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="mexiletine" sem="G_DRUG">mexiletine</cons> has been proposed based on the interaction with <cons lex="theophylline" sem="G_DRUG">theophylline</cons> which is mainly <cons sem="G_MECHANISM">metabolized</cons> by <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>.</sentence>
<sentence>The aim of this study was to clarify the role of human <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> in <cons lex="mexiletine" sem="G_DRUG">mexiletine</cons> <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
<sentence>Human CYP isoforms involved in <cons lex="mexiletine" sem="G_DRUG">mexiletine</cons> <cons sem="G_MECHANISM">metabolism</cons> were investigated using microsomes from human liver and B-lymphoblastoid cells expressing human CYPs.</sentence>
<sentence>The contributions of <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> and <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> to <cons lex="mexiletine" sem="G_DRUG">mexiletine</cons> <cons sem="G_MECHANISM">metabolism</cons> were estimated by the relative activity factor (RAF).</sentence>
<annotation sem="INVITROCDDIS" ddi="(ethoxyresorufin, Mexiletine p- hydroxylase,DDI)(ethoxyresorufin, Mexiletine 2- hydroxylase,DDI)(furafylline, Mexiletine p- hydroxylase,DDI)(furafylline, Mexiletine 2- hydroxylase,DDI)(quinidine, Mexiletine p- hydroxylase,DDI)(quinidine, Mexiletine 2- hydroxylase,DDI)">
<sentence><cons lex="mexiletine" sem="G_DRUG">Mexiletine</cons> p- and 2-hydroxylase activities in human liver microsomes were <cons sem="G_MECHANISM">inhibited</cons> by ethoxyresorufin and <cons lex="furafylline" sem="G_DRUG">furafylline</cons> as well as <cons lex="quinidine" sem="G_DRUG">quinidine</cons>.</sentence>
</annotation>
<sentence><cons lex="mexiletine" sem="G_DRUG">Mexiletine</cons> p- and 2-hydroxylase activities in microsomes from nine human livers <cons sem="G_MECHANISM">correlated</cons> <cons sem="G_CHANGE">significantly</cons> with <cons sem="G_DRUG">bufuralol</cons> 1'-hydroxylase activity <cons sem="G_NUMBER">(<cons sem="G_NUMBER">r = 0.907, P &lt; 0.001 and r = 0.886, P &lt; 0.01</cons>, respectively)</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(CYP1A2, Mexiletine p- hydroxylase,ADEI)(CYP1A2, Mexiletine 2- hydroxylase,ADEI)(CYP2D6, Mexiletine p- hydroxylase,DDI)(CYP2D6, Mexiletine 2- hydroxylase,DDI)">
<sentence>Microsomes of B-lymphoblastoid cells expressing human <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> exhibited lower <cons lex="mexiletine" sem="G_DRUG">mexiletine</cons> p- and 2-hydroxylase activities than those expressing human <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(CYP1A2, Mexiletine p- hydroxylase,ADEI)(CYP1A2, Mexiletine 2- hydroxylase,ADEI)">
<sentence>It was estimated by RAF that the major isoform involved in <cons lex="mexiletine" sem="G_DRUG">mexiletine</cons> <cons sem="G_MECHANISM">metabolism</cons> was <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>, and the contribution of <cons sem="G_CYP">CYPIA2</cons> to both <cons lex="mexiletine" sem="G_DRUG">mexiletine</cons> p- and 2-hydroxylase activities was <cons sem="G_NUMBER">7-30%</cons> in human liver microsomes.</sentence>
</annotation>
<sentence>However, the <cons sem="G_IVITPARA">Km</cons> values of the expressed <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> (approximately <cons sem="G_NUMBER">15 microM</cons>) were almost identical with those of the expressed <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> (approximately <cons sem="G_NUMBER">22 microM</cons>) and human liver microsomes.</sentence>
<sentence><cons lex="mexiletine" sem="G_DRUG">Mexiletine</cons> is a substrate of <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>.</sentence>
<sentence>The data obtained in this study suggest that the interaction of <cons lex="mexiletine" sem="G_DRUG">mexiletine</cons> with <cons lex="theophylline" sem="G_DRUG">theophylline</cons> <cons sem="G_CHANGE">might</cons> be due to competitive <cons sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9660842</bibliomisc>
</articleinfo>
<title>
<sentence>Characterization of the selectivity and mechanism of human cytochrome P450 <cons sem="G_MECHANISM">inhibition</cons> by the human immunodeficiency virus-protease <cons sem="G_MECHANISM">inhibitor</cons> <cons lex="nelfinavir" sem="G_DRUG">nelfinavir</cons> mesylate.</sentence>
</title>
<abstract>
<sentence>In vitro studies with human liver microsomes and P450 probe substrates were performed to characterize selectivity and mechanism of cytochrome P450 <cons sem="G_MECHANISM">inhibition</cons> by <cons lex="nelfinavir" sem="G_DRUG">nelfinavir</cons> mesylate.</sentence>
<sentence>At therapeutic concentrations (steady-state <cons sem="G_IVITPARA">plasma concentrations</cons> approximately <cons sem="G_NUMBER">4 microM</cons>), <cons lex="nelfinavir" sem="G_DRUG">nelfinavir</cons> was found to be a competitive <cons sem="G_MECHANISM">inhibitor</cons> of only <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6beta-hydroxylase (<cons sem="G_CYP">CYP3A4</cons>) with a <cons sem="G_IVITPARA">Ki</cons> concentration of <cons sem="G_NUMBER">4.8 microM</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(nelfinavir, dextromethorphan O-demethylase,ADDI)(nelfinavir, S-mephenytoin 4-hydroxylase,NDDI)(nelfinavir, phenacetin O-deethylase,NDDI)">
<sentence>At supratherapeutic concentrations, <cons lex="nelfinavir" sem="G_DRUG">nelfinavir</cons> competitively <cons sem="G_MECHANISM">inhibited</cons> <cons lex="dextromethorphan" sem="G_DRUG">dextromethorphan</cons> O-demethylase (<cons sem="G_CYP">CYP2D6</cons>), S-<cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons> 4-hydroxylase (<cons sem="G_CYP">CYP2C19</cons>), and <cons lex="phenacetin" sem="G_DRUG">phenacetin</cons> O-deethylase (<cons sem="G_CYP">CYP1A2</cons>) with <cons sem="G_IVITPARA">Ki</cons> concentrations of <cons sem="G_NUMBER">68, 126, and 190 microM</cons> respectively.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(nelfinavir, tolbutamide 4-hydroxylase,NDDI)(nelfinavir, paclitaxel 6alpha-hydroxylase,NDDI)(nelfinavir, chlorzoxaxone 6beta-hydroxylase e,NDDI)">
<sentence><cons lex="nelfinavir" sem="G_DRUG">Nelfinavir</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> appreciably <cons sem="G_MECHANISM">inhibit</cons> <cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons> 4-hydroxylase (<cons sem="G_CYP">CYP2C9</cons>), <cons lex="paclitaxel" sem="G_DRUG">paclitaxel</cons> 6alpha-hydroxylase (<cons sem="G_CYP">CYP2C8</cons>), or <cons sem="G_DRUG">chlorzoxaxone</cons> 6beta-hydroxylase (<cons sem="G_CYP">CYP2E1</cons>) activities.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(nelfinavir, CYP3A4,DEI)">
<sentence>The <cons sem="G_MECHANISM">inhibitory</cons> potency of <cons lex="nelfinavir" sem="G_DRUG">nelfinavir</cons> toward <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> suggested the possibility of in vivo <cons sem="G_MECHANISM">inhibition</cons> of this isoform, whereas in vivo <cons sem="G_MECHANISM">inhibition</cons> of other P450s was considered unlikely.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(nelfinavir, terfenadine,DDI)">
<sentence>In a one-sequence crossover study in 12 healthy volunteers, <cons lex="nelfinavir" sem="G_DRUG">nelfinavir</cons> <cons sem="G_MECHANISM">inhibited</cons> the elimination of the <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> substrate <cons lex="terfenadine" sem="G_DRUG">terfenadine</cons> and the carboxylate metabolite of <cons lex="terfenadine" sem="G_DRUG">terfenadine</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(nelfinavir, 6beta-hydroxycortisol,ADDI)">
<sentence>The 24-hr urinary recoveries of 6beta-hydroxycortisol were <cons sem="G_CHANGE">reduced</cons> by an average of <cons sem="G_NUMBER">27%</cons> during <cons lex="nelfinavir" sem="G_DRUG">nelfinavir</cons> treatment, consistent with <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> <cons sem="G_MECHANISM">inhibition</cons> by <cons lex="nelfinavir" sem="G_DRUG">nelfinavir</cons>.</sentence>
</annotation>
<sentence><cons sem="G_MECHANISM">Inhibition</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> by <cons lex="nelfinavir" sem="G_DRUG">nelfinavir</cons> in vitro was NADPH-dependent requiring the catalytic <cons sem="G_MECHANISM">formation</cons> of a metabolite or a metabolic intermediate.</sentence>
<sentence>The catechol metabolite of <cons lex="nelfinavir" sem="G_DRUG">nelfinavir</cons> (M3) was considered unlikely to be responsible for <cons sem="G_MECHANISM">inhibition</cons> as the addition of catechol O-methyl transferase, S-adenosyl methionine, and ascorbic acid to the preincubation mixture did <cons sem="G_NEGATIVEEFFECT">not</cons> protect against the loss of <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6beta-hydroxylase activity.</sentence>
<sentence>Also, the addition of M3 to human liver microsomes did <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_MECHANISM">inhibit</cons> <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
<sentence>Although incubations with <cons lex="nelfinavir" sem="G_DRUG">nelfinavir</cons> showed a time- and concentration-dependent loss of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activity, the partial or complete recovery of enzyme activity upon dialysis indicated that <cons sem="G_MECHANISM">inhibition</cons> was reversible.</sentence>
<sentence>Microsomal incubations with <cons lex="nelfinavir" sem="G_DRUG">nelfinavir</cons> and NADPH did <cons sem="G_NEGATIVEEFFECT">not</cons> result in a loss of spectral P450 content compared with the NADPH control.</sentence>
<annotation sem="INVITROCDDIS" ddi="(nelfinavir, Glutathione,NDDI)(nelfinavir, N-acetylcysteine,NDDI)(nelfinavir, catalase,NDDI)">
<sentence>Glutathione, N-<cons lex="acetylcysteine" sem="G_DRUG">acetylcysteine</cons>, and catalase did <cons sem="G_NEGATIVEEFFECT">not</cons> attenuate <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibition</cons> by <cons lex="nelfinavir" sem="G_DRUG">nelfinavir</cons>.</sentence>
</annotation>
<sentence>Collectively, these results suggest that the <cons sem="G_CHANGE">probable</cons> mechanism for <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibition</cons> by <cons lex="nelfinavir" sem="G_DRUG">nelfinavir</cons> is a transient metabolic intermediate or stable metabolite that coordinates tightly but reversibly to the <cons lex="heme" sem="G_DRUG">heme</cons> moiety of the P450.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9626925</bibliomisc>
</articleinfo>
<title>
<sentence>Prediction of drug-drug interactions of <cons lex="zonisamide" sem="G_DRUG">zonisamide</cons> <cons sem="G_MECHANISM">metabolism</cons> in humans from in vitro data.</sentence>
</title>
<abstract>
<sentence>The purposes of this study were to identify the P450 enzyme (CYP) responsible for <cons lex="zonisamide" sem="G_DRUG">zonisamide</cons> <cons sem="G_MECHANISM">metabolism</cons> in humans by using expressed human CYPs and to predict drug interaction of <cons lex="zonisamide" sem="G_DRUG">zonisamide</cons> in vivo from in vitro data.</sentence>
<sentence>Ten expressed human CYPs and human liver microsomes were used in the experiments for the identification of enzymes responsible for <cons lex="zonisamide" sem="G_DRUG">zonisamide</cons> <cons sem="G_MECHANISM">metabolism</cons> and for the prediction of drug-drug interactions of <cons lex="zonisamide" sem="G_DRUG">zonisamide</cons> <cons sem="G_MECHANISM">metabolism</cons> in humans from in vitro data, respectively.</sentence>
<sentence>Two-sulfamoylacetyl <cons lex="phenol" sem="G_DRUG">phenol</cons>, a <cons sem="G_CHANGE">reductive</cons> metabolite of <cons lex="zonisamide" sem="G_DRUG">zonisamide</cons>, was measured by the HPLC method.</sentence>
<annotation sem="INVITROCDDIS" ddi="(CYP2C19, zonisamide,DEI)(CYP3A4, zonisamide,DEI)(CYP3A5, zonisamide,DEI)">
<sentence>From the experiments using ten expressed human CYPs, <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>, <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and <cons lex="cyp3a5" sem="G_CYP">CYP3A5</cons> were shown to be capable of catalyzing <cons lex="zonisamide" sem="G_DRUG">zonisamide</cons> <cons sem="G_CHANGE">reduction</cons>.</sentence>
</annotation>
<sentence>However, an <cons sem="G_IVITPARA">intrinsic clearance</cons>, <cons sem="G_IVITPARA">Vmax/kM</cons>, of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> was much higher than those of <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> and <cons lex="cyp3a5" sem="G_CYP">CYP3A5</cons>.</sentence>
<sentence>From the point of view of enzyme amount in human liver CYPs isoform and their <cons sem="G_IVITPARA">intrinsic clearance</cons>, it was suggested that <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> is mainly responsible for <cons lex="zonisamide" sem="G_DRUG">zonisamide</cons> <cons sem="G_MECHANISM">metabolism</cons> in human CYPs.</sentence>
<annotation sem="INVITROCDDIS" ddi="(cyclosporin A, zonisamide,DDI)(dihydroergotamine, zonisamide,DDI)(ketoconazole, zonisamide,DDI)(itraconazole, zonisamide,DDI)(miconazole, zonisamide,DDI)(triazolam, zonisamide,DDI)">
<sentence><cons lex="zonisamide" sem="G_DRUG">Zonisamide</cons> <cons sem="G_MECHANISM">metabolism</cons> in human liver microsomes was <cons sem="G_CHANGE">markedly</cons> <cons sem="G_MECHANISM">inhibited</cons> by <cons sem="G_DRUG">cyclosporin A</cons>, <cons sem="G_DRUG">dihydroergotamine</cons>, <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>, <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>, <cons lex="miconazole" sem="G_DRUG">miconazole</cons> and <cons lex="triazolam" sem="G_DRUG">triazolam</cons>.</sentence>
</annotation>
<sentence>We estimated the possibility and degree of change of <cons lex="zonisamide" sem="G_DRUG">zonisamide</cons> <cons sem="G_IVITPARA">clearance</cons> in vivo in clinical dose range from in vitro <cons sem="G_MECHANISM">inhibition</cons> constant of other drugs against <cons lex="zonisamide" sem="G_DRUG">zonisamide</cons> <cons sem="G_MECHANISM">metabolism</cons> (<cons sem="G_IVITPARA">Ki</cons>) and unbound <cons sem="G_MECHANISM">inhibitor</cons> concentration in blood (Iu) in clinical usage.</sentence>
<annotation sem="INVITROCDDIS" ddi="(ketoconazole, zonisamide,ADDI)(cyclospolin A, zonisamide,ADDI)(miconazole, zonisamide,ADDI)">
<sentence><cons sem="G_IVITPARA">Clearance</cons> of <cons lex="zonisamide" sem="G_DRUG">zonisamide</cons> was maximally estimated to <cons sem="G_CHANGE">decrease</cons> by <cons sem="G_NUMBER">31%, 23% and 17%</cons> of the <cons sem="G_IVITPARA">clearance</cons> without <cons sem="G_MECHANISM">inhibitors</cons> i.e. <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>, cyclospolin A and <cons lex="miconazole" sem="G_DRUG">miconazole</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Fluconazole, zonisamide,ADDI)(carbamazepine A, zonisamide,ADDI)">
<sentence><cons lex="fluconazole" sem="G_DRUG">Fluconazole</cons> and <cons lex="carbamazepine" sem="G_DRUG">carbamazepine</cons> are estimated to <cons sem="G_CHANGE">decrease</cons> by <cons sem="G_NUMBER">5-6%</cons> of the clearance of <cons lex="zonisamide" sem="G_DRUG">zonisamide</cons>.</sentence>
</annotation>
<sentence>On the other hand, there <cons sem="G_CHANGE">may</cons> be lack of interaction of <cons lex="zonisamide" sem="G_DRUG">zonisamide</cons> <cons sem="G_MECHANISM">metabolism</cons> by dihydroergotamine, <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> and <cons lex="triazolam" sem="G_DRUG">triazolam</cons> in clinical dose range.</sentence>
<sentence>We demonstrated that: (1) <cons lex="zonisamide" sem="G_DRUG">zonisamide</cons> is <cons sem="G_MECHANISM">metabolized</cons> by recombinant <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> and <cons lex="cyp3a5" sem="G_CYP">CYP3A5</cons>, (2) the <cons sem="G_MECHANISM">metabolism</cons> is <cons sem="G_MECHANISM">inhibited</cons> to a variable extent by known <cons lex="cyp3a4/5" sem="G_CYP">CYP3A4/5</cons> substrates and/or <cons sem="G_MECHANISM">inhibitors</cons> in human liver microsomes, and (3) in vitro-in vivo predictive calculations suggest that several compounds demonstrating <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>-affinity <cons sem="G_CHANGE">might</cons> cause in vivo drug-drug interactions with <cons lex="zonisamide" sem="G_DRUG">zonisamide</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9622079</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem="G_MECHANISM">Metabolism</cons> of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations.</sentence>
</title>
<abstract>
<sentence>17-(Allylamino)-17-demethoxygeldanamycin (<cons sem="G_DRUG">17AAG</cons>), a compound that is proposed for clinical development, shares the ability of <cons lex="geldanamycin" sem="G_DRUG">geldanamycin</cons> to bind to heat shock protein 90 and GRP94, thereby depleting cells of p185erbB2, mutant p53, and Raf-1.</sentence>
<sentence>Urine and plasma from mice treated i.v. with <cons sem="G_DRUG">17AAG</cons> contained six materials with absorption spectra similar to that of <cons sem="G_DRUG">17AAG</cons>.</sentence>
<sentence>Therefore, in vitro <cons sem="G_MECHANISM">metabolism</cons> of <cons sem="G_DRUG">17AAG</cons> by mouse and human hepatic preparations was studied to characterize: (a) the enzymes responsible for <cons sem="G_DRUG">17AAG</cons> <cons sem="G_MECHANISM">metabolism</cons>; and (b) the structures of the metabolites produced.</sentence>
<sentence>These materials had retention times on high-performance liquid chromatography of approximately 2, 4, 5, 6, 7, and 9 min.</sentence>
<sentence>When incubated in an aerobic environment with <cons sem="G_DRUG">17AAG</cons>, murine hepatic supernatant (9000 x g) produced each of these compounds; the 4-min metabolite was the major product.</sentence>
<sentence>This <cons sem="G_MECHANISM">metabolism</cons> required an electron donor, and NADPH was favored over <cons lex="nadh" sem="G_DRUG">NADH</cons>.</sentence>
<sentence>Metabolic activity resided predominantly in the microsomal fraction.</sentence>
<sentence><cons sem="G_MECHANISM">Metabolism</cons> was <cons sem="G_CHANGE">decreased</cons> by approximately 80% in anaerobic conditions and was essentially ablated by CO. Microsomes prepared from human livers produced essentially the same metabolites as produced by murine hepatic microsomes, but the 2-min metabolite was the major product, and the 4-min metabolite was next largest.</sentence>
<sentence>There was <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem="G_MECHANISM">metabolism</cons> of <cons sem="G_DRUG">17AAG</cons> by human liver cytosol.</sentence>
<sentence><cons sem="G_MECHANISM">Metabolism</cons> of <cons sem="G_DRUG">17AAG</cons> by human liver microsomes also required an electron donor, with NADPH being preferred over <cons lex="nadh" sem="G_DRUG">NADH</cons>, was <cons sem="G_MECHANISM">inhibited</cons> by approximately 80% under anaerobic conditions, and was essentially ablated by CO. Liquid chromatography/mass spectrometry analysis of human and mouse in vitro reaction mixtures indicated the presence of materials with molecular weights of 545, 601, and 619, compatible with 17-(amino)-17-demethoxygeldanamycin (<cons sem="G_DRUG">17AG</cons>), an epoxide, and a diol, respectively.</sentence>
<sentence>The metabolite with retention time of 4 min was identified as <cons sem="G_DRUG">17AG</cons> by cochromatography and mass spectral concordance with authentic standard.</sentence>
<annotation sem="INVITROCDDIS" ddi="(ketoconazole, 17AAG,DDI)">
<sentence>Human microsomal <cons sem="G_MECHANISM">metabolism</cons> of <cons sem="G_DRUG">17AAG</cons> was <cons sem="G_MECHANISM">inhibited</cons> by <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>, implying <cons lex="3a4" sem="G_CYP">3A4</cons> as the responsible cytochrome P450 isoform.</sentence>
</annotation>
<sentence>Incubation of <cons sem="G_DRUG">17AAG</cons> with cloned <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> produced metabolites 4 and 6.</sentence>
<sentence>Incubation of <cons sem="G_DRUG">17AAG</cons> with cloned <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and cloned microsomal epoxide hydrolase produced metabolites 2 and 4, with <cons sem="G_CHANGE">greatly</cons> <cons sem="G_CHANGE">decreased</cons> amounts of metabolite 6.</sentence>
<annotation sem="INVITROCDDIS" ddi="(cyclohexene oxide, 17AAG,DDI)">
<sentence>Incubation of <cons sem="G_DRUG">17AAG</cons> with human hepatic microsomes and cyclohexene oxide, a known <cons sem="G_MECHANISM">inhibitor</cons> of microsomal epoxide hydrolase, did <cons sem="G_NEGATIVEEFFECT">not</cons> affect the production of metabolite 4 but <cons sem="G_CHANGE">decreased</cons> the production of metabolite 2 while <cons sem="G_CHANGE">increasing</cons> the production of metabolite 6.</sentence>
</annotation>
<sentence>These data imply that metabolite 2 is a diol and metabolite 6 is an epoxide.</sentence>
<sentence>Mass spectral fragmentation patterns and the fact that <cons sem="G_DRUG">17AG</cons> is <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_MECHANISM">metabolized</cons> argue for the epoxide and diol being <cons sem="G_MECHANISM">formed</cons> on the 17-allylamino portion of <cons sem="G_DRUG">17AAG</cons> and <cons sem="G_NEGATIVEEFFECT">not</cons> on its ansamycin ring.</sentence>
<sentence>These data have implications with regard to preclinical toxicology and activity testing of <cons sem="G_DRUG">17AAG</cons> as well as its proposed clinical development because: (a) production of <cons sem="G_DRUG">17AG</cons> requires concomitant production of acrolein from the cleaved allyl moiety; and (b) <cons sem="G_DRUG">17AG</cons>, which was <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_MECHANISM">metabolized</cons> by microsomes, has been described as being as active as <cons sem="G_DRUG">17AAG</cons> in <cons sem="G_CHANGE">decreasing</cons> cellular p185erbB2.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9531525</bibliomisc>
</articleinfo>
<title>
<sentence>Overlapping substrate specificities of cytochrome P450 <cons lex="3a" sem="G_CYP">3A</cons> and P-glycoprotein for a novel <cons lex="cysteine" sem="G_DRUG">cysteine</cons> protease <cons sem="G_MECHANISM">inhibitor</cons>.</sentence>
</title>
<abstract>
<sentence>K02 (morpholine-<cons lex="urea" sem="G_DRUG">urea</cons>-Phe-Hphe-vinylsulfone), a newly developed peptidomimetic, acts as a potent <cons lex="cysteine" sem="G_DRUG">cysteine</cons> protease <cons sem="G_MECHANISM">inhibitor</cons>, especially of cathepsins B and L (which are associated with cancer progression) and cruzain (a <cons lex="cysteine" sem="G_DRUG">cysteine</cons> protease of Trypanosoma cruzi, which is responsible for Chagas' disease).</sentence>
<sentence>Here we investigated features of the disposition of K02 using in vitro systems, characterizing the interaction of the drug with human cytochrome P450 (CYP) <cons lex="3a" sem="G_CYP">3A</cons> and P-glycoprotein (P-gp), a mediator of multidrug resistance (MDR) to cancer chemotherapy and a countertransporter in the intestine that limits oral drug bioavailability.</sentence>
<sentence>P-gp functions as an ATP-dependent drug efflux pump to <cons sem="G_CHANGE">reduce</cons> intracellular cytotoxic concentrations.</sentence>
<sentence>An HPLC assay was developed to analyze K02 and its metabolites <cons sem="G_MECHANISM">formed</cons> in human liver microsomes.</sentence>
<sentence>Three major primary metabolites were determined by LC/MS/MS to be hydroxylated products of the parent compound.</sentence>
<sentence>A rabbit anti-<cons lex="cyp3a" sem="G_CYP">CYP3A</cons> polyclonal antibody (200 microl antibody/mg microsomal protein) produced <cons sem="G_NUMBER">75-94%</cons> <cons sem="G_MECHANISM">inhibition</cons> of the <cons sem="G_MECHANISM">formation</cons> of these three hydroxylated metabolites.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Ketoconazole, quinidine,DDI)(Ketoconazole, 7,8-benzoflavone,DDI)(Ketoconazole, sulfaphenazole,DDI)">
<sentence><cons lex="ketoconazole" sem="G_DRUG">Ketoconazole</cons> (<cons sem="G_NUMBER">5 microM</cons>), a selective <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> <cons sem="G_MECHANISM">inhibitor</cons>, produced up to <cons sem="G_NUMBER">75%</cons> <cons sem="G_MECHANISM">inhibition</cons>, whereas other CYP-specific <cons sem="G_MECHANISM">inhibitors</cons>, i.e. <cons lex="quinidine" sem="G_DRUG">quinidine</cons> (<cons sem="G_CYP">CYP2D6</cons>), 7,8-benzoflavone (<cons sem="G_CYP">CYP1A2</cons>), and <cons sem="G_DRUG">sulfaphenazole</cons> (<cons sem="G_CYP">CYP2C9</cons>), showed <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem="G_CHANGE">significant</cons> effects.</sentence>
</annotation>
<sentence>An identical metabolite <cons sem="G_MECHANISM">formation</cons> profile for K02 was observed with cDNA-expressed human <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> (Gentest).</sentence>
<sentence>These data demonstrate that K02 is a substrate for <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(K02, 1'-hydroxymidazolam,DDI)">
<sentence><cons sem="G_MECHANISM">Formation</cons> of 1'-hydroxymidazolam, the primary human <cons lex="midazolam" sem="G_DRUG">midazolam</cons> metabolite, was <cons sem="G_CHANGE">markedly</cons> <cons sem="G_MECHANISM">inhibited</cons> by K02 via competitive processes, which suggests the potential for drug-drug interactions of K02 with other <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> substrates.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(K02, azidopine,DDI)(K02, LU-49888,DDI)">
<sentence>K02 <cons sem="G_CHANGE">significantly</cons> <cons sem="G_MECHANISM">inhibited</cons> the photoaffinity labeling of P-gp with <cons sem="G_DRUG">azidopine</cons> and <cons sem="G_DRUG">LU-49888</cons>, a photoaffinity analogue of <cons lex="verapamil" sem="G_DRUG">verapamil</cons>.</sentence>
</annotation>
<sentence>Transport studies with  [14C]K02, using MDR1-transfected Madin-Darby canine kidney cell monolayers in the Transwell system, demonstrated that the basolateral-to-apical flux of K02 across MDR1-transfected Madin-Darby canine kidney cells was <cons sem="G_CHANGE">markedly</cons> <cons sem="G_CHANGE">greater</cons> than the apical-to-basolateral flux (ratio of <cons sem="G_NUMBER">63 with 10 microM</cons>  [14C]K02).</sentence>
<sentence>This suggests that K02 is also a P-gp substrate.</sentence>
<sentence>These studies are important for formulating strategies to <cons sem="G_CHANGE">increase</cons> the absorption and/or <cons sem="G_CHANGE">decrease</cons> the elimination of K02 and to optimize its delivery to malignant cells and parasite-infected host cells.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9580580</bibliomisc>
</articleinfo>
<title>
<sentence>Identification and characterization of human cytochrome P450 isoforms interacting with <cons lex="pimozide" sem="G_DRUG">pimozide</cons>.</sentence>
</title>
<abstract>
<sentence>Using human liver microsomes (HLMs) and recombinant human cytochrome P450 (CYP450) isoforms, we identified the major route of <cons lex="pimozide" sem="G_DRUG">pimozide</cons> <cons sem="G_MECHANISM">metabolism</cons>, the CYP450 isoforms involved, and documented the <cons sem="G_MECHANISM">inhibitory</cons> effect of <cons lex="pimozide" sem="G_DRUG">pimozide</cons> on CYP450 isoforms.</sentence>
<sentence><cons lex="pimozide" sem="G_DRUG">Pimozide</cons> was predominantly N-dealkylated to 1,3-dihydro-1-(4-piperidinyl)-2H-benzimidazol-2-one (DHPBI).</sentence>
<sentence>The <cons sem="G_MECHANISM">formation</cons> rate of DHPBI showed biphasic kinetics in HLMs, which suggests the participation of at least two activities.</sentence>
<sentence>These were characterized as high-affinity (<cons sem="G_IVITPARA">K(m1)</cons> and <cons sem="G_IVITPARA">Vmax1</cons>) and low-affinity (<cons sem="G_IVITPARA">K(m2)</cons> and <cons sem="G_IVITPARA">Vmax2</cons>) components.</sentence>
<sentence>The ratio of <cons sem="G_IVITPARA">Vmax1</cons> (<cons sem="G_NUMBER">14 pmol/min/mg protein</cons>)/<cons sem="G_IVITPARA">K(m1)</cons> (<cons sem="G_NUMBER">0.73 microM</cons>) was 5.2 times higher than the ratio of <cons sem="G_IVITPARA">Vmax2</cons> (<cons sem="G_NUMBER">244 pmol/min/mg protein</cons>)/<cons sem="G_IVITPARA">K(m2)</cons> (<cons sem="G_NUMBER">34 microM</cons>).</sentence>
<sentence><cons sem="G_IVITPARA">K(m2)</cons> was 91 times higher than <cons sem="G_IVITPARA">K(m1)</cons>.</sentence>
<sentence>The <cons sem="G_MECHANISM">formation</cons> rate of DHPBI from <cons sem="G_NUMBER">25 microM</cons> <cons lex="pimozide" sem="G_DRUG">pimozide</cons> in nine human livers <cons sem="G_MECHANISM">correlated</cons> <cons sem="G_CHANGE">significantly</cons> with the catalytic activity of <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> (Spearman <cons sem="G_NUMBER">r = 0.79, P = .028</cons>), but <cons sem="G_NEGATIVEEFFECT">not</cons> with other isoforms.</sentence>
<annotation sem="INVITROCDDIS" ddi="(ketoconazole , DHPBI,DDI)(troleandomycin , DHPBI,DDI)(furafylline, DHPBI,DDI)(furafylline+ ketoconazole, DHPBI,DDI)">
<sentence>Potent <cons sem="G_MECHANISM">inhibition</cons> of DHPBI <cons sem="G_MECHANISM">formation</cons> from <cons sem="G_NUMBER">10 microM</cons> <cons lex="pimozide" sem="G_DRUG">pimozide</cons> was observed with <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> (<cons sem="G_NUMBER">88%</cons>), <cons lex="troleandomycin" sem="G_DRUG">troleandomycin</cons> (<cons sem="G_NUMBER">79%</cons>), <cons lex="furafylline" sem="G_DRUG">furafylline</cons> (<cons sem="G_NUMBER">48%</cons>) and a combination of <cons lex="furafylline" sem="G_DRUG">furafylline</cons> and <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> (<cons sem="G_NUMBER">96%</cons>).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(pimozide, DHPBI,DDI)">
<sentence>Recombinant human <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">catalyzed</cons> DHPBI <cons sem="G_MECHANISM">formation</cons> from <cons sem="G_NUMBER">10 microM</cons> <cons lex="pimozide" sem="G_DRUG">pimozide</cons> at the highest rate (V = <cons sem="G_NUMBER">2.2 +/- 0.89 pmol/min/pmol</cons> P450) followed by <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> (V = <cons sem="G_NUMBER">0.23 +/- 0.08 pmol/min/pmol</cons> P450), but other isoforms tested did <cons sem="G_NEGATIVEEFFECT">not</cons>.</sentence>
</annotation>
<sentence>The <cons sem="G_IVITPARA">K(m)</cons> values derived with recombinant <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> were <cons sem="G_NUMBER">5.7 microM and 36.1 microM</cons>, respectively.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Pimozide, CYP2D6,DEI)(Pimozide, CYP3A,ADEI)">
<sentence><cons lex="pimozide" sem="G_DRUG">Pimozide</cons> itself was a potent <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> in HLMs when preincubated for 15 min (<cons sem="G_IVITPARA">Ki</cons> = <cons sem="G_NUMBER">0.75 +/- 0.98 microM</cons>) and a <cons sem="G_CHANGE">moderate</cons> <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> (<cons sem="G_IVITPARA">Ki</cons> = <cons sem="G_NUMBER">76.7 +/- 34.5 microM</cons>), with <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem="G_CHANGE">significant</cons> effect on other isoforms tested.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Pimozide, CYP3A,DEI)">
<sentence>Our results suggest that <cons lex="pimozide" sem="G_DRUG">pimozide</cons> <cons sem="G_MECHANISM">metabolism</cons> is <cons sem="G_MECHANISM">catalyzed</cons> mainly by <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>, but <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> also contributes.</sentence>
</annotation>
<sentence><cons lex="pimozide" sem="G_DRUG">Pimozide</cons> <cons sem="G_MECHANISM">metabolism</cons> is likely to be subject to interindividual variability in <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> and <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> expression and to drug interactions involving these isoforms.</sentence>
<sentence><cons lex="pimozide" sem="G_DRUG">Pimozide</cons> itself <cons sem="G_CHANGE">may</cons> <cons sem="G_MECHANISM">inhibit</cons> the <cons sem="G_MECHANISM">metabolism</cons> of drugs that are substrates of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9517377</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem="G_DRUG">Ipriflavone</cons> as an <cons sem="G_MECHANISM">inhibitor</cons> of human cytochrome P450 enzymes.</sentence>
</title>
<abstract>
<sentence>1.</sentence>
<sentence><cons sem="G_CHANGE">Reduction</cons> of <cons lex="theophylline" sem="G_DRUG">theophylline</cons> <cons sem="G_MECHANISM">metabolism</cons> and elimination were observed in a <cons lex="theophylline" sem="G_DRUG">theophylline</cons>-treated patient during <cons sem="G_DRUG">Ipriflavone</cons> administration.</sentence>
<sentence>After withdrawal of <cons sem="G_DRUG">Ipriflavone</cons>, the serum <cons lex="theophylline" sem="G_DRUG">theophylline</cons> level <cons sem="G_CHANGE">decreased</cons> to an extent similar to that found before administration of <cons sem="G_DRUG">Ipriflavone</cons>.</sentence>
<sentence>The effects of <cons sem="G_DRUG">Ipriflavone</cons> and its major metabolites 7-hydroxy-isoflavone and 7-(1-carboxy-ethoxy)-isoflavone on cytochrome P450 activities were studied in vitro in human liver microsomes from three donors.</sentence>
<sentence>2.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Ipriflavone, phenacetin O-deethylase,DDI)(Ipriflavone, tolbutamide hydroxylase,DDI)(7-hydroxy-isoflavone, phenacetin O-deethylase,DDI)(7-hydroxy-isoflavone, tolbutamide hydroxylase,DDI)">
<sentence><cons sem="G_DRUG">Ipriflavone</cons> and 7-hydroxy-isoflavone competitively <cons sem="G_MECHANISM">inhibited</cons> <cons lex="phenacetin" sem="G_DRUG">phenacetin</cons> O-deethylase and <cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons> hydroxylase activity.</sentence>
</annotation>
<sentence>The parent compound and its dealkylated metabolite were strong <cons sem="G_MECHANISM">inhibitors</cons> exhibiting <cons sem="G_IVITPARA">Ki</cons> values around <cons sem="G_NUMBER">10-20 microM</cons>, while 7-(1-carboxy-ethoxy)-isoflavone had <cons sem="G_NEGATIVEEFFECT">no</cons> effect on the cytochrome P450 activities investigated.</sentence>
<annotation sem="INVITROCDDIS" ddi="(7-Hydroxy-isoflavone, nifedipine oxidase,DDI)">
<sentence>7-Hydroxy-isoflavone is the only one that influenced <cons lex="nifedipine" sem="G_DRUG">nifedipine</cons> oxidase activity.</sentence>
</annotation>
<sentence>It competitively <cons sem="G_MECHANISM">inhibited</cons> this activity with a <cons sem="G_IVITPARA">Ki</cons> value of <cons sem="G_NUMBER">129.5 microM</cons>.</sentence>
<sentence>3.</sentence>
<sentence>The steady state concentrations of <cons sem="G_DRUG">Ipriflavone</cons> and 7-hydroxy-isoflavone in plasma of patients receiving <cons sem="G_NUMBER">3 x 200 mg</cons> daily doses of <cons sem="G_DRUG">Ipriflavone</cons> for 48 weeks were found to be <cons sem="G_NUMBER">0.33 +/- 0.32 microM and 1.44 +/- 0.77 microM</cons>, respectively.</sentence>
<sentence>4.</sentence>
<annotation sem="INVITROCDDIS" ddi="(ipriflavone, theophylline,DDI)">
<sentence>The results indicate that the <cons sem="G_CHANGE">decrease</cons> in <cons lex="theophylline" sem="G_DRUG">theophylline</cons> <cons sem="G_MECHANISM">metabolism</cons> observed in a patient treated with <cons sem="G_DRUG">Ipriflavone</cons> <cons sem="G_CHANGE">may</cons> be due to a competitive interaction of <cons sem="G_DRUG">Ipriflavone</cons> or its metabolite, 7-hydroxy-isoflavone with <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>.</sentence>
</annotation>
<sentence>On the other hand, our in vitro findings predict some more interaction with <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9456308</bibliomisc>
</articleinfo>
<title>
<sentence>Mutual <cons sem="G_MECHANISM">inhibition</cons> between <cons lex="quinine" sem="G_DRUG">quinine</cons> and <cons lex="etoposide" sem="G_DRUG">etoposide</cons> by human liver microsomes. Evidence for cytochrome P4503A4 involvement in their major metabolic pathways.</sentence>
</title>
<abstract>
<sentence>The mutual <cons sem="G_MECHANISM">inhibition</cons> between <cons lex="quinine" sem="G_DRUG">quinine</cons> and <cons lex="etoposide" sem="G_DRUG">etoposide</cons> with their major metabolic pathways (i.e. <cons lex="quinine" sem="G_DRUG">quinine</cons> 3-hydroxylation and <cons lex="etoposide" sem="G_DRUG">etoposide</cons> 3'-demethylation) was examined in vitro by human liver microsomes.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Etoposide, quinine 3-hydroxylation,DDI)">
<sentence><cons lex="etoposide" sem="G_DRUG">Etoposide</cons> <cons sem="G_MECHANISM">inhibited</cons> <cons lex="quinine" sem="G_DRUG">quinine</cons> 3-hydroxylation in a concentration-dependent manner with a mean <cons sem="G_IVITPARA">IC50</cons> of <cons sem="G_NUMBER">65 microM</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Etoposide, quinine 3-hydroxylation,DDI)">
<sentence>The mean maximum <cons sem="G_MECHANISM">inhibition</cons> by <cons lex="etoposide" sem="G_DRUG">etoposide</cons> (<cons sem="G_NUMBER">100 micro</cons>) of <cons lex="quinine" sem="G_DRUG">quinine</cons> 3-hydroxylation was about <cons sem="G_NUMBER">60%</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Etoposide, etoposide 3'-demethylation,DDI)">
<sentence>Similarly, <cons lex="etoposide" sem="G_DRUG">etoposide</cons> 3'-demethylation was <cons sem="G_MECHANISM">inhibited</cons> by <cons lex="quinine" sem="G_DRUG">quinine</cons> in a concentration-related manner with a mean <cons sem="G_IVITPARA">IC50</cons> value of <cons sem="G_NUMBER">90 microM</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Etoposide, etoposide 3'-demethylation,DDI)">
<sentence>The mean maximum <cons sem="G_MECHANISM">inhibition</cons> by <cons lex="quinine" sem="G_DRUG">quinine</cons> (<cons sem="G_NUMBER">100 M</cons>) of <cons lex="etoposide" sem="G_DRUG">etoposide</cons> 3'-demethylation was about <cons sem="G_NUMBER">52%</cons>.</sentence>
</annotation>
<sentence>An excellent <cons sem="G_MECHANISM">correlation</cons> (<cons sem="G_NUMBER">r = 0.947, p &lt; 0.01</cons>) between <cons lex="quinine" sem="G_DRUG">quinine</cons> 3-hydroxylase and <cons lex="etoposide" sem="G_DRUG">etoposide</cons> 3'-demethylase activities in six different human liver microsomes was observed.</sentence>
<annotation sem="INVITROCDDIS" ddi="(ketoconazole, quinine 3'- hydroxylation,DDI)(troleandomycin, quinine 3'- hydroxylation,DDI)(ketoconazole, etoposide 3'-demethylation,DDI)(troleandomycin, etoposide 3'-demethylation,DDI)">
<sentence>Two <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> (<cons sem="G_NUMBER">1 microM</cons>) and <cons lex="troleandomycin" sem="G_DRUG">troleandomycin</cons> (<cons sem="G_NUMBER">100 microM</cons>), <cons sem="G_MECHANISM">inhibited</cons> <cons lex="quinine" sem="G_DRUG">quinine</cons> 3-hydroxylation by about <cons sem="G_NUMBER">90% and 80%</cons>, and <cons lex="etoposide" sem="G_DRUG">etoposide</cons> 3'-demethylation by about <cons sem="G_NUMBER">75% and 65%</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(quinine, etoposide,DDI)">
<sentence>We conclude that <cons lex="quinine" sem="G_DRUG">quinine</cons> and <cons lex="etoposide" sem="G_DRUG">etoposide</cons> mutually <cons sem="G_MECHANISM">inhibit</cons> the <cons sem="G_MECHANISM">metabolism</cons> of each other, consistent with the previous finding that <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> catalyzes the <cons sem="G_MECHANISM">metabolism</cons> of both substrates.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9491822</bibliomisc>
</articleinfo>
<title>
<sentence>Differential selectivity of cytochrome P450 <cons sem="G_MECHANISM">inhibitors</cons> against probe substrates in human and rat liver microsomes.</sentence>
</title>
<abstract>
<sentence>Chemical <cons sem="G_MECHANISM">inhibitors</cons> of cytochrome P450 (CYP) are a useful tool in defining the role of individual CYPs involved in drug <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
<sentence>The aim of the present study was to evaluate the selectivity and rank the order of potency of a range of isoform-selective CYP <cons sem="G_MECHANISM">inhibitors</cons> and to compare directly the effects of these <cons sem="G_MECHANISM">inhibitors</cons> in human and rat hepatic microsomes.</sentence>
<sentence>Four chemical <cons sem="G_MECHANISM">inhibitors</cons> of human cytochrome P450 isoforms, <cons lex="furafylline" sem="G_DRUG">furafylline</cons> (<cons sem="G_CYP">CYP1A2</cons>), <cons sem="G_DRUG">sulphaphenazole</cons> (<cons sem="G_CYP">CYP2C9</cons>), <cons lex="diethyldithiocarbamate" sem="G_DRUG">diethyldithiocarbamate</cons> (<cons sem="G_CYP">CYP2E1</cons>), and <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> (<cons sem="G_CYP">CYP3A4</cons>) were screened for their <cons sem="G_MECHANISM">inhibitory</cons> specificity towards CYP-mediated reactions in both human and rat liver microsomal preparations.</sentence>
<sentence><cons lex="phenacetin" sem="G_DRUG">Phenacetin</cons> O-deethylation, <cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons> 4-hydroxylation, <cons lex="chlorzoxazone" sem="G_DRUG">chlorzoxazone</cons> 6-hydroxylation and <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6beta-hydroxylation were monitored for enzyme activity.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Furafylline, phenacetin O-deethylation,DDI)(Furafylline, tolbutamide 4-hydroxylation,DDI)">
<sentence><cons lex="furafylline" sem="G_DRUG">Furafylline</cons> was a potent, selective <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="phenacetin" sem="G_DRUG">phenacetin</cons> O-deethylation (<cons sem="G_CYP">CYP1A2</cons>-mediated) in human liver microsomes (<cons sem="G_IVITPARA">IC50</cons> = <cons sem="G_NUMBER">0.48 microM</cons>), but <cons sem="G_MECHANISM">inhibited</cons> both <cons lex="phenacetin" sem="G_DRUG">phenacetin</cons> O-deethylation and <cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons> 4-hydroxylation (<cons sem="G_CYP">CYP2C9</cons>-mediated) at equimolar concentrations in rat liver microsomes (<cons sem="G_IVITPARA">IC50</cons> = <cons sem="G_NUMBER">20.8 and 24.0 microM</cons> respectively).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Sulphaphenazole, tolbutamide hydroxylation,DDI)">
<sentence><cons sem="G_DRUG">Sulphaphenazole</cons> demonstrated selective <cons sem="G_MECHANISM">inhibition</cons> of <cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons> hydroxylation in human liver microsomes but <cons sem="G_NEGATIVEEFFECT">failed</cons> to <cons sem="G_MECHANISM">inhibit</cons> this reaction in rat liver microsomes.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(DDC, chlorzoxazone 6-hydroxylation,DDI)">
<sentence><cons lex="ddc" sem="G_DRUG">DDC</cons> demonstrated a low level of selectivity as an <cons sem="G_MECHANISM">inhibitory</cons> probe for <cons lex="chlorzoxazone" sem="G_DRUG">chlorzoxazone</cons> 6-hydroxylation (<cons sem="G_CYP">CYP2E1</cons>-mediated).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(DDC, testosterone 6beta-hydroxylation,DDI)">
<sentence><cons lex="ddc" sem="G_DRUG">DDC</cons> also <cons sem="G_MECHANISM">inhibited</cons> <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6beta-hydroxylation (<cons sem="G_CYP">CYP3A</cons>-mediated) in man and rat, and <cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons> 4-hydroxylase activity in rat.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Ketoconazole, CYP3A4,DEI)">
<sentence><cons lex="ketoconazole" sem="G_DRUG">Ketoconazole</cons> was a very potent, selective <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activity in human liver (<cons sem="G_IVITPARA">IC50</cons> = <cons sem="G_NUMBER">0.04 microM</cons>).</sentence>
</annotation>
<sentence>Although <cons sem="G_MECHANISM">inhibiting</cons> <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> in rat liver it also <cons sem="G_MECHANISM">inhibited</cons> all other reactions at concentrations &lt; or = <cons sem="G_NUMBER">5 microM</cons>.</sentence>
<sentence>It is evident that CYP <cons sem="G_MECHANISM">inhibitors</cons> do <cons sem="G_NEGATIVEEFFECT">not</cons> exhibit the same selectivity in human and rat liver microsomes.</sentence>
<sentence>This is due to differential selectivity of the <cons sem="G_MECHANISM">inhibitors</cons> and/or differences in the CYP isoform responsible for <cons sem="G_MECHANISM">metabolism</cons> in the different species.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9454781</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem="G_MECHANISM">Oxidation</cons> of histamine H1 antagonist <cons lex="mequitazine" sem="G_DRUG">mequitazine</cons> is <cons sem="G_MECHANISM">catalyzed</cons> by cytochrome P450 <cons lex="2d6" sem="G_CYP">2D6</cons> in human liver microsomes.</sentence>
</title>
<abstract>
<sentence><cons lex="mequitazine" sem="G_DRUG">Mequitazine</cons>  [10-(3-quinuclidinylmethyl) phenothiazine] is a long-acting and selective histamine H1-receptor antagonist that is mainly biotransformed by human liver microsomes to yield hydroxylated and S-oxidized metabolites.</sentence>
<annotation sem="INVITROCDDIS" ddi="(propranolol, Mequitazine hydroxylase,DDI)(quinidine, Mequitazine hydroxylase,DDI)">
<sentence><cons lex="mequitazine" sem="G_DRUG">Mequitazine</cons> hydroxylase was <cons sem="G_MECHANISM">inhibited</cons> by <cons lex="propranolol" sem="G_DRUG">propranolol</cons> and <cons lex="quinidine" sem="G_DRUG">quinidine</cons>.</sentence>
</annotation>
<sentence>Lineweaver-Burk plots for the hydroxylation and the S-<cons sem="G_MECHANISM">oxidation</cons> indicated that the hydroxylation occurred with a low <cons sem="G_IVITPARA">Km</cons> (<cons sem="G_NUMBER">0.72 +/- .26 microM</cons>) in human liver microsomes.</sentence>
<sentence>Microsomes from genetically engineered human B-lymphoblastoid cells expressing cytochrome P450 <cons lex="2d6" sem="G_CYP">2D6</cons> (<cons sem="G_CYP">CYP2D6</cons>) efficiently <cons sem="G_MECHANISM">metabolized</cons> <cons lex="mequitazine" sem="G_DRUG">mequitazine</cons> to the hydroxylated and S-oxidized metabolites.</sentence>
<sentence>The results indicate that <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> isozyme is a major form of CYP responsible for the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="mequitazine" sem="G_DRUG">mequitazine</cons> in human liver microsomes.</sentence>
<annotation sem="INVITROCDDIS" ddi="(mequitazine, midazolam 1'-hydroxylase,DDI)">
<sentence><cons sem="G_MECHANISM">Inhibition</cons> of <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>-<cons sem="G_MECHANISM">catalyzed</cons> <cons lex="midazolam" sem="G_DRUG">midazolam</cons> 1'-hydroxylase by various histamine H1 antagonists, including <cons lex="mequitazine" sem="G_DRUG">mequitazine</cons>, suggested that <cons lex="mequitazine" sem="G_DRUG">mequitazine</cons> and some other histamine H1 antagonists could also be <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> in human liver microsomes.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9399990</bibliomisc>
</articleinfo>
<title>
<sentence>The In vitro hepatic <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="quinine" sem="G_DRUG">quinine</cons> in mice, rats and dogs: comparison with human liver microsomes.</sentence>
</title>
<abstract>
<sentence>The major metabolic pathway of <cons lex="quinine" sem="G_DRUG">quinine</cons> in the human has been shown to be 3-hydroxylation mediated mainly by human cytochrome P450 (CYP) <cons lex="3a4" sem="G_CYP">3A4</cons>.</sentence>
<sentence>In this extended in vitro study, <cons lex="quinine" sem="G_DRUG">quinine</cons> 3-hydroxylation was further investigated using microsomes from mouse, rat, dog and human livers and was compared among them in terms of the in vitro enzyme-kinetic parameters and <cons lex="quinine" sem="G_DRUG">quinine</cons>-drug interaction screenings.</sentence>
<sentence>In all species, 3-hydroxyquinine was the principal metabolite of <cons lex="quinine" sem="G_DRUG">quinine</cons>.</sentence>
<sentence>There was intra- and interspecies variability among all the kinetic parameters, and dogs exhibited a closer resemblance to humans in terms of the mean kinetic data.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Ketoconazole, quinine 3-hydroxylation,DDI)(troleandomycin, quinine 3-hydroxylation,DDI)">
<sentence><cons lex="ketoconazole" sem="G_DRUG">Ketoconazole</cons> and <cons lex="troleandomycin" sem="G_DRUG">troleandomycin</cons> <cons sem="G_MECHANISM">inhibited</cons> the 3-hydroxylation of <cons lex="quinine" sem="G_DRUG">quinine</cons> in all species.</sentence>
</annotation>
<sentence>Both alpha-naphthoflavone and <cons lex="diazepam" sem="G_DRUG">diazepam</cons> showed an interspecies difference in <cons lex="quinine" sem="G_DRUG">quinine</cons> 3-hydroxylation: a trend toward an <cons sem="G_MECHANISM">activation</cons> in dog and human, and a <cons sem="G_CHANGE">significant</cons> <cons sem="G_MECHANISM">inhibition</cons> in mouse and rat, liver microsomes.</sentence>
<sentence>Antisera raised against rat <cons sem="G_CYP">CYP3A2</cons> strongly <cons sem="G_MECHANISM">inhibited</cons> <cons lex="quinine" sem="G_DRUG">quinine</cons> 3-hydroxylation by about <cons sem="G_NUMBER">96, 84 and 92%</cons> with mouse, rat and dog liver microsomes, respectively, but neither anti-rat <cons sem="G_CYP">2C11</cons> and <cons lex="2e1" sem="G_CYP">2E1</cons> antisera did so with rat liver microsomes.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Primaquine, quinine 3-hydroxylation,DDI)(doxycycline, quinine 3-hydroxylation,DDI)(tetracycline, quinine 3-hydroxylation,DDI)">
<sentence><cons lex="primaquine" sem="G_DRUG">Primaquine</cons>, <cons lex="doxycycline" sem="G_DRUG">doxycycline</cons> and <cons lex="tetracycline" sem="G_DRUG">tetracycline</cons> substantially <cons sem="G_MECHANISM">inhibited</cons> the <cons sem="G_MECHANISM">formation</cons> of 3-hydroxyquinine in rat, dog and human species, but <cons lex="proguanil" sem="G_DRUG">proguanil</cons> had <cons sem="G_NEGATIVEEFFECT">no</cons> such effect in any species.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Chloroquine, quinine 3-hydroxylation,NDDI)">
<sentence><cons lex="chloroquine" sem="G_DRUG">Chloroquine</cons> <cons sem="G_MECHANISM">inhibited</cons> <cons lex="quinine" sem="G_DRUG">quinine</cons> 3-hydroxylation with rat and dog liver microsomes but <cons sem="G_NEGATIVEEFFECT">not</cons> with human liver microsomes.</sentence>
</annotation>
<sentence>There was a <cons sem="G_CHANGE">significant</cons> <cons sem="G_MECHANISM">correlation</cons> (<cons sem="G_NUMBER">r = 0.986, P &lt; .001</cons>) between the <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> contents and the <cons sem="G_MECHANISM">formation</cons> rates of 3-hydroxyquinine in eight human liver microsomal samples.</sentence>
<sentence>It is concluded that 3-hydroxyquinine is a main metabolite of <cons lex="quinine" sem="G_DRUG">quinine</cons> and that <cons sem="G_CYP">CYP3A/Cyp3a</cons> is a principal isoform involved in this metabolic pathway in the respective (rat, dog and human/mouse) species tested.</sentence>
<sentence>The dog and possibly the rat <cons sem="G_CHANGE">may</cons> be qualitatively and quantitatively suitable animal models for exploring the <cons lex="quinine" sem="G_DRUG">quinine</cons> 3-hydroxylase activity and for screening <cons lex="quinine" sem="G_DRUG">quinine</cons>-drug interactions in vitro, at certain inconsistency with the human liver microsomal data.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9384467</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem="G_MECHANISM">Inhibition</cons> of <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> by selective serotonin reuptake <cons sem="G_MECHANISM">inhibitors</cons> in vitro: studies of <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons> p-hydroxylation.</sentence>
</title>
<abstract>
<sentence><cons sem="G_MECHANISM">Inhibition</cons> of cytochrome P450 (CYP) activity by selective serotonin reuptake <cons sem="G_MECHANISM">inhibitors</cons> (SSRIs) has frequently been reported with regard to pathways mediated by <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>, <cons lex="cyp3a4/5" sem="G_CYP">CYP3A4/5</cons>, and <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>.</sentence>
<sentence><cons sem="G_CHANGE">little</cons> data exist on the capability of SSRIs to <cons sem="G_MECHANISM">inhibit</cons> <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>.</sentence>
<sentence>We investigated the effect of SSRIs on p-hydroxylation of <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons> (PPH), an established index reaction reflecting <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> activity, in an in vitro assay using liver tissue from six different human donors.</sentence>
<sentence>In control incubations (without <cons sem="G_MECHANISM">inhibitor</cons>), 5-(p-hydroxy-phenyl)-5-phenylhydantoin (HPPH) <cons sem="G_MECHANISM">formation</cons> rates were: <cons sem="G_IVITPARA">Vmax</cons> <cons sem="G_NUMBER">0.023 nmol min(-1) mg(-1)</cons>; <cons sem="G_IVITPARA">Km</cons> <cons sem="G_NUMBER">14.3 microM</cons>.</sentence>
<annotation sem="INVITROVDDIS" ddi="(fluvoxamine, phenytoin,DDI)(R-fluoxetine, phenytoin,ADDI)(norfluoxetine, phenytoin,ADDI)(RS-fluoxetine, phenytoin,ADDI)(sertraline, phenytoin,ADDI)(paroxetine, phenytoin,ADDI)(S-fluoxetine, phenytoin,ADDI)(desmethylsertraline, phenytoin,ADDI)">
<sentence>Average <cons sem="G_MECHANISM">inhibition</cons> constants (<cons sem="G_IVITPARA">Ki</cons>) differed <cons sem="G_CHANGE">significantly</cons> among the SSRIs, with <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> having the lowest <cons sem="G_IVITPARA">Ki</cons> (<cons sem="G_NUMBER">6 microM</cons>) followed by R-<cons lex="fluoxetine" sem="G_DRUG">fluoxetine</cons> (<cons sem="G_NUMBER">13 microM</cons>), <cons sem="G_DRUG">norfluoxetine</cons> (<cons sem="G_NUMBER">17 microM</cons>), RS-<cons lex="fluoxetine" sem="G_DRUG">fluoxetine</cons> (<cons sem="G_NUMBER">19 microM</cons>), <cons lex="sertraline" sem="G_DRUG">sertraline</cons> (<cons sem="G_NUMBER">33 microM</cons>), <cons lex="paroxetine" sem="G_DRUG">paroxetine</cons> (<cons sem="G_NUMBER">35 microM</cons>), S-<cons lex="fluoxetine" sem="G_DRUG">fluoxetine</cons> (<cons sem="G_NUMBER">62 microM</cons>), and <cons sem="G_DRUG">desmethylsertraline</cons> (<cons sem="G_NUMBER">66 microM</cons>).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(fluvoxamine, phenytoin,DDI)">
<sentence>Thus, assuming comparable molar concentrations at the site of <cons sem="G_MECHANISM">inhibition</cons>, <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> can be expected to have the highest probability of interfering with the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> substrates.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(S-fluoxetine, CYP2C9,ADEI)(R-fluoxetine, CYP2C9,ADEI)">
<sentence>S-<cons lex="fluoxetine" sem="G_DRUG">fluoxetine</cons> is on average a 5 fold weaker <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> <cons sem="G_MECHANISM">inhibitor</cons> than either R-<cons lex="fluoxetine" sem="G_DRUG">fluoxetine</cons> or the racemic mixture.</sentence>
</annotation>
<sentence>These findings are consistent with published case reports describing SSRI-related increments in plasma <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons> levels.</sentence>
<sentence>Because <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons> has a narrow therapeutic index, plasma levels should be closely monitored when SSRIs are coadministered.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9348445</bibliomisc>
</articleinfo>
<title>
<sentence>Both cytochromes P450 <cons lex="2e1" sem="G_CYP">2E1</cons> and <cons lex="3a" sem="G_CYP">3A</cons> are involved in the O-hydroxylation of p-nitrophenol, a catalytic activity known to be specific for P450 <cons lex="2e1" sem="G_CYP">2E1</cons>.</sentence>
</title>
<abstract>
<sentence>4-Nitrophenol 2-hydroxylation activity was previously shown to be mainly <cons sem="G_MECHANISM">catalyzed</cons> by P450 <cons lex="2e1" sem="G_CYP">2E1</cons> in animal species and humans.</sentence>
<sentence>As this chemical compound is widely used as an in vitro probe for P450 <cons lex="2e1" sem="G_CYP">2E1</cons>, this study was carried out to test its catalytic specificity.</sentence>
<sentence>First, experiments were carried out on liver microsomes and hepatocyte cultures of rat treated with different inducers.</sentence>
<sentence>Liver microsomes from pyrazole- and <cons lex="dexamethasone" sem="G_DRUG">dexamethasone</cons>-treated rats hydroxylated p-nitrophenol with a metabolic rate <cons sem="G_CHANGE">increased</cons> by <cons sem="G_NUMBER">2.5- and 2.7-fold</cons> vs control.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Dexamethasone, CYP3A,DEI)(Dexamethasone, CYP2E1,NDEI)">
<sentence><cons lex="dexamethasone" sem="G_DRUG">Dexamethasone</cons> treatment <cons sem="G_CHANGE">increased</cons> the hepatic content of P450 <cons lex="3a" sem="G_CYP">3A</cons> but <cons sem="G_NEGATIVEEFFECT">not</cons> that of P450 <cons lex="2e1" sem="G_CYP">2E1</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(ketoconazole, 4-nitrophenol hydroxylation,DDI)(troleandomycin, 4-nitrophenol hydroxylation,DDI)">
<sentence>Two specific <cons sem="G_MECHANISM">inhibitors</cons> of P450 <cons lex="3a" sem="G_CYP">3A</cons> catalytic activities, namely, <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> and <cons lex="troleandomycin" sem="G_DRUG">troleandomycin</cons> (TAO), <cons sem="G_MECHANISM">inhibited</cons> up to <cons sem="G_NUMBER">50%</cons> of 4-nitrophenol hydroxylation in <cons lex="dexamethasone" sem="G_DRUG">dexamethasone</cons>-treated rats but <cons sem="G_NEGATIVEEFFECT">not</cons> in controls.</sentence>
</annotation>
<sentence>Hepatocyte cultures from <cons lex="dexamethasone" sem="G_DRUG">dexamethasone</cons>-treated rats transformed p-nitrophenol into 4-nitrocatechol 7.8 times more than controls.</sentence>
<sentence>This catalytic activity was <cons sem="G_MECHANISM">inhibited</cons> by <cons sem="G_DRUG">TAO</cons>.</sentence>
<sentence>Similarly, hepatocyte cultures from pyrazole-treated rats hydroxylated p-nitrophenol with a metabolic ratio <cons sem="G_CHANGE">increased</cons> by about 8-fold vs control.</sentence>
<sentence>This reaction was <cons sem="G_MECHANISM">inhibited</cons> by diethyl dithiocarbamate and dimethyl sulfoxide, both <cons sem="G_MECHANISM">inhibitors</cons> of P450 <cons lex="2e1" sem="G_CYP">2E1</cons>.</sentence>
<sentence>Second, the capability of human P450s other than P450 <cons lex="2e1" sem="G_CYP">2E1</cons> to catalyze the <cons sem="G_MECHANISM">formation</cons> of 4-nitrocatechol was examined in a panel of 13 human liver microsomes.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Diethyl dithiocarbamate, 4-nitrophenol hydroxylase,DDI)(ketoconazole, 4-nitrophenol hydroxylase,ADDI)">
<sentence>Diethyl dithiocarbamate and <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> <cons sem="G_CHANGE">reduced</cons> 4-nitrophenol hydroxylase activity by <cons sem="G_NUMBER">77% (+/- 11) and 13% (+/- 16)</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(diethyl dithiocarbamate, CYP3A4,DEI)">
<sentence>Furthermore, the residual activity following diethyl dithiocarbamate <cons sem="G_MECHANISM">inhibition</cons> was <cons sem="G_CHANGE">significantly</cons> <cons sem="G_MECHANISM">correlated</cons> with seven P450 <cons lex="3a4" sem="G_CYP">3A4</cons> catalytic activities.</sentence>
</annotation>
<sentence>Finally, the use of human cell lines genetically engineered for expression of human P450s demonstrated that P450 <cons lex="2e1" sem="G_CYP">2E1</cons> and <cons lex="3a4" sem="G_CYP">3A4</cons> hydroxylated 4-nitrophenol with turnovers of <cons sem="G_NUMBER">19.5 and 1.65 min-1</cons>, respectively.</sentence>
<sentence>In conclusion, P450 <cons lex="3a" sem="G_CYP">3A</cons> <cons sem="G_CHANGE">may</cons> make a <cons sem="G_CHANGE">significant</cons> contribution to 4-nitrophenol hydroxylase activity in man and rat.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9351903</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem="G_MECHANISM">Formation</cons> of <cons sem="G_DRUG">guanoxabenz</cons> from <cons lex="guanabenz" sem="G_DRUG">guanabenz</cons> in human liver. A new metabolic marker for <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>.</sentence>
</title>
<abstract>
<sentence>The in vitro N-hydroxylation of <cons lex="guanabenz" sem="G_DRUG">guanabenz</cons> as well as the corresponding N-dehydroxylation of <cons sem="G_DRUG">guanoxabenz</cons> has been previously detected in biotransformation studies with microsomal fractions of different species including human hepatic microsomes.</sentence>
<sentence>Furthermore, the N-hydroxylation of <cons lex="guanabenz" sem="G_DRUG">guanabenz</cons> was found to be <cons sem="G_MECHANISM">catalyzed</cons> by enriched cytochrome P450 (P450) fractions in reconstituted systems.</sentence>
<sentence>Strong <cons sem="G_MECHANISM">correlations</cons> between 7-ethoxyresorufin O-deethylation (<cons sem="G_NUMBER">r = 0.96; p &lt; 0.001</cons>), <cons lex="caffeine" sem="G_DRUG">caffeine</cons> N-demethylation (<cons sem="G_NUMBER">r = 0.92; p &lt; 0.001</cons>), respectively, and <cons lex="guanabenz" sem="G_DRUG">guanabenz</cons> N-hydroxylation activities were demonstrated in 10 human liver microsomal preparations.</sentence>
<sentence>Studies with microsomes from human B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes proved that <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> is the major isozyme responsible for this metabolic pathway.</sentence>
<sentence>Further, P450 isozymes did <cons sem="G_NEGATIVEEFFECT">not</cons> show any detectable conversion rates.</sentence>
<annotation sem="INVITROCDDIS" ddi="(alpha-naphthoflavone, CYP1A2,DEI)(furafylline, CYP1A2,DEI)">
<sentence>The reaction was <cons sem="G_MECHANISM">inhibited</cons> in presence of the potent <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> <cons sem="G_MECHANISM">inhibitors</cons> alpha-naphthoflavone (7, 8-benzoflavone) and <cons lex="furafylline" sem="G_DRUG">furafylline</cons>.</sentence>
</annotation>
<sentence>The N-reduction of <cons sem="G_DRUG">guanoxabenz</cons> to <cons lex="guanabenz" sem="G_DRUG">guanabenz</cons> exhibits a <cons sem="G_CHANGE">significant</cons> <cons sem="G_MECHANISM">correlation</cons> to the benzamidoxime N-reduction after incubation with 10 human liver microsomal preparations (<cons sem="G_NUMBER">r = 0.97; p &lt; 0.001</cons>).</sentence>
<sentence>The <cons sem="G_MECHANISM">formation</cons> of <cons lex="benzamidine" sem="G_DRUG">benzamidine</cons> from benzamidoxime was described previously to be <cons sem="G_MECHANISM">catalyzed</cons> by the benzamidoxime reductase.</sentence>
<sentence>These results suggest that the <cons lex="guanabenz" sem="G_DRUG">guanabenz</cons> N-hydroxylation is mediated via <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, whereas the corresponding <cons sem="G_DRUG">guanoxabenz</cons> N-reduction is <cons sem="G_MECHANISM">catalyzed</cons> by an enzyme system composed of cytochrome b5, <cons lex="nadh" sem="G_DRUG">NADH</cons> cytochrome b5-reductase, and benzamidoxime reductase.</sentence>
<sentence>The high affinity of <cons lex="guanabenz" sem="G_DRUG">guanabenz</cons> to <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> and the distinct selectivity of this P450 isozyme toward <cons lex="guanabenz" sem="G_DRUG">guanabenz</cons> confirms the in vitro <cons lex="guanabenz" sem="G_DRUG">guanabenz</cons> N-hydroxylation to be a suitable metabolic marker for <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> in biotransformation studies.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9328296</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="progesterone" sem="G_DRUG">Progesterone</cons> and <cons lex="testosterone" sem="G_DRUG">testosterone</cons> hydroxylation by cytochromes P450 <cons lex="2c19" sem="G_CYP">2C19</cons>, <cons lex="2c9" sem="G_CYP">2C9</cons>, and <cons lex="3a4" sem="G_CYP">3A4</cons> in human liver microsomes.</sentence>
</title>
<abstract>
<sentence>Roles of human cytochrome P450 (P450 or CYP) <cons lex="2c9" sem="G_CYP">2C9</cons>, <cons lex="2c19" sem="G_CYP">2C19</cons>, and <cons lex="3a4" sem="G_CYP">3A4</cons> in the <cons sem="G_MECHANISM">oxidation</cons> of <cons lex="progesterone" sem="G_DRUG">progesterone</cons> and <cons lex="testosterone" sem="G_DRUG">testosterone</cons> were studied in recombinant P450 enzymes and in human liver microsomes.</sentence>
<sentence>In vitro <cons sem="G_MECHANISM">inhibition</cons> experiments showed that <cons lex="progesterone" sem="G_DRUG">progesterone</cons> and its 17alpha- and 21-hydroxylated metabolites and 11-deoxycortisol <cons sem="G_MECHANISM">suppressed</cons> the <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>-dependent R-<cons lex="warfarin" sem="G_DRUG">warfarin</cons> 7-hydroxylation activities, with <cons lex="progesterone" sem="G_DRUG">progesterone</cons> being the most active.</sentence>
<sentence>These steroid chemicals also <cons sem="G_MECHANISM">inhibited</cons> <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>-dependent S-<cons lex="warfarin" sem="G_DRUG">warfarin</cons> 7-hydroxylation activities though lesser extents seen with those in <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> enzyme.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Progesterone, CYP2C19,DEI)(Progesterone, CYP2C9,DEI)">
<sentence><cons lex="progesterone" sem="G_DRUG">Progesterone</cons> was found to be a competitive <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> and <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> in human liver microsomes.</sentence>
</annotation>
<sentence>Recombinant <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> <cons sem="G_MECHANISM">catalyzed</cons> <cons lex="progesterone" sem="G_DRUG">progesterone</cons> to form 21-hydroxyprogesterone as a major product and 16alpha- and 17alpha-hydroxyprogesterone as <cons sem="G_CHANGE">minor</cons> products.</sentence>
<sentence><cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> also had <cons lex="progesterone" sem="G_DRUG">progesterone</cons> 21-hydroxylation activities, although the activities were lower than those <cons sem="G_MECHANISM">catalyzed</cons> by <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>.</sentence>
<sentence><cons sem="G_IVITPARA">Vmax/Km</cons> ratios for the <cons lex="progesterone" sem="G_DRUG">progesterone</cons> 21-hydroxylation activity of <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> were determined to be <cons sem="G_NUMBER">13- and 32-fold</cons> <cons sem="G_CHANGE">higher</cons> than those of <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> and <cons lex="3a4" sem="G_CYP">3A4</cons>, respectively.</sentence>
<sentence><cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> oxidized <cons lex="progesterone" sem="G_DRUG">progesterone</cons> to form 16alpha-, 6beta-, and 2beta-hydroxyprogesterone as major products and 21-hydroxyprogesterone as a <cons sem="G_CHANGE">minor</cons> product, but did <cons sem="G_NEGATIVEEFFECT">not</cons> produce detectable levels of 17alpha-hydroxyprogesterone.</sentence>
<annotation sem="INVITROCDDIS" ddi="(anti-CYP2C9 antibody, progesterone 21-hydroxylation,DDI)(anti-CYP2C11 antibody, progesterone 21-hydroxylation,DDI)">
<sentence>Immunoinhibition experiments suggested that anti-<cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> (which <cons sem="G_MECHANISM">inhibits</cons> both <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> and <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> catalytic activities) <cons sem="G_MECHANISM">suppressed</cons> the <cons lex="progesterone" sem="G_DRUG">progesterone</cons> 21-hydroxylation activities <cons sem="G_MECHANISM">catalyzed</cons> by liver microsomes of humans and monkeys and that anti-CYP2C11 <cons sem="G_MECHANISM">inhibited</cons> the <cons lex="progesterone" sem="G_DRUG">progesterone</cons> 21-hydroxylation activities <cons sem="G_MECHANISM">catalyzed</cons> by liver microsomes of male rats.</sentence>
</annotation>
<sentence><cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> was also found to oxidize <cons lex="testosterone" sem="G_DRUG">testosterone</cons> at 17-position to form androstenedione.</sentence>
<annotation sem="INVITROCDDIS" ddi="(anti-CYP2C9 antibody, Androstenedione,DDI)(anti-CYP2C11 antibody, Androstenedione,DDI)">
<sentence>Androstenedione <cons sem="G_MECHANISM">formation</cons> <cons sem="G_MECHANISM">catalyzed</cons> by liver microsomes of humans and monkeys and of male rats was <cons sem="G_MECHANISM">suppressed</cons> by anti-<cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> and anti-CYP2C11, respectively.</sentence>
</annotation>
<sentence>These results suggest that <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> plays important roles in the <cons sem="G_MECHANISM">oxidation</cons> of <cons lex="progesterone" sem="G_DRUG">progesterone</cons> and <cons lex="testosterone" sem="G_DRUG">testosterone</cons> in human liver microsomes, although the physiological <cons sem="G_CHANGE">significance</cons> of these metabolic pathways remains unclear.</sentence>
<sentence><cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> <cons sem="G_CHANGE">may</cons> have some, but lesser extent than those by <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>, of the catalytic roles for the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="progesterone" sem="G_DRUG">progesterone</cons> and <cons lex="testosterone" sem="G_DRUG">testosterone</cons> by human liver microsomes.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9278209</bibliomisc>
</articleinfo>
<title>
<sentence>Differential <cons sem="G_MECHANISM">inhibition</cons> of cytochrome P450 isoforms by the protease <cons sem="G_MECHANISM">inhibitors</cons>, <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons>, <cons lex="saquinavir" sem="G_DRUG">saquinavir</cons> and <cons lex="indinavir" sem="G_DRUG">indinavir</cons>.</sentence>
</title>
<abstract>
<sentence>To compare the <cons sem="G_MECHANISM">inhibitory</cons> potential of the HIV protease <cons sem="G_MECHANISM">inhibitors</cons> <cons lex="saquinavir" sem="G_DRUG">saquinavir</cons>, <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> and <cons lex="indinavir" sem="G_DRUG">indinavir</cons> against <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> catalysed metabolic reactions in human liver microsomes in vitro.</sentence>
<sentence>Microsomes from six human livers were utilized in this study.</sentence>
<sentence>The probe substrates were <cons lex="phenacetin" sem="G_DRUG">phenacetin</cons> (<cons sem="G_CYP">CYP1A2</cons>), <cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons> (<cons sem="G_CYP">CYP2C9</cons>), <cons lex="chlorzoxazone" sem="G_DRUG">chlorzoxazone</cons> (<cons sem="G_CYP">CYP2E1</cons>) and <cons lex="testosterone" sem="G_DRUG">testosterone</cons> (CYP3A4).</sentence>
<sentence>Metabolites were analysed by high performance liquid chromatography.</sentence>
<sentence><cons sem="G_IVITPARA">IC50</cons> (concentration of <cons sem="G_MECHANISM">inhibitor</cons> giving <cons sem="G_NUMBER">50%</cons> <cons sem="G_CHANGE">decrease</cons> in enzyme activity) and, where appropriate, <cons sem="G_IVITPARA">K(i)</cons> values were calculated.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Ritonavir, testosterone 6beta-hydroxylation,DDI)(Ritonavir, tolbutamide hydroxylation,DDI)">
<sentence><cons lex="ritonavir" sem="G_DRUG">Ritonavir</cons> was a very potent <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> mediated <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6beta-hydroxylation (mean <cons sem="G_IVITPARA">K(i)</cons> = <cons sem="G_NUMBER">0.019 +/- 0.004 microM, mean +/- s.d.; n = 6</cons>) and also <cons sem="G_MECHANISM">inhibited</cons> <cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons> hydroxylation (<cons sem="G_IVITPARA">IC50</cons> = <cons sem="G_NUMBER">4.2 +/- 1.3 microM, mean +/- s.d.; n = 6</cons>).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Ritonavir, phenacetin O-deethylation,NDDI)(Ritonavir, chlorzoxazone 6-hydroxylation,NDDI)">
<sentence><cons sem="G_MECHANISM">Inhibition</cons> of <cons lex="phenacetin" sem="G_DRUG">phenacetin</cons> O-deethylation and <cons lex="chlorzoxazone" sem="G_DRUG">chlorzoxazone</cons> 6-hydroxylation was <cons sem="G_NEGATIVEEFFECT"> <cons sem="G_CHANGE">negligible</cons></cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Indinavir, CYP3A4,DEI)">
<sentence><cons lex="indinavir" sem="G_DRUG">Indinavir</cons> was an order-of-magnitude less potent in inhibiting <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> (<cons sem="G_IVITPARA">K(i)</cons> = <cons sem="G_NUMBER">0.17 +/- 0.01 microM</cons>) and did <cons sem="G_NEGATIVEEFFECT">not</cons> produce appreciable <cons sem="G_MECHANISM">inhibition</cons> of the <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> or <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons> catalysed reactions.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Saquinavir, CYP3A4,DEI)(Saquinavir, CYP2C9,DEI)">
<sentence><cons lex="saquinavir" sem="G_DRUG">Saquinavir</cons> was the least potent <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitor</cons> (<cons sem="G_IVITPARA">K(i)</cons> = <cons sem="G_NUMBER">2.99 +/- 0.87 microM</cons>) and produced some <cons sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> (approximately <cons sem="G_NUMBER">50%</cons> at <cons sem="G_NUMBER">50 microM</cons>).</sentence>
</annotation>
<sentence>The HIV protease <cons sem="G_MECHANISM">inhibitors</cons> have differential effects on CYP isozymes.</sentence>
<sentence>There is <cons sem="G_CHANGE">obvious</cons> potential for clinically <cons sem="G_CHANGE">significant</cons> drug interactions particularly with <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons>.</sentence>
<sentence>Pharmacokinetic drug interaction studies are crucial to gain an overall understanding of the beneficial and potentially harmful effects of this important group of drugs.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9298257</bibliomisc>
</articleinfo>
<title>
<sentence>Applications of primary human hepatocytes in the evaluation of pharmacokinetic drug-drug interactions: evaluation of model drugs <cons lex="terfenadine" sem="G_DRUG">terfenadine</cons> and <cons lex="rifampin" sem="G_DRUG">rifampin</cons>.</sentence>
</title>
<abstract>
<sentence>The utility of primary human hepatocytes in the evaluation of drug-drug interactions is being investigated in our laboratories.</sentence>
<sentence>Our initial approach was to investigate whether drug-drug interactions observed in humans in vivo could be reproduced in vitro using human hepatocytes.</sentence>
<sentence>Two model drugs were studied: <cons lex="terfenadine" sem="G_DRUG">terfenadine</cons> and <cons lex="rifampin" sem="G_DRUG">rifampin</cons>, representing compounds subjected to drug-drug interactions via <cons sem="G_MECHANISM">inhibitory</cons> and <cons sem="G_MECHANISM">induction</cons> mechanisms, respectively.</sentence>
<sentence><cons lex="terfenadine" sem="G_DRUG">Terfenadine</cons> was found to be <cons sem="G_MECHANISM">metabolized</cons> by human hepatocytes to C-<cons sem="G_MECHANISM">oxidation</cons> and N-dealkylation products as observed in humans in vivo.</sentence>
<sentence><cons sem="G_MECHANISM">Metabolism</cons> by human hepatocytes was found to be <cons sem="G_MECHANISM">inhibited</cons> by drugs which are known to be <cons sem="G_MECHANISM">inhibitory</cons> in vivo.</sentence>
<annotation sem="INVITROCDDIS" ddi="(ketoconazole, C-oxidation,DDI)(itraconazole, C-oxidation,DDI)(cyclosporin, C-oxidation,DDI)(troleandomycin, C-oxidation,DDI)(erythromycin, C-oxidation,DDI)(naringenin, C-oxidation,DDI)">
<sentence><cons sem="G_IVITPARA">Ki</cons> values for the various <cons sem="G_MECHANISM">inhibitors</cons> were derived from the in vitro <cons sem="G_MECHANISM">metabolism</cons> data, resulting in the following ranking of <cons sem="G_MECHANISM">inhibitory</cons> potency: For the <cons sem="G_MECHANISM">inhibition</cons> of C-<cons sem="G_MECHANISM">oxidation</cons>, <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> &gt; <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> &gt; cyclosporin approximately <cons lex="troleandomycin" sem="G_DRUG">troleandomycin</cons> &gt; <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> &gt; <cons lex="naringenin" sem="G_DRUG">naringenin</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(itraconazole, N-dealkylation,DDI)(ketoconazole, N-dealkylation,DDI)(cyclosporin, N-dealkylation,DDI)(naringenin, N-dealkylation,DDI)(erythromycin, N-dealkylation,DDI)(troleandomycin, N-dealkylation,DDI)">
<sentence>For the <cons sem="G_MECHANISM">inhibition</cons> of N-dealkylation, <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> &gt; or = <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> &gt; <cons sem="G_DRUG">cyclosporin</cons> &gt; or = <cons lex="naringenin" sem="G_DRUG">naringenin</cons> &gt; or = <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> &gt; or = <cons lex="troleandomycin" sem="G_DRUG">troleandomycin</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Rifampin, CYP3A,DEI)">
<sentence><cons lex="rifampin" sem="G_DRUG">Rifampin</cons> <cons sem="G_MECHANISM">induction</cons> of <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>, a known effect of <cons lex="rifampin" sem="G_DRUG">rifampin</cons> in vivo, was also reproduced in primary human hepatocytes.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Rifampin, testosterone 6 beta-hydroxylation,DDI)">
<sentence><cons sem="G_MECHANISM">Induction</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, measured as <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6 beta-hydroxylation, was found to be dose-dependent, treatment duration-dependent, and reversible.</sentence>
</annotation>
<sentence>The <cons sem="G_MECHANISM">induction</cons> effect of <cons lex="rifampin" sem="G_DRUG">rifampin</cons> was observed in hepatocytes isolated from all 7 human donors studied, with ages ranging from 1.7 to 78 years.</sentence>
<sentence>To demonstrate that the <cons lex="rifampin" sem="G_DRUG">rifampin</cons>-<cons sem="G_MECHANISM">induction</cons> of <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6 beta-hydroxylation could be generalized to other <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> substrates, we evaluated the <cons sem="G_MECHANISM">metabolism</cons> of another known substrate of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, <cons lex="lidocaine" sem="G_DRUG">lidocaine</cons>.</sentence>
<sentence>Dose-dependent <cons sem="G_MECHANISM">induction</cons> of <cons lex="lidocaine" sem="G_DRUG">lidocaine</cons> <cons sem="G_MECHANISM">metabolism</cons> by <cons lex="rifampin" sem="G_DRUG">rifampin</cons> is observed.</sentence>
<sentence>Our results suggest that primary human hepatocytes <cons sem="G_CHANGE">may</cons> be a useful experimental system for preclinical evaluation of drug-drug interaction potential during drug development, and as a tool to evaluate the mechanism of clinically observed drug-drug interactions.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9224780</bibliomisc>
</articleinfo>
<title>
<sentence>Evaluation of <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> and <cons lex="lansoprazole" sem="G_DRUG">lansoprazole</cons> as <cons sem="G_MECHANISM">inhibitors</cons> of cytochrome P450 isoforms.</sentence>
</title>
<abstract>
<sentence>The human clearance of <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> and <cons lex="lansoprazole" sem="G_DRUG">lansoprazole</cons> is conducted primarily by the hepatic cytochrome P450 (CYP) system.</sentence>
<sentence>Efficacy data indicate few differences between these two drugs, but they <cons sem="G_CHANGE">may</cons> exhibit discrete drug interaction profiles.</sentence>
<sentence>To compare the potency and specificity of these drugs as <cons sem="G_MECHANISM">inhibitors</cons> of CYP isoforms, we performed in vitro studies with human liver microsomal preparations.</sentence>
<annotation sem="INVITROCDDIS" ddi="(omeprazole, 4-hydroxymephenytoin,DDI)(lansoprazole, 4-hydroxymephenytoin,DDI)">
<sentence>Both drugs were potent, competitive <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>, as measured by the conversion of S-<cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons> to 4-hydroxymephenytoin (<cons sem="G_IVITPARA">k(i)</cons> = <cons sem="G_NUMBER">3.1 +/- 2.2 microM</cons> for <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons>, <cons sem="G_IVITPARA">K(i)</cons> = <cons sem="G_NUMBER">3.2 +/- 1.3 microM</cons> for <cons sem="G_DRUG">lansoprazole</cons>).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(omeprazole, CYP2C19,DEI)">
<sentence>For <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons>, the highest concentration at which <cons sem="G_NUMBER">&gt;70%</cons> <cons sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> was observed with <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem="G_CHANGE">significant</cons> <cons sem="G_MECHANISM">inhibitory</cons> effect on other isoforms was at least <cons sem="G_NUMBER">20</cons> times <cons sem="G_CHANGE">greater</cons> than <cons sem="G_IVITPARA">K(i)</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(omeprazole, 4-hydroxytolbutamide,DDI)(lansoprazole, 4-hydroxytolbutamide,DDI)">
<sentence>Both drugs were competitive <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>-<cons sem="G_MECHANISM">catalyzed</cons> conversion of <cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons> to 4-hydroxytolbutamide (<cons sem="G_IVITPARA">K(i)</cons> = <cons sem="G_NUMBER">40.1 +/- 14.8 microM</cons> for <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons>, <cons sem="G_IVITPARA">K(i)</cons> = <cons sem="G_NUMBER">52.1 +/- 1.4 microM</cons>for <cons sem="G_DRUG">lansoprazole</cons>) and were noncompetitive <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>-<cons sem="G_MECHANISM">catalyzed</cons> conversion of <cons lex="dextromethorphan" sem="G_DRUG">dextromethorphan</cons> to 3-methoxymorphinan (<cons sem="G_IVITPARA">K(i)</cons> = <cons sem="G_NUMBER">84.4 +/- 4.0 microM</cons> for <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons>, <cons sem="G_IVITPARA">K(i)</cons> = <cons sem="G_NUMBER">170.4 +/- 7.1 microM</cons> for <cons sem="G_DRUG">lansoprazole</cons>).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(omeprazole, dextrorphan,NDDI)(Lansoprazole, dextrorphan,ADDI)">
<sentence><cons lex="lansoprazole" sem="G_DRUG">Lansoprazole</cons> was at least 5 times more potent (<cons sem="G_IVITPARA">K(i)</cons> = <cons sem="G_NUMBER">44.7 +/- 22.0 microM</cons>) than <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> (<cons sem="G_IVITPARA">k(i)</cons> = <cons sem="G_NUMBER">240.7 +/- 102.0 microM</cons>) as an <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>-mediated conversion of <cons lex="dextromethorphan" sem="G_DRUG">dextromethorphan</cons> to <cons sem="G_DRUG">dextrorphan</cons>.</sentence>
</annotation>
<annotation sem="INVITROVDDIS" ddi="(omeprazole, acetaminophen,NDDI)(Lansoprazole, acetaminophen,NDDI)">
<sentence><cons sem="G_NEGATIVEEFFECT">No</cons> <cons sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, assessed by measuring the conversion of <cons lex="phenacetin" sem="G_DRUG">phenacetin</cons> to <cons lex="acetaminophen" sem="G_DRUG">acetaminophen</cons>, was noted.</sentence>
</annotation>
<sentence>Our data suggest that whereas the <cons sem="G_MECHANISM">inhibitory</cons> profiles of these two drugs are similar, <cons lex="lansoprazole" sem="G_DRUG">lansoprazole</cons> <cons sem="G_CHANGE">may</cons> be the more important in vitro <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>.</sentence>
<sentence>Since its <cons sem="G_MECHANISM">inhibition</cons> is very potent and has a broad "window of selectivity," <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> seems to be a useful, selective <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9152599</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem="G_MECHANISM">Inhibition</cons> of human drug metabolizing cytochromes P450 by <cons lex="anastrozole" sem="G_DRUG">anastrozole</cons>, a potent and selective <cons sem="G_MECHANISM">inhibitor</cons> of aromatase.</sentence>
</title>
<abstract>
<sentence><cons lex="anastrozole" sem="G_DRUG">Anastrozole</cons> (2,2' [5(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]- bis(2-methylproprionitrile)) is a potent third-generation <cons sem="G_MECHANISM">inhibitor</cons> of aromatase, currently marketed as a treatment for postmenopausal women with advanced breast cancer.</sentence>
<sentence>While its potency and selectivity for <cons sem="G_MECHANISM">inhibition</cons> of estrogen synthesis has been established in both preclinical and clinical studies, this study used in vitro methods to examine the effects of <cons lex="anastrozole" sem="G_DRUG">anastrozole</cons> on several drug metabolizing CYP enzymes found in human liver.</sentence>
<sentence>Human liver microsomes were co-incubated with <cons lex="anastrozole" sem="G_DRUG">anastrozole</cons> and probe substrates for <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> (<cons sem="G_DRUG">phenacetin</cons>), <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons> (<cons sem="G_DRUG">coumarin</cons>), <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> (<cons sem="G_DRUG">tolbutamide</cons>), <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> (<cons sem="G_DRUG">dextromethorphan</cons>), and <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> (<cons sem="G_DRUG">nifedipine</cons>).</sentence>
<sentence>The <cons sem="G_MECHANISM">formation</cons> of the CYP-specific metabolites following co-incubation with various <cons lex="anastrozole" sem="G_DRUG">anastrozole</cons> concentrations was determined to establish <cons sem="G_IVITPARA">IC50</cons> and <cons sem="G_IVITPARA">Ki</cons> values for these enzymes.</sentence>
<annotation sem="INVITROCDDIS" ddi="(anastrozole, CYP2A6,NDEI)(anastrozole, CYP2D6,NDEI)(anastrozole, CYP1A2,NDEI)(anastrozole, CYP2C9,NDEI)(anastrozole, CYP3A,NDEI)">
<sentence>While <cons lex="anastrozole" sem="G_DRUG">anastrozole</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_MECHANISM">inhibit</cons> <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons> and <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> activities at concentrations below <cons sem="G_NUMBER">500 microM</cons>, this compound <cons sem="G_MECHANISM">inhibited</cons> <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, and <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> activities with <cons sem="G_IVITPARA">Ki</cons> values of <cons sem="G_NUMBER">8, 10, and 10 microM</cons>, respectively.</sentence>
</annotation>
<sentence>Dixon plots used to determine the <cons sem="G_IVITPARA">Ki</cons> values for the <cons sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> and <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> activities by <cons lex="anastrozole" sem="G_DRUG">anastrozole</cons> were biphasic, indicating additional lower affinity <cons sem="G_IVITPARA">Ki</cons> values.</sentence>
<annotation sem="INVITROCDDIS" ddi="(anastrozole, nifedipine,NDDI)">
<sentence>Major metabolites of <cons lex="anastrozole" sem="G_DRUG">anastrozole</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> retain the ability to <cons sem="G_MECHANISM">inhibit</cons> the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="nifedipine" sem="G_DRUG">nifedipine</cons> (<cons sem="G_CYP">CYP3A</cons>).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(anastrozole, CYP1A2,DEI)(anastrozole, CYP2C9,DEI)(anastrozole, CYP3A,DEI)">
<sentence>The results of this study indicate that, although <cons lex="anastrozole" sem="G_DRUG">anastrozole</cons> can <cons sem="G_MECHANISM">inhibit</cons> <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, <cons lex="2c9" sem="G_CYP">2C9</cons>, and <cons lex="3a" sem="G_CYP">3A</cons>-mediated catalytic activities, this compound would <cons sem="G_NEGATIVEEFFECT">not</cons> be expected to cause clinically <cons sem="G_CHANGE">significant</cons> interactions with other CYP-<cons sem="G_MECHANISM">metabolized</cons> drugs at physiologically relevant concentrations achieved during therapy with <cons sem="G_DRUG">Arimidex</cons> (Zeneca, Ltd., Macclesfield, UK) <cons sem="G_NUMBER">1-mg</cons>.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9143352</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem="G_MECHANISM">Inhibition</cons> of <cons sem="G_DRUG">coumarin</cons> 7-hydroxylase activity in human liver microsomes.</sentence>
</title>
<abstract>
<sentence>Nine organic solvents and 47 commonly used P450 substrates and <cons sem="G_MECHANISM">inhibitors</cons> were examined for their effects on <cons sem="G_DRUG">coumarin</cons> 7-hydroxylase (<cons sem="G_CYP">CYP2A6</cons>) activity in human liver microsomes.</sentence>
<sentence>Of the nine organic solvents examined (<cons sem="G_IVITPARA">final concentration</cons> 1%, v/v), only methanol did <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_MECHANISM">inhibit</cons> the 7-hydroxylation of coumarin (<cons sem="G_NUMBER">0.5 to 50 microM</cons>) by human liver microsomes.</sentence>
<sentence><cons sem="G_DRUG">Dioxane</cons> and tetra-hydrofuran, which are structurally related to <cons sem="G_DRUG">coumarin</cons>, were the most <cons sem="G_MECHANISM">inhibitory</cons> solvents examined.</sentence>
<sentence>Although the rates of <cons sem="G_DRUG">coumarin</cons> 7-hydroxylation varied enormously among nine samples of human liver microsomes and cDNA-expressed <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons> (<cons sem="G_IVITPARA">Vmax</cons> = <cons sem="G_NUMBER">179 to 2470 pmol/ mg protein/min</cons>), the <cons sem="G_IVITPARA">Km</cons> for <cons sem="G_DRUG">coumarin</cons> 7-hydroxylation was fairly constant (ranging from <cons sem="G_NUMBER">0.50 to 0.70 microM</cons>).</sentence>
<annotation sem="INVITROCDDIS" ddi="(caffeine, CYP2A6,NDEI)(chlorzoxazone, CYP2A6,NDEI)(cimetidine, CYP2A6,NDEI)(dextromethorphan, CYP2A6,NDEI)(diazepam, CYP2A6,NDEI)(diclofenac, CYP2A6,NDEI)(erythromycin, CYP2A6,NDEI)(ethinylestradiol, CYP2A6,NDEI)(ethynyltestosterone, CYP2A6,NDEI)(fluconazole, CYP2A6,NDEI)(furafylline, CYP2A6,NDEI)(furfural, CYP2A6,NDEI)(hexobarbital, CYP2A6,NDEI)(itraconazole, CYP2A6,NDEI)(mephenytoin, CYP2A6,NDEI)(methimazole, CYP2A6,NDEI)(metronidazole, CYP2A6,NDEI)(naringenin, CYP2A6,NDEI)(naringin, CYP2A6,NDEI)(nifedipine, CYP2A6,NDEI)(norfloxacin, CYP2A6,NDEI)(norgestrel, CYP2A6,NDEI)(orphenadrine, CYP2A6,NDEI)(quinidine, CYP2A6,NDEI)(papaverine, CYP2A6,NDEI)(phenacetin, CYP2A6,NDEI)(pyrimethamine, CYP2A6,NDEI)(ranitidine, CYP2A6,NDEI)(spironolactone, CYP2A6,NDEI)(sulfaphenazole, CYP2A6,NDEI)(testosterone, CYP2A6,NDEI)(tolbutamide, CYP2A6,NDEI)(troleandomycin, CYP2A6,NDEI)(warfarin, CYP2A6,NDEI)">
<sentence>The following chemicals caused <cons sem="G_CHANGE">little</cons> or <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons> as defined by a <cons sem="G_IVITPARA">Ki</cons> <cons sem="G_NUMBER">&gt; 200 microM</cons>: <cons lex="caffeine" sem="G_DRUG">caffeine</cons>, <cons lex="chlorzoxazone" sem="G_DRUG">chlorzoxazone</cons>, <cons lex="cimetidine" sem="G_DRUG">cimetidine</cons>, <cons lex="dextromethorphan" sem="G_DRUG">dextromethorphan</cons>, <cons lex="diazepam" sem="G_DRUG">diazepam</cons>, <cons lex="diclofenac" sem="G_DRUG">diclofenac</cons>, <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons>, <cons lex="ethinylestradiol" sem="G_DRUG">ethinylestradiol</cons>, <cons sem="G_DRUG">ethynyltestosterone</cons>, <cons lex="fluconazole" sem="G_DRUG">fluconazole</cons>, <cons lex="furafylline" sem="G_DRUG">furafylline</cons>, <cons sem="G_DRUG">furfural</cons>, <cons lex="hexobarbital" sem="G_DRUG">hexobarbital</cons>, <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>, <cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons>, <cons lex="methimazole" sem="G_DRUG">methimazole</cons>, <cons lex="metronidazole" sem="G_DRUG">metronidazole</cons>, <cons lex="naringenin" sem="G_DRUG">naringenin</cons>, <cons sem="G_DRUG">naringin</cons>, <cons lex="nifedipine" sem="G_DRUG">nifedipine</cons>, <cons lex="norfloxacin" sem="G_DRUG">norfloxacin</cons>, <cons lex="norgestrel" sem="G_DRUG">norgestrel</cons>, <cons lex="orphenadrine" sem="G_DRUG">orphenadrine</cons>, <cons lex="quinidine" sem="G_DRUG">quinidine</cons>, <cons lex="papaverine" sem="G_DRUG">papaverine</cons>, <cons lex="phenacetin" sem="G_DRUG">phenacetin</cons>, <cons lex="pyrimethamine" sem="G_DRUG">pyrimethamine</cons>, <cons lex="ranitidine" sem="G_DRUG">ranitidine</cons>, <cons lex="spironolactone" sem="G_DRUG">spironolactone</cons>, sulfaphenazole, <cons lex="sulfinpyrazone" sem="G_DRUG">sulfinpyrazone</cons>, <cons lex="testosterone" sem="G_DRUG">testosterone</cons>, <cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons>, <cons lex="troleandomycin" sem="G_DRUG">troleandomycin</cons>, and <cons lex="warfarin" sem="G_DRUG">warfarin</cons>.</sentence>
</annotation>
<sentence>In other words, these chemicals, at a final concentration of <cons sem="G_NUMBER">100 microM</cons>, failed to <cons sem="G_MECHANISM">inhibit</cons> <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons> when the concentration of coumarin was equal to <cons sem="G_IVITPARA">Km</cons> (<cons sem="G_NUMBER">0.50 microM</cons>).</sentence>
<annotation sem="INVITROCDDIS" ddi="(clotrimazole, CYP2A6,DEI)(diethyldithiocarbamate, CYP2A6,DEI)(ellipticine, CYP2A6,DEI)(ketoconazole, CYP2A6,DEI)(8-methoxypsoralen, CYP2A6,DEI)(4-methylpyrazole, CYP2A6,DEI)(metyrapone, CYP2A6,DEI)(miconazole, CYP2A6,DEI)(alpha-naphthoflavone, CYP2A6,DEI)(nicotine, CYP2A6,DEI)(p-nitrophenol, CYP2A6,DEI)(tranylcypromine, CYP2A6,DEI)">
<sentence>The following chemicals were classified as strong <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons> (defined by <cons sem="G_IVITPARA">Ki</cons> <cons sem="G_NUMBER">&lt; 200 microM</cons>): <cons lex="clotrimazole" sem="G_DRUG">clotrimazole</cons>, <cons lex="diethyldithiocarbamate" sem="G_DRUG">diethyldithiocarbamate</cons>, <cons sem="G_DRUG">ellipticine</cons>, <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>, <cons sem="G_DRUG">8-methoxypsoralen</cons>, <cons sem="G_DRUG">4-methylpyrazole</cons>, <cons lex="metyrapone" sem="G_DRUG">metyrapone</cons>, <cons lex="miconazole" sem="G_DRUG">miconazole</cons>, <cons sem="G_DRUG">alpha-naphthoflavone</cons>, <cons lex="nicotine" sem="G_DRUG">nicotine</cons>, <cons sem="G_DRUG">p-nitrophenol</cons>, and <cons lex="tranylcypromine" sem="G_DRUG">tranylcypromine</cons>.</sentence>
</annotation>
<sentence>The potency with which each chemical <cons sem="G_MECHANISM">inhibited</cons> the 7-hydroxylation of coumarin was independent of which sample of human liver microsomes was studied.</sentence>
<annotation sem="INVITROCDDIS" ddi="(8-methoxypsoralen, coumarin 7-hydroxylase,DDI)">
<sentence>One of the most potent <cons sem="G_MECHANISM">inhibitors</cons> of <cons sem="G_DRUG">coumarin</cons> 7-hydroxylase was <cons sem="G_DRUG">8-methoxypsoralen (methoxsalen)</cons>, which was determined to be a mechanism-based <cons sem="G_MECHANISM">inhibitor</cons> (suicide substrate) of <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons> <cons sem="G_DRUG">(k(inactivation)</cons> <cons sem="G_NUMBER">0.5 min-1</cons>).</sentence>
</annotation>
<sentence>With the exception of 8-methoxypsoralen, preincubation of human liver microsomes and NADPH with the aforementioned <cons sem="G_MECHANISM">inhibitors</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">increase</cons> their ability to <cons sem="G_MECHANISM">inhibit</cons> <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(tranylcypromine, CYP2A6,DEI)">
<sentence>The most potent competitive <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons> was <cons lex="tranylcypromine" sem="G_DRUG">tranylcypromine</cons> (<cons sem="G_IVITPARA">Ki</cons> = <cons sem="G_NUMBER">0.04 microM</cons>).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(ketoconazole, CYP2A6,DEI)(tranylcypromine, CYP2A6,DEI)">
<sentence>Several of the chemicals that strongly <cons sem="G_MECHANISM">inhibited</cons> <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons>, such as <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> and <cons lex="tranylcypromine" sem="G_DRUG">tranylcypromine</cons>, are often used with the intention of selectively inhibiting human P450 enzymes other than <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons>.</sentence>
</annotation>
<sentence>The results of this study underscore the need for a systematic evaluation of the specificity of commonly used P450 <cons sem="G_MECHANISM">inhibitors</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9107550</bibliomisc>
</articleinfo>
<title>
<sentence>Human cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4</cons>-<cons sem="G_MECHANISM">catalyzed</cons> <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6 beta-hydroxylation and <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> N-demethylation. Competition during catalysis.</sentence>
</title>
<abstract>
<sentence>Cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4</cons> is known to catalyze the <cons sem="G_MECHANISM">metabolism</cons> of both endogenous substrates (such as the 6 beta-hydroxylation of testosterone) and many important therapeutic agents, including the N-demethylation of <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons>.</sentence>
<sentence>However, <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> and <cons lex="testosterone" sem="G_DRUG">testosterone</cons> have been reported to have <cons sem="G_CHANGE">little</cons> or <cons sem="G_NEGATIVEEFFECT">no</cons> effect on the <cons sem="G_MECHANISM">metabolism</cons> of each other by recombinant <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
<sentence>In an effort to understand the basis of these observations, we studied the N-demethylation of <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> and the 6 beta-hydroxylation of <cons lex="testosterone" sem="G_DRUG">testosterone</cons> in human liver microsomes and in microsomes from cells containing recombinant human <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and P450 reductase under a variety of experimental conditions.</sentence>
<annotation sem="INVITROCDDIS" ddi="(erythromycin, testosterone 6 beta-hydroxylation,DDI)">
<sentence>In both human liver microsomal and recombinant <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> systems, <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> <cons sem="G_MECHANISM">inhibited</cons> <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6 beta-hydroxylation in a concentration dependent manner, and vice versa.</sentence>
</annotation>
<sentence>However, the <cons sem="G_MECHANISM">inhibition</cons> mechanism was complex.</sentence>
<annotation sem="INVITROCDDIS" ddi="(testosterone, erythromycin,DDI)">
<sentence>At low substrate concentrations, <cons lex="testosterone" sem="G_DRUG">testosterone</cons> and <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> acted as competitive <cons sem="G_MECHANISM">inhibitors</cons> to each other.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(erythromycin, testosterone 6 beta-hydroxylation,DDI)">
<sentence>Under these experimental conditions, an apparent competitive <cons sem="G_MECHANISM">inhibition</cons> of <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6 beta-hydroxylation by <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> was observed, with <cons sem="G_IVITPARA">Ki</cons> values similar to that of the <cons sem="G_IVITPARA">K(m)</cons> values for <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons>.</sentence>
</annotation>
<sentence>When the rates of <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6 beta-hydroxylation and <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> N-demethylation were determined in microsomal incubations containing both substrates at lower concentrations, the observed rates for each reaction were in good agreement with the calculated rates based on the rate equation describing simultaneous <cons sem="G_MECHANISM">metabolism</cons> of two substrates by a single enzyme.</sentence>
<sentence>However, at high substrate concentrations, the kinetic results could be best explained by a mechanism involving partial competitive <cons sem="G_MECHANISM">inhibition</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(testosterone, erythromycin,DDI)">
<sentence>We conclude from these studies that <cons lex="testosterone" sem="G_DRUG">testosterone</cons> and <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> mutually <cons sem="G_MECHANISM">inhibit</cons> the <cons sem="G_MECHANISM">metabolism</cons> of each other, consistent with the fact that CYP <cons lex="3a4" sem="G_CYP">3A4</cons> catalyzes the <cons sem="G_MECHANISM">metabolism</cons> of both substrates.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9103523</bibliomisc>
</articleinfo>
<title>
<sentence>Cytochrome P450 <cons lex="2e1" sem="G_CYP">2E1</cons> is the principal catalyst of human oxidative <cons lex="halothane" sem="G_DRUG">halothane</cons> <cons sem="G_MECHANISM">metabolism</cons> in vitro.</sentence>
</title>
<abstract>
<sentence>The volatile anesthetic <cons lex="halothane" sem="G_DRUG">halothane</cons> undergoes substantial biotransformation generating metabolites that mediate hepatotoxicity.</sentence>
<sentence>Aerobically, <cons lex="halothane" sem="G_DRUG">halothane</cons> undergoes cytochrome P450-<cons sem="G_MECHANISM">catalyzed</cons> <cons sem="G_MECHANISM">oxidation</cons> to <cons sem="G_DRUG">trifluoroacetic acid (TFA)</cons>, bromide and a reactive intermediate that can acetylate liver proteins.</sentence>
<sentence>These protein neo-antigens <cons sem="G_MECHANISM">stimulate</cons> an immune reaction that mediates severe hepatic necrosis ("halothane hepatitis").</sentence>
<sentence>This investigation identified the human P450 isoform(s) that catalyze oxidative <cons lex="halothane" sem="G_DRUG">halothane</cons> <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
<sentence><cons lex="halothane" sem="G_DRUG">Halothane</cons> <cons sem="G_MECHANISM">oxidation</cons> by human liver microsomes was assessed by <cons sem="G_DRUG">TFA</cons> and bromide <cons sem="G_MECHANISM">formation</cons>.</sentence>
<sentence>Eadie-Hofstee plots of <cons sem="G_DRUG">TFA</cons> and bromide <cons sem="G_MECHANISM">formation</cons> were both nonlinear, suggesting the participation of multiple P450s.</sentence>
<annotation sem="INVITROCDDIS" ddi="(8-methoxypsoralen, TFA,DDI)(coumarin, TFA,DDI)(4-methylpyrazole, TFA,DDI)(diethyldithiocarbamate, TFA,DDI)(8-methoxypsoralen, bromide,DDI)(coumarin, bromide,DDI)(4-methylpyrazole, bromide,DDI)(diethyldithiocarbamate, bromide,DDI)">
<sentence>Microsomal TFA and bromide <cons sem="G_MECHANISM">formation</cons> were <cons sem="G_MECHANISM">inhibited</cons> <cons sem="G_NUMBER">45 to 66% and 21 to 26%</cons>, respectively, by the P450 <cons lex="2a6" sem="G_CYP">2A6</cons> <cons sem="G_MECHANISM">inhibitors</cons> <cons sem="G_DRUG">8-methoxypsoralen</cons> and <cons sem="G_DRUG">coumarin</cons>, <cons sem="G_NUMBER">84 to 90%</cons> by the P450 <cons lex="2e1" sem="G_CYP">2E1</cons> <cons sem="G_MECHANISM">inhibitor</cons> <cons sem="G_DRUG">4-methylpyrazole</cons> and <cons sem="G_NUMBER">55%</cons> by <cons lex="diethyldithiocarbamate" sem="G_DRUG">diethyldithiocarbamate</cons>, an <cons sem="G_MECHANISM">inhibitor</cons> of both P450 <cons lex="2a6" sem="G_CYP">2A6</cons> and <cons lex="2e1" sem="G_CYP">2E1</cons>.</sentence>
</annotation>
<annotation sem="INVITROVDDIS" ddi="(CYP1A, halothane oxidation,NDEI)(CYP2B6, halothane oxidation,NDEI)(CYP2C9/10, halothane oxidation,NDEI)(CYP2D6, halothane oxidation,NDEI)(CYP3A4, halothane oxidation,NDEI)">
<sentence>Selective <cons sem="G_MECHANISM">inhibitors</cons> of P450s <cons lex="1a" sem="G_CYP">1A</cons>, <cons lex="2b6" sem="G_CYP">2B6</cons>, <cons sem="G_CYP">2C9/10</cons>, <cons lex="2d6" sem="G_CYP">2D6</cons> and <cons lex="3a4" sem="G_CYP">3A4</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> affect <cons lex="halothane" sem="G_DRUG">halothane</cons> <cons sem="G_MECHANISM">oxidation</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(CYP2A6, TFA,DEI)(CYP2B6, TFA,DEI)(CYP2E1, TFA,NDEI)">
<sentence>At saturating <cons lex="halothane" sem="G_DRUG">halothane</cons> concentrations (<cons sem="G_NUMBER">2.4 vol%</cons>) only cDNA-expressed P450 <cons lex="2a6" sem="G_CYP">2A6</cons> and <cons lex="2b6" sem="G_CYP">2B6</cons> <cons sem="G_MECHANISM">catalyzed</cons> <cons sem="G_CHANGE">significant</cons> rates of TFA and bromide <cons sem="G_MECHANISM">formation</cons>, and P450 <cons lex="2e1" sem="G_CYP">2E1</cons> <cons sem="G_MECHANISM">catalyzed</cons> comparatively minimal <cons sem="G_MECHANISM">oxidation</cons>.</sentence>
</annotation>
<sentence>Conversely, at subsaturating <cons lex="halothane" sem="G_DRUG">halothane</cons> concentrations (<cons sem="G_NUMBER">0.30 vol%</cons>), <cons sem="G_MECHANISM">metabolism</cons> by P450 <cons lex="2e1" sem="G_CYP">2E1</cons> exceeded that by P450 <cons lex="2a6" sem="G_CYP">2A6</cons>.</sentence>
<sentence>Among a panel of human liver microsomes, there were <cons sem="G_CHANGE">significant</cons> linear correlations between <cons lex="halothane" sem="G_DRUG">halothane</cons> <cons sem="G_MECHANISM">oxidation</cons> and P450 <cons lex="2a6" sem="G_CYP">2A6</cons> activity and protein content at saturating <cons lex="halothane" sem="G_DRUG">halothane</cons> concentrations (<cons sem="G_NUMBER">2.4 vol%</cons>), and a <cons sem="G_CHANGE">significant</cons> <cons sem="G_MECHANISM">correlation</cons> between metabolite <cons sem="G_MECHANISM">formation</cons> and P450 <cons lex="2e1" sem="G_CYP">2E1</cons> activity (but <cons sem="G_NEGATIVEEFFECT">not</cons> P450 <cons lex="2a6" sem="G_CYP">2A6</cons> activity) at subsaturating concentrations (<cons sem="G_NUMBER">0.12 vol%</cons>).</sentence>
<sentence>These experiments suggested P450 <cons lex="2a6" sem="G_CYP">2A6</cons> and <cons lex="2e1" sem="G_CYP">2E1</cons> as the predominant catalysts at saturating and subsaturating <cons lex="halothane" sem="G_DRUG">halothane</cons> concentrations, respectively.</sentence>
<sentence>Further kinetic analysis using cDNA-expressed P450 and liver microsomes clearly demonstrated that P450 <cons lex="2e1" sem="G_CYP">2E1</cons> is the high affinity/low capacity isoform (<cons sem="G_IVITPARA">Km</cons> = <cons sem="G_NUMBER">0.030-0.053 vol%</cons>) and P450 <cons lex="2a6" sem="G_CYP">2A6</cons> is the low affinity/high capacity isoform (<cons sem="G_IVITPARA">Km</cons> = <cons sem="G_NUMBER">0.77-1.2 vol%</cons>).</sentence>
<sentence>Evidence was also obtained for substrate <cons sem="G_MECHANISM">inhibition</cons> of P450 <cons lex="2e1" sem="G_CYP">2E1</cons>.</sentence>
<sentence>The in vitro clearance estimates <cons sem="G_IVITPARA">(Vmax/Km)</cons> for microsomal P450 <cons lex="2e1" sem="G_CYP">2E1</cons> (<cons sem="G_NUMBER">4.3-5.7 ml/min/g</cons>) were substantially <cons sem="G_CHANGE">greater</cons> than those for microsomal P450 <cons lex="2a6" sem="G_CYP">2A6</cons> (0.12-0.21).</sentence>
<sentence>These clearances, as well as rates of apparent <cons lex="halothane" sem="G_DRUG">halothane</cons> <cons sem="G_MECHANISM">oxidation</cons> predicted from kinetic parameters in conjunction with plasma <cons lex="halothane" sem="G_DRUG">halothane</cons> concentrations measured during clinical anesthesia in humans, demonstrated that both P450 <cons lex="2e1" sem="G_CYP">2E1</cons> and P450 <cons lex="2a6" sem="G_CYP">2A6</cons> participate in human <cons lex="halothane" sem="G_DRUG">halothane</cons> <cons sem="G_MECHANISM">metabolism</cons>, and that P450 <cons lex="2e1" sem="G_CYP">2E1</cons> is the predominant catalytic isoform.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9105404</bibliomisc>
</articleinfo>
<title>
<sentence>Distinction of <cons lex="cyp1a1" sem="G_CYP">CYP1A1</cons> and <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> activity by selective <cons sem="G_MECHANISM">inhibition</cons> using <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> and <cons sem="G_DRUG">Isosafrole</cons>.</sentence>
</title>
<abstract>
<sentence><cons sem="G_DRUG">Ethoxyresorufin</cons> O-deethylation (EROD) has been used as a specific probe for <cons lex="cyp1a1" sem="G_CYP">CYP1A1</cons> and <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>.</sentence>
<sentence>Selective <cons sem="G_MECHANISM">inhibition</cons> of one of these cytochromes P450 <cons sem="G_CHANGE">may</cons> differentiate their activity in human liver.</sentence>
<sentence>Four <cons sem="G_MECHANISM">inhibitors</cons> were chosen to examine the selective <cons sem="G_MECHANISM">inhibition</cons> of EROD activity, using cDNA of <cons lex="cyp1a1" sem="G_CYP">CYP1A1</cons> and <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>.</sentence>
<sentence>The two flavones, alpha-naphthoflavone and apigenin, while differing in potency, <cons sem="G_MECHANISM">inhibited</cons> expressed human <cons lex="cyp1a1" sem="G_CYP">CYP1A1</cons>, <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, and human liver microsomes to a similar extent.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Isosafrole, CYP1A2,ADEI)(fluvoxamine, CYP1A2,NDEI)">
<sentence><cons sem="G_DRUG">Isosafrole</cons> and <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> were found to <cons sem="G_MECHANISM">inhibit</cons> <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> selectively, with <cons sem="G_IVITPARA">Ki</cons> values of <cons sem="G_NUMBER">14 and 800</cons> times, respectively, lower than those for <cons sem="G_CYP">CYP1A1</cons>.</sentence>
</annotation>
<sentence>A set of equations was developed to estimate both <cons lex="cyp1a1" sem="G_CYP">CYP1A1</cons> and <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> activity.</sentence>
<sentence>Levels of <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> in four human liver specimens ranged from <cons sem="G_NUMBER">44.4 to 76.7 pmol/mg</cons> protein, which <cons sem="G_CHANGE">significantly</cons> <cons sem="G_MECHANISM">correlated</cons> with <cons lex="phenacetin" sem="G_DRUG">phenacetin</cons> O-deethylase activity (<cons sem="G_NUMBER">r = 0.99; P &lt; 0.001</cons>).</sentence>
<sentence>Low levels of <cons lex="cyp1a1" sem="G_CYP">CYP1A1</cons> activity were present in all four investigated livers, ranging from <cons sem="G_NUMBER">0.4 to 2.7 pmol/mg</cons> protein.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9023313</bibliomisc>
</articleinfo>
<title>
<sentence>Biotransformation of parathion in human liver: participation of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and its <cons sem="G_MECHANISM">inactivation</cons> during microsomal parathion <cons sem="G_MECHANISM">oxidation</cons>.</sentence>
</title>
<abstract>
<sentence>Studies in rat liver have shown that cytochrome P450 (CYP) enzymes mediate the oxidative biotransformation of the phosphorothioate pesticide parathion to paraoxon and 4-nitrophenol.</sentence>
<sentence>Transfer of the phosphorothioate thionosulfur atom to the CYP apoprotein results in amino acid modification and enzyme <cons sem="G_MECHANISM">inactivation</cons>.</sentence>
<sentence>Our study investigated the role of human hepatic CYP in parathion <cons sem="G_MECHANISM">oxidation</cons> and their relative susceptibilities to <cons sem="G_MECHANISM">inhibition</cons> and <cons sem="G_MECHANISM">inactivation</cons>.</sentence>
<sentence>Rates of parathion <cons sem="G_MECHANISM">oxidation</cons> varied about 10-fold in microsomes from 23 individual livers (<cons sem="G_NUMBER">1.72-18.33 nmol</cons> total metabolites/mg protein/min).</sentence>
<sentence>Linear regression of rates of parathion <cons sem="G_MECHANISM">oxidation</cons> with those of other microsomal CYP reactions implicated <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> in the reaction.</sentence>
<sentence>Thus, parathion <cons sem="G_MECHANISM">oxidation</cons> was <cons sem="G_MECHANISM">correlated</cons> strongly with <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6beta-hydroxylation (<cons sem="G_NUMBER">r2 = 0.95, n = 11</cons>), but <cons sem="G_NEGATIVEEFFECT">not</cons> with activities mediated by CYP <cons lex="1a2" sem="G_CYP">1A2</cons>, <cons lex="2c9" sem="G_CYP">2C9</cons> or <cons lex="2e1" sem="G_CYP">2E1</cons>.</sentence>
<sentence>CYP <cons lex="3a4" sem="G_CYP">3A4</cons> expressed in lymphoblastoid cell lines was an efficient catalyst of parathion <cons sem="G_MECHANISM">oxidation</cons>, although CYP <cons lex="1a2" sem="G_CYP">1A2</cons> and <cons lex="2b6" sem="G_CYP">2B6</cons> also <cons sem="G_MECHANISM">catalyzed</cons> the activity.</sentence>
<sentence>The <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitors</cons> <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> and triacetyloleandomycin <cons sem="G_CHANGE">decreased</cons> the observed rate of microsomal parathion <cons sem="G_MECHANISM">oxidation</cons>, but chemicals known to interact preferentially with other human CYP were essentially noninhibitory.</sentence>
<sentence>P450 was lost during parathion biotransformation in human hepatic microsomes.</sentence>
<sentence>Thus, incubation (10 min) of parathion (<cons sem="G_NUMBER">25 microM</cons>) with NADPH-supplemented microsomes led to an apparent <cons sem="G_NUMBER">19 +/- 4%</cons> <cons sem="G_CHANGE">decrease</cons> in holo-P450 content.</sentence>
<sentence>Several CYP-specific <cons sem="G_MECHANISM">oxidation</cons> reactions were <cons sem="G_MECHANISM">inhibited</cons> and <cons sem="G_MECHANISM">inactivated</cons> by parathion.</sentence>
<sentence><cons lex="testosterone" sem="G_DRUG">Testosterone</cons> 6beta-hydroxylation (mediated by <cons sem="G_CYP">CYP3A4</cons>), 7-ethylresorufin O-deethylation (<cons sem="G_CYP">CYP1A2</cons>) and <cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons> methyl hydroxylation (<cons sem="G_CYP">CYP<cons sem="G_CYP">2C9/10</cons></cons>), but <cons sem="G_NEGATIVEEFFECT">not</cons> aniline 4-hydroxylation (<cons sem="G_CYP">CYP2E1</cons>), were <cons sem="G_MECHANISM">inhibited</cons> effectively by parathion.</sentence>
<sentence>Preincubation of microsomes with parathion and NADPH intensified the extent of <cons sem="G_MECHANISM">inhibition</cons> (i.e., elicited <cons sem="G_MECHANISM">inactivation</cons>) of reactions mediated by <cons lex="3a4" sem="G_CYP">3A4</cons> and <cons lex="1a2" sem="G_CYP">1A2</cons> and, to a lesser extent, <cons lex="2c9" sem="G_CYP">2C9</cons>.</sentence>
<sentence>In summary, these findings strongly implicate CYP <cons lex="3a4" sem="G_CYP">3A4</cons> as the principal catalyst of parathion <cons sem="G_MECHANISM">oxidation</cons> in human liver, although other CYP <cons sem="G_CHANGE">may</cons> play a lesser role.</sentence>
<sentence>During parathion <cons sem="G_MECHANISM">oxidation</cons> <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> undergoes <cons sem="G_CHANGE">significant</cons> <cons sem="G_MECHANISM">inactivation</cons>.</sentence>
<sentence>In view of the role of this enzyme in the <cons sem="G_MECHANISM">oxidation</cons> of many therapeutic agents, exposure to phosphorothioate pesticides <cons sem="G_CHANGE">may</cons> adversely affect drug elimination in humans.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9023308</bibliomisc>
</articleinfo>
<title>
<sentence>Identification of cytochrome P450 isoforms involved in <cons lex="citalopram" sem="G_DRUG">citalopram</cons> N-demethylation by human liver microsomes.</sentence>
</title>
<abstract>
<sentence>Studies to assess the enzyme kinetic behavior and to identify the cytochrome P450 (CYP) isoform(s) involved in the major metabolic pathway (N-demethylation) for <cons lex="citalopram" sem="G_DRUG">citalopram</cons> (<cons sem="G_DRUG">CIT</cons>), a selective serotonin reuptake <cons sem="G_MECHANISM">inhibitor</cons>, were performed using human liver microsomes and cDNA-expressed human cytochrome P450 isoforms.</sentence>
<sentence>The N-demethylation activities showed <cons sem="G_CHANGE">significant</cons> correlations with the alpha- and 4-hydroxylation activities of <cons lex="triazolam" sem="G_DRUG">triazolam</cons> (r(s) = 0.818 and 0.851, respectively; P &lt; .01) in 10 different human liver microsomes.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Anti-CYP3A antibodies, CIT N-demethylation,DDI)(ketoconazole, CIT N-demethylation,DDI)">
<sentence>Anti-<cons lex="cyp3a" sem="G_CYP">CYP3A</cons> antibodies and <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> strongly <cons sem="G_MECHANISM">inhibited</cons> <cons sem="G_DRUG">CIT</cons> N-demethylation.</sentence>
</annotation>
<sentence>In addition, there was a <cons sem="G_CHANGE">significant</cons> <cons sem="G_MECHANISM">correlation</cons> between <cons sem="G_DRUG">CIT</cons> N-demethylation and (S)-<cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons> 4'-hydroxylation (<cons sem="G_NUMBER">r(s) = 0.773, P &lt; .05</cons>), although <cons sem="G_CHANGE">little</cons> <cons sem="G_MECHANISM">inhibition</cons> was observed in the presence of anti-<cons sem="G_CYP">CYP2C</cons> antibodies or (S)-<cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(CYP3A4, CIT N-demethylation,DEI)(CYP2C19, CIT N-demethylation,DEI)(CYP1A2, CIT N-demethylation,NDEI)(CYP2A6, CIT N-demethylation,NDEI)(CYP2B6, CIT N-demethylation,NDEI)(CYP2C9, CIT N-demethylation,NDEI)(CYP2D6, CIT N-demethylation,NDEI)(CYP2E1, CIT N-demethylation,NDEI)">
<sentence>cDNA-expressed <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> <cons sem="G_MECHANISM">catalyzed</cons> <cons sem="G_DRUG">CIT</cons> N-demethylation, whereas <cons sem="G_NEGATIVEEFFECT">no</cons> appreciable activities were observed for <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons>, <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons>, <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> and <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons>.</sentence>
</annotation>
<sentence>The percentage contributions of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> to the overall N-demethylation of <cons sem="G_DRUG">CIT</cons> in human liver microsomes were estimated using a relative activity factor; respective values of <cons sem="G_NUMBER">70% and 7%</cons> were calculated for microsomes obtained from livers from putative extensive metabolizers for (S)-<cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons> 4'-hydroxylation.</sentence>
<sentence>These results suggest that <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> is the major isoenzyme and <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> is the <cons sem="G_CHANGE">minor</cons> form involved in the major metabolic pathway for <cons sem="G_DRUG">CIT</cons> in human liver microsomes.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9023285</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem="G_MECHANISM">Inhibition</cons> by <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> of <cons lex="proguanil" sem="G_DRUG">proguanil</cons> <cons sem="G_MECHANISM">metabolism</cons>: mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments.</sentence>
</title>
<abstract>
<sentence>Both the antimalarial prodrug <cons lex="proguanil" sem="G_DRUG">proguanil</cons> and the gastric proton pump <cons sem="G_MECHANISM">inhibitor</cons> <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> are substrates for cytochrome P450 (CYP)<cons sem="G_CYP">2C19</cons> and <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>.</sentence>
<sentence>However, the relative contribution of each enzyme to <cons lex="proguanil" sem="G_DRUG">proguanil</cons> bioactivation to <cons sem="G_DRUG">cycloguanil</cons> and to the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons>, as well as their potential to interact, remains to be examined.</sentence>
<sentence>The bioactivation of <cons lex="proguanil" sem="G_DRUG">proguanil</cons> to its active metabolite <cons sem="G_DRUG">cycloguanil</cons> was studied in vitro in human liver microsomes and in vivo in 12 healthy subjects, in the absence and in the presence of <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons>.</sentence>
<sentence>The <cons sem="G_MECHANISM">formation</cons> of <cons sem="G_DRUG">cycloguanil</cons> from <cons lex="proguanil" sem="G_DRUG">proguanil</cons> exhibited biphasic kinetic behavior in four of six human livers, indicating that at least two enzymes are responsible for this metabolic step.</sentence>
<sentence><cons sem="G_DRUG">Cycloguanil</cons> <cons sem="G_MECHANISM">formation</cons> activity did <cons sem="G_NEGATIVEEFFECT">not</cons> correlate with immunoreactive <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> content or with <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activity, as measured by <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6beta-hydroxylation, suggesting that <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> plays a limited role in <cons sem="G_DRUG">cycloguanil</cons> <cons sem="G_MECHANISM">formation</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(troleandomycin, cycloguanil,ADDI)">
<sentence>Furthermore, <cons lex="troleandomycin" sem="G_DRUG">troleandomycin</cons> (<cons sem="G_NUMBER">10 microM</cons>) <cons sem="G_MECHANISM">inhibited</cons> only <cons sem="G_NUMBER">10 to 17%</cons> of <cons sem="G_DRUG">cycloguanil</cons> <cons sem="G_MECHANISM">formation</cons> at <cons lex="proguanil" sem="G_DRUG">proguanil</cons> concentrations of <cons sem="G_NUMBER">100 and 500 microM</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(omeprazole, cycloguanil,DDI)">
<sentence>At a <cons lex="proguanil" sem="G_DRUG">proguanil</cons> concentration of <cons sem="G_NUMBER">20 microM</cons>, <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> at <cons sem="G_NUMBER">10 microM</cons> <cons sem="G_MECHANISM">inhibited</cons> <cons sem="G_DRUG">cycloguanil</cons> <cons sem="G_MECHANISM">formation</cons> in vitro by <cons sem="G_NUMBER">47 +/- 59%</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(omeprazole, proguanil,DDI)">
<sentence>These in vitro results were consistent with the results of our in vivo study in healthy subjects, which showed a <cons sem="G_NUMBER">32 +/- 11%</cons> <cons sem="G_CHANGE">decrease</cons> in <cons lex="proguanil" sem="G_DRUG">proguanil</cons> apparent oral clearance and a <cons sem="G_NUMBER">65 +/- 8%</cons> <cons sem="G_CHANGE">decrease</cons> in <cons lex="proguanil" sem="G_DRUG">proguanil</cons> partial metabolic <cons sem="G_IVITPARA">clearance</cons> to <cons sem="G_DRUG">cycloguanil</cons> in the presence of <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> (both <cons sem="G_NUMBER">P &lt; .001</cons>).</sentence>
</annotation>
<sentence>We conclude that in vitro studies of <cons lex="proguanil" sem="G_DRUG">proguanil</cons> <cons sem="G_MECHANISM">metabolism</cons> and interactions are predictive of in vivo situations, that <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> is the main enzyme responsible for <cons lex="proguanil" sem="G_DRUG">proguanil</cons> bioactivation to <cons sem="G_DRUG">cycloguanil</cons> and that <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> <cons sem="G_MECHANISM">inhibits</cons> this biotransformation in vitro and in vivo by inhibiting this enzyme.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9037249</bibliomisc>
</articleinfo>
<title>
<sentence>Variable contribution of cytochromes P450 <cons lex="2d6" sem="G_CYP">2D6</cons>, <cons lex="2c9" sem="G_CYP">2C9</cons> and <cons lex="3a4" sem="G_CYP">3A4</cons> to the 4-hydroxylation of <cons lex="tamoxifen" sem="G_DRUG">tamoxifen</cons> by human liver microsomes.</sentence>
</title>
<abstract>
<sentence>4-Hydroxylation is an important pathway of <cons lex="tamoxifen" sem="G_DRUG">tamoxifen</cons> <cons sem="G_MECHANISM">metabolism</cons> because the product of this reaction is intrinsically 100 times more potent as an oestrogen receptor antagonist than is the parent drug.</sentence>
<sentence>Although <cons lex="tamoxifen" sem="G_DRUG">tamoxifen</cons> 4-hydroxylation is catalysed by human cytochrome P450 (CYP), data conflict on the specific isoforms responsible.</sentence>
<sentence>The aim of this study was to define unequivocally the role of individual CYPs in the 4-hydroxylation of <cons lex="tamoxifen" sem="G_DRUG">tamoxifen</cons> by human liver microsomes.</sentence>
<sentence>Microsomes from each of 10 human livers catalysed the reaction  [range = <cons sem="G_NUMBER">0.6-2.9 pmol/mg protein/min</cons> (<cons sem="G_NUMBER">1 microM</cons> substrate concentration) and <cons sem="G_NUMBER">6-25 pmol/mg protein/min (18 microM)</cons>].</sentence>
<sentence>Three of the livers with the lowest <cons lex="tamoxifen" sem="G_DRUG">tamoxifen</cons> 4-hydroxylation activity were from genetically poor metabolisers with respect to <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(quinidine, CYP2D6,ADEI)(sulphaphenazole, CYP2D6,ADEI)(ketoconazole, CYP2D6,ADEI)(quinidine, CYP2C9,ADEI)(sulphaphenazole, CYP2C9,ADEI)(ketoconazole, CYP2C9,ADEI)(quinidine, CYP3A4,ADEI)(sulphaphenazole, CYP3A4,ADEI)(ketoconazole, CYP3A4,ADEI)">
<sentence><cons sem="G_MECHANISM">Inhibition</cons> of activity by <cons lex="quinidine" sem="G_DRUG">quinidine</cons> (<cons sem="G_NUMBER">1 microM</cons>), <cons sem="G_DRUG">sulphaphenazole</cons> (<cons sem="G_NUMBER">20 microM</cons>) and <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> (<cons sem="G_NUMBER">2 microM</cons>), selective <cons sem="G_MECHANISM">inhibitors</cons> of CYPs <cons lex="2d6" sem="G_CYP">2D6</cons>, <cons lex="2c9" sem="G_CYP">2C9</cons> and <cons lex="3a4" sem="G_CYP">3A4</cons>, respectively, was <cons sem="G_NUMBER">0-80%, 0-80% and 12-57%</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(quinidine, tamoxifen 4-hydroxylation,DDI)">
<sentence>The proportion of activity <cons sem="G_MECHANISM">inhibited</cons> by <cons lex="quinidine" sem="G_DRUG">quinidine</cons> <cons sem="G_MECHANISM">correlated</cons> positively with total microsomal <cons lex="tamoxifen" sem="G_DRUG">tamoxifen</cons> 4-hydroxylation activity (<cons sem="G_NUMBER">rs = 0.89, P &lt; 0.01</cons>), indicating a major involvement of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> in this reaction.</sentence>
</annotation>
<sentence>Recombinant human CYPs <cons lex="2d6" sem="G_CYP">2D6</cons>, <cons lex="2c9" sem="G_CYP">2C9</cons> and <cons lex="3a4" sem="G_CYP">3A4</cons> but <cons sem="G-NEGATIVEEFFECT">not</cons> CYPs <cons lex="1a1" sem="G_CYP">1A1</cons>, <cons lex="1a2" sem="G_CYP">1A2</cons>, <cons lex="2c19" sem="G_CYP">2C19</cons> and <cons lex="2e1" sem="G_CYP">2E1</cons> displayed <cons sem="G_CHANGE">significant</cons> 4-hydroxylation activity.</sentence>
<annotation sem="INVITROCDDIS" ddi="(CYP3A4, tamoxifen N-demethylation,DEI)">
<sentence>Similar <cons sem="G_MECHANISM">inhibition</cons> and <cons sem="G_MECHANISM">correlation</cons> experiments confirmed that <cons lex="tamoxifen" sem="G_DRUG">tamoxifen</cons> N-demethylation is catalysed predominantly by <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(CYP3A4, tamoxifen 4-hydroxylation,DEI)(CYP2D6, tamoxifen 4-hydroxylation,DEI)(CYP2C9, tamoxifen 4-hydroxylation,DEI)">
<sentence>These findings indicate that the 4-hydroxylation of <cons lex="tamoxifen" sem="G_DRUG">tamoxifen</cons> is catalysed almost exclusively by CYPs <cons lex="2d6" sem="G_CYP">2D6</cons>, <cons lex="2c9" sem="G_CYP">2C9</cons> and <cons lex="3a4" sem="G_CYP">3A4</cons> in human liver microsomes.</sentence>
</annotation>
<sentence>However, the <cons sem="G_CHANGE">marked</cons> between-subject variation in the contribution of these isoforms underlines the need to study metabolic reactions in a sufficient number of livers that are characterised with respect to a range of cytochrome P450 activities.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9074808</bibliomisc>
</articleinfo>
<title>
<sentence>Aryl acetylenes as mechanism-based <cons sem="G_MECHANISM">inhibitors</cons> of cytochrome P450-dependent monooxygenase enzymes.</sentence>
</title>
<abstract>
<sentence>Aryl acetylenes have been investigated as <cons sem="G_MECHANISM">inhibitors</cons> of cytochrome P450 (P450)-dependent alkoxyresorufin dealkylation dealkylation activities in liver microsomes prepared from rats exposed to beta-naphthoflavone, <cons sem="G_DRUG">Isosafrole</cons>, or <cons lex="phenobarbital" sem="G_DRUG">phenobarbital</cons>.</sentence>
<sentence>Many of the acetylenes investigated produce pseudo-first-order time-dependent and NADPH-dependent losses of the dealkylation activities characteristic of mechanism-based irreversible <cons sem="G_MECHANISM">inactivation</cons> (suicide inhibition).</sentence>
<sentence>Replacing the terminal hydrogen of aryl acetylenes with a methyl group to convert ethynes into propynes enhances the <cons sem="G_MECHANISM">inhibition</cons> of P450 <cons lex="1a" sem="G_CYP">1A</cons> enzymes; in some instances, this modification converts a reversible <cons sem="G_MECHANISM">inhibitor</cons> of P450s into a suicide <cons sem="G_MECHANISM">inhibitor</cons>.</sentence>
<sentence>In contrast, ethynes are more effective suicide <cons sem="G_MECHANISM">inhibitors</cons> of P450 <cons lex="2b" sem="G_CYP">2B</cons>-dependent dealkylations than the corresponding propynes.</sentence>
<sentence>Aryl acetylenes with an ethynyl group on the 2 position of naphthalene or on the 9 position of phenanthrene and arylalkyl acetylenes with alkyl chains containing 2, 3, or 4 methylene groups are selective <cons sem="G_MECHANISM">inhibitors</cons> of P450 2B1/2B2 in liver microsomes from rats.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Aryl acetylenes, CYP1A2,DEI)">
<sentence>Aryl acetylenes also act as suicide <cons sem="G_MECHANISM">inhibitors</cons> of P450 <cons lex="1a2" sem="G_CYP">1A2</cons> in human liver microsomes, of purified P450 <cons lex="1a2" sem="G_CYP">1A2</cons> from rabbit or rat liver in reconstituted systems, and of purified recombinant human P450 <cons lex="1a2" sem="G_CYP">1A2</cons> and <cons lex="1a1" sem="G_CYP">1A1</cons> in reconstituted systems.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(4-(1-Propynyl)biphenyl (4PBi), ethoxyresourfin deethylation,DDI)">
<sentence>4-(1-Propynyl)biphenyl (4PBi) inactivated P450 <cons lex="1a2" sem="G_CYP">1A2</cons>-dependent ethoxyresourfin deethylation (EROD) activity in human liver microsomes in an NADPH-dependent process (<cons sem="G_IVITPARA">k(inactivation)</cons>, <cons sem="G_NUMBER">0.23 min-1</cons>; <cons sem="G_IVITPARA">KI</cons>, <cons sem="G_NUMBER">2.3 microM</cons>).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(4PBi, CYP1A2,DEI)">
<sentence>4PBi also <cons sem="G_MECHANISM">inactivated</cons> purified recombinant human P450 <cons lex="1a2" sem="G_CYP">1A2</cons> (<cons sem="G_IVITPARA">k(inactivation)</cons>, <cons sem="G_NUMBER">0.24 min-1</cons>; <cons sem="G_IVITPARA">KI</cons>, <cons sem="G_NUMBER">4.3 microM</cons>).</sentence>
</annotation>
<sentence>In agreement with previous reports  [Yun, C.-H., Hammons, G. J., Jones, G., Martin, M. V., Hopkins, N. E., Alworth, W. L., and Guengerich, F. P. (1992) Biochemistry 31, 10556-10563],</sentence>
<annotation sem="INVITROCDDIS" ddi="(2-ethynylnaphthalene, CYP1A2,NDEI)">
<sentence> 2-ethynylnaphthalene (2EN) was <cons sem="G_NEGATIVEEFFECT">not</cons> a suicide <cons sem="G_MECHANISM">inhibitor</cons> of the P450 <cons lex="1a2" sem="G_CYP">1A2</cons> activity in human liver microsomes but did <cons sem="G_MECHANISM">inactivate</cons> purified human P450 <cons lex="1a2" sem="G_CYP">1A2</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(4PBi, CYP2E1,NDEI)(4PBi, CYP2C9/10,NDEI)(4PBi, CYP3A4,NDEI)(4PBi, CYP2C19,NDEI)(2EN, CYP2E1,NDEI)(2EN, CYP2C9/10,NDEI)(2EN, CYP3A4,NDEI)(2EN, CYP2C19,NDEI)">
<sentence>Neither 4PBi nor 2EN affected diagnostic activities of human microsomal P450 <cons lex="2e1" sem="G_CYP">2E1</cons>, <cons sem="G_CYP">2C9/10</cons>, <cons lex="3a4" sem="G_CYP">3A4</cons>, or <cons lex="2c19" sem="G_CYP">2C19</cons>.</sentence>
</annotation>
<sentence>In the systems examined, the losses of P450-dependent activity produced by these aryl acetylenes were <cons sem="G_NEGATIVEEFFECT">not</cons> accompanied by corresponding <cons sem="G_CHANGE">decreases</cons> in the measured P450 absorption spectra.</sentence>
<sentence>Thus P450 <cons sem="G_MECHANISM">inactivation</cons> by these aryl acetylenes does <cons sem="G_NEGATIVEEFFECT">not</cons> involve labeling and destruction of the <cons lex="heme" sem="G_DRUG">heme</cons>.</sentence>
<sentence>Incubation of 4PBi with microsomal P450 <cons lex="1a1" sem="G_CYP">1A1</cons> or <cons lex="1a2" sem="G_CYP">1A2</cons> from rat liver under conditions that lead to P450-dependent, enzyme <cons sem="G_MECHANISM">inactivations</cons> generates a 2-biphenylylpropionic acid product.</sentence>
<sentence>This suggests that the suicide <cons sem="G_MECHANISM">inhibition</cons> of P450s by propynylaryl acetylenes proceeds via a methylaryl ketene <cons sem="G_MECHANISM">formed</cons> by a 1,2-methyl rearrangement, analogous to the mechanism of suicide <cons sem="G_MECHANISM">inhibition</cons> by ethynyl acetylenes that proceed via ketene intermediates <cons sem="G_MECHANISM">formed</cons> by 1,2-hydrogen shifts  [Ortiz de Montellano, P. R., and Kunze, K. L.(1981) Arch. Biochem. Biophys. 209, 710-712].</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:8986010</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="phenacetin" sem="G_DRUG">Phenacetin</cons> O-deethylation by human liver microsomes in vitro: <cons sem="G_MECHANISM">inhibition</cons> by chemical probes, SSRI antidepressants, <cons lex="nefazodone" sem="G_DRUG">nefazodone</cons> and <cons lex="venlafaxine" sem="G_DRUG">venlafaxine</cons>.</sentence>
</title>
<abstract>
<sentence>Biotransformation of <cons lex="phenacetin" sem="G_DRUG">phenacetin</cons> via O-deethylation to <cons lex="acetaminophen" sem="G_DRUG">acetaminophen</cons>, an index reaction reflecting activity of Cytochrome P450-<cons lex="1a2" sem="G_CYP">1A2</cons>, was studied in microsomal preparations from a series of human livers.</sentence>
<sentence><cons lex="acetaminophen" sem="G_DRUG">Acetaminophen</cons> <cons sem="G_MECHANISM">formation</cons> was consistent with a double Michaelis-Menten system, with low-<cons sem="G_IVITPARA">Km</cons> (mean <cons sem="G_IVITPARA">Km1</cons> = <cons sem="G_NUMBER">68 microM</cons>) and high-<cons sem="G_IVITPARA">Km</cons> (mean <cons sem="G_IVITPARA">Km2</cons> = <cons sem="G_NUMBER">7691 microM</cons>) components.</sentence>
<sentence>The low-<cons sem="G_IVITPARA">K(m)</cons> enzyme accounted for an average of <cons sem="G_NUMBER">96%</cons> of estimated <cons sem="G_IVITPARA">ntrinsic clearance</cons>i, and was predicted to contribute more than <cons sem="G_NUMBER">50%</cons> of net reaction velocity at <cons lex="phenacetin" sem="G_DRUG">phenacetin</cons> concentrations less than <cons sem="G_NUMBER">2000 microM</cons>.</sentence>
<annotation sem="INVITROVDDIS" ddi="(alpha-naphthoflavone, CYP1A2,DEI)(furafylline, CYP1A2,DEI)">
<sentence>Among index <cons sem="G_MECHANISM">inhibitor</cons> probes, alpha-naphthoflavone was a highly potent <cons sem="G_MECHANISM">inhibitor</cons> of the low-<cons sem="G_IVITPARA">Km</cons> enzyme (<cons sem="G_IVITPARA">Ki1</cons> = <cons sem="G_NUMBER">0.013 microM</cons>); <cons lex="furafylline" sem="G_DRUG">furafylline</cons> also was a <cons sem="G_CHANGE">moderately</cons> active <cons sem="G_MECHANISM">inhibitor</cons> (<cons sem="G_IVITPARA">Ki1</cons> = <cons sem="G_NUMBER">4.4 microM</cons>), but its inhibiting potency was <cons sem="G_CHANGE">increased</cons> by preincubation with microsomes.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Ketoconazole, CYP1A2,ADEI)(quinidine, CYP1A2,NDEI)(cimetidine, CYP1A2,NDEI)">
<sentence><cons lex="ketoconazole" sem="G_DRUG">Ketoconazole</cons> was a relatively <cons sem="G_CHANGE">weak</cons> <cons sem="G_MECHANISM">inhibitor</cons> (<cons sem="G_IVITPARA">Ki1</cons> = <cons sem="G_NUMBER">32 microM</cons>); <cons lex="quinidine" sem="G_DRUG">quinidine</cons> and <cons lex="cimetidine" sem="G_DRUG">cimetidine</cons> showed minimal inhibiting activity.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(fluvoxamine, CYP1A2,DEI)">
<sentence>Among six selective serotonin reuptake <cons sem="G_MECHANISM">inhibitor</cons> (SSRI) antidepressants, <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> was a potent <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="1a2" sem="G_CYP">1A2</cons> (mean <cons sem="G_IVITPARA">Ki1</cons> = <cons sem="G_NUMBER">0.24 microM</cons>).</sentence>
</annotation>
<sentence>The other SSRIs were more than tenfold less potent.</sentence>
<annotation sem="INVITROVDDIS" ddi="(fluoxetine, CYP1A2,DEI)(sertraline, CYP1A2,ADEI)(desmethylsertraline, CYP1A2,DEI)(paroxetine, CYP1A2,DEI)">
<sentence>Mean <cons sem="G_IVITPARA">Ki1</cons> values were: <cons lex="fluoxetine" sem="G_DRUG">fluoxetine</cons>, <cons sem="G_NUMBER">4.4 microM</cons>; <cons sem="G_DRUG">norfluoxetine</cons>, <cons sem="G_NUMBER">15.9 microM</cons>; <cons lex="sertraline" sem="G_DRUG">sertraline</cons>, <cons sem="G_NUMBER">8.8 microM</cons>; <cons sem="G_DRUG">desmethylsertraline</cons>, <cons sem="G_NUMBER">9.5 microM</cons>; <cons lex="paroxetine" sem="G_DRUG">paroxetine</cons>, <cons sem="G_NUMBER">5.5 microM</cons>.</sentence>
</annotation>
<sentence>The antidepressant <cons lex="nefazodone" sem="G_DRUG">nefazodone</cons> and four of its metabolites (meta-chloro-phenylpiperazine, two hydroxylated derivatives, and a triazoledione) were very weak <cons sem="G_MECHANISM">inhibitors</cons> of P450-<cons lex="1a2" sem="G_CYP">1A2</cons>.</sentence>
<sentence><cons lex="venlafaxine" sem="G_DRUG">Venlafaxine</cons> and its O- and N-desmethyl metabolites showed minimal <cons sem="G_MECHANISM">inhibitory</cons> activity.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:8946477</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> is the principal cytochrome P450 responsible for <cons sem="G_MECHANISM">metabolism</cons> of the histamine H1 antagonist <cons lex="promethazine" sem="G_DRUG">promethazine</cons> in human liver microsomes.</sentence>
</title>
<abstract>
<sentence>To determine which cytochrome P450 form is involved in the <cons lex="promethazine" sem="G_DRUG">promethazine</cons>  [10-(2-dimethylaminopropyl) phenothiazine] <cons sem="G_MECHANISM">metabolism</cons>, in vitro analysis using human liver microsomes were performed.</sentence>
<sentence><cons lex="promethazine" sem="G_DRUG">Promethazine</cons> was mainly biotransformed to ring-hydroxylated, S-oxidized and N-demethylated metabolites.</sentence>
<annotation sem="INVITROCDDIS" ddi="(SKF-525A, promethazine ,DEI)(propranolol, promethazine,DEI)(sparteine, promethazine,DEI)(quinidine, promethazine,DEI)(anti-CYP2D6 serum, promethazine,DEI)">
<sentence>The <cons lex="promethazine" sem="G_DRUG">promethazine</cons> hydroxylase in human liver microsomes was <cons sem="G_MECHANISM">inhibited</cons> by SKF-525A, <cons lex="propranolol" sem="G_DRUG">propranolol</cons>, <cons sem="G_DRUG">sparteine</cons>, <cons lex="quinidine" sem="G_DRUG">quinidine</cons> and anti-<cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> serum suggesting involvement of a P450 related to <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>.</sentence>
</annotation>
<sentence>Lineweaver-Burk plots for the hydroxylation, S-<cons sem="G_MECHANISM">oxidation</cons> and N-demethylation indicated that the hydroxylation occurred with a low <cons sem="G_IVITPARA">K(m)</cons> value in human liver microsomes.</sentence>
<sentence>Microsomes from genetically-engineered human B-lymphoblastoid cells expressing <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> hydroxylated <cons lex="promethazine" sem="G_DRUG">promethazine</cons> most efficiently as compared to other P450 forms, indicating that it was the principal P450 responsible for the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="promethazine" sem="G_DRUG">promethazine</cons> in human liver microsomes.</sentence>
<annotation sem="INVITROCDDIS" ddi="(promethazine, bufuralol 1'-hydroxylase,DDI)">
<sentence>The <cons sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>-catalysed <cons sem="G_DRUG">bufuralol</cons> 1'-hydroxylase by various histamine H3 antagonists including <cons lex="promethazine" sem="G_DRUG">promethazine</cons> suggested that <cons lex="promethazine" sem="G_DRUG">promethazine</cons> and some other histamine H1 antagonists could be <cons sem="G_MECHANISM">inhibitors</cons> of this P450 in human liver microsomes.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:8870687</bibliomisc>
</articleinfo>
<title>
<sentence>Inter-individual variability in the <cons sem="G_MECHANISM">oxidation</cons> of 1,2-dibromoethane: use of heterologously expressed human cytochrome P450 and human liver microsomes.</sentence>
</title>
<abstract>
<sentence>1,2-Dibromoethane (1,2-DBE) is mainly used as an additive in leaded gasoline and as a soil fumigant and it is a suspected carcinogen in humans.</sentence>
<sentence>In this study, the oxidative bioactivation of 1,2-DBE to 2-bromoacetaldehyde (2-BA) was studied using heterologously expressed human cytochrome P450 (P450) isoenzymes and human liver microsomes.</sentence>
<sentence>Out of ten heterologously expressed human P450 isoenzymes (CYP1A1, <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons>, <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons>, <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons>, <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons>, <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, <cons lex="cyp2c18" sem="G_CYP">CYP2C18</cons>, <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and <cons sem="G_CYP">CYP3A5</cons>), only human <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons>, <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> and <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons> <cons sem="G_MECHANISM">metabolized</cons> 1,2-DBE, albeit with strongly differing catalytic efficiencies.</sentence>
<sentence>The apparent <cons sem="G_IVITPARA">Km</cons> and <cons sem="G_IVITPARA">Vmax</cons> values were <cons sem="G_NUMBER">3.3 mM and 0.17 pmol/min per pmol</cons> P450 for <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons>, <cons sem="G_NUMBER">9.7 mM and 3.18 pmol/min per pmol</cons> P450 for <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> and <cons sem="G_NUMBER">42 microM and 1.3 pmol/min per pmol</cons> P450 for <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons>, respectively.</sentence>
<sentence>In all of 21 human liver samples studied, 1,2-DBE was oxidized with activities ranging from <cons sem="G_NUMBER">22.2 to 1027.6 pmol/min per mg</cons> protein, thus showing a 46-fold inter-individual variability.</sentence>
<sentence>The kinetics of the oxidative <cons sem="G_MECHANISM">metabolism</cons> of 1,2-DBE to 2-BA in human liver microsomes were linear, indicating the involvement of primarily one single P450 isoenzyme.</sentence>
<sentence>There was a tendency towards a positive <cons sem="G_MECHANISM">correlation</cons> between the oxidative <cons sem="G_MECHANISM">metabolism</cons> of 1,2-DBE in the human liver microsomes and the 6-hydroxylation of <cons lex="chlorzoxazone" sem="G_DRUG">chlorzoxazone</cons>, a selective substrate for <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons>.</sentence>
<sentence>Furthermore, the oxidative <cons sem="G_MECHANISM">metabolism</cons> of 1,2-DBE was <cons sem="G_MECHANISM">inhibited</cons> by the specific <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons> <cons sem="G_MECHANISM">inhibitors</cons> <cons lex="disulfiram" sem="G_DRUG">disulfiram</cons> (DS) and <cons lex="diethyldithiocarbamate" sem="G_DRUG">diethyldithiocarbamate</cons> (DDC).</sentence>
<sentence>In contrast, a poor <cons sem="G_MECHANISM">correlation</cons> was found between the immunochemically quantified amount of <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons> and the microsomal <cons lex="chlorzoxazone" sem="G_DRUG">chlorzoxazone</cons> 6-hydroxylation or the 1,2-DBE <cons sem="G_MECHANISM">oxidation</cons>.</sentence>
<sentence>The results indicate that <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons> is <cons sem="G_CHANGE">probably</cons> the major P450 isoenzyme involved in the oxidative hepatic <cons sem="G_MECHANISM">metabolism</cons> of 1,2-DBE in humans.</sentence>
<sentence>The inter-individual variability in the oxidative bioactivation of 1,2-DBE in humans, largely due to inter-individual variability in the catalytic activity of hepatic <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons>, <cons sem="G_CHANGE">may</cons> have important consequences for the risk assessment for human exposure to 1,2-DBE.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:8886607</bibliomisc>
</articleinfo>
<title>
<sentence>Human <cons sem="G_CHANGE">reductive</cons> <cons lex="halothane" sem="G_DRUG">halothane</cons> <cons sem="G_MECHANISM">metabolism</cons> in vitro is <cons sem="G_MECHANISM">catalyzed</cons> by cytochrome P450 <cons lex="2a6" sem="G_CYP">2A6</cons> and <cons lex="3a4" sem="G_CYP">3A4</cons>.</sentence>
</title>
<abstract>
<sentence>The anesthetic <cons lex="halothane" sem="G_DRUG">halothane</cons> undergoes extensive oxidative and <cons sem="G_CHANGE">reductive</cons> biotransformation, resulting in metabolites that cause hepatotoxicity.</sentence>
<sentence><cons lex="halothane" sem="G_DRUG">Halothane</cons> is <cons sem="G_CHANGE">reduced</cons> anaerobically by cytochrome P450 (P450) to the volatile metabolites 2-chloro-1,1-difluoroethene (<cons sem="G_DRUG">CDE</cons>) and 2-chloro-1,1,1-trifluoroethane (<cons sem="G_DRUG">CTE</cons>).</sentence>
<sentence>The purpose of this investigation was to identify the human P450 isoform(s) responsible for <cons sem="G_CHANGE">reductive</cons> <cons lex="halothane" sem="G_DRUG">halothane</cons> <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
<sentence><cons sem="G_DRUG">CDE</cons> and <cons sem="G_DRUG">CTE</cons> <cons sem="G_MECHANISM">formation</cons> from <cons lex="halothane" sem="G_DRUG">halothane</cons> <cons sem="G_MECHANISM">metabolism</cons> by human liver microsomes was determined by GC/MS analysis.</sentence>
<annotation sem="INVITROCDDIS" ddi="(carbon monoxide, Halothane,DDI)">
<sentence><cons lex="halothane" sem="G_DRUG">Halothane</cons> <cons sem="G_MECHANISM">metabolism</cons> to <cons sem="G_DRUG">CDE</cons> and <cons sem="G_DRUG">CTE</cons> under <cons sem="G_CHANGE">reductive</cons> conditions was completely <cons sem="G_MECHANISM">inhibited</cons> by carbon monoxide, which implicates exclusively P450 in this reaction.</sentence>
</annotation>
<sentence>Eadie-Hofstee plots of both <cons sem="G_DRUG">CDE</cons> and <cons sem="G_DRUG">CTE</cons> <cons sem="G_MECHANISM">formation</cons> were nonlinear, suggesting multiple P450 isoform involvement.</sentence>
<annotation sem="INVITROCDDIS" ddi="(coumarin, CDE,DDI)(8-methoxypsoralen, CDE,DDI)(ketoconazole, CTE,DDI)(troleandomycin, CTE,DDI)">
<sentence>Microsomal <cons sem="G_DRUG">CDE</cons> and <cons sem="G_DRUG">CTE</cons> <cons sem="G_MECHANISM">formation</cons> were each <cons sem="G_MECHANISM">inhibited</cons> <cons sem="G_NUMBER">40-50%</cons> by P450 <cons lex="2a6" sem="G_CYP">2A6</cons>-selective <cons sem="G_MECHANISM">inhibitors</cons> (<cons sem="G_DRUG">coumarin</cons> and <cons sem="G_DRUG">8-methoxypsoralen</cons>) and <cons sem="G_NUMBER">55-60%</cons> by P450 <cons lex="3a4" sem="G_CYP">3A4</cons>-selective <cons sem="G_MECHANISM">inhibitors</cons> (ketoconazole and troleandomycin).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(7,8-benzoflavone, halothane,NDDI)(furafylline, halothane,NDDI)(orphenadrine, halothane,NDDI)(sulfaphenazole, halothane,NDDI)(quinidine, halothane,NDDI)">
<sentence>P450 <cons lex="1a" sem="G_CYP">1A</cons>-, <cons lex="2b6" sem="G_CYP">2B6</cons>-, <cons sem="G_CYP">2C9/10</cons>-, and <cons lex="2d6" sem="G_CYP">2D6</cons>-selective <cons sem="G_MECHANISM">inhibitors</cons> (7,8-benzoflavone, <cons lex="furafylline" sem="G_DRUG">furafylline</cons>, <cons lex="orphenadrine" sem="G_DRUG">orphenadrine</cons>, sulfaphenazole, and quinidine) had <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem="G_CHANGE">significant</cons> effect on <cons sem="G_CHANGE">reductive</cons> <cons lex="halothane" sem="G_DRUG">halothane</cons> <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(CDE, CYP2A6,DEI)(CDE, 3A4,DEI)">
<sentence>Measurement of product <cons sem="G_MECHANISM">formation</cons> <cons sem="G_MECHANISM">catalyzed</cons> by a panel of cDNA-expressed P450 isoforms revealed that maximal rates of <cons sem="G_DRUG">CDE</cons> <cons sem="G_MECHANISM">formation</cons> occurred with P450 <cons lex="2a6" sem="G_CYP">2A6</cons>, followed by P450 <cons lex="3a4" sem="G_CYP">3A4</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(CDE, 3A4,DEI)">
<sentence>P450 <cons lex="3a4" sem="G_CYP">3A4</cons> was the most effective catalyst of <cons sem="G_DRUG">CTE</cons> <cons sem="G_MECHANISM">formation</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(CDE, CYP2A6,DEI)(CDE, 3A4,DEI)">
<sentence>Among a panel of 11 different human livers, there were <cons sem="G_CHANGE">significant</cons> linear correlations between the rate of <cons sem="G_DRUG">CDE</cons> <cons sem="G_MECHANISM">formation</cons> and both <cons lex="2a6" sem="G_CYP">2A6</cons> activity (<cons sem="G_NUMBER">r = 0.64, p &lt; 0.04</cons>) and <cons lex="3a4" sem="G_CYP">3A4</cons> activity (<cons sem="G_NUMBER">r = 0.64, p &lt; 0.03</cons>).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(CDE, CYP2A6,DEI)(CDE, 3A4,DEI)">
<sentence>Similarly, there were <cons sem="G_CHANGE">significant</cons> linear <cons sem="G_MECHANISM">correlations</cons> between <cons sem="G_DRUG">CTE</cons> <cons sem="G_MECHANISM">formation</cons> and both <cons lex="2a6" sem="G_CYP">2A6</cons> activity (<cons sem="G_NUMBER">r = 0.55, p &lt; 0.08</cons>) and <cons lex="3a4" sem="G_CYP">3A4</cons> activity (<cons sem="G_NUMBER">r = 0.77, p &lt; 0.005</cons>).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(4-methylpyrazole, CDE,ADDI)(diethyldithiocarbamate, CDE,ADDI)(4-methylpyrazole, CTE,ADDI)(diethyldithiocarbamate, CTE,ADDI)(CYP2E1, CDE,NDEI)(CYP2E1, CTE,NDEI)">
<sentence>The P450 <cons lex="2e1" sem="G_CYP">2E1</cons> <cons sem="G_MECHANISM">inhibitors</cons> 4-methylpyrazole and <cons lex="diethyldithiocarbamate" sem="G_DRUG">diethyldithiocarbamate</cons> <cons sem="G_MECHANISM">inhibited</cons> <cons sem="G_DRUG">CDE</cons> and <cons sem="G_DRUG">CTE</cons> <cons sem="G_MECHANISM">formation</cons> by <cons sem="G_NUMBER">20-45%</cons> and <cons sem="G_NUMBER">40-50%</cons>, respectively; however, cDNA-expressed P450 <cons lex="2e1" sem="G_CYP">2E1</cons> did <cons sem="G_NEVATIVEEFFECT">not</cons> catalyze <cons sem="G_CHANGE">significant</cons> amounts of <cons sem="G_DRUG">CDE</cons> or <cons sem="G_DRUG">CTE</cons> production, and microsomal metabolite <cons sem="G_MECHANISM">formation</cons> was <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_MECHANISM">correlated</cons> with P450 <cons lex="2e1" sem="G_CYP">2E1</cons> activity.</sentence>
</annotation>
<sentence>This investigation demonstrated that human liver microsomal <cons sem="G_CHANGE">reductive</cons> <cons lex="halothane" sem="G_DRUG">halothane</cons> <cons sem="G_MECHANISM">metabolism</cons> is <cons sem="G_MECHANISM">catalyzed</cons> predominantly by P450 <cons lex="2a6" sem="G_CYP">2A6</cons> and <cons lex="3a4" sem="G_CYP">3A4</cons>.</sentence>
<sentence>This isoform selectivity for anaerobic <cons lex="halothane" sem="G_DRUG">halothane</cons> <cons sem="G_MECHANISM">metabolism</cons> contrasts with that for oxidative human <cons lex="halothane" sem="G_DRUG">halothane</cons> <cons sem="G_MECHANISM">metabolism</cons>, which is <cons sem="G_MECHANISM">catalyzed</cons> predominantly by P450 <cons lex="2e1" sem="G_CYP">2E1</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:8818577</bibliomisc>
</articleinfo>
<title>
<sentence>Identification of human liver cytochrome P450 isoforms involved in the in vitro <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="cyclobenzaprine" sem="G_DRUG">cyclobenzaprine</cons>.</sentence>
</title>
<abstract>
<sentence><cons lex="cyclobenzaprine" sem="G_DRUG">Cyclobenzaprine</cons> (Flexeril) is a muscle relaxant, possessing a tricyclic structure.</sentence>
<sentence>Numerous therapeutic agents containing this structure are known to be <cons sem="G_MECHANISM">metabolized</cons> by polymorphic cytochrome <cons sem="G_CYP">P4502D6</cons>.</sentence>
<sentence>The aim of this study was to determine if cytochrome <cons sem="G_CYP">P4502D6</cons> and other isoforms are involved in the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="cyclobenzaprine" sem="G_DRUG">cyclobenzaprine</cons> in human liver microsomes.</sentence>
<annotation sem="INVITROCDDIS" ddi="(furafylline, desmethylcyclobenzaprine,DDI)(7,8-benzoflavone, desmethylcyclobenzaprine,DDI)(troleandomycin, desmethylcyclobenzaprine,DDI)(gestodene, desmethylcyclobenzaprine,DDI)(ketoconazole, desmethylcyclobenzaprine,DDI)">
<sentence>Selective cytochrome P450 <cons sem="G_MECHANISM">inhibitors</cons> for <cons sem="G_CYP">CYP1A1/2</cons> (<cons sem="G_DRUG">furafylline</cons> and <cons sem="G_DRUG">7,8-benzoflavone</cons>) and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> (<cons sem="G_DRUG">troleandomycin</cons>, <cons sem="G_DRUG">gestodene</cons>, and <cons sem="G_DRUG">ketoconazole</cons>) <cons sem="G_MECHANISM">inhibited</cons> the <cons sem="G_MECHANISM">formation</cons> of <cons sem="G_DRUG">desmethylcyclobenzaprine</cons>, a major metabolite of <cons lex="cyclobenzaprine" sem="G_DRUG">cyclobenzaprine</cons>, in human liver microsomes.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Anti-CYP1A1/2 antibody, demethylation,DDI)(Anti-CYP3A4 antibody, demethylation,DDI)(Anti-CYP2C9/10antibody, demethylation,NDDI)(Anti-CYP2C19antibody, demethylation,NDDI)(Anti-CYP2E1antibody, demethylation,NDDI)">
<sentence>Antibodies directed against <cons sem="G_CYP">CYP1A1/2</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibited</cons> the demethylation reaction whereas anti-human <cons sem="G_CYP">CYP<cons sem="G_CYP">2C9/10</cons></cons>, <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>, and <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons> antibodies did <cons sem="G_NEGATIVEEFFECT">not</cons> show any <cons sem="G_MECHANISM">inhibitory</cons> effects.</sentence>
</annotation>
<sentence>When a panel of microsomes prepared from human B-lymphoblastoid cells that expressed specific human cytochrome P450 isoforms were used, only microsomes containing cytochromes <cons sem="G_CYP">P4501A2</cons>, <cons lex="2d6" sem="G_CYP">2D6</cons>, and <cons lex="3a4" sem="G_CYP">3A4</cons> <cons sem="G_MECHANISM">catalyzed</cons> N-demethylation.</sentence>
<sentence>In addition, demethylation <cons sem="G_MECHANISM">catalyzed</cons> by these recombinant cytochromes P450 can be completely <cons sem="G_MECHANISM">inhibited</cons> with selective <cons sem="G_MECHANISM">inhibitors</cons> at concentrations as low as <cons sem="G_NUMBER">1 to 20 microM</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(cyclobenzaprine N-demethylation, caffeine 3-demethylation,DDI)(cyclobenzaprine N-demethylation, testosterone 6 beta-hydroxylation,DDI)(cyclobenzaprine N-demethylation, dextromethorphan O-demethylation,NDDI)">
<sentence>Interestingly, <cons lex="cyclobenzaprine" sem="G_DRUG">cyclobenzaprine</cons> N-demethylation was <cons sem="G_CHANGE">significantly</cons> <cons sem="G_MECHANISM">correlated</cons> with <cons lex="caffeine" sem="G_DRUG">caffeine</cons> 3-demethylation (<cons sem="G_CYP">1A2</cons>) and <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6 beta-hydroxylation (3A4) but <cons sem="G_NEGATIVEEFFECT">not</cons> with <cons lex="dextromethorphan" sem="G_DRUG">dextromethorphan</cons> O-demethylation (<cons sem="G_CYP">2D6</cons>) in human liver microsomes.</sentence>
</annotation>
<sentence>To further determine the involvement of cytochrome <cons sem="G_CYP">P4502D6</cons> in <cons lex="cyclobenzaprine" sem="G_DRUG">cyclobenzaprine</cons> <cons sem="G_MECHANISM">metabolism</cons>, liver microsomes from a human that lacked <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> enzyme activities was included in this study.</sentence>
<sentence>The data showed that <cons lex="cyclobenzaprine" sem="G_DRUG">cyclobenzaprine</cons> N-demethylation still occurred in the incubation with this microsome.</sentence>
<sentence>These results suggested that cytochrome <cons sem="G_CYP">P4502D6</cons> plays only a <cons sem="G_CHANGE">minor</cons> role in <cons lex="cyclobenzaprine" sem="G_DRUG">cyclobenzaprine</cons> N-demethylation whereas <cons lex="3a4" sem="G_CYP">3A4</cons> and <cons lex="1a2" sem="G_CYP">1A2</cons> are primarily responsible for <cons lex="cyclobenzaprine" sem="G_DRUG">cyclobenzaprine</cons> <cons sem="G_MECHANISM">metabolism</cons> in human liver microsomes.</sentence>
<sentence>Due to the minimum involvement of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> in the vitro <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="cyclobenzaprine" sem="G_DRUG">cyclobenzaprine</cons>, the polymorphism of cytochrome <cons sem="G_CYP">P4502D6</cons> in man should <cons sem="G_NEGATIVEEFFECT">not</cons> be of muci concern in the clinical use of <cons lex="cyclobenzaprine" sem="G_DRUG">cyclobenzaprine</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:8818573</bibliomisc>
</articleinfo>
<title>
<sentence>Microsomal <cons lex="codeine" sem="G_DRUG">codeine</cons> N-demethylation: cosegregation with cytochrome <cons sem="G_CYP">P4503A4</cons> activity.</sentence>
</title>
<abstract>
<sentence><cons lex="codeine" sem="G_DRUG">Codeine</cons> is <cons sem="G_MECHANISM">metabolized</cons> by glucuronidation, by O-demethylation to <cons lex="morphine" sem="G_DRUG">morphine</cons>, and by N-demethylation to <cons sem="G_DRUG">norcodeine</cons>.</sentence>
<sentence>The enzyme responsible for the O-demethylation to <cons lex="morphine" sem="G_DRUG">morphine</cons> has been identified as cytochrome <cons sem="G_CYP"> <cons sem="G_CYP">P4502D6</cons> (CYP2D6)</cons>.</sentence>
<sentence>The purpose of the present study was to identify the specific P450 enzyme responsible for <cons lex="codeine" sem="G_DRUG">codeine</cons> N-demethylation.</sentence>
<sentence>Microsomal preparations (250 pmol of P450) obtained from 12 human liver donors were incubated with <cons sem="G_NUMBER">20 microM</cons> <cons lex="codeine" sem="G_DRUG">codeine</cons> and analyzed for <cons sem="G_DRUG">norcodeine</cons> <cons sem="G_MECHANISM">formation</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Codeine N-demethylation, nifedipine oxidation,DDI)(Codeine N-demethylation, codeine O-demethylation,NDDI)">
<sentence><cons lex="codeine" sem="G_DRUG">Codeine</cons> N-demethylation activity was linearly <cons sem="G_MECHANISM">correlated</cons> with <cons lex="nifedipine" sem="G_DRUG">nifedipine</cons> <cons sem="G_MECHANISM">oxidation</cons> activity (<cons sem="G_NUMBER">r = 0.90, p &lt; 0.001</cons>), a marker of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, but <cons sem="G_NEGATIVEEFFECT">not</cons> with <cons lex="codeine" sem="G_DRUG">codeine</cons> O-demethylation, a marker of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(troleandomycin, norcodeine,DDI)(gestodene, norcodeine,ADDI)">
<sentence>Preincubation with <cons lex="troleandomycin" sem="G_DRUG">troleandomycin</cons> (<cons sem="G_NUMBER">50 microM</cons>), or <cons sem="G_DRUG">gestodene</cons> (<cons sem="G_NUMBER">50 microM</cons>) <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, <cons sem="G_CHANGE">decreased</cons> the rate of production of norcodeine by <cons sem="G_NUMBER">60 and 45%</cons> compared to control values, respectively.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(ketoconazole, codeine N-demethylation,DDI)(erythromycin, codeine O-demethylation,DDI)">
<sentence>Similarly, <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> (<cons sem="G_NUMBER">10 microM</cons>) and <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> (<cons sem="G_NUMBER">10 microM</cons>) <cons sem="G_MECHANISM">inhibited</cons> <cons lex="codeine" sem="G_DRUG">codeine</cons> N-demethylation by <cons sem="G_NUMBER">75 and 35%</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(quinidine, norcodeine,NDDI)(sulfaphenazole, norcodeine,NDDI)(diethyldithiocarbamate, norcodeine,NDDI)">
<sentence>In contrast, the presence of <cons lex="quinidine" sem="G_DRUG">quinidine</cons>, <cons sem="G_DRUG">sulfaphenazole</cons>, or <cons lex="diethyldithiocarbamate" sem="G_DRUG">diethyldithiocarbamate</cons> in the incubation mixture had <cons sem="G_NEGATIVEEFFECT">no</cons> effect on <cons sem="G_DRUG">norcodeine</cons> <cons sem="G_MECHANISM">formation</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Anti-CYP3A4 antibody, norcodeine,DDI)(Anti- CYP2A6 antibody, norcodeine,NDDI)(Anti- CYP2C antibody, norcodeine,NDDI)">
<sentence>Preincubation with antibodies raised to <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> (<cons sem="G_NUMBER">5 mg lgG/nmol</cons> P450) caused <cons sem="G_NUMBER">96%</cons> <cons sem="G_MECHANISM">inhibition</cons> of <cons sem="G_DRUG">norcodeine</cons> production, whereas preimmune IgG or antibodies raised to <cons lex="cyp2a6" sem="G_CYP">CYP2A6</cons> and <cons sem="G_CYP">CYP2C</cons> had <cons sem="G_NEGATIVEEFFECT">no</cons> effect.</sentence>
</annotation>
<sentence>Additionally, <cons sem="G_CHANGE">significant</cons> norcodeine production was observed with purified <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> derived from human liver microsomes.</sentence>
<sentence>In conclusion, <cons lex="codeine" sem="G_DRUG">codeine</cons> N-demethylation activity cosegregates with <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activity.</sentence>
<annotation sem="INVITROCDDIS" ddi="(codeine, morphine,DDI)">
<sentence>Coadministration of <cons lex="codeine" sem="G_DRUG">codeine</cons> with selective <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_CHANGE">may</cons> result in <cons sem="G_CHANGE">increased</cons> <cons lex="morphine" sem="G_DRUG">morphine</cons> production and enhanced pharmacodynamic effects due to shunting down the <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> pathway.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:8627546</bibliomisc>
</articleinfo>
<title>
<sentence>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 <cons lex="2d6" sem="G_CYP">2D6</cons>, <cons lex="1a2" sem="G_CYP">1A2</cons> and <cons lex="3a4" sem="G_CYP">3A4</cons>--implications for susceptibility to Parkinson's disease.</sentence>
</title>
<abstract>
<sentence>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induces a Parkinson-like syndrome through biotransformation by monoamine oxidase B to the neurotoxic metabolite 1-methyl-4-phenylpyridine.</sentence>
<sentence>Neuroprotection <cons sem="G_CHANGE">may</cons> be provided by parallel N-demethylation and N-<cons sem="G_MECHANISM">oxidation</cons> pathways mediated by the microsomal cytochrome P450 and flavin monooxygenase systems, respectively.</sentence>
<sentence>The aims of this study were to characterise the N-demethylation of MPTP by human liver microsomes over a wide range of concentrations, and to identify the cytochrome P450 enzymes involved in this reaction.</sentence>
<sentence>The kinetics of the N-demethylation of MPTP (<cons sem="G_NUMBER">1 microM - 3 mM</cons>) by microsomes from the liver of an extensive metabolizer with respect to cytochrome <cons sem="G_CYP">P4502D6</cons> (<cons sem="G_CYP">CYP2D6</cons>) activity were biphasic (apparent <cons sem="G_IVITPARA">Km1</cons> and <cons sem="G_IVITPARA">Km2</cons> values = <cons sem="G_NUMBER">48 and 2882 microM</cons>).</sentence>
<sentence>The high affinity activity was abolished in the presence of <cons lex="quinidine" sem="G_DRUG">quinidine</cons> (<cons sem="G_NUMBER">1 microM</cons>) and was absent in microsomes from a genotypically poor metabolizer with respect to <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>.</sentence>
<sentence>Yeast microsomes containing heterologously expressed <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> N-demethylated MPTP (<cons sem="G_IVITPARA">Km</cons> = <cons sem="G_NUMBER">39 microM</cons>), and there was a high <cons sem="G_MECHANISM">correlation</cons> between the <cons lex="quinidine" sem="G_DRUG">quinidine</cons>-inhibitable N-demethylation of MPTP <cons sem="G_NUMBER">(50 microM) (0.7-91%, mean 44%, of total activity)</cons> and the alpha-hydroxylation of <cons lex="metoprolol" sem="G_DRUG">metoprolol</cons> in microsomes from 11 human livers (<cons sem="G_NUMBER">rs = 0.92; P &lt; .001</cons>).</sentence>
<sentence>At <cons sem="G_NUMBER">50 microM</cons> MPTP, N-demethylase activity in human liver microsomes was also <cons sem="G_MECHANISM">inhibited</cons> by <cons lex="furafylline" sem="G_DRUG">furafylline</cons> (<cons sem="G_NUMBER">10 microM</cons>) and <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> (<cons sem="G_NUMBER">2 microM</cons>) (mean <cons sem="G_MECHANISM">inhibition</cons> <cons sem="G_NUMBER">39 and 13%</cons>, respectively; n = 11 livers).</sentence>
<sentence>Yeast microsomes containing heterologously expressed human <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> N-demethylated MPTP with a <cons sem="G_IVITPARA">Km</cons> of <cons sem="G_NUMBER">2246 microM</cons>.</sentence>
<sentence>These findings indicate that <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>, <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> and, to a lesser extent <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, <cons sem="G_CHANGE">may</cons> have a role in protecting against Parkinson's disease <cons sem="G_MECHANISM">induced</cons> by MPTP and other potential environmental neurotoxins.</sentence>
<sentence>The data provide some biochemical support for the proposition that genotypically poor metabolizers with respect to <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> are overrepresented in some populations of Parkinson's patients, and that smokers (induced <cons sem="G_CYP">CYP1A2</cons>?)</sentence>
<sentence>are underrepresented.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:8861656</bibliomisc>
</articleinfo>
<title>
<sentence>Use of electrospray ionization liquid chromatography-mass spectrometry to study the role of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> in the in vitro <cons sem="G_MECHANISM">metabolism</cons> of 5-hydroxytryptamine receptor antagonists.</sentence>
</title>
<abstract>
<sentence>An electrospray ionization liquid chromatographic-mass spectrometric (ESI-LC-MS) method has been developed to study the involvement of the cytochrome P450 isoenzyme <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> in the in vitro <cons sem="G_MECHANISM">metabolism</cons> of the <cons lex="indole" sem="G_DRUG">indole</cons> containing 5-hydroxytryptamine (5-HT(3)++) receptor antagonists <cons sem="G_DRUG">tropisetron</cons>, <cons lex="ondansetron" sem="G_DRUG">ondansetron</cons> and <cons lex="dolasetron" sem="G_DRUG">dolasetron</cons> in human liver microsomes.</sentence>
<sentence>Compounds were eluted using linear gradients of acetonitrile-20 mM ammonium acetate, solvent A, (10:90, v/v) (pH 6.0) and solvent B, (60:40, v/v) (pH 6.0) and a Nucleosil C(4) column.</sentence>
<sentence>Microsomal incubations were analysed using selected ion monitoring of the molecular ion of parent drug and the molecular ion of hydroxylated metabolites.</sentence>
<sentence>The involvement of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> in drug <cons sem="G_MECHANISM">metabolism</cons> was assessed by <cons sem="G_MECHANISM">inhibition</cons> studies using <cons lex="quinidine" sem="G_DRUG">quinidine</cons> (<cons sem="G_NUMBER">5 mu M</cons>), a specific <cons sem="G_MECHANISM">inhibitor</cons> of human <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>, as well as by incubating compounds with microsomes prepared from cells transfected with cDNA encoding human <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(quinidine, tropisetron,DDI)">
<sentence>Results showed that the <cons sem="G_MECHANISM">oxidation</cons> of all three compounds involved <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>, but only that of tropisetron was <cons sem="G_MECHANISM">inhibited</cons> by over <cons sem="G_NUMBER">90%</cons> in the presence of <cons lex="quinidine" sem="G_DRUG">quinidine</cons>.</sentence>
</annotation>
<sentence>The present method can be applied to pre-clinical compounds, at an early stage of drug discovery, to assess the involvement of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> in their <cons sem="G_MECHANISM">metabolism</cons> and to screen for those compounds where <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> is the only isoenzyme implicated in the <cons sem="G_MECHANISM">formation</cons> of major metabolites.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:8615894</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem="G_MECHANISM">Metabolism</cons> of the new immunosuppressor <cons sem="G_DRUG">cyclosporin G</cons> by human liver cytochromes P450.</sentence>
</title>
<abstract>
<sentence><cons sem="G_DRUG">Cyclosporin G</cons> is a new immunosuppressor structurally similar to <cons sem="G_DRUG">cyclosporin A</cons>.</sentence>
<sentence>Although this drug is pharmacologically as active as <cons sem="G_DRUG">cyclosporin A</cons>, it is less toxic, in particular at the kidney level.</sentence>
<annotation sem="INVITROCDDIS" ddi="(troleandomycin, cyclosporin G oxidase,DDI)(ketoconazole, cyclosporin G oxidase,DDI)(antiCYP3A4 antibodies, cyclosporin G oxidase,DDI)(cyclosporin A, cyclosporin G oxidase,DDI)
CDDIS 
(cyclosporin G, CYP3A4,DEI)(cyclosporin A, CYP3A4,DEI)(rifampicin, cyclosporin G oxidase,DDI)(phenobarbital, cyclosporin G oxidase,DDI)(beta-naphthoflavone, cyclosporin G oxidase,NDDI)">
<sentence>The aim of this work was to identify the enzyme system(s) involved in the oxidative <cons sem="G_MECHANISM">metabolism</cons> of <cons sem="G_DRUG">cyclosporin G</cons> in man: (1) in a bank of human liver microsomes (n = 22), <cons sem="G_DRUG">cyclosporin G</cons> oxidase activity <cons sem="G_MECHANISM">correlated</cons> <cons sem="G_CHANGE">significantly</cons> with <cons sem="G_DRUG">cyclosporin A</cons> oxidase activity (<cons sem="G_NUMBER">P &lt; 0.0001</cons>) and with the level of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> (<cons sem="G_NUMBER">P &lt; 0.002</cons>), determined by immunoblot; (2) specific <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, <cons lex="troleandomycin" sem="G_DRUG">troleandomycin</cons>, and <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>, <cons sem="G_MECHANISM">inhibited</cons> <cons sem="G_DRUG">cyclosporin G</cons> oxidase activity by more than <cons sem="G_NUMBER">80%</cons>; (3) anti<cons sem="G_CYP">CYP3A4</cons> antibodies specifically <cons sem="G_MECHANISM">inhibited</cons> this activity by nearly <cons sem="G_NUMBER">90%</cons>; (4) <cons sem="G_DRUG">cyclosporin A</cons> was a competitive <cons sem="G_MECHANISM">inhibitor</cons> of <cons sem="G_DRUG">cyclosporin G</cons> oxidase and vice versa; (5). Among a battery of cDNA-expressed CYPs, only <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> was able to generate detectable amounts of metabolites of  <cons sem="G_DRUG">cyclosporin G</cons> and  <cons sem="G_DRUG">cyclosporin A</cons> with a turnover number close to that calculated from experiments with liver microsomes; (6) in human hepatocytes in culture, pretreatment of cells with rifampicin and <cons lex="phenobarbital" sem="G_DRUG">phenobarbital</cons>, 2 inducers of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, produced a <cons sem="G_CHANGE">great</cons> <cons sem="G_CHANGE">increase</cons> in cyclosporin G oxidase activity, while beta-naphthoflavone, an <cons sem="G_MECHANISM">inducer</cons> of <cons sem="G_CYP">CYP1A</cons>s, did <cons sem="G_NEGATIVEEFFECT">not</cons>.</sentence>
</annotation>
<sentence>We conclude that <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> is the major enzyme involved in the oxidative <cons sem="G_MECHANISM">metabolism</cons> of <cons sem="G_DRUG">cyclosporin G</cons> in human liver.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:8866916</bibliomisc>
</articleinfo>
<title>
<sentence>In vitro interaction of the antipsychotic agent <cons lex="olanzapine" sem="G_DRUG">olanzapine</cons> with human cytochromes P450 <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>, <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> and <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>.</sentence>
</title>
<abstract>
<sentence>1.</sentence>
<sentence>The ability of <cons lex="olanzapine" sem="G_DRUG">olanzapine</cons> to <cons sem="G_MECHANISM">inhibit</cons> the <cons sem="G_MECHANISM">metabolism</cons> of marker catalytic activities for the cytochromes P450 <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>, <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>, <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, and <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> was examined.</sentence>
<sentence>This <cons sem="G_MECHANISM">inhibitory</cons> capability was compared with that obtained with <cons lex="clozapine" sem="G_DRUG">clozapine</cons> and known <cons sem="G_MECHANISM">inhibitory</cons> compounds for the same cytochromes P450.</sentence>
<sentence>2.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Olanzapine, 1'-hydroxy midazolam,NDDI)(clozapine, 1'-hydroxy midazolam,ADDI)(ketoconazole, 1'-hydroxy midazolam,DDI)">
<sentence><cons lex="olanzapine" sem="G_DRUG">Olanzapine</cons>, <cons lex="clozapine" sem="G_DRUG">clozapine</cons>, and <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> were all found to non-competitively <cons sem="G_MECHANISM">inhibit</cons> 1'-hydroxy <cons lex="midazolam" sem="G_DRUG">midazolam</cons> <cons sem="G_MECHANISM">formation</cons>, form selective for <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>, yielding <cons sem="G_IVITPARA">Ki</cons> values of <cons sem="G_NUMBER">491, 99 and 0.11 microM</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Olanzapine, 1'-hydroxylation bufuralol,ADDI)(clozapine, 1'-hydroxylation bufuralol,ADDI)(quinidine, 1'-hydroxylation bufuralol,DDI)">
<sentence>The 1'-hydroxylation of <cons sem="G_DRUG">bufuralol</cons>, form selective for <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>, was competitively <cons sem="G_MECHANISM">inhibited</cons> by <cons lex="olanzapine" sem="G_DRUG">olanzapine</cons> (<cons sem="G_IVITPARA">Ki</cons> = <cons sem="G_NUMBER">89 microM</cons>), <cons lex="clozapine" sem="G_DRUG">clozapine</cons> (<cons sem="G_IVITPARA">Ki</cons> = <cons sem="G_NUMBER">19 microM</cons>), and <cons lex="quinidine" sem="G_DRUG">quinidine</cons> (<cons sem="G_IVITPARA">Ki</cons> = <cons sem="G_NUMBER">0.03 microM</cons>).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(clozapine, 4-hydroxy tolbutamide,ADDI)(phenytoin, 4-hydroxy tolbutamide,ADDI)">
<sentence><cons lex="tolbutamide" sem="G_DRUG">Tolbutamide</cons> <cons sem="G_MECHANISM">metabolism</cons> to 4-hydroxy <cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons>, form selective for <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, was competitively <cons sem="G_MECHANISM">inhibited</cons> by <cons lex="clozapine" sem="G_DRUG">clozapine</cons> and <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons> (<cons sem="G_IVITPARA">Ki</cons> of <cons sem="G_NUMBER">31 microM and 17 microM</cons>, respectively).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Olanzapine, 4-hydroxy tolbutamide,NDDI)">
<sentence><cons lex="olanzapine" sem="G_DRUG">Olanzapine</cons> non-competitively <cons sem="G_MECHANISM">inhibited</cons> <cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons> <cons sem="G_MECHANISM">metabolism</cons> with a <cons sem="G_IVITPARA">Ki</cons> of <cons sem="G_NUMBER">715 microM</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(clozapine, 4'-hydroxy S-mephenytoin,ADDI)(omeprazole, 4'-hydroxy S-mephenytoin,DDI)">
<sentence>The marker catalytic activity for <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> mediated <cons sem="G_MECHANISM">metabolism</cons>, 4'-hydroxy S-<cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons> <cons sem="G_MECHANISM">formation</cons>, was competitively <cons sem="G_MECHANISM">inhibited</cons> by <cons lex="clozapine" sem="G_DRUG">clozapine</cons> (<cons sem="G_IVITPARA">Ki</cons> = <cons sem="G_NUMBER">69 microM</cons>) and <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> (<cons sem="G_IVITPARA">Ki</cons> = <cons sem="G_NUMBER">4.1 microM</cons>).</sentence>
</annotation>
<annotation sem="INVITROVDDIS" ddi="(olanzapine, 4'-hydroxy S-mephenytoin,NDDI)">
<sentence>Non-competitive <cons sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> mediated <cons sem="G_MECHANISM">metabolism</cons> was seen with <cons lex="olanzapine" sem="G_DRUG">olanzapine</cons> with a <cons sem="G_IVITPARA">Ki</cons> of <cons sem="G_NUMBER">920 microM</cons>.</sentence>
</annotation>
<sentence>3.</sentence>
<annotation sem="INVITROCDDIS" ddi="(olanzapine, CYP3A,DEI)(olanzapine, CYP2D6,DEI)(olanzapine, CYP2C9,DEI)(olanzapine, CYP2C19,DEI)">
<sentence>The calculated percent <cons sem="G_MECHANISM">inhibition</cons> by <cons lex="olanzapine" sem="G_DRUG">olanzapine</cons> of substrates <cons sem="G_MECHANISM">metabolized</cons> by <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>, <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>, <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, and <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> was modeled assuming a total plasma concentration in the therapeutic range (<cons sem="G_NUMBER">0.2 microM</cons>).</sentence>
</annotation>
<sentence>Total <cons lex="olanzapine" sem="G_DRUG">olanzapine</cons> vs unbound <cons lex="olanzapine" sem="G_DRUG">olanzapine</cons> was used to model the worst case (most conservative) situation.</sentence>
<sentence>In all cases, the calculated percent <cons sem="G_MECHANISM">inhibition</cons> of these cytochromes P450 by <cons lex="olanzapine" sem="G_DRUG">olanzapine</cons> was <cons sem="G_NUMBER">&lt; 0.3%</cons>, suggesting that there would be <cons sem="G_CHANGE">little</cons> in vivo <cons sem="G_MECHANISM">inhibition</cons> of the <cons sem="G_MECHANISM">metabolism</cons> of substrates of these enzymes when co-administered with <cons lex="olanzapine" sem="G_DRUG">olanzapine</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:8820421</bibliomisc>
</articleinfo>
<title>
<sentence>Role of cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4</cons> in human <cons sem="G_MECHANISM">metabolism</cons> of <cons sem="G_DRUG">MK-639</cons>, a potent human immunodeficiency virus protease <cons sem="G_MECHANISM">inhibitor</cons>.</sentence>
</title>
<abstract>
<sentence><cons sem="G_DRUG">MK-639 (L-735,524)</cons> is a potent human immunodeficiency virus protease <cons sem="G_MECHANISM">inhibitor</cons> under investigation in the treatment of acquired immunodeficiency syndrome.</sentence>
<sentence>Five in vitro approaches have been used to identify the cytochrome P450 isoform(s) responsible for the human microsomal oxidative <cons sem="G_MECHANISM">metabolism</cons> of MK-639.</sentence>
<sentence>These approaches are: 1) chemical inhibition; 2) immunochemical inhibition; 3) <cons sem="G_MECHANISM">metabolism</cons> by cDNA-expressed human cytochrome P450 enzymes; 4) a <cons sem="G_MECHANISM">correlation</cons> analysis; and 5) competitive <cons sem="G_MECHANISM">inhibition</cons> of marker activities.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Ketoconazole, MK-639,DEI)(troleandomycin, MK-639,DEI)(furafylline, MK-639,DEI)(sulfaphenazole, MK-639,DEI)(quinidine, MK-639,DEI)(S-mephenytoin, MK-639,DEI)">
<sentence><cons lex="ketoconazole" sem="G_DRUG">Ketoconazole</cons> and <cons lex="troleandomycin" sem="G_DRUG">troleandomycin</cons>, both selective <cons sem="G_MECHANISM">inhibitors</cons> for cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4</cons> (<cons sem="G_CYP">CYP3A4</cons>), <cons sem="G_CHANGE">markedly</cons> <cons sem="G_MECHANISM">inhibited</cons> the <cons sem="G_MECHANISM">formation</cons> of all oxidative metabolites of <cons sem="G_DRUG">MK-639</cons>; whereas other <cons sem="G_MECHANISM">inhibitors</cons> (<cons sem="G_DRUG">furafylline</cons>, <cons sem="G_DRUG">sulfaphenazole</cons>, <cons lex="quinidine" sem="G_DRUG">quinidine</cons>, S-<cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons>, and <cons sem="G_DRUG">diethyldithiocarbamate</cons>) had <cons sem="G_CHANGE">little</cons> effect on <cons sem="G_DRUG">MK-639</cons> <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
</annotation>
<sentence>This suggested the involvement of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> in <cons sem="G_DRUG">MK-639</cons> <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Anti-CYP3A1 antibody, testosterone 6beta-hydroxylation,DDI)">
<sentence>Consistent with this, an anti-rat <cons sem="G_CYP">CYP3A1</cons> rabbit polyclonal antibody, which shows a cross-reactive <cons sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>-dependent <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6beta-hydroxylation in human liver microsomes, completely <cons sem="G_MECHANISM">inhibited</cons> MK-639 <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
</annotation>
<sentence>Human recombinant <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> showed a high metabolic activity to form all MK-639 metabolites found in native human liver microsomes.</sentence>
<sentence>In addition, the <cons sem="G_MECHANISM">formation</cons> of individual MK-639 metabolites <cons sem="G_MECHANISM">correlated</cons> well with each other and with <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6beta-hydroxylation in 12 different human liver microsomes, whereas <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem="G_MECHANISM">correlation</cons> was observed between MK-639 metabolite <cons sem="G_MECHANISM">formation</cons> and <cons sem="G_DRUG">bufuralol</cons> 1'-hydroxylation (or <cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons> methyl hydroxylation).</sentence>
<annotation sem="INVITROCDDIS" ddi="(MK-639, testosterone 6beta-hydroxylation,DDI)">
<sentence>Furthermore, <cons sem="G_DRUG">MK-639</cons> <cons sem="G_CHANGE">strongly</cons> <cons sem="G_MECHANISM">inhibited</cons> <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6beta-hydroxylation in a concentration-dependent manner.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(MK-639, testosterone 6beta-hydroxylation,DDI)">
<sentence>Kinetic analysis showed that <cons sem="G_DRUG">MK-639</cons> is a very potent competitive <cons sem="G_MECHANISM">inhibitor</cons> for <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6beta-hydroxylation, with a <cons sem="G_IVITPARA">Ki</cons> value of approximately <cons sem="G_NUMBER">0.5 mu M</cons>.</sentence> 
</annotation>
<sentence>Collectively, these results consistently indicate that <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> is the isoform responsible for the oxidative <cons sem="G_MECHANISM">metabolism</cons> of <cons sem="G_DRUG">MK-639</cons> in human liver microsomes.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:8730921</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem="G_MECHANISM">Induction</cons> of cytochrome P450 isoenzymes in cultured precision-cut rat and human liver slices.</sentence>
</title>
<abstract>
<sentence>1.</sentence>
<sentence>The effect of some xenobiotics on levels of selected cytochrome P450 (CYP) isoenzymes determined by Western immunoblotting and associated enzyme activities has been studied in 72-h cultured rat and human precision-cut liver slices.</sentence>
<sentence>2.</sentence>
<sentence>In cultured rat liver slices, <cons sem="G_NUMBER">0.5 mM</cons> sodium <cons sem="G_DRUG">phenobarbitone (PB)</cons>, <cons sem="G_NUMBER">25 microM</cons> <cons sem="G_DRUG">beta-naphthoflavone (BNF)</cons>, and <cons sem="G_NUMBER">20 micrograms/ml</cons> <cons sem="G_DRUG">Aroclor 1254 (ARO)</cons> <cons sem="G_MECHANISM">induced</cons> mixed-function oxidase enzyme activities.</sentence>
<sentence>Western immunoblotting of liver slice microsomes was performed with antibodies to rat <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, <cons sem="G_CYP">2B1/2</cons> and <cons lex="3a" sem="G_CYP">3A</cons>.</sentence>
<sentence>Compared with 72-h control (dimethyl sulphoxide only treated) rat liver slice microsomes, PB <cons sem="G_MECHANISM">induced</cons> <cons sem="G_CYP">CYP2B1/2</cons> and <cons lex="3a" sem="G_CYP">3A</cons>, BNF <cons sem="G_MECHANISM">induced</cons> <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, and <cons sem="G_DRUG">ARO</cons> <cons sem="G_MECHANISM">induced</cons> <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, <cons sem="G_CYP">2B1/2</cons>, and <cons lex="3a" sem="G_CYP">3A</cons>.</sentence>
<sentence>3.</sentence>
<sentence>The peroxisome proliferators <cons sem="G_DRUG">methylclofenapate (MCP)</cons>, <cons sem="G_DRUG">ciprofibrate (CIP)</cons> and <cons sem="G_DRUG">Wy-14,643 (WY)</cons> <cons sem="G_MECHANISM">induced</cons> palmitoyl-CoA <cons sem="G_MECHANISM">oxidation</cons> in 72-h cultured rat liver slices.</sentence>
<sentence>Compared with 72-h control rat liver slice microsomes, <cons sem="G_DRUG">MCP</cons>, <cons sem="G_DRUG">CIP</cons>, and <cons sem="G_DRUG">WY</cons> all <cons sem="G_MECHANISM">induced</cons> levels of <cons sem="G_CYP">CYP4A</cons>.</sentence>
<sentence>4.</sentence>
<annotation sem="INVITROCDDIS" ddi="(ARO, 7-ethoxyresorufin O-deethylase,DDI)(MCP, 7-ethoxyresorufin O-deethylase,NDDI)">
<sentence>In cultured human liver slices, 20 micrograms/ml <cons sem="G_DRUG">ARO</cons>, but <cons sem="G_NEGATIVEEFFECT">not</cons> 0.5 mM MCP, <cons sem="G_MECHANISM">induced</cons> 7-<cons sem="G_DRUG">Ethoxyresorufin</cons> O-deethylase activity.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(ARO, palmitoyl-CoA oxidation,NDDI)(MCP, palmitoyl-CoA oxidation,NDDI)(ARO, lauric acid 11- and 12-hydroxylase,NDDI)(MCP, lauric acid 11- and 12-hydroxylase,NDDI)">
<sentence><cons sem="G_NEGATIVEEFFECT">Neither</cons> <cons sem="G_DRUG">ARO</cons> <cons sem="G_NEGATIVEEFFECT">nor</cons> <cons sem="G_DRUG">MCP</cons> had any effect on homogenate palmitoyl-CoA <cons sem="G_MECHANISM">oxidation</cons> and microsomal <cons lex="lauric" sem="G_DRUG">lauric acid</cons>  11- and 12-hydroxylase activities.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(ARO, CYP1A2,DEI)(ARO, CYP4A,DEI)">
<sentence>Compared with 72-h control human liver slice microsomes, <cons sem="G_DRUG">ARO</cons> <cons sem="G_MECHANISM">induced</cons> <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, and <cons sem="G_DRUG">MCP</cons> appeared to <cons sem="G_MECHANISM">induce</cons> CYP4A.</sentence>
</annotation>
<sentence>Further studies would be required to confirm that CYP4A isoenzymes could be <cons sem="G_MECHANISM">induced</cons> by xenobiotics in human liver slices.</sentence>
<sentence>5.</sentence>
<sentence>These results demonstrate that cultured liver slices <cons sem="G_CHANGE">may</cons> be used in evaluating the effect of xenobiotics on both rat and human CYP isoenzymes.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:8737761</bibliomisc>
</articleinfo>
<title>
<sentence>In vitro comparative <cons sem="G_MECHANISM">inhibition</cons> profiles of major human drug <cons sem="G_MECHANISM">metabolising</cons> cytochrome P450 isozymes (<cons sem="G_CYP">CYP2C9</cons>, <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> and <cons sem="G_CYP">CYP3A4</cons>) by HMG-CoA reductase <cons sem="G_MECHANISM">inhibitors</cons>.</sentence>
</title>
<abstract>
<sentence>The affinity of (+)-, (-)- and (+/-)- <cons lex="fluvastatin" sem="G_DRUG">fluvastatin</cons>, a new synthetic HMG-CoA reductase <cons sem="G_MECHANISM">inhibitor</cons> developed as a racemate, for specific human P450 monooxygenases in liver microsomes was compared with that of the pharmacologically active acidic forms of <cons lex="lovastatin" sem="G_DRUG">lovastatin</cons>, <cons lex="pravastatin" sem="G_DRUG">pravastatin</cons> and <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons>.</sentence>
<sentence>Affinity was determined as the <cons sem="G_MECHANISM">inhibitory</cons> potency for prototype reactions for 3 major drug metabolising enzymes: <cons lex="diclofenac" sem="G_DRUG">diclofenac</cons> 4'-hydroxylation (<cons sem="G_CYP">CYP2C9</cons>), <cons lex="dextromethorphan" sem="G_DRUG">dextromethorphan</cons> O-demethylation (<cons sem="G_CYP">CYP2D6</cons>), and <cons lex="midazolam" sem="G_DRUG">midazolam</cons> 1'-hydroxylation (<cons sem="G_CYP">CYP3A4</cons>).</sentence>
<annotation sem="INVITROCDDIS" ddi="(Lovastatin acid, CYP2C9,ADEI)(Lovastatin acid, CYP2D6,ADEI)(Lovastatin acid, CYP3A4,ADEI)(pravastatin, CYP2C9,ADEI)(pravastatin, CYP2D6,ADEI)(pravastatin, CYP3A4,ADEI)(simvastatin acid, CYP2C9,ADEI)(simvastatin acid, CYP2D6,ADEI)(simvastatin acid, CYP3A4,ADEI)">
<sentence><cons lex="lovastatin" sem="G_DRUG">Lovastatin acid</cons>, <cons lex="pravastatin" sem="G_DRUG">pravastatin</cons> and <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons> acid displayed <cons sem="G_CHANGE">moderate</cons> affinity for all three P450 isozymes (estimated <cons sem="G_IVITPARA">Ki</cons> <cons sem="G_NUMBER">&gt; 50 micromol.1(-1)</cons>).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Racemic, CYP2D6,ADEI)(Racemic, CYP3A4,ADEI)((+)- and (-)-fluvastatin, CYP2D6,ADEI)((+)- and (-)-fluvastatin, CYP3A4,ADEI)(Racemic, CYP2C9,DEI)((+)- and (-)-fluvastatin, CYP2C9,DEI)">
<sentence>Racemic and (+)- and (-)-<cons lex="fluvastatin" sem="G_DRUG">fluvastatin</cons> showed <cons sem="G_CHANGE">moderate</cons> affinity (estimated <cons sem="G_IVITPARA">Ki</cons> <cons sem="G_NUMBER">&gt; 50 micromol.1(-1)</cons>) for <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, whereas their affinity for <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> was high (estimated <cons sem="G_IVITPARA">Ki</cons> <cons sem="G_NUMBER">&lt; 1 micromol.1(-1)</cons>).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="((+)- and (-)- fluvastatin, Diclofenac 4'-hydroxylation,DDI)">
<sentence><cons lex="diclofenac" sem="G_DRUG">Diclofenac</cons> 4'-hydroxylation was competitively and stereoselectively <cons sem="G_MECHANISM">inhibited</cons>, with measured <cons sem="G_IVITPARA">Ki</cons>'s of <cons sem="G_NUMBER">0.06 and 0.28 micromol.1(-1)</cons> for (+)- and (-)- <cons lex="fluvastatin" sem="G_DRUG">fluvastatin</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Fluvastatin, CYP2C9,DEI)">
<sentence><cons lex="fluvastatin" sem="G_DRUG">Fluvastatin</cons> selectively <cons sem="G_MECHANISM">inhibits</cons> a major drug metabolising enzyme (<cons sem="G_CYP">CYP2C9</cons>), the (+)-isomer (pharmacologically more active) showing <cons sem="G_NUMBER">4-5 fold</cons> higher affinity.</sentence>
</annotation>
<sentence>As already reported for <cons lex="lovastatin" sem="G_DRUG">lovastatin</cons> and <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons>, in vivo drug interactions by <cons sem="G_MECHANISM">inhibition</cons> of liver <cons sem="G_MECHANISM">oxidation</cons> of <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> substrates (e.g. hypoglyceamic sulphonylureas and oral anticoagulants) <cons sem="G_CHANGE">may</cons> be expected.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:8531125</bibliomisc>
</articleinfo>
<title>
<sentence>Potent and selective <cons sem="G_MECHANISM">inactivation</cons> of human liver microsomal cytochrome P-450 isoforms by <cons sem="G_DRUG">L-754,394</cons>, an investigational human immune deficiency virus protease <cons sem="G_MECHANISM">inhibitor</cons>.</sentence>
</title>
<abstract>
<sentence><cons sem="G_DRUG">L-754,394</cons>, N- [2(R)-hydroxy-1(S)-indanyl]-5- [2(S)-(1,1-dimethylethylaminocarbonyl)-4-  [(furo [2,3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R) - phenylmethylpentanamide, is a potent and specific <cons sem="G_MECHANISM">inhibitor</cons> of the human immune deficiency virus (HIV) protease.</sentence>
<annotation sem="INVITROVDDIS" ddi="(L-754,394, testosterone 6 beta-hydroxylase,DDI)(L-754,394, bufuralol 1'-hydroxylase,DDI)">
<sentence>The drug selectively <cons sem="G_MECHANISM">inhibited</cons> human liver microsomal CYP <cons lex="3a4" sem="G_CYP">3A4</cons>-dependent <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6 beta-hydroxylase and CYP <cons lex="2d6" sem="G_CYP">2D6</cons>-dependent <cons sem="G_DRUG">bufuralol</cons> 1'-hydroxylase activities in a time- and concentration-dependent manner in the presence of an NADPH-generating system.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(L-754,394, CYP3A4,DEI)">
<sentence><cons sem="G_DRUG">L-754,394</cons> was found to be a very potent <cons sem="G_MECHANISM">inactivator</cons> of CYP <cons lex="3a4" sem="G_CYP">3A4</cons>.</sentence>
</annotation>
<sentence>Thus, for <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6 beta-hydroxylase, the <cons sem="G_MECHANISM">inactivation</cons> kinetic constants, <cons sem="G_IVITPARA">Kl</cons> and <cons sem="G_IVITPARA">kinact</cons>, were <cons sem="G_NUMBER">7.5 microM and 1.62 min-1</cons>, respectively, and the partition ratio (moles product <cons sem="G_MECHANISM">formed</cons> per moles enzyme inactivated) was approximately <cons sem="G_NUMBER">1.35</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(L-754,394, CYP2D6,ADEI)">
<sentence>To a lesser extent, <cons sem="G_DRUG">L-754,394</cons> also was an <cons sem="G_MECHANISM">inactivator</cons> of CYP <cons lex="2d6" sem="G_CYP">2D6</cons>, for which the corresponding values for <cons sem="G_IVITPARA">Kl</cons>, <cons sem="G_IVITPARA">kinact</cons> and partition ratio were <cons sem="G_NUMBER">32 microM, 0.18 min-1 and 40</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(ketoconazole, CYP3A4,DEI)">
<sentence>CYP <cons lex="3a4" sem="G_CYP">3A4</cons> <cons sem="G_MECHANISM">inactivation</cons> was <cons sem="G_CHANGE">reduced</cons> <cons sem="G_CHANGE">markedly</cons> by <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>, a selective CYP <cons lex="3a4" sem="G_CYP">3A4</cons> <cons sem="G_MECHANISM">inhibitor</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(quinidine, CYP2D6,DEI)">
<sentence>Similarly, CYP <cons lex="2d6" sem="G_CYP">2D6</cons> <cons sem="G_MECHANISM">inactivation</cons> also was prevented by <cons lex="quinidine" sem="G_DRUG">quinidine</cons>, a specific competitive <cons sem="G_MECHANISM">inhibitor</cons> of this isoform.</sentence>
</annotation>
<sentence>However, exogenously added nucleophiles (GSH, semicarbazide and N-acetylcysteine) failed to protect against P-450 <cons sem="G_MECHANISM">inactivation</cons>.</sentence>
<sentence>These results suggest that the <cons sem="G_MECHANISM">inactivation</cons> process likely is mediated by a reactive metabolite of L-754,394 that alkylates, and thereby destroys, the enzyme.</sentence>
<sentence>Furthermore, this electrophilic intermediate <cons sem="G_CHANGE">may</cons> <cons sem="G_NEGATIVEEFFECT">not</cons> be released into the medium before the <cons sem="G_MECHANISM">inactivation</cons> event.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:8615855</bibliomisc>
</articleinfo>
<title>
<sentence>Validation of the (omega-1)-hydroxylation of <cons lex="lauric" sem="G_DRUG">lauric acid</cons> as an in vitro <cons sem="G_MECHANISM">substrate</cons> probe for human liver <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons>.</sentence>
</title>
<abstract>
<sentence>The (omega-1)-hydroxylation of <cons lex="lauric" sem="G_DRUG">lauric acid</cons> (11-OH-LA), a model substrate of fatty acids, was previously shown to be due to <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons> in rat liver microsomes.</sentence>
<sentence>The present study examined changes in hepatic <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons> content and 11-OH-LA in a panel of 29 human liver microsomes.</sentence>
<sentence>The 11-OH-LA activity was strongly <cons sem="G_MECHANISM">correlated</cons> with the <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons> content, quantitated by immunoblot (<cons sem="G_NUMBER">r = 0.75</cons>) and with four monooxygenase activities known to be mediated by <cons sem="G_CYP">CYP2E1</cons>: <cons lex="chlorzoxazone" sem="G_DRUG">chlorzoxazone</cons>-6-hydroxylation (<cons sem="G_NUMBER">r = 0.73</cons>), 4-nitrophenol hydroxylation (<cons sem="G_NUMBER">r = 0.84</cons>), N-nitrosodimethylamine demethylation (<cons sem="G_NUMBER">r = 0.79</cons>) and n-butanol <cons sem="G_MECHANISM">oxidation</cons> (<cons sem="G_NUMBER">r = 0.73</cons>).</sentence>
<annotation sem="INVITROCDDIS" ddi="(ethanol, lauric acid (omega-1)-hydroxylation,DDI)(dimethylsulfoxide, lauric acid (omega-1)-hydroxylation,DDI)(chlorzoxazone, lauric acid (omega-1)-hydroxylation,DDI)(diethyldithiocarbamate, lauric acid (omega-1)-hydroxylation,DDI)(diallylsulfide, lauric acid (omega-1)-hydroxylation,DDI)">
<sentence>The (omega-1)-hydroxylation of <cons lex="lauric" sem="G_DRUG">lauric acid</cons> was <cons sem="G_MECHANISM">inhibited</cons> by <cons lex="ethanol" sem="G_DRUG">ethanol</cons> (<cons sem="G_IVITPARA">Ki</cons> = <cons sem="G_NUMBER">3.5 mM</cons>), <cons sem="G_DRUG">acetone</cons> (<cons sem="G_IVITPARA">IC50</cons> = <cons sem="G_NUMBER">10 mM</cons>) <cons lex="dimethylsulfoxide" sem="G_DRUG">dimethylsulfoxide</cons>, <cons lex="chlorzoxazone" sem="G_DRUG">chlorzoxazone</cons> (competitive <cons sem="G_MECHANISM">inhibitors</cons> of <cons sem="G_CYP">CYP2E1</cons>), <cons lex="diethyldithiocarbamate" sem="G_DRUG">diethyldithiocarbamate</cons>, and <cons sem="G_DRUG">diallylsulfide</cons> (both selective mechanism-based <cons sem="G_MECHANISM">inactivators</cons> of <cons sem="G_CYP">CYP2E1</cons>).</sentence>
</annotation>
<sentence>The weak value of <cons lex="ethanol" sem="G_DRUG">ethanol</cons> <cons sem="G_IVITPARA">Ki</cons> on the (omega-1)-hydroxylation of <cons lex="lauric" sem="G_DRUG">lauric</cons> acid suggested that low levels of alcohol could modify fatty acid <cons sem="G_MECHANISM">metabolism</cons> in the liver.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Furafylline, lauric acid 11-hydroxylation,NDDI)(gestodene, lauric acid 11-hydroxylation,NDDI)(suicide, lauric acid 11-hydroxylation,NDDI)">
<sentence><cons lex="furafylline" sem="G_DRUG">Furafylline</cons> and <cons sem="G_DRUG">gestodene</cons>, suicide substrates of CYP1A and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, respectively, did <cons sem="G_NEGATIVEEFFECT">not</cons> modify the 11-hydroxylation of <cons lex="lauric" sem="G_DRUG">lauric acid</cons>.</sentence>
</annotation>
<sentence>Polyclonal antibody directed against rat <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons> <cons sem="G_MECHANISM">inhibited</cons> the <cons sem="G_MECHANISM">formation</cons> of 11-OH-LA without affecting 12-OH-LA activity.</sentence>
<sentence>Taken together, these results suggest that <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons> is involved in the (omega-1)-hydroxylation of <cons lex="lauric" sem="G_DRUG">lauric</cons> acid in human liver microsomes, and omega-hydroxylation is mediated by another enzyme.</sentence>
<sentence>Finally, the use of yeasts and mammalian cells genetically engineered for expression of 9 human P450s demonstrated that <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons> was the one enzyme involved in the (omega-1)-hydroxylation of <cons lex="lauric" sem="G_DRUG">lauric</cons> acid.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:8703653</bibliomisc>
</articleinfo>
<title>
<sentence>The effects of selective serotonin reuptake <cons sem="G_MECHANISM">inhibitors</cons> and their metabolites on S-<cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons> 4'-hydroxylase activity in human liver microsomes.</sentence>
</title>
<abstract>
<sentence>The <cons sem="G_MECHANISM">inhibitory</cons> effects of four selective serotonin reuptake <cons sem="G_MECHANISM">inhibitors</cons> (SSRIs), <cons lex="fluoxetine" sem="G_DRUG">fluoxetine</cons>, <cons lex="sertraline" sem="G_DRUG">sertraline</cons>, <cons lex="paroxetine" sem="G_DRUG">paroxetine</cons> and <cons lex="citalopram" sem="G_DRUG">citalopram</cons>, and three metabolites (<cons sem="G_DRUG">norfluoxetine</cons>, <cons sem="G_DRUG">demethylcitalopram</cons> and <cons sem="G_DRUG">didemethylcitalopram</cons>), on S-<cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons> 4'-hydroxylation activities in human liver microsomes were studied.</sentence>
<annotation sem="INVITROVDDIS" ddi="(fluoxetine, S-mephenytoin 4'-hydroxylation,DDI)(sertraline, S-mephenytoin 4'-hydroxylation,DDI)(paroxetine, S-mephenytoin 4'-hydroxylation,DDI)(citalopram, S-mephenytoin 4'-hydroxylation,DDI)(norfluoxetine, S-mephenytoin 4'-hydroxylation,DDI)(demethylcitalopram, S-mephenytoin 4'-hydroxylation,DDI)(didemethylcitalopram, S-mephenytoin 4'-hydroxylation,DDI)">
<sentence>The 4'-hydroxylation of S-<cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons>, a representative substrate toward <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>, was competitively <cons sem="G_MECHANISM">inhibited</cons> by all the SSRIs and their metabolites studied.</sentence>
</annotation>
<annotation sem="INVITROVDDIS" ddi="(fluoxetine, S-mephenytoin 4'-hydroxylation,DDI)(norfluoxetine, S-mephenytoin 4'-hydroxylation,DDI)(sertraline, S-mephenytoin 4'-hydroxylation,DDI)(paroxetine, S-mephenytoin 4'-hydroxylation,DDI)(citalopram, S-mephenytoin 4'-hydroxylation,ADDI)(demethylcitalopram, S-mephenytoin 4'-hydroxylation,DDI)(demethylcitalopram, S-mephenytoin 4'-hydroxylation,DDI)">
<sentence>The mean <cons sem="G_IVITPARA">Ki</cons> values of <cons lex="fluoxetine" sem="G_DRUG">fluoxetine</cons>, <cons sem="G_DRUG">norfluoxetine</cons>, <cons lex="sertraline" sem="G_DRUG">sertraline</cons>, <cons lex="paroxetine" sem="G_DRUG">paroxetine</cons>, <cons lex="citalopram" sem="G_DRUG">citalopram</cons>, <cons sem="G_DRUG">demethylcitalopram</cons> and <cons sem="G_DRUG">didemethylcitalopram</cons> were <cons sem="G_NUMBER">5.2, 1.1, 2.0, 7.5, 87.3, 55.8 and 7.7 microM</cons>, respectively.</sentence>
</annotation>
<sentence>The findings suggest that some SSRIs and their metabolites with a low <cons sem="G_IVITPARA">Ki</cons> value (e.g., <cons lex="fluoxetine" sem="G_DRUG">fluoxetine</cons>, norfluoxetine) <cons sem="G_CHANGE">may</cons> <cons sem="G_CHANGE">reduce</cons> the clearance of drugs <cons sem="G_MECHANISM">metabolized</cons> by this isoform of P450, thereby resulting in a possible drug-drug interaction, when administered simultaneously.</sentence>
<sentence>In addition, SSRIs and their metabolites examined herein <cons sem="G_CHANGE">may</cons> be substrates toward <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:7473143</bibliomisc>
</articleinfo>
<title>
<sentence>N-demethylation of <cons lex="amitriptyline" sem="G_DRUG">amitriptyline</cons> in vitro: role of cytochrome P-450 <cons lex="3a" sem="G_CYP">3A</cons> (CYP3A) isoforms and effect of metabolic <cons sem="G_MECHANISM">inhibitors</cons>.</sentence>
</title>
<abstract>
<sentence>Biotransformation of <cons lex="amitriptyline" sem="G_DRUG">amitriptyline (AMI)</cons> to its demethylated product <cons lex="nortriptyline" sem="G_DRUG">nortriptyline</cons> (NT) was studied in vitro with human liver microsomes from four different donors, preselected to reflect a range of metabolic rates.</sentence>
<sentence>Reaction velocity versus substrate concentration was consistent with a sigmoid <cons sem="G_IVITPARA">Vmax</cons> model.</sentence>
<sentence><cons sem="G_IVITPARA">Vmax</cons> varied from <cons sem="G_NUMBER">0.42 to 3.42 nmol/mg/min</cons>, <cons sem="G_IVITPARA">Km</cons> from <cons sem="G_NUMBER">33 to 89 microM</cons> AMI.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Ketoconazole, N-demethylation,DDI)(quinidine, N-demethylation,NDDI)(alpha-naphthoflavone, N-demethylation,NDDI)">
<sentence><cons lex="ketoconazole" sem="G_DRUG">Ketoconazole</cons> was a highly potent <cons sem="G_MECHANISM">inhibitor</cons> of N-demethylation, with a mean <cons sem="G_IVITPARA">Ki</cons> value of <cons sem="G_NUMBER">0.11 +/- 0.013 microM (+/- S.D.)</cons>, whereas <cons lex="quinidine" sem="G_DRUG">quinidine</cons> (up to <cons sem="G_NUMBER">50 microM</cons>), a <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> <cons sem="G_MECHANISM">inhibitor</cons>, and alpha-naphthoflavone (up to <cons sem="G_NUMBER">5 microM</cons>), a <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> <cons sem="G_MECHANISM">inhibitor</cons> only at low concentrations, showed <cons sem="G_NEGATIVEEFFECT">no</cons> effect.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(sertraline, NT,DDI)(desmethylsertraline, NT,DDI)(fluvoxamine, NT,DDI)(norfluoxetine, NT,ADDI)(paroxetine, NT,ADDI)(fluoxetine, NT,ADDI)">
<sentence>All selective serotonin reuptake <cons sem="G_MECHANISM">inhibitors</cons> (SSRIs) tested had an <cons sem="G_MECHANISM">inhibitory</cons> effect on the <cons sem="G_MECHANISM">formation</cons> of NT, with mean <cons sem="G_IVITPARA">Ki</cons> values of <cons sem="G_NUMBER">4.37 (+/- 3.38) microM</cons> for <cons lex="sertraline" sem="G_DRUG">sertraline</cons>, <cons sem="G_NUMBER">5.46 (+/- 1.95) microM</cons> for <cons sem="G_DRUG">desmethylsertraline</cons>, <cons sem="G_NUMBER">9.22 (+/- 3.69) microM</cons> for <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons>, <cons sem="G_NUMBER">12.26 (+/- 5.67) microM</cons> for <cons sem="G_DRUG">norfluoxetine</cons>, <cons sem="G_NUMBER">15.76 (+/- 5.05) microM</cons> for <cons lex="paroxetine" sem="G_DRUG">paroxetine</cons>, and <cons sem="G_NUMBER">43.55 (+/- 18.28) microM</cons> for <cons lex="fluoxetine" sem="G_DRUG">fluoxetine</cons>.</sentence>
</annotation>
<sentence>A polyclonal rabbit antibody against rat liver <cons sem="G_CYP">CYP3A1</cons>, in antibody/microsomal protein ratios varying from <cons sem="G_NUMBER">1:1 to 10:1</cons>, <cons sem="G_MECHANISM">inhibited</cons> N-demethylation of AMI to an asymptotic maximum of <cons sem="G_NUMBER">60%</cons>.</sentence>
<sentence>These results are consistent with several case reports describing impairment of AMI <cons sem="G_MECHANISM">metabolism</cons> by SSRIs.</sentence>
<sentence><cons sem="G_MECHANISM">Inhibition</cons> of AMI demethylation by low concentrations of <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> and by anti-<cons lex="3a" sem="G_CYP">3A</cons> antibody supports an important role for <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> isoforms in mediating this reaction.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:7503788</bibliomisc>
</articleinfo>
<title>
<sentence>Human liver oxidative <cons sem="G_MECHANISM">metabolism</cons> of <cons sem="G_DRUG">O6-benzylguanine</cons>.</sentence>
</title>
<abstract>
<sentence>The <cons sem="G_MECHANISM">oxidation</cons> of <cons sem="G_DRUG">O6-benzylguanine</cons>, an <cons sem="G_MECHANISM">inactivator</cons> of O6-alkylguanine-DNA alkyltransferase, was examined using human liver cytosol, microsomes, and several P450 isoforms.</sentence>
<annotation sem="INVITROCDDIS" ddi="(menadione, O6-benzyl-8-oxoguanine,DDI)(menadione, aldehyde oxidase,DDI)">
<sentence>Incubation of <cons sem="G_DRUG">O6-benzylguanine</cons> with human liver cytosol resulted in the <cons sem="G_MECHANISM">formation</cons> of O6-benzyl-8-oxoguanine, which was <cons sem="G_MECHANISM">inhibited</cons> by <cons lex="menadione" sem="G_DRUG">menadione</cons>, a potent <cons sem="G_MECHANISM">inhibitor</cons> of aldehyde oxidase.</sentence>
</annotation>
<sentence><cons sem="G_MECHANISM">Inhibition</cons> by <cons lex="allopurinol" sem="G_DRUG">allopurinol</cons>, a xanthine oxidase <cons sem="G_MECHANISM">inhibitor</cons>, was less dramatic.</sentence>
<annotation sem="INVITROCDDIS" ddi="(furafylline, O6-benzyl-8-oxoguanine,DDI)(troleandomycin, aldehyde oxidase,DDI)">
<sentence><cons sem="G_MECHANISM">Oxidation</cons> of <cons sem="G_DRUG">O6-benzylguanine</cons> also occurred with pooled human liver microsomes and was <cons sem="G_MECHANISM">inhibited</cons> by both <cons lex="furafylline" sem="G_DRUG">furafylline</cons> and <cons lex="troleandomycin" sem="G_DRUG">troleandomycin</cons>, selective <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, respectively.</sentence>
</annotation>
<sentence>Human P450s <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons>, <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons>, <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons>, and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> expressed in Hep G2 hepatoma cells using vaccinia virus vectors were incubated with <cons sem="G_NUMBER">10 or 200 microM</cons> <cons sem="G_DRUG">O6-benzylguanine</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(CYP1A2, O6-benzylguanine,DDI)(CYP3A4, O6-benzylguanine,DDI)">
<sentence>At <cons sem="G_NUMBER">10 microM</cons>, <cons sem="G_DRUG">O6-benzylguanine</cons> was <cons sem="G_MECHANISM">oxidized</cons> primarily by <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> and to a lesser extent by <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
</annotation>
<sentence>However, an appreciable <cons sem="G_CHANGE">increase</cons> in <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> contribution was noted at <cons sem="G_NUMBER">200 microM</cons>.</sentence>
<sentence><cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> exhibited a more than <cons sem="G_NUMBER">200-fold</cons> higher relative catalytic activity <cons sem="G_IVITPARA">(Vmax/Km)</cons> compared with <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(CYP1A2, O6-benzylguanine,DDI)">
<sentence>Therefore, at therapeutically relevant concentrations of <cons sem="G_DRUG">O6-benzylguanine</cons>, <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> could be primarily involved in its <cons sem="G_MECHANISM">oxidation</cons> since it shows a much lower <cons sem="G_IVITPARA">Km</cons> value (<cons sem="G_NUMBER">1.3 microM</cons>) than <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> (<cons sem="G_NUMBER">52.2 microM</cons>) and cytosol (<cons sem="G_NUMBER">81.5 microM</cons>).</sentence>
</annotation>
<sentence>However, one would expect interindividual variation in the extent of <cons sem="G_MECHANISM">oxidation</cons> of <cons sem="G_DRUG">O6-benzylguanine</cons> depending on the levels of aldehyde oxidase, <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:8554939</bibliomisc>
</articleinfo>
<title>
<sentence>An investigation of the interaction between <cons lex="halofantrine" sem="G_DRUG">halofantrine</cons>, <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> and <cons sem="G_CYP">CYP3A4</cons>: studies with human liver microsomes and heterologous enzyme expression systems.</sentence>
</title>
<abstract>
<sentence>1.</sentence>
<sentence>We have assessed the interaction of the antimalarial <cons lex="halofantrine" sem="G_DRUG">halofantrine</cons> with cytochrome P450 (CYP) enzymes in vitro, with the use of microsomes from human liver and recombinant cell lines.</sentence>
<sentence>2.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Rac-halofantrine, bufuralol 1-hydroxylation,DDI)">
<sentence>Rac-<cons lex="halofantrine" sem="G_DRUG">halofantrine</cons> was a potent <cons sem="G_MECHANISM">inhibitor</cons> (<cons sem="G_IVITPARA">IC50</cons> = <cons sem="G_NUMBER">1.06 microM</cons>, <cons sem="G_IVITPARA">Ki</cons> = <cons sem="G_NUMBER">4.3 microM</cons>) of the 1-hydroxylation of <cons sem="G_DRUG">bufuralol</cons>, a marker for <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> activity.</sentence>
</annotation>
<sentence>Of a group of structurally related antimalarials tested, only <cons lex="quinidine" sem="G_DRUG">quinidine</cons> (<cons sem="G_IVITPARA">IC50</cons> = <cons sem="G_NUMBER">0.04 microM</cons>) was more potent.</sentence>
<sentence>3.</sentence>
<annotation sem="INVITROCDDIS" ddi="(CYP2D6, halofantrine N-debutylation,DEI)(CYP3A4, halofantrine N-debutylation,DEI)">
<sentence>Microsomes prepared from recombinant <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> cell lines were shown to <cons sem="G_MECHANISM">catalyse</cons> <cons lex="halofantrine" sem="G_DRUG">halofantrine</cons> N-debutylation.</sentence>
</annotation>
<sentence>4.</sentence>
<annotation sem="INVITROCDDIS" ddi="(quinidine, halofantrine N-desbutyl,DDI)">
<sentence>The <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="halofantrine" sem="G_DRUG">halofantrine</cons> to its N-desbutyl metabolite by human liver microsomes showed <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem="G_MECHANISM">correlation</cons> with <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> genotypic or phenotypic status and there was <cons sem="G_NEGATIVEEFFECT">no</cons> consistent <cons sem="G_MECHANISM">inhibition</cons> by <cons lex="quinidine" sem="G_DRUG">quinidine</cons>.</sentence>
</annotation>
<sentence>5.</sentence>
<annotation sem="INVITROCDDIS" ddi="(felodipine, halofantrine,DDI)">
<sentence>The rate of <cons lex="halofantrine" sem="G_DRUG">halofantrine</cons> <cons sem="G_MECHANISM">metabolism</cons> showed a <cons sem="G_CHANGE">significant</cons> <cons sem="G_MECHANISM">correlation</cons> with both <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> protein levels (<cons sem="G_NUMBER">r = 0.88, P = 0.01</cons>) and the rate of <cons lex="felodipine" sem="G_DRUG">felodipine</cons> <cons sem="G_MECHANISM">metabolism</cons> (<cons sem="G_NUMBER">r = 0.86, P = 0.013</cons>), a marker substrate for <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activity.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(ketoconazole, halofantrine,DDI)">
<sentence><cons sem="G_MECHANISM">Inhibition</cons> studies showed that <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> is a potent <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="halofantrine" sem="G_DRUG">halofantrine</cons> <cons sem="G_MECHANISM">metabolism</cons> (<cons sem="G_IVITPARA">IC50</cons> = <cons sem="G_NUMBER">1.57 microM</cons>).</sentence>
</annotation>
<sentence>6.</sentence>
<sentence>In conclusion, we have demonstrated that <cons lex="halofantrine" sem="G_DRUG">halofantrine</cons> is a potent <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> in vitro and can also be <cons sem="G_MECHANISM">metabolised</cons> by the enzyme.</sentence>
<sentence>However, in human liver microsomes it appears to be <cons sem="G_MECHANISM">metabolised</cons> largely by <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:7870052</bibliomisc>
</articleinfo>
<title>
<sentence>Oxidative <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="lansoprazole" sem="G_DRUG">lansoprazole</cons> by human liver cytochromes P450.</sentence>
</title>
<abstract>
<sentence>The aim of this work was to identify the form(s) of human cytochrome P450 (P450) involved in the hepatic biotransformation of <cons lex="lansoprazole" sem="G_DRUG">lansoprazole</cons> to its two main metabolites, i.e., the sulfone and the hydroxy derivative.</sentence>
<sentence>In liver microsomes, the production of the sulfone of <cons lex="lansoprazole" sem="G_DRUG">lansoprazole</cons> <cons sem="G_MECHANISM">correlated</cons> with the level of P450 <cons lex="3a4" sem="G_CYP">3A4</cons>, cyclosporin oxidase, and the production of the hydroxy derivative, as well as of <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> sulfone.</sentence>
<sentence>The production of hydroxylansoprazole <cons sem="G_CHANGE">moderately</cons> <cons sem="G_MECHANISM">correlated</cons> with the level of P450 <cons lex="3a4" sem="G_CYP">3A4</cons>, cyclosporin oxidase, and (S)-<cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons> 4'-hydroxylase.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Anti-2C8 antibody, sulfone,DDI)(Anti-2C8 antibody, lansoprazole,DDI)(cyclosporin, sulfone,DDI)(cyclosporin, lansoprazole,DDI)(ketoconazole, sulfone,DDI)(ketoconazole, lansoprazole,DDI)(tolbutamide, sulfone,DDI)(tolbutamide, lansoprazole,DDI)">
<sentence>The production of the sulfone and of the hydroxy derivative of <cons lex="lansoprazole" sem="G_DRUG">lansoprazole</cons> was <cons sem="G_CHANGE">significantly</cons> <cons sem="G_MECHANISM">inhibited</cons> by anti-P450 <cons lex="3a4" sem="G_CYP">3A4</cons> antibodies, by cyclosporin and <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>, and by <cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Anti-2C8 antibody, lansoprazole,DDI)(Anti-2C3 antibody, lansoprazole,DDI)(Anti-2C8 antibody, (S)-mephenytoin 4'-hydroxylase,DDI)(Anti-2C3 antibody, (S)-mephenytoin 4'-hydroxylase,DDI)">
<sentence>Anti-P450 <cons lex="2c8" sem="G_CYP">2C8</cons> and <cons sem="G_CYP">2C3</cons> antibodies <cons sem="G_CHANGE">moderately</cons> <cons sem="G_MECHANISM">inhibited</cons> the biotransformation of <cons lex="lansoprazole" sem="G_DRUG">lansoprazole</cons>, whereas they completely <cons sem="G_MECHANISM">inhibited</cons> (S)-<cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons> 4'-hydroxylase activity under the same conditions.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(rifampicin, lansoprazole,DDI)(rifampicin, cyclosporin,DDI)(phenobarbital, lansoprazole,DDI)(phenobarbital, cyclosporin,DDI)((S)-mephenytoin 4'-hydroxylation, lansoprazole,NDDI)((S)-mephenytoin 4'-hydroxylation, cyclosporin,NDDI)">
<sentence>In primary cultures of human hepatocytes, the biotransformation of <cons lex="lansoprazole" sem="G_DRUG">lansoprazole</cons> and the <cons sem="G_MECHANISM">oxidation</cons> of cyclosporin were strongly <cons sem="G_CHANGE">increased</cons> by rifampicin and <cons lex="phenobarbital" sem="G_DRUG">phenobarbital</cons>, whereas (S)-<cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons> 4'-hydroxylation was <cons sem="G_NEGATIVEEFFECT">not</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(beta-Naphthoflavone, sulfones,NDDI)(beta-Naphthoflavone, hydroxylansoprazole,DDI)">
<sentence>beta-Naphthoflavone did <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_MECHANISM">induce</cons> the <cons sem="G_MECHANISM">formation</cons> of the sulfones but <cons sem="G_MECHANISM">stimulated</cons> the production of hydroxylansoprazole.</sentence>
</annotation>
<sentence>Among several forms of cDNA-expressed human P450s, <cons lex="3a4" sem="G_CYP">3A4</cons> generated <cons sem="G_CHANGE">significant</cons> amounts of the sulfones of <cons lex="lansoprazole" sem="G_DRUG">lansoprazole</cons> and <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> and <cons lex="2c18" sem="G_CYP">2C18</cons> was active for the production of hydroxylansoprazole but inactive in the 4'-hydroxylation of (S)-<cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons>.</sentence>
<sentence>We conclude that P450 <cons lex="3a4" sem="G_CYP">3A4</cons> is the major enzyme involved in the production of the sulfone of <cons lex="lansoprazole" sem="G_DRUG">lansoprazole</cons> and that this P450, as well as P450 <cons lex="2c18" sem="G_CYP">2C18</cons> and/or another <cons lex="2c" sem="G_CYP">2C</cons>-related form, could contribute to the production of hydroxylansoprazole.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:7736913</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem="G_IVITPARA">Biotransformation</cons> of <cons lex="losartan" sem="G_DRUG">losartan</cons> to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and <cons lex="3a" sem="G_CYP">3A</cons> subfamily members.</sentence>
</title>
<abstract>
<sentence><cons lex="losartan" sem="G_DRUG">Losartan</cons> is a 4-chloro-5-hydroxymethylimidazole derivative that is a potent and highly selective angiotensin II receptor antagonist.</sentence>
<sentence><cons lex="losartan" sem="G_DRUG">Losartan</cons> is <cons sem="G_MECHANISM">metabolized</cons> in vivo in rats, monkeys, and humans to a carboxylic acid derivative E3174 that is pharmacologically more active than the parent compound.</sentence>
<sentence>We have investigated the mechanism of this <cons sem="G_IVITPARA">biotransformation</cons> in human liver preparations.</sentence>
<sentence>The <cons sem="G_MECHANISM">oxidation</cons> of both <cons lex="losartan" sem="G_DRUG">losartan</cons> and the putative aldehyde intermediate E3179 was <cons sem="G_MECHANISM">catalyzed</cons> by the microsomal fraction, required both NADPH and molecular oxygen, and was <cons sem="G_MECHANISM">inhibited</cons> by SKF 525-A, implicating cytochrome P450 (CYP).</sentence>
<sentence>When incubations with each substrate were performed under an atmosphere of 18O2, the extent of 18O incorporation into the carboxylic acid product was consistent with a mechanism for <cons lex="losartan" sem="G_DRUG">losartan</cons> <cons sem="G_MECHANISM">oxidation</cons> involving an aldehyde intermediate.</sentence>
<sentence>To substantiate the involvement of CYP in these reactions, incubations with <cons lex="losartan" sem="G_DRUG">losartan</cons> and the aldehyde E3179 were performed in the presence of isoform-selective <cons sem="G_MECHANISM">inhibitors</cons>.</sentence>
<annotation sem="INVITROVDDIS" ddi="(gestodene, Losartan,DDI)(gestodene, E3179,DDI)(ketoconazole, Losartan,DDI)(ketoconazole, E3179,DDI)(sulfaphenazole, Losartan,DDI)(sulfaphenazole, E3179,DDI)">
<sentence><cons sem="G_MECHANISM">Inhibitors</cons> of <cons lex="cyp3a4/5" sem="G_CYP">CYP3A4/5</cons> (<cons sem="G_DRUG">gestodene</cons> and <cons sem="G_DRUG">ketoconazole</cons>) and <cons sem="G_CYP"> <cons sem="G_CYP">CYP<cons sem="G_CYP">2C9/10</cons></cons></cons> (<cons sem="G_DRUG">sulfaphenazole</cons>) <cons sem="G_MECHANISM">attenuated</cons> the <cons sem="G_MECHANISM">oxidation</cons> of both substrates.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(CYP2C9, Losartan,DEI)(CYP2C9, E3179,DEI)(CYP3A4, Losartan,DEI)(CYP3A4, E3179,DEI)">
<sentence>It was then demonstrated that microsomes containing either recombinant human liver <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> or <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> were capable of oxidizing both <cons lex="losartan" sem="G_DRUG">losartan</cons> and the aldehyde E3179 to the carboxylic acid E3174.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(anti-CYP2C9 antibody, Losartan,DEI)(anti-CYP2C9 antibody, E3179,DEI)(anti- CYP3A3/4 antibody, Losartan,DEI)(anti- CYP3A3/4 antibody, E3179,DEI)">
<sentence>Subsequently, it was shown that rabbit anti-<cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> and anti-<cons sem="G_CYP">CYP3A3/4</cons> <cons sem="G_MECHANISM">inhibited</cons> the <cons sem="G_MECHANISM">oxidation</cons> of <cons lex="losartan" sem="G_DRUG">losartan</cons> to E3174 in incubations with human liver microsomes.</sentence>
</annotation>
<sentence>These studies support the hypothesis that the aldehyde E3179 is an intermediate in the <cons sem="G_MECHANISM">oxidation</cons> of <cons lex="losartan" sem="G_DRUG">losartan</cons> and that this two-step reaction is <cons sem="G_MECHANISM">catalyzed</cons> in human liver microsomes by members of the <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> and <cons sem="G_CYP">CYP2C</cons> subfamilies.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:7756104</bibliomisc>
</articleinfo>
<title>
<sentence>Evidence for a role of cytochrome P450 <cons lex="2d6" sem="G_CYP">2D6</cons> and <cons lex="3a4" sem="G_CYP">3A4</cons> in <cons lex="ethylmorphine" sem="G_DRUG">ethylmorphine</cons> <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
</title>
<abstract>
<sentence><cons lex="ethylmorphine" sem="G_DRUG">Ethylmorphine</cons> is <cons sem="G_MECHANISM">metabolised</cons> by N-demethylation (to <cons sem="G_DRUG">norethylmorphine</cons>) and by O-deethylation (to <cons sem="G_DRUG">morphine</cons>).</sentence>
<sentence>The O-deethylation reaction was previously shown in vivo to co-segregate with the O-demethylation of <cons lex="dextromethorphan" sem="G_DRUG">dextromethorphan</cons> indicating that <cons lex="ethylmorphine" sem="G_DRUG">ethylmorphine</cons> is a substrate of polymorphic cytochrome P450(CYP)<cons sem="G_CYP">2D6</cons>.</sentence>
<sentence>To study further the features of <cons lex="ethylmorphine" sem="G_DRUG">ethylmorphine</cons> <cons sem="G_MECHANISM">metabolism</cons> we investigated its N-demethylation and O-deethylation in human liver microsomes from eight extensive (EM) and one poor metaboliser (PM) of <cons lex="dextromethorphan" sem="G_DRUG">dextromethorphan</cons>.</sentence>
<sentence>Whereas N-demethylation varied only two-fold there was a <cons sem="G_NUMBER">4.3-fold</cons> variation in the O-deethylation of <cons lex="ethylmorphine" sem="G_DRUG">ethylmorphine</cons>, the lowest rate being observed in the PM.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Quinidine, O-deethylation,DDI)">
<sentence><cons lex="quinidine" sem="G_DRUG">Quinidine</cons>, at a concentration of <cons sem="G_NUMBER">1 microM</cons>, <cons sem="G_MECHANISM">inhibited</cons> O-deethylation in microsomes from an EM, but was unable to do so in microsomes from the PM.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(O-deethylation, CYP2D6,DEI)(O-deethylation, CYP3A4,DEI)(N-demethylation, CYP2D6,DEI)(N-demethylation, CYP3A4,DEI)">
<sentence>The immunoidentified <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">correlated</cons> with the rates of O-deethylation (<cons sem="G_NUMBER">r = 0.972</cons>) and N-demethylation (<cons sem="G_NUMBER">r = 0.969</cons>), respectively.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(ethylmorphine O-deethylation, CYP2D6,DEI)">
<sentence>We conclude that the O-deethylation of <cons lex="ethylmorphine" sem="G_DRUG">ethylmorphine</cons> is catalysed by the <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> in human liver microsomes consistent with previous findings in healthy volunteers.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:7720517</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="budesonide" sem="G_DRUG">Budesonide</cons> is <cons sem="G_MECHANISM">metabolized</cons> by cytochrome P450 <cons lex="3a" sem="G_CYP">3A</cons> (CYP3A) enzymes in human liver.</sentence>
</title>
<abstract>
<sentence><cons lex="budesonide" sem="G_DRUG">Budesonide</cons> is a synthetic glucocorticosteroid that is commonly used in topical treatment of asthma and rhinitis.</sentence>
<sentence>The main metabolites <cons sem="G_MECHANISM">formed</cons> from <cons lex="budesonide" sem="G_DRUG">budesonide</cons> in human liver microsomes have been identified as 16 alpha-hydroxyprednisolone and 6 beta-hydroxy-<cons lex="budesonide" sem="G_DRUG">budesonide</cons>.</sentence>
<sentence>Although it is apparent that the cytochrome P450 (CYP) system is involved, the actual subfamily has <cons sem="G_NEGATIVEEFFECT">not</cons> been identified.</sentence>
<sentence>In attempts to do this, <cons lex="budesonide" sem="G_DRUG">budesonide</cons> was incubated with microsomes from ten different human liver samples where various CYP activities had been rank ordered.</sentence>
<sentence>We found a strong <cons sem="G_MECHANISM">correlation</cons> between <cons sem="G_MECHANISM">formation</cons> of the two main metabolites and <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6 beta-hydroxylation (correlation <cons sem="G_NUMBER">0.98 and 0.95</cons>), a marker for <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>.</sentence>
<annotation sem="INVITROCDDIS" ddi="(ketoconazole, budesonide,DDI)(troleandomycin, budesonide,DDI)(erythromycin, budesonide,DDI)(cyclosporin, budesonide,DDI)">
<sentence>When <cons lex="budesonide" sem="G_DRUG">budesonide</cons> (<cons sem="G_NUMBER">10 microM</cons>) was incubated with human liver microsomes in the presence of compounds known to interact with different isoforms or subfamilies of CYP, <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> was found to be the <cons sem="G_CHANGE">strongest</cons> <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="budesonide" sem="G_DRUG">budesonide</cons> <cons sem="G_MECHANISM">metabolism</cons> (<cons sem="G_IVITPARA">IC50</cons>: approximately <cons sem="G_NUMBER">0.1 microM</cons>) followed by <cons lex="troleandomycin" sem="G_DRUG">troleandomycin</cons> (<cons sem="G_IVITPARA">IC50</cons>: approximately <cons sem="G_NUMBER">1 microM</cons>), <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons>, and <cons sem="G_DRUG">cyclosporin</cons>, all substances known to interact with <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> isoenzymes.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(sulfaphenazole, budesonide,DDI)(mephenytoin, budesonide,DDI)(tolbutamide, budesonide,DDI)(bufuralol, budesonide,DDI)(quinidine, budesonide,DDI)">
<sentence>Substances known to interact with <cons sem="G_CYP">CYP2C</cons> (<cons sem="G_DRUG">sulfaphenazole</cons>, <cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons>, and <cons sem="G_DRUG">tolbutamide</cons>) and with <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> (<cons sem="G_DRUG">bufuralol</cons> and <cons sem="G_DRUG">quinidine</cons>) did <cons sem="G_NEGATIVEEFFECT">not</cons> specifically <cons sem="G_MECHANISM">inhibit</cons> the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="budesonide" sem="G_DRUG">budesonide</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(Anti-CYP1A antibody, 16 alpha-hydroxyprednisolone,DDI)(Anti-CYP1A antibody, 6 beta-hydroxybudesonide,DDI)">
<sentence>In addition, <cons sem="G_MECHANISM">formation</cons> of the <cons lex="budesonide" sem="G_DRUG">budesonide</cons> metabolites (16 alpha-hydroxyprednisolone and 6 beta-hydroxybudesonide) was <cons sem="G_MECHANISM">inhibited</cons> by antibodies against the <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> subfamily, but <cons sem="G_NEGATIVEEFFECT">not</cons> by antibodies against the <cons sem="G_CYP">CYP1A</cons> subfamily or control immunoglobulin G. We conclude that the <cons sem="G_MECHANISM">formation</cons> of 16 alpha-hydroxyprednisolone and 6 beta-hydroxybudesonide from <cons lex="budesonide" sem="G_DRUG">budesonide</cons> is <cons sem="G_MECHANISM">catalyzed</cons> by isoenzymes within the <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> subfamily.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:7951142</bibliomisc>
</articleinfo>
<title>
<sentence>Involvement of a cytochrome P4502D subfamily in human liver microsomal <cons sem="G_DRUG">bunitrolol</cons> 4-hydroxylation.</sentence>
</title>
<abstract>
<sentence>The oxidative <cons sem="G_MECHANISM">metabolism</cons> of <cons sem="G_DRUG">bunitrolol</cons>, an adrenergic beta-receptor antagonist was examined in human liver microsomes fortified with an NADPH-generating system.</sentence>
<annotation sem="INVITROCDDIS" ddi="(bunitrolol 4-hydroxylase, debrisoquine 4-hydroxylase,DDI)(bunitrolol 4-hydroxylase, imipramine 2-hydroxylase,DDI)">
<sentence>The microsomal fractions (n = 11) showed <cons sem="G_DRUG">bunitrolol</cons> 4-hydroxylase activities, which <cons sem="G_MECHANISM">correlated</cons> well with <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> contents (correlation coefficient, <cons sem="G_NUMBER">r = 0.854</cons>), <cons lex="debrisoquine" sem="G_DRUG">debrisoquine</cons> 4-hydroxylase (<cons sem="G_NUMBER">r = 0.953</cons>) and <cons lex="imipramine" sem="G_DRUG">imipramine</cons> 2-hydroxylase (<cons sem="G_NUMBER">r = 0.976</cons>) activities.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(bunitrolol 4-hydroxylase, testosterone 6 beta-hydroxylase,DDI)">
<sentence>On the other hand, the <cons sem="G_DRUG">bunitrolol</cons> 4-hydroxylase activity showed relatively poor correlations with <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> content (<cons sem="G_NUMBER">r = 0.552</cons>) and <cons lex="testosterone" sem="G_DRUG">testosterone</cons> 6 beta-hydroxylase activity (<cons sem="G_NUMBER">r = 0.668</cons>).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(quinidine, bunitrolol 4-hydroxylase,DDI)">
<sentence>The <cons sem="G_DRUG">bunitrolol</cons> 4-hydroxylase activity was <cons sem="G_CHANGE">significantly</cons> <cons sem="G_MECHANISM">inhibited</cons> by <cons lex="quinidine" sem="G_DRUG">quinidine</cons>, a selective <cons sem="G_MECHANISM">inhibitor</cons> for <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(CYP2D, bunitrolol 4-hydroxylase,DDI)">
<sentence>Polyclonal antibodies raised against rat liver microsomal cytochrome P450BTL, which is thought to belong to the CYP2D subfamily, effectively <cons sem="G_MECHANISM">inhibited</cons> <cons sem="G_DRUG">bunitrolol</cons> 4-hydroxylation.</sentence>
</annotation>
<annotation sem="INVITROVDDIS" ddi="(CYP3A4, bunitrolol 4-hydroxylase,DDI)">
<sentence>In contrast, polyclonal antibodies raised against human liver microsomal <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> show any <cons sem="G_MECHANISM">inhibitory</cons> effect on the activity.</sentence>
</annotation>
<sentence>These results suggest that <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> is involved in the <cons sem="G_DRUG">bunitrolol</cons> 4-hydroxylase activity in human liver microsomes.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:8204093</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="caffeine" sem="G_DRUG">Caffeine</cons> <cons sem="G_MECHANISM">metabolism</cons> by human hepatic cytochromes P450: contributions of <cons lex="1a2" sem="G_CYP">1A2</cons>, <cons lex="2e1" sem="G_CYP">2E1</cons> and <cons lex="3a" sem="G_CYP">3A</cons> isoforms.</sentence>
</title>
<abstract>
<sentence><cons lex="caffeine" sem="G_DRUG">Caffeine (CA)</cons> N1-, N3- and <cons sem="G_DRUG">N7-demethylase</cons>, CA 8-hydroxylase and <cons lex="phenacetin" sem="G_DRUG">phenacetin</cons> O-deethylase activities were measured in microsomes from 18 separate human livers which had been characterized previously for a range of cytochrome P450 (CYP) isoform-specific activities and immunoreactive CYP protein contents.</sentence>
<sentence>Correlations between the high affinity components of the three separate CA N-demethylations were highly <cons sem="G_CHANGE">significant</cons> (<cons sem="G_NUMBER">r = 0.77-0.91, P &lt; 0.001</cons>) and each of the three high affinity <cons sem="G_DRUG">CA</cons> N-demethylations <cons sem="G_MECHANISM">correlated</cons> <cons sem="G_CHANGE">significantly</cons> (<cons sem="G_NUMBER">r = 0.64-0.93, P &lt; 0.05-0.001</cons>) with the high affinity <cons lex="phenacetin" sem="G_DRUG">phenacetin</cons> O-deethylase, <cons sem="G_DRUG">2-acetylaminofluorene</cons> N-hydroxylation and <cons sem="G_DRUG">2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine (PhIP)</cons> and <cons sem="G_DRUG">2-amino-3-methylimidazo [4,5-f]quinoline (IQ)</cons> mutagenicity (all predominantly <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>-mediated reactions).</sentence>
<annotation sem="INVITROCDDIS" ddi="(CYP1A2, CA N1-demethylation,DDI)(CYP1A2, CA N3-demethylation,DDI)(CYP1A2, CA N7-demethylation,DDI)">
<sentence>Consistent with these observations, cDNA-expressed human <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> <cons sem="G_MECHANISM">catalyzed</cons> the N1-, N3- and <cons sem="G_DRUG">N7-demethylation</cons> of <cons sem="G_DRUG">CA</cons> and apparent <cons sem="G_IVITPARA">Km</cons> values were similar (<cons sem="G_NUMBER">0.24-0.28 mM</cons>) for all three reactions and comparable to those observed previously with human liver microsomes.</sentence>
</annotation>
<sentence>The low affinity components of CA N1- and N7-demethylation <cons sem="G_MECHANISM">correlated</cons> <cons sem="G_CHANGE">significantly</cons> (<cons sem="G_NUMBER">r = 0.55-0.85, P &lt; 0.05-0.001</cons>) with immunoreactive <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons> content and the <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons>-specific activities 4-nitrophenol and <cons lex="chlorzoxazone" sem="G_DRUG">chlorzoxazone</cons> hydroxylation.</sentence>
<annotation sem="INVITROCDDIS" ddi="(Diethyldithiocarbamate, CA N1-demethylation,ADDI)(Diethyldithiocarbamate, CA N7-demethylation,ADDI)">
<sentence><cons lex="diethyldithiocarbamate" sem="G_DRUG">Diethyldithiocarbamate</cons>, a selective <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons>, <cons sem="G_MECHANISM">inhibited</cons> the low affinity <cons sem="G_DRUG">CA</cons> N1- and <cons sem="G_DRUG">N7-demethylation</cons>, with <cons sem="G_IVITPARA">IC50</cons> values of <cons sem="G_NUMBER">23 microM and 11 microM</cons>, respectively.</sentence>
</annotation>
<sentence>The apparent <cons sem="G_IVITPARA">Km</cons> values for <cons sem="G_DRUG">CA</cons> N1- and <cons sem="G_DRUG">N7-demethylation</cons> by cDNA-expressed <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons> (namely <cons sem="G_NUMBER">28 and 43 mM</cons>, respectively) were of a similar order to those calculated for the low affinity microsomal activities.</sentence>
<annotation sem="INVITROCDDIS" ddi="(CA 8-hydroxylation, benzo(a)pyrene hydroxylation,DDI)(CA 8-hydroxylation, omeprazole sulfoxidation,DDI)(CA 8-hydroxylation, aflatoxin B1 mutagenesis,DDI)">
<sentence><cons sem="G_CHANGE">significant</cons> correlations (<cons sem="G_NUMBER">r = 0.87-0.97, P &lt; 0.001</cons>) were observed between <cons sem="G_DRUG">CA</cons> 8-hydroxylation and immunoreactive <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> content and the <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>-mediated reactions benzo(a)pyrene hydroxylation, <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> sulfoxidation and aflatoxin B1 mutagenesis.</sentence>
</annotation>
<sentence>Effects of alpha-naphthoflavone, <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons>, <cons lex="troleandomycin" sem="G_DRUG">troleandomycin</cons> and <cons lex="nifedipine" sem="G_DRUG">nifedipine</cons> on microsomal CA 8-hydroxylation were generally consistent with <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> involvement.</sentence>
<sentence>Taken together with previous data, the results indicate a major involvement of <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> in the high affinity component of all three human hepatic CA N-demethylations.</sentence>
<sentence>In contrast, <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons> appears to be the main enzyme involved in the low affinity components of CA N1- and N7-demethylation while CA 8-hydroxylation is catalysed predominantly by a <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> isoform(s).</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:8221648</bibliomisc>
</articleinfo>
<title>
<sentence>Involvement of human liver cytochrome P450 <cons lex="3a" sem="G_CYP">3A</cons> in <cons lex="vinblastine" sem="G_DRUG">vinblastine</cons> <cons sem="G_MECHANISM">metabolism</cons>: drug interactions.</sentence>
</title>
<abstract>
<sentence><cons lex="vinblastine" sem="G_DRUG">Vinblastine</cons> biotransformation was investigated by using a human liver microsomes library.</sentence>
<sentence>The drug was converted into one major metabolite (M) upon incubation with the microsomes.</sentence>
<sentence>A large interindividual variation in <cons lex="vinblastine" sem="G_DRUG">vinblastine</cons> <cons sem="G_MECHANISM">metabolism</cons> was observed among the samples tested, with a 4.4 ratio between the lowest and the highest metabolic rates.</sentence>
<sentence>The <cons sem="G_IVITPARA">biotransformation</cons> of <cons lex="vinblastine" sem="G_DRUG">vinblastine</cons> followed Michaelis-Menten kinetics (<cons sem="G_IVITPARA">Km</cons> = <cons sem="G_NUMBER">6.82 +/- 0.27 microM</cons> and <cons sem="G_IVITPARA">Vmax</cons> = <cons sem="G_NUMBER">0.64 +/- 0.06 nmol/min/mg protein</cons>).</sentence>
<annotation sem="INVITROCDDIS" ddi="(ketoconazole, vinblastine,DDI)(erythromycin, vinblastine,ADDI)(troleandomycin, vinblastine,ADDI)(vindesine, vinblastine,ADDI)(erythromycin, N-demethylase,DDI)(erythromycin, vinblastine,DDI)(CYP3A4, vinblastine,DEI)">
<sentence>The involvement of the cytochrome P450 <cons lex="3a" sem="G_CYP">3A</cons> subfamily in <cons lex="vinblastine" sem="G_DRUG">vinblastine</cons> <cons sem="G_MECHANISM">metabolism</cons> was demonstrated by the following body of evidence: (a) the competitive <cons sem="G_MECHANISM">inhibition</cons> of <cons lex="vinblastine" sem="G_DRUG">vinblastine</cons> <cons sem="G_IVITPARA">biotransformation</cons> by cytochrome P450 <cons lex="3a" sem="G_CYP">3A</cons> specific probes with <cons sem="G_IVITPARA">Ki</cons> values of <cons sem="G_NUMBER">0.17, 22.5, 14.8, and 35.3 microM</cons> for <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>, <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons>, <cons lex="troleandomycin" sem="G_DRUG">troleandomycin</cons>, and <cons lex="vindesine" sem="G_DRUG">vindesine</cons>, respectively; (b) the immunoinhibition of <cons lex="vinblastine" sem="G_DRUG">vinblastine</cons> <cons sem="G_MECHANISM">metabolism</cons> by polyclonal anti-cytochrome P450 <cons lex="3a" sem="G_CYP">3A</cons> antibodies; (c) the highly <cons sem="G_CHANGE">significant</cons> <cons sem="G_MECHANISM">correlation</cons> between the level of cytochrome P450 <cons lex="3a" sem="G_CYP">3A</cons> determined by Western blots and <cons lex="vinblastine" sem="G_DRUG">vinblastine</cons> <cons sem="G_MECHANISM">metabolism</cons> (<cons sem="G_NUMBER">r = 0.759, P &lt; 0.001</cons>); (d) the highly <cons sem="G_CHANGE">significant</cons> <cons sem="G_MECHANISM">correlation</cons> between <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> N-demethylase activity (mediated by cytochrome P450 <cons sem="G_CYP">3A</cons>) and <cons lex="vinblastine" sem="G_DRUG">vinblastine</cons> <cons sem="G_MECHANISM">metabolism</cons> (<cons sem="G_NUMBER">r = 0.83, P &lt; 0.001</cons>); (e) the <cons sem="G_CHANGE">significant</cons> <cons sem="G_MECHANISM">correlation</cons> between the <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> mRNA level and <cons lex="vinblastine" sem="G_DRUG">vinblastine</cons> <cons sem="G_MECHANISM">metabolism</cons> (<cons sem="G_NUMBER">r = 0.60, P &lt; 0.1</cons>).</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(vincristine, vinblastine,DDI)(navelbine, vinblastine,DDI)(etoposide, vinblastine,DDI)(Adriamycin, vinblastine,DDI)(lomustine, vinblastine,DDI)(teniposide, vinblastine,DDI)">
<sentence>Although <cons lex="vincristine" sem="G_DRUG">vincristine</cons> and navelbine (members of the Vinca alkaloid family) also <cons sem="G_MECHANISM">inhibit</cons> the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="vinblastine" sem="G_DRUG">vinblastine</cons>, suggesting the involvement of the cytochrome subfamily in their respective <cons sem="G_MECHANISM">metabolism</cons>, other anticancer drugs currently associated with <cons lex="vinblastine" sem="G_DRUG">vinblastine</cons> in chemotherapy (<cons sem="G_DRUG">etoposide</cons>, <cons sem="G_DRUG">Adriamycin</cons>, <cons lex="lomustine" sem="G_DRUG">lomustine</cons>, and <cons sem="G_DRUG">teniposide</cons>) also interfere with <cons lex="vinblastine" sem="G_DRUG">vinblastine</cons> biotransformation.</sentence>
</annotation>
<sentence>These metabolic drug interactions <cons sem="G_CHANGE">may</cons> alter the antitumor activity and/or toxicity of the drug during anticancer chemotherapy.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:8474022</bibliomisc>
</articleinfo>
<title>
<sentence>Specificity of <cons sem="G_MECHANISM">substrate</cons> and <cons sem="G_MECHANISM">inhibitor</cons> probes for human cytochromes P450 <cons lex="1a1" sem="G_CYP">1A1</cons> and <cons lex="1a2" sem="G_CYP">1A2</cons>.</sentence>
</title>
<abstract>
<sentence>Kinetic and <cons sem="G_MECHANISM">inhibitor</cons> studies using cDNA-expressed enzymes and human liver microsomes have characterized the specificity of a range of cytochrome P450 (CYP) <cons lex="1a" sem="G_CYP">1A</cons> <cons sem="G_MECHANISM">substrate</cons> and <cons sem="G_MECHANISM">inhibitor</cons> probes towards the two isoforms comprising this subfamily.</sentence>
<sentence>Expressed <cons lex="cyp1a1" sem="G_CYP">CYP1A1</cons> and <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> both <cons sem="G_MECHANISM">catalyzed</cons> the O-deethylation of <cons lex="phenacetin" sem="G_DRUG">phenacetin</cons>, although the apparent <cons sem="G_IVITPARA">Km</cons> was about <cons sem="G_NUMBER">4-fold</cons> <cons sem="G_CHANGE">lower</cons> for <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> (<cons sem="G_NUMBER">25 vs. 108 microM</cons>).</sentence>
<sentence><cons lex="phenacetin" sem="G_DRUG">Phenacetin</cons> O-deethylation exhibited biphasic kinetics in human liver microsomes, and the apparent <cons sem="G_IVITPARA">Km</cons> for the high-affinity component (<cons sem="G_NUMBER">9 +/- 6 microM</cons>) was consistent with the involvement of <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> in this reaction.</sentence>
<annotation sem="INVITROCDDIS" ddi="(alpha-naphthoflavone, phenacetin O-deethylation,DDI)(alpha-naphthoflavone, phenacetin O-deethylase,DDI)(ellipticine, phenacetin O-deethylation,DDI)(ellipticine, phenacetin O-deethylase,DDI)(7-ethoxycoumarin, phenacetin O-deethylation,DDI)(7-ethoxycoumarin, phenacetin O-deethylase,DDI)(7-ethoxyresorufin, phenacetin O-deethylation,DDI)(7-ethoxyresorufin, phenacetin O-deethylase,DDI)">
<sentence>The prototypic CYP1A xenobiotic <cons sem="G_MECHANISM">inhibitor</cons> and substrate probes <cons sem="G_DRUG">alpha-naphthoflavone</cons>, <cons sem="G_DRUG">ellipticine</cons>, <cons sem="G_DRUG">7-ethoxycoumarin</cons> and <cons sem="G_DRUG">7-<cons sem="G_DRUG">Ethoxyresorufin</cons></cons> all <cons sem="G_MECHANISM">inhibited</cons> <cons lex="cyp1a1" sem="G_CYP">CYP1A1</cons>- and <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>-mediated <cons lex="phenacetin" sem="G_DRUG">phenacetin</cons> O-deethylation as well as the high-affinity component of human liver <cons lex="phenacetin" sem="G_DRUG">phenacetin</cons> O-deethylase activity.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(alpha-naphthoflavone, CYP1A2,DEI)(alpha-naphthoflavone, CYP1A1,DEI)(7-ethoxycoumarin, CYP1A2,DEI)(7-ethoxycoumarin, CYP1A1,DEI)">
<sentence><cons sem="G_DRUG">alpha-Naphthoflavone</cons> and <cons sem="G_DRUG">7-ethoxycoumarin</cons> were, however, approximately <cons sem="G_NUMBER">10-fold</cons> more potent as <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> than <cons lex="cyp1a1" sem="G_CYP">CYP1A1</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(caffeine, phenacetin O-deethylation,DDI)(caffeine, phenacetin O-deethylase,DDI)(5- and 8-methoxypsoralen, phenacetin O-deethylation,DDI)(5- and 8-methoxypsoralen, phenacetin O-deethylase,DDI)(nifedipine, phenacetin O-deethylation,DDI)(nifedipine, phenacetin O-deethylase,DDI)(paraxanthine, phenacetin O-deethylation,DDI)(paraxanthine, phenacetin O-deethylase,DDI)(propranolol, phenacetin O-deethylation,DDI)(propranolol, phenacetin O-deethylase,DDI)(theophylline, phenacetin O-deethylation,DDI)(theophylline, phenacetin O-deethylase,DDI)">
<sentence>Other putative human <cons sem="G_CYP">CYP1A</cons> xenobiotic substrates and <cons sem="G_MECHANISM">inhibitors</cons>, including <cons lex="caffeine" sem="G_DRUG">caffeine</cons>, 5- and <cons sem="G_DRUG">8-methoxypsoralen</cons>, <cons lex="nifedipine" sem="G_DRUG">nifedipine</cons>, <cons sem="G_DRUG">paraxanthine</cons>, <cons lex="propranolol" sem="G_DRUG">propranolol</cons> and <cons lex="theophylline" sem="G_DRUG">theophylline</cons> similarly <cons sem="G_MECHANISM">inhibited</cons> <cons lex="cyp1a1" sem="G_CYP">CYP1A1</cons>- and <cons lex="1a2" sem="G_CYP">1A2</cons>-<cons sem="G_MECHANISM">catalyzed</cons> <cons lex="phenacetin" sem="G_DRUG">phenacetin</cons> O-deethylation and the high-affinity human liver <cons lex="phenacetin" sem="G_DRUG">phenacetin</cons> O-deethylase.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(MAb 1-7-1, phenacetin O-deethylation,DDI)(MAb 1-7-1, phenacetin dealkylation,NDDI)">
<sentence>In contrast, the monoclonal antibody MAb 1-7-1, raised against 3-methylcholanthrene-inducible rat cytochromes 450, almost abolished <cons lex="cyp1a1" sem="G_CYP">CYP1A1</cons>-mediated <cons lex="phenacetin" sem="G_DRUG">phenacetin</cons> O-deethylation, but had <cons sem="G_NEGATIVEEFFECT">no</cons> effect on human liver microsomal- or <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>-<cons sem="G_MECHANISM">catalyzed</cons> <cons lex="phenacetin" sem="G_DRUG">phenacetin</cons> dealkylation.</sentence>
</annotation>
<sentence>Together with previous data, the results indicate that the majority of human <cons sem="G_CYP">CYP1A</cons> xenobiotic <cons sem="G_MECHANISM">inhibitor</cons> and substrate probes are nonspecific in their recognition of <cons lex="cyp1a1" sem="G_CYP">CYP1A1</cons> and <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, although selectivity is apparent for some compounds.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:1388041</bibliomisc>
</articleinfo>
<title>
<sentence>The role of cytochrome <cons sem="G_CYP"> <cons sem="G_CYP">P4502D6</cons></cons> in the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="paroxetine" sem="G_DRUG">paroxetine</cons> by human liver microsomes.</sentence>
</title>
<abstract>
<sentence><cons lex="paroxetine" sem="G_DRUG">Paroxetine</cons> is a selective serotonin reuptake <cons sem="G_MECHANISM">inhibitor</cons> possessing anti-depressant activity.</sentence>
<sentence>Demethylenation of the methylenedioxy phenyl group is the initial step in its <cons sem="G_MECHANISM">metabolism</cons>, the liberated carbon appearing in vitro as formate.</sentence>
<sentence>A radioassay involving  [14C-methylenedioxy] <cons lex="paroxetine" sem="G_DRUG">paroxetine</cons> was developed and used to examine the role of cytochrome <cons sem="G_CYP"> <cons sem="G_CYP">P4502D6</cons></cons> in <cons lex="paroxetine" sem="G_DRUG">paroxetine</cons> <cons sem="G_MECHANISM">metabolism</cons> by human liver microsomes.</sentence>
<sentence>The rate of formate production was much higher in microsomes from an extensive metaboliser of <cons lex="debrisoquine" sem="G_DRUG">debrisoquine</cons> than from a poor metaboliser.</sentence>
<annotation sem="INVITROCDDIS" ddi="(quinidine, paroxetine demethylenation,DDI)(quinine, paroxetine demethylenation,DDI)">
<sentence>Also, demethylenation of <cons lex="paroxetine" sem="G_DRUG">paroxetine</cons> was <cons sem="G_MECHANISM">inhibited</cons> by the <cons lex="quinidine" sem="G_DRUG">quinidine</cons> and <cons lex="quinine" sem="G_DRUG">quinine</cons> isomer pair in microsomes from the extensive metaboliser only.</sentence>
</annotation>
<sentence>These observations strongly suggested that the process was catalysed by the enzyme cytochrome <cons sem="G_CYP"> <cons sem="G_CYP">P4502D6</cons></cons>.</sentence>
<annotation sem="INVITROVDDIS" ddi="(quinidine, paroxetine demethylenation,DDI)(quinidine, paroxetine demethylenation,DDI)">
<sentence><cons sem="G_MECHANISM">Metabolism</cons> could <cons sem="G_NEGATIVEEFFECT">not</cons> be completely <cons sem="G_MECHANISM">inhibited</cons> by <cons lex="quinidine" sem="G_DRUG">quinidine</cons>, the residual activity representing the contribution of at least one other enzyme.</sentence>
</annotation>
<sentence>The ability of microsomes from a poor metaboliser of <cons lex="debrisoquine" sem="G_DRUG">debrisoquine</cons> to demethylenate <cons lex="paroxetine" sem="G_DRUG">paroxetine</cons> provided further evidence for the involvement of an enzyme distinct from <cons sem="G_CYP">P4502D6</cons>.</sentence>
<sentence>This was confirmed by kinetic analysis of the process in microsomes from both poor and extensive metabolisers.</sentence>
<sentence>It is concluded that, in man, the initial step of <cons lex="paroxetine" sem="G_DRUG">paroxetine</cons> <cons sem="G_MECHANISM">metabolism</cons> is performed by at least two enzymes, one of which is cytochrome <cons sem="G_CYP">P4502D6</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:1355711</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem="G_MECHANISM">Inhibition</cons> of <cons sem="G_DRUG">debrisoquin</cons> <cons sem="G_IVITPARA">clearance</cons> in perfused rat livers and <cons sem="G_MECHANISM">inhibition</cons> of <cons lex="dextromethorphan" sem="G_DRUG">dextromethorphan</cons> <cons sem="G_MECHANISM">metabolism</cons> in human liver microsomes by <cons sem="G_DRUG">4-hydroxydebrisoquin</cons> or other metabolites of <cons sem="G_DRUG">debrisoquin</cons>.</sentence>
</title>
<abstract>
<sentence><cons sem="G_DRUG">Debrisoquin</cons> undergoes oxidative <cons sem="G_MECHANISM">metabolism</cons> to <cons sem="G_DRUG">4-hydroxydebrisoquin</cons>, <cons sem="G_MECHANISM">catalyzed</cons> by cytochrome CYP2D1 in rats and <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> in humans.</sentence>
<sentence>Cytochrome <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> also plays a major role in <cons lex="dextromethorphan" sem="G_DRUG">dextromethorphan</cons> O-demethylation.</sentence>
<sentence>In preliminary studies in perfused Lewis rat livers, we observed a difference in repeat <cons sem="G_IVITPARA">clearance</cons> experiments using <cons sem="G_DRUG">debrisoquin</cons>, but <cons sem="G_NEGATIVEEFFECT">not</cons> <cons lex="dextromethorphan" sem="G_DRUG">dextromethorphan</cons>.</sentence>
<sentence>To determine whether this change in <cons sem="G_IVITPARA">clearance</cons> with time was due to the accumulation of <cons sem="G_DRUG">4-hydroxydebrisoquin</cons>, we sequentially used a recirculating and nonrecirculating perfusion system in the same liver perfusion experiment.</sentence>
<sentence>We also studied the kinetics of <cons lex="dextromethorphan" sem="G_DRUG">dextromethorphan</cons> O-demethylation in microsomes prepared from human and rat livers in the presence and absence of 4-hydroxydebrisoquin.</sentence>
<sentence>Results from the perfused rat liver experiments showed a <cons sem="G_CHANGE">drop</cons> in <cons sem="G_IVITPARA">clearance</cons> from <cons sem="G_NUMBER">3.27 +/- 0.57 ml/min</cons> (<cons sem="G_IVITPARA">clearance 1</cons>) to <cons sem="G_NUMBER">1.61 +/- 0.27 ml/min</cons> (<cons sem="G_IVITPARA">clearance 2</cons>) (p less than 0.05 vs. clearance 1) during recirculation, but <cons sem="G_IVITPARA">clearance</cons> <cons sem="G_CHANGE">returned</cons> to <cons sem="G_NUMBER">3.21 +/- 0.46 ml/min</cons> (clearance 3, <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem="G_CHANGE">significance</cons> vs. <cons sem="G_IVITPARA">clearance 1</cons>) after a 30-min period of liver perfusion using a nonrecirculating system.</sentence>
<sentence>There was <cons sem="G_CHANGE">significant</cons> accumulation of <cons sem="G_DRUG">4-hydroxydebrisoquin</cons> in the liver perfusate during recirculation, and concentrations fell when the nonrecirculating system was used.</sentence>
<annotation sem="INVITROCDDIS" ddi="(4-hydroxydebrisoquin, dextromethorphan,DDI)">
<sentence>In microsomal studies, <cons sem="G_DRUG">4-hydroxydebrisoquin</cons> competitively <cons sem="G_MECHANISM">inhibited</cons> <cons lex="dextromethorphan" sem="G_DRUG">dextromethorphan</cons> <cons sem="G_MECHANISM">metabolism</cons> in human microsomes was <cons sem="G_NUMBER">600 microM</cons>.</sentence>
</annotation>
<annotation sem="INVITROCDDIS" ddi="(4-hydroxydebrisoquin, CYP2D1,DEI)(4-hydroxydebrisoquin, CYP2D6,DEI)">
<sentence>These data suggest that: (a) 4-hydroxydebrisoquin and/or other metabolites of <cons sem="G_DRUG">debrisoquin</cons> have an <cons sem="G_MECHANISM">inhibitory</cons> effect on <cons sem="G_CYP">CYP2D1</cons> and <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>; (b) the active site of human <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> has different substrate specificity than the rat isozyme (<cons sem="G_CYP">CYP2D1</cons>) and/or that the pathways of <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="dextromethorphan" sem="G_DRUG">dextromethorphan</cons> are different in the Lewis rat and <cons sem="G_NEGATIVEEFFECT">not</cons> primarily dependent on the activity of <cons sem="G_CYP">CYP2D1</cons>.</sentence>
</annotation>
</abstract>
</article>
</set>
